<SEC-DOCUMENT>0001628280-16-020671.txt : 20161103
<SEC-HEADER>0001628280-16-020671.hdr.sgml : 20161103
<ACCEPTANCE-DATETIME>20161103074052
ACCESSION NUMBER:		0001628280-16-020671
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20160930
FILED AS OF DATE:		20161103
DATE AS OF CHANGE:		20161103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CURIS INC
		CENTRAL INDEX KEY:			0001108205
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043505116
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30347
		FILM NUMBER:		161970163

	BUSINESS ADDRESS:	
		STREET 1:		4 MAGUIRE ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		617-503-6500

	MAIL ADDRESS:	
		STREET 1:		4 MAGUIRE ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cris-9302016x10q3.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6A439F7CF2EA2805408B7789A97BBA15"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-Q</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark one)</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#253;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;to </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: 000-30347</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">CURIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:3%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-3505116</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or Other Jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 Maguire Road</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexington, Massachusetts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">02421</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registrant&#8217;s Telephone Number, Including Area Code: (617)&#160;503-6500</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.7109375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;No</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;No</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:55%;"></td><td style="width:23%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#253;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Yes&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#253;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;No</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">October&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">140,549,019</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the registrant&#8217;s common stock outstanding.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s21EB443801643A9ADD697789AA1A71B6"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURIS, INC. AND SUBSIDIARIES QUARTERLY REPORT ON FORM 10-Q</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:13%;"></td><td style="width:78%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;I.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL INFORMATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s953F89A214FC53BB46577789AD2946B0"><font style="font-family:inherit;font-size:10pt;">Unaudited Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s953F89A214FC53BB46577789AD2946B0">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s827377A50EF8AC2E0BA2778999A76ED8"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets as of September 30, 2016 and December&#160;31, 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s827377A50EF8AC2E0BA2778999A76ED8">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE60DF520724D38E536E1778999D473D8"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE60DF520724D38E536E1778999D473D8">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s071951F8E5A1965DDCC6778999F413F6"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s071951F8E5A1965DDCC6778999F413F6">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2DA0EB38602B1543C56D7789AEFC8C6C"><font style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2DA0EB38602B1543C56D7789AEFC8C6C">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5976B5DFFB9D03D740467789B6F9531B"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5976B5DFFB9D03D740467789B6F9531B">17</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s63C71B99782FE3318E8E7789B95CC234"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s63C71B99782FE3318E8E7789B95CC234">28</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s87AC8F681284172CF43B7789B9CA6ED9"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s87AC8F681284172CF43B7789B9CA6ED9">28</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s57DC8E938FDBFE3D09BB7789B9E6036D"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s557CBBD7A46988DAE9987789B9FC508C"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s557CBBD7A46988DAE9987789B9FC508C">29</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item&#160;6.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB11099F9A8FE459E3ECD7789BA5849F9"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB11099F9A8FE459E3ECD7789BA5849F9">59</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4082AC0CEA6809ED49537789BA71C0C7"><font style="font-family:inherit;font-size:10pt;">SIGNATURE</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4082AC0CEA6809ED49537789BA71C0C7">60</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s9ECBEF0849B781ECE0D27789ACC7F53B"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I&#8212;FINANCIAL INFORMATION</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div><a name="s953F89A214FC53BB46577789AD2946B0"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED FINANCIAL STATEMENTS</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s827377A50EF8AC2E0BA2778999A76ED8"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;CURIS, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,204</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,501</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">406</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investment &#8211; restricted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,965</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,934</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,607</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,484</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value&#8212;225,000,000 shares authorized; 141,217,276 shares issued and 139,994,430 shares outstanding at September&#160;30, 2016; 130,213,224 shares issued and 128,990,378 shares outstanding at December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,412</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,302</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">903,240</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Treasury stock (at cost, 1,222,846 shares)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,524</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,524</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(887,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(838,536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,870</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,510</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,965</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sE60DF520724D38E536E1778999D473D8"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURIS, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,403</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,759</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,045</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,165</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of royalty revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,989</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,989</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,348</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,743</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,844</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,276</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,235</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">325</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(657</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,537</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(556</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,285</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,077</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share (basic and diluted)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares (basic and diluted)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132,065,947</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,392,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,122,698</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,634,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,376</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,079</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s071951F8E5A1965DDCC6778999F413F6"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURIS, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,077</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,311</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,875</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal of assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense on investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock in consideration for rights granted under collaboration agreement</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(265</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(339</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,109</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,653</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,028</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sale of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,816</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,521</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Decrease in restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of equipment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by/(used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,062</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,089</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock associated with offerings, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,619</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock under the Company&#8217;s share-based compensation plans</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments on Curis Royalty&#8217;s debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,219</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,793</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in)/provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,058</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (decrease)/increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,420</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of period </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,091</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,747</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, end of period </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,671</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,659</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s2DA0EB38602B1543C56D7789AEFC8C6C"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURIS, INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div><a name="s95466C04BCA15F8AB81A77899A09BBE8"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nature of Business</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of cancers. As used throughout these consolidated financial statements, the term &#8220;the Company&#8221; refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term &#8220;Curis&#8221; refers to Curis, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts its research and development programs both internally and through strategic collaborations. The Company&#8217;s most advanced drug candidate is CUDC-907, which is being investigated in clinical studies in patients with diffuse large B-cell lymphoma and solid tumors.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene. In September 2016, the Company entered into an amendment to this agreement, pursuant to which Aurigene received </font><font style="font-family:inherit;font-size:10pt;">10,208,333</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock in lieu of receiving up to </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of milestone and other payments from Curis (see Note 4(b)). </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaboration comprises multiple programs, in which Curis has the option to exclusively license each program, including data, intellectual property and compounds associated with each respective program, once a development candidate is nominated within that program. In October 2015, the Company exercised options to license the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;programs under this collaboration. The first licensed program is focused on the development of orally-available small molecule antagonists of programmed death-1 (PD1) and V-domain Ig suppressor of T-cell activation (VISTA) pathways in the immuno-oncology field. The Company has named CA-170, a programmed death ligand-1 (PDL1)/VISTA antagonist, as the development candidate from this program. The second licensed program is focused on orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) enzyme in the precision oncology field and the Company has named CA-4948 as the development candidate from this program. In addition, in October 2015, the Company selected a third program for further development under the collaboration, the second preclinical program within the immuno-oncology field, which is focused on evaluating small molecule antagonists of PD1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3) pathways, including small molecules that target PDL1 and TIM3.  In October 2016, the Company exercised its option to license this third program, and designated CA-327 as the development candidate. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">&#32;(vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor, in advanced basal cell carcinoma, or BCC. In addition to BCC, Roche and Genentech are separately conducting studies of Erivedge in other diseases, including in idiopathic pulmonary fibrosis and myelofibrosis.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s proprietary small molecule compounds also include CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis, or IAP proteins, and CUDC-305, an orally-available, small molecule antagonist of Heat Shock Protein 90.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United&#160;States by the United States Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company&#8217;s business, including, but not limited to: the Company&#8217;s ability to advance and expand its research and development programs; the Company&#8217;s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties&#8217; collaboration agreement; the Company&#8217;s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company&#8217;s ability to obtain adequate financing to fund its operations; the ability of the Company&#8217;s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.&#224;.r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company&#8217;s ability to obtain and maintain necessary intellectual property protection; development by the Company&#8217;s competitors of new or better technological innovations; dependence on key personnel; the Company&#8217;s ability to comply with regulatory requirements; and the Company&#8217;s ability to execute on its overall business strategies.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it receives and makes under its current and potential future collaborations. The results of the Company&#8217;s operations may vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company&#8217;s preclinical studies and clinical trials for its drug candidates; Aurigene&#8217;s ability to successfully discover and develop preclinical programs under the Company&#8217;s collaboration with Aurigene, as well as the Company&#8217;s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech&#8217;s ability to successfully commercialize Erivedge; positive results in Roche and Genentech&#8217;s ongoing clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company anticipates that its existing cash, cash equivalents and investments at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;should enable it to maintain current and planned operations into the second half of 2017. The Company&#8217;s ability to continue funding its planned operations beyond this period is dependent upon, among other things, its ability to control expenses and its ability to raise additional funds through equity or debt financings, the success of its collaboration with Genentech, including its receipt of additional contingent cash payments under this collaboration, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of such events is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE64E72E67EFB3956E96077899A0C0FD4"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the United States, or GAAP, for complete financial statements and should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission, or the SEC, on </font><font style="font-family:inherit;font-size:10pt;">February&#160;29, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of the Company, the unaudited financial statements contain all adjustments (all of which were considered normal and recurring) necessary for a fair statement of the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and the results of operations for the three- and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and the cash flows for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. The condensed consolidated balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company&#8217;s collaboration agreements; the estimated repayment term of the Company&#8217;s debt and related short- and long-term classification; the fair value of the Company&#8217;s debt; the collectability of receivables; the carrying value of property and equipment and intangible assets; the assumptions used in the Company&#8217;s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sEA05F0294E96664BB22277899A0D4669"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Revenue Recognition</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is currently a party to a collaboration agreement with Genentech, the terms of which provide for Genentech to make a non-refundable license fee payment, research and development funding payments, contingent cash payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. For a complete discussion of the Company&#8217;s revenue recognition policy, see Note 2(c) included in its </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2179CB9BD7758C84D4AE77899A0ED25D"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Collaboration Agreements</font></div></td></tr></table><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Genentech, Inc.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2003, the Company licensed its proprietary Hedgehog pathway technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop molecules that inhibit the Hedgehog pathway for the treatment of various cancers. The collaboration is currently focused on the development of Erivedge, which is being commercialized by Genentech in the United States and by Genentech&#8217;s parent company, Roche, in several other countries for the treatment of advanced BCC. Pursuant to the agreement, the Company is eligible to receive up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$115.0 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">million</font><font style="font-family:inherit;font-size:10pt;">&#32;in contingent cash milestone payments, exclusive of royalty payments, in connection with the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. Of this amount, the Company has received </font><font style="font-family:inherit;font-size:10pt;">$59.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to these payments and pursuant to the agreement, the Company is entitled to a royalty on net sales of Erivedge that ranges from </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;">. The royalty rate applicable to Erivedge may be decreased by </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">&#32;on a country-by-country basis in certain specified circumstances, including when a competing product that binds to the same molecular target as Erivedge is approved by the applicable regulatory authority in another country, and is being sold in such country, by a third party for use in the same indication as Erivedge, or, when there is no issued intellectual property covering Erivedge in a territory in which sales are recorded. In 2015, the FDA and the European Medicine Agency&#8217;s Committee for Medicinal Products for Human Use, or CHMP, approved another Hedgehog signaling pathway inhibitor, Odomzo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(sonidegib), which is marketed by Novartis, for use in locally advanced BCC. Beginning in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Genentech applied the </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;">&#32;royalty reduction on United States sales of Erivedge as a result of the first commercial sale of sonidegib in the United States.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, Curis formed a wholly owned subsidiary, Curis Royalty, which received a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;loan at an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">12.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;pursuant to a credit agreement between Curis Royalty and BioPharma-II (see Note 7). In connection with the loan, Curis transferred to Curis Royalty its right to receive royalty and royalty-related payments on the commercial sales of Erivedge that it receives from Genentech. The loan and accrued interest is being repaid by Curis Royalty using such royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty and is non-recourse to Curis.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in royalty revenue under the Genentech collaboration during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company recorded costs of royalty revenues within the costs and expenses section of its condensed consolidated statements of operations and comprehensive loss of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. For each of these periods, these amounts are comprised of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the royalties earned by Curis Royalty that the Company is obligated to pay to university licensors. As further discussed in Note 7, the Company expects that all royalty revenues received by Curis Royalty from Genentech on net sales of Erivedge will be used by Curis Royalty to pay principal and interest under the loan that Curis Royalty received from BioPharma-II, subject to specified quarterly caps, until such time as the loan is fully repaid.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded research and development revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and research and development revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to expenses incurred by the Company on behalf of Genentech that were paid by the Company and for which Genentech is obligated to reimburse the Company.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech incurred expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, under this collaboration, for which the Company is obligated to reimburse to Genentech, and which the Company has recorded as contra-revenues in its condensed consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aurigene Agreement</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and selected precision oncology targets. Under the collaboration agreement, Aurigene granted the Company an option to obtain exclusive, royalty-bearing licenses to relevant Aurigene technology to develop, manufacture and commercialize products containing certain of such compounds.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each program, Aurigene has granted the Company an exclusive option, exercisable within </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;">&#32;after Aurigene delivers the relevant data regarding a development candidate, to obtain an exclusive, royalty-bearing license to develop, manufacture and commercialize compounds from such program, including the development candidate and products containing such compounds, anywhere in the world, except for India and Russia. For the development, manufacture, and commercialization of compounds from a particular program and products containing such compounds in India and Russia, Aurigene will grant the Company the royalty-bearing license described above for such program, and the Company will grant Aurigene an exclusive, royalty-free, fully paid license under the Company&#8217;s relevant technology upon exercise of the relevant option.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company exercised options to license the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;programs under this collaboration, resulting in an aggregate one-time payment of </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(comprised of a </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;option exercise fee for each program) by the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company to Aurigene. Effective October 2015, the Company agreed to make additional payments to Aurigene totaling up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for supplemental research, development and/or manufacturing activities in support of these </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;programs.&#160;The Company incurred and recognized </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of such costs in the three months ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which was paid in the three months ended March 31, 2016.&#160;The remaining </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was incurred and recognized in the three months ended March&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and paid in the three months ended June 30, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also in </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company selected a preclinical program for potential further development within the immuno-oncology part of the collaboration resulting in a one-time </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment. In October 2016, the Company licensed the program and designated CA-327 as the development candidate as described in Note 1, resulting in a one-time </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company anticipates that it will select additional programs under this collaboration in the future, and the Company intends to have the collaboration&#8217;s steering committee recommend such additional programs in order for Aurigene to initiate or continue the relevant preclinical activities described in each program&#8217;s written plan.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each option to license (as described above) exercised by the Company, the Company is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;product in each of the United States, specified countries in the European Union, and Japan, and Aurigene is obligated to use commercially reasonable efforts to perform its obligations under the development plan for such licensed program in an expeditious manner.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to specified exceptions, Aurigene and the Company have agreed to collaborate exclusively with each other on the discovery, research, development and commercialization of programs and compounds within immuno-oncology for an initial period of approximately </font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;">&#32;from the effective date of the collaboration agreement. At the Company&#8217;s option, and subject to specified conditions, it may extend such exclusivity for up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;additional </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year periods by paying to Aurigene exclusivity option fees on an annual basis. The first of such option fees will be </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, to be paid in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;equal installments, and the Company currently estimates that these payments will be due in the first and third quarters of 2017.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, beyond the up-to </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">&#32;of exclusivity described above, and subject to specified exceptions and payment by the Company of an annual exclusivity fee on a program-by-program basis, Aurigene and the Company have agreed to collaborate exclusively with each other on each program for which there are ongoing activities in research or development, or for which the Company has exercised its option to acquire an exclusive license (as described above) and the Company or its affiliates or sublicensees are actively developing or commercializing a compound or product from such program in a major market.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each product that may be commercialized, the Company has granted Aurigene the right, subject to certain conditions, to nominate </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;global drug substance or drug product supplier to provide up to </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total requirements in the Company&#8217;s territory.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research Payments, Option Exercise Fees and Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company has agreed to make the following research, option exercise fees and milestone payments to Aurigene:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for the PD1/VISTA and IRAK4 programs: up to </font><font style="font-family:inherit;font-size:10pt;">$52.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per program, comprised of: </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each option exercise, </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon acceptance of each IND filing, </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon dosing of the fifth patient in the Company&#8217;s first Phase 1 clinical trial in each program, as well as specified approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. Effective October 2015, the Company agreed to make additional payments to Aurigene totaling up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for supplemental research, development and/or manufacturing activities in support of these </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;programs. During the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized and paid </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Aurigene upon the acceptance of the IND filing for CA-170, a PDL1/VISTA antagonist. Since the inception of the agreement through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has incurred costs totaling </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to these programs under the collaboration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for the third and fourth programs: up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per program, comprised of: </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for a program selection fee, </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for an option exercise, </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon acceptance of an IND filing, as well as development, approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. Since the inception of the agreement through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has made payments to Aurigene totaling </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the third program under this collaboration; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for any program thereafter: up to </font><font style="font-family:inherit;font-size:10pt;">$140.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per program, comprised of: up to a total of </font><font style="font-family:inherit;font-size:10pt;">$53.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for research fees, an option exercise fee, a preclinical milestone and development milestones, as well as specified filing, approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;payments have been made to Aurigene related to such programs under the collaboration.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Amendment to Collaboration Agreement</font><font style="font-family:inherit;font-size:10pt;">. On September 7, 2016, the Company and Aurigene entered into an amendment to the January 2015 collaboration agreement. Under the terms of the amendment, in exchange for the issuance by </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Company to Aurigene of </font><font style="font-family:inherit;font-size:10pt;">10,208,333</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock, Aurigene waived payment of up to a total of </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in milestones and other payments from the Company that may become due under the 2015 collaboration agreement. The following milestones and other payments have been waived: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment for extended exclusivity related to the IRAK4 program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment upon acceptance of IND filing related to the IRAK4 program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment upon dosing of the fifth patient in the Company's Phase 1 clinical trial for the IRAK4 program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment for extended exclusivity related to the PD1/VISTA program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment upon dosing of the fifth patient in the Company's Phase 1 clinical trial for the PD1/VISTA program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, of the payment related to the option exercise payment of the third program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment upon acceptance of IND filing related to the third program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment for program selection fee of the fourth program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment for option exercise of the fourth program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment upon acceptance of IND filing related to the fourth program; </font></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent any of these milestone or other payments described&#160;above would not otherwise be payable by Curis,&#160;e.g.&#160;in the event one or more of the listed milestone events do not occur, the Company will have the right to deduct the unused waiver amount from any one or more of the milestone payment obligations tied to achievement of commercial milestone events. The amendment also provides that upon exercise the option for the third and fourth programs, the Company will provide up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of additional funding for each such licensed program provided that supplemental program activities are performed by Aurigene. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Summary. </font><font style="font-family:inherit;font-size:10pt;">Under the terms of this amendment, the value of common stock issued to Aurigene equaled </font><font style="font-family:inherit;font-size:10pt;">$18.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the closing share price of the Company&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;">$1.76</font><font style="font-family:inherit;font-size:10pt;">&#32;per share on September 6, 2016, which was the last closing price prior to execution of the amendment. As a result, the Company recognized in-process research and development expense of </font><font style="font-family:inherit;font-size:10pt;">$18.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;within its condensed consolidated statement of operations and comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;in recognition of the fact that any compounds that have been and may be licensed from Aurigene are in clinical or preclinical development and will require substantial development, regulatory and marketing approval efforts in order to reach technological feasibility.</font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s45622283A92B58EEFFD977899A563046"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Fair Value Measurements</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company discloses fair value measurements based on a framework outlined by GAAP which requires expanded disclosures regarding fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and (iv)&#160;willing to transact. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the fair value hierarchy, the following table shows the fair value as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;of those financial assets and liabilities that are measured at fair value on a recurring basis.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other&#160;Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs&#160;(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2016:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, stock, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Quoted&#160;Prices&#160;in</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other&#160;Observable</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Inputs&#160;(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2015:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,999</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, stock, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,644</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,304</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,517</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No investments held at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were transferred between levels.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDB8C184210BD6648793777899A77ED15"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Investments</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds and notes &#8211; short-term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,657</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments have maturities ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;">&#32;with a weighted-average maturity of </font><font style="font-family:inherit;font-size:10pt;">2.5</font><font style="font-family:inherit;font-size:10pt;">&#32;months at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds and notes &#8211; short-term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,072</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,072</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments have maturities ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;">&#32;with a weighted-average maturity of </font><font style="font-family:inherit;font-size:10pt;">4.2</font><font style="font-family:inherit;font-size:10pt;">&#32;months at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF8D3352A3465BCF48B9D77899A8F5ACB"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Debt</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, Curis&#8217; wholly owned subsidiary, Curis Royalty, received a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;loan at an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">12.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;pursuant to a credit agreement between Curis Royalty and BioPharma-II. In connection with the loan, Curis transferred to Curis Royalty its right to receive royalty and royalty-related payments on the commercial sales of Erivedge that it receives from Genentech (see Note 4(a)). The loan and accrued interest is being repaid by Curis Royalty using such royalty and royalty-related payments. To secure repayment of the loan, Curis Royalty granted a first priority lien and security interest (subject only to permitted liens) to BioPharma-II in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty, and is non-recourse to Curis. Under the terms of the loan, quarterly royalty payments received by Curis Royalty from Genentech will first be applied to pay (i)&#160;escrow fees payable by Curis pursuant to an escrow agreement between Curis, Curis Royalty, BioPharma-II and Boston Private Bank and Trust Company, (ii)&#160;Curis&#8217; royalty obligations to university licensors, (iii)&#160;certain expenses incurred by BioPharma-II in connection with the credit agreement and related transaction documents, including enforcement of its rights in the case of an event of default under the credit agreement and (iv)&#160;expenses incurred by Curis enforcing its right to indemnification under the collaboration agreement with Genentech. Remaining amounts are applied first to pay interest and second, principal on the loan. Curis remains entitled to receive any contingent payments upon achievement of clinical development objectives. Curis Royalty retains its right to royalty payments related to sales of Erivedge following repayment of the loan.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final maturity date of the loan will be the earlier of the date when the principal is paid in full or the termination of Curis Royalty&#8217;s right to receive royalties under the collaboration agreement with Genentech. Because the repayment of the term loan is contingent upon the level of Erivedge royalties received, the short- and long-term classification of the debt is based on the Company&#8217;s estimate of the timing of amounts to be repaid. The Company cannot estimate when the loan will be repaid as repayment is impacted by numerous factors, all of which are beyond the Company&#8217;s control. The repayment term may be shortened or extended depending on the actual level of Erivedge royalties received. In addition, if Erivedge royalties are insufficient to pay the accrued interest on the outstanding loan, any unpaid interest outstanding will be added to the principal on a quarterly basis. The length of the actual repayment period could vary materially to the extent that royalty payments Curis Royalty receives are lower than the Company&#8217;s current estimates, which could arise due to factors beyond the Company&#8217;s control, such as the sale of competing products that result in a lowering of the royalty rates that Curis Royalty is entitled to receive, decreased market acceptance or a failure by Genentech and/or Roche to successfully commercialize Erivedge in territories where it has received regulatory approval. At any time after January&#160;1, 2017, Curis Royalty may, subject to certain limitations, prepay the outstanding principal of the loan in whole or in part, at a price equal to </font><font style="font-family:inherit;font-size:10pt;">105%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the outstanding principal on the loan, plus accrued but unpaid interest. The obligations of Curis Royalty under the credit agreement to repay the loan may be accelerated upon the occurrence of an event of default as defined in the credit agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Curis Royalty made payments totaling </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;have been applied to the principal, respectively, with the remainder applied to accrued interest. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded short- and long-term debt of </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$15.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded short- and long-term debt of </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$19.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the loan, with such amounts recorded within the Company&#8217;s condensed consolidated balance sheets. In the three months ended March&#160;31, 2016, the Company adopted ASU No.&#160;2015-3</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Interest&#8212;Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:inherit;font-size:10pt;">. In accordance with the updated standard, the Company reclassified certain of its debt issuance costs, related to the loan, from assets to a direct deduction from the carrying amount of the related debt liability. The adoption of this guidance did not impact the consolidated statement of operations and comprehensive loss and the impact to the balance sheet was not material.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company recorded related accrued interest on the debt of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, with such amounts included in the Company&#8217;s accrued liabilities section of its condensed consolidated balance sheets. For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized interest expense related to the loan with BioPharma-II of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statement of operations and comprehensive loss. For the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized interest expense related to the loan with BioPharma-II of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the debt approximates its carrying value due to the expected repayment period and because the interest rate yield is near current market rate yields. Due to the assumptions required in estimating </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">future Erivedge royalties, the expected repayment period and weighting of various royalty projection scenarios, the fair value of the debt is measured using Level 3 inputs.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB8D56646AE55E0A3A59B77899AACB09A"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accrued Liabilities</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest on debt (Note 7)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">&#160;</font></div><div><a name="s65EAAFFDF2F53BB0798377899AB4CC60"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accounting for Stock-Based Compensation</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;shareholder-approved, share-based compensation plans: (i)&#160;the Amended and Restated 2010 Stock Incentive Plan, or the 2010 Plan, adopted as amended by the board of directors in March 2015 and approved by shareholders in May 2015 and (ii)&#160;the 2010 Employee Stock Purchase Plan, or the ESPP, adopted by the board of directors in April 2010 and approved by shareholders in June 2010.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s board of directors granted options to purchase a total of </font><font style="font-family:inherit;font-size:10pt;">4,621,225</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock to officers and employees of the Company, both under the 2010 Plan or in the form of inducement awards pursuant to NASDAQ Marketplace Rules. These options vest as to </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the shares underlying the award after the first year and as to an additional </font><font style="font-family:inherit;font-size:10pt;">6.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the shares underlying the award in each subsequent quarter, based upon continued employment over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period, and are exercisable at a price equal to the closing price of the Company&#8217;s common stock on the NASDAQ Global Market on the grant dates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s board of directors also granted options to its non-employee directors to purchase </font><font style="font-family:inherit;font-size:10pt;">470,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the 2010 Plan, which will vest and become exercisable in equal monthly installments over a period of </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;">&#32;from the date of grant. These options were granted at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.76</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, which equals the closing market price of the Company&#8217;s common stock on the NASDAQ Global Market on the grant date.</font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Employee and Director Grants</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vesting Tied to Service Conditions</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the fair value of stock options, the Company generally uses the Black-Scholes option pricing model. As discussed below, for employee stock options with market performance conditions, the Company uses a Monte Carlo simulation valuation model. The Black-Scholes option pricing model employs the following key assumptions for employee and director options awarded during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the assumptions noted in the following table:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:67%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years) - employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years) &#8211; officers and directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4-1.8%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5-1.9%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63-70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68-70%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividends</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected volatility is based on the annualized daily historical volatility of the Company&#8217;s stock price for a time period consistent with the expected term of each grant. Management believes that the historical volatility of the Company&#8217;s stock price best represents the future volatility of the stock price.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free rate is based on the U.S. Treasury yield in effect at the time of grant for the expected term of the respective grant. The Company has not historically paid cash dividends, and does not expect to pay cash dividends in the foreseeable future.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected terms and stock price volatility utilized in the calculation involve management&#8217;s best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. GAAP also requires that the Company recognize compensation expense for only the portion of options that are expected to vest. Therefore, management calculated an estimated annual pre-vesting forfeiture rate that is derived from historical employee termination behavior since the inception of the Company, as adjusted. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">15,487,348</font><font style="font-family:inherit;font-size:10pt;">&#32;stock options outstanding.&#160;The aggregate intrinsic value of employee options outstanding at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$9.2 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to exercisable options. The weighted average grant-date fair values of these stock options granted during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1.08</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.71</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">, net of the impact of estimated forfeitures, of unrecognized compensation cost related to unvested employee stock option awards outstanding that is expected to be recognized as expense over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.84</font><font style="font-family:inherit;font-size:10pt;">&#32;years. The intrinsic value of employee stock options exercised during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock-Based Compensation Expense</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Daniel Passeri resigned from his position as Vice Chairman of the Company's board of directors. In connection with the related letter agreement with the Company, the board of directors approved a modification to Mr.&#160;Passeri&#8217;s vested common stock options such that the exercise period for all such options shall be </font><font style="font-family:inherit;font-size:10pt;">twenty-four months</font><font style="font-family:inherit;font-size:10pt;">. As a result, </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of additional stock based compensation expense was recorded to account for this modification during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded a total of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in compensation expense for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in compensation expense for the three and the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to employee and director stock option grants. The total fair values of vested stock options for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Non-Employee Grants</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has periodically granted stock options to consultants for services pursuant to the Company&#8217;s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would also be cancelled.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized expense related to non-employee stock options of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and reversed expense of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and reversed expense of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and recognized expense of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Total Stock-Based Compensation Expense</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the condensed consolidated statements of operations and comprehensive loss, including expense related to its ESPP:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,425</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,780</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s19BFA323193685ACA5D577899AD9DCD4"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accumulated Other Comprehensive Income (Loss)</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss) as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized&#160;Gain&#160;on</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities&#160; Available-for-Sale</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current period other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above amounts do not reflect a tax effect because the Company expects to record a net loss for </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized&#160;Losses and</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain&#160;on</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities&#160;Available-for-Sale</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current period other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB81CD524C13283930F4177899AF16FE0"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Loss Per Common Share</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, because the effect of the potential common stock equivalents would be antidilutive due to the Company&#8217;s net loss position for these periods. Antidilutive securities consist only of stock options outstanding of </font><font style="font-family:inherit;font-size:10pt;">15,487,348</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">13,678,899</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB06B84DE52AE5BEDC94277899AF5B1D2"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Related Party Transactions</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consulting agreement with Daniel R. Passeri</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;2, 2014, Daniel R. Passeri resigned as Chief Executive Officer of the Company and the Company&#8217;s board of directors appointed Mr.&#160;Passeri to serve as the Vice Chairman of the board of directors. Also on June 2, 2014, the Company and Mr.&#160;Passeri entered into a consulting agreement. The agreement was for an initial term of </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;">, subject to renewal or earlier termination by the parties. The agreement was renewed by the parties through </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, after which the agreement between Mr. Passeri and the Company was terminated. Pursuant to the terms of the agreement, Mr.&#160;Passeri was paid an hourly fee or a monthly retainer as consideration for the services rendered by Mr.&#160;Passeri to the Company. During the five months ended </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, Mr.&#160;Passeri provided consulting services to the Company on intellectual property, corporate and strategic matters in exchange for payments of </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per month. During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, Mr.&#160;Passeri had full-time employment with a third party and was paid an hourly fee for services rendered to the Company during this time. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2016, the Company and Mr. Passeri entered into a letter agreement pursuant to which Mr. Passeri resigned as director and Vice Chairman of the Company's board of directors, which became effective on September 14, 2016. Pursuant to the terms of the Letter Agreement, and in recognition of his many years of service to the Company in varying roles, including as a director and Vice Chairman of the Board, and formerly as Chief Executive Officer, President, and as a consultant, the Board authorized a </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">&#32;recognition bonus payment to Mr.&#160;Passeri and also approved a modification to Mr.&#160;Passeri&#8217;s vested common stock options such that the exercise period for all such options shall be </font><font style="font-family:inherit;font-size:10pt;">24 months</font><font style="font-family:inherit;font-size:10pt;">. Mr.&#160;Passeri </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">agreed to provide continued assistance to the Company, without further remuneration, for up to </font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;">, if and when requested by the Board or the Chief Executive Officer. The letter agreement also contains other customary terms and conditions relating to Mr.&#160;Passeri&#8217;s end of service with the Company.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized expenses related to the consulting and letter agreements of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBBC18476AB52A97AC5BE77899B01ACA9"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">New Accounting Pronouncements</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standard Board (FASB) issued Accounting Standard Update (ASU) 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which simplifies share-based payment accounting through a variety of amendments. The standard will be effective for annual reporting periods and interim periods within those annual periods, beginning after December&#160;15, 2016, and early adoption is permitted. The Company does not expect the impact of this guidance to be material to its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The standard requires organizations that lease assets to recognize on the balance sheet assets or liabilities, as applicable, for the rights and obligations created by those leases. Additionally, the guidance modifies current guidance for lessor accounting and leveraged leases, and is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within such years. Early adoption is permitted, but the Company does not anticipate electing early adoption. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU, 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities,</font><font style="font-family:inherit;font-size:10pt;">&#32;which amends prior guidance on accounting for equity investments and financial liabilities. The new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within such years. Early adoption is permitted but the Company does not anticipate electing early adoption. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2014, the FASB issued ASU 2014-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to continue as a Going Concern.</font><font style="font-family:inherit;font-size:10pt;">&#160;This update is intended to define management&#8217;s responsibility to evaluate whether there is substantial doubt about an organization&#8217;s ability to continue as a going concern within one year of the date of issuance of the entity&#8217;s financial statements and to provide related footnote disclosures. This guidance is effective for fiscal years ending after December&#160;15, 2016, and early adoption is permitted. The Company is currently evaluating what effect, if any, the adoption of this guidance will have on the disclosures included in its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:inherit;font-size:10pt;">, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;">, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;">, related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact that these standards may have on its consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5976B5DFFB9D03D740467789B6F9531B"></a></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the related notes appearing elsewhere in this report. Some of the information contained in this discussion and analysis and set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. As used throughout this report, the terms &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term &#8220;Curis&#8221; refers to Curis, Inc.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDA88ED90EED0FDBFA4607789B70F7B1E"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of cancers. Our most advanced drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K, enzymes. Based on findings of our Phase 1 clinical trial of this molecule in patients with relapsed or refractory lymphomas or multiple myeloma, we initiated an open-label Phase 2 clinical trial of CUDC-907 in patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, including patients with MYC-altered DLBCL. We are also conducting a Phase 1 trial in patients with solid tumors, and have directed our efforts in this study to enroll patients whose cancers have MYC involvement, including patients with nut midline carcinoma.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we are party to an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene, a specialized, discovery-stage biotechnology company and wholly owned subsidiary of Dr.&#160;Reddy&#8217;s Laboratories. In October 2015, we exercised options to license the first two programs under this collaboration. The first licensed program is focused on the development of orally-available small molecule antagonists of programmed death-1, or PD1, and V-domain Ig suppressor of T-cell activation, or VISTA, pathways in the immuno-oncology field, including the development candidate designated CA-170, which targets programmed death ligand-1, or PDL1, and VISTA. The second licensed program is focused on orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4, or IRAK4, in the precision oncology field, with the lead development candidate designated CA-4948. In June 2016, we announced the FDA acceptance of the IND for CA-170 and dosed the first patient in a Phase 1 trial of CA-170. In addition, in October 2015 we selected a third program for potential development under the collaboration, which represents the second preclinical program within the immuno-oncology field. This third program in the collaboration is focused on evaluating small molecule antagonists of PD1 and T-cell immunoglobulin and mucin domain containing protein-3, or TIM3, pathways, including small molecules that target PDL1 and TIM3.  In October 2016, we exercised our option to license this third program, and designated CA-327 as the development candidate. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our other collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">&#32;(vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor, in advanced basal cell carcinoma, or BCC. Roche and Genentech are also conducting clinical studies of Erivedge in idiopathic pulmonary fibrosis, or IPF, and myelofibrosis, or MF.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on our clinical development plans for our pipeline, in the near term we intend to predominantly focus our available resources on the continued development of CUDC-907, as well as CA-170, CA-4948 and CA-327 in collaboration with Aurigene.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s286E9AE4C580974096AA7789B75F3F7C"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Collaborations and License Agreements</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January&#160;18, 2015, we entered into a collaboration agreement with Aurigene for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology, which we refer to as the Aurigene agreement. In September 2016, we entered into an amendment to this agreement, pursuant to which Aurigene received </font><font style="font-family:inherit;font-size:10pt;">10,208,333</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock in lieu of receiving up to $24.5 million in milestone and other payments from Curis. There are currently three licensed programs under this collaboration as described under &#8220;Overview&#8221; above.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2003, we entered into a collaborative research, development and license agreement with Genentech, which we refer to as the collaboration agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For additional information regarding our collaboration and license agreements, refer to Note 4, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Agreements</font><font style="font-family:inherit;font-size:10pt;">, in the notes to the accompanying financial statements in this Quarterly Report on Form 10-Q and Items 7 and 8 of the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on </font><font style="font-family:inherit;font-size:10pt;">February&#160;29, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception, we have funded our operations primarily through private and public placement of our equity securities, license fees, contingent cash payments, research and development funding from our corporate collaborators, debt financings and the monetization of certain royalty rights. We have never been profitable on an annual basis, and have an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$887.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will need to generate significant revenues to achieve profitability, and do not expect to achieve profitability in the foreseeable future, if at all. We anticipate that existing capital resources as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;should enable us to maintain current and planned operations into the second half of 2017. Our ability to continue funding our planned operations into and beyond this point is dependent on our ability to raise additional funds through equity or debt financings, future contingent payments that we may receive from Genentech upon the achievement of development and regulatory approval objectives, through additional corporate collaborations that we may establish, or from other sources of financing.</font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Key Drivers</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that near-term key drivers to our success will include:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to successfully plan, finance and complete current and planned clinical trials for our lead proprietary drug candidate, CUDC-907, as well as for such clinical trials to generate favorable data;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to successfully advance CA-170, and for us to finance and complete the current and planned Phase 1 clinical trials of this drug candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our and Aurigene&#8217;s ability to complete preclinical development and IND-enabling studies for CA-4948 and CA-327, and for us to then finance and complete planned Phase 1 clinical trials for each of these development candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aurigene&#8217;s ability to advance additional preclinical immuno-oncology, and precision oncology drug candidates, and our ability to license these programs from Aurigene and further progress them clinically;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech and Roche&#8217;s ability to successfully commercialize Erivedge in advanced BCC in the United&#160;States and in other global territories; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech and Roche&#8217;s initiation and completion of additional clinical studies of Erivedge, including in diseases other than BCC, such as IPF or MF.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the longer term, a key driver to our success will be our ability, and the ability of any current or future collaborator or licensee, to successfully develop and commercialize additional product candidates.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6B2BF9BB610BE18764EB7789B771E30A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General.</font><font style="font-family:inherit;font-size:10pt;">&#32;Our future operating results will largely depend on the progress of drug candidates currently in our research and development pipeline. The results of our operations will vary significantly from year to year and quarter to quarter and depend on, among other factors, the cost and outcome of any preclinical development or clinical trials then being conducted. We anticipate that existing capital resources as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;should enable us to maintain current and planned operations into the second half of 2017.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A discussion of certain risks and uncertainties that could affect our liquidity, capital requirements and ability to raise additional funds is set forth under &#8220;Part II, Item&#160;1A&#8212;Risk Factors.&#8221;</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt.</font><font style="font-family:inherit;font-size:10pt;">&#32;In December 2012, our wholly owned subsidiary, Curis Royalty, entered into a $30.0 million debt transaction with BioPharma-II at an annual interest rate of 12.25% collateralized with certain future Erivedge royalty and royalty-related payment streams.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the loan, we transferred to Curis Royalty our right to receive certain royalty and royalty-related payments on the commercial sales of Erivedge that we receive from Genentech. The loan and accrued interest is being repaid by Curis Royalty using such royalty and royalty-related payments. To secure repayment of the loan, Curis Royalty granted a first priority lien and security interest (subject only to permitted liens) to BioPharma-II in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the royalty and royalty-related payments. The loan </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">constitutes an obligation of Curis Royalty, and is non-recourse to us. Under the terms of the loan, quarterly royalty payments received by Curis Royalty from Genentech will first be applied to pay (i)&#160;escrow fees payable by us pursuant to an escrow agreement between Curis, Curis Royalty, BioPharma-II and Boston Private Bank and Trust Company, (ii)&#160;our royalty obligations to university licensors, (iii)&#160;certain expenses incurred by BioPharma-II in connection with the credit agreement and related transaction documents, including enforcement of its rights in the case of an event of default under the credit agreement and (iv)&#160;expenses incurred by us enforcing our right to indemnification under the collaboration agreement with Genentech. Remaining amounts are applied first, to pay interest and second, principal on the loan. We remain entitled to receive any contingent payments upon achievement of clinical development objectives. Beginning in 2016, there are no quarterly caps to the amounts Curis Royalty will be required to make to BioPharma-II. Curis Royalty retains the right to royalty payments related to sales of Erivedge following repayment of the loan.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final maturity date of the loan will be the earlier of such date as the principal is paid in full, or Curis Royalty&#8217;s right to receive royalties under the collaboration agreement with Genentech terminates. At any time after January&#160;1, 2017, Curis Royalty may, subject to certain limitations, prepay the outstanding principal of the loan in whole or in part, at a price equal to 105% of the outstanding principal on the loan, plus accrued but unpaid interest. The obligations of Curis Royalty under the credit agreement to repay the loan may be accelerated upon the occurrence of an event of default as defined in the credit agreement. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the outstanding principal and interest due under the loan is $21.3 million.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue.</font><font style="font-family:inherit;font-size:10pt;">&#32;We do not expect to generate any revenues from our direct sale of products for several years, if ever. Substantially all of our revenues to date have been derived from license fees, research and development payments, and other amounts that we have received from our strategic collaborators and licensees, including royalty payments. Since the first quarter of 2012, we have recognized royalty revenues related to Genentech&#8217;s sales of Erivedge, and we expect to continue to recognize royalty revenue in future quarters from Genentech&#8217;s sales of Erivedge in the U.S. and Roche&#8217;s sales of Erivedge outside of the U.S. However, we expect that all of such royalty revenues will be used by our wholly owned subsidiary, Curis Royalty, to pay principal and interest under the loan that Curis Royalty received from BioPharma-II, until such time as the loan is fully repaid. We currently estimate that all Erivedge royalties will be applied to the loan with BioPharma-II for the foreseeable future. The repayment period is highly uncertain and could vary materially to the extent that royalty payments received are higher or lower than our current estimates, which could arise due to factors beyond our control, such as the sale of competing products that result in a lowering of the royalty rates we are entitled to receive, decreased market acceptance, a failure by Genentech and/or Roche to obtain required regulatory approvals, and other factors described under &#8220;Part II, Item&#160;1A&#8212;Risk Factors.&#8221;</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We could receive additional milestone payments from Genentech, provided that contractually-specified development and regulatory objectives are met. Our only source of revenues and/or cash flows from operations for the foreseeable future will be royalty payments that are contingent upon the continued commercialization of Erivedge under this collaboration, and contingent cash payments for the achievement of clinical, development and regulatory objectives, if any, are met, under our existing collaboration with Genentech. Our receipt of additional payments under our existing collaboration with Genentech cannot be assured, nor can we predict the timing of any such payments, as the case may be.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Royalty Revenues.</font><font style="font-family:inherit;font-size:10pt;">&#160;Cost of royalty revenues consists of all expenses incurred that are associated with royalty revenues that we record as revenues in our consolidated statements of operations and comprehensive loss. These costs currently consist of payments we are obligated to make to university licensors on royalties that Curis Royalty receives from Genentech on net sales of Erivedge. In all territories other than Australia, our obligation is equal to 5% of the royalty payments that we receive from Genentech for a period of 10 years from the first commercial sale of Erivedge, which occurred in February 2012. In addition, for royalties that Curis Royalty receives from Roche&#8217;s sales of Erivedge in Australia, we will be obligated to make payments to university licensors of 2% of Roche&#8217;s direct net sales in Australia until expiration of the patent in April 2019. After April 2019, the amount we are obligated to pay will decrease to 5% of the royalty payments that Curis Royalty receives from Genentech through February 2022.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development.</font><font style="font-family:inherit;font-size:10pt;">&#160;Research and development expense consists of costs incurred to develop our drug candidates. These expenses consist primarily of: salaries and related expenses for personnel, including stock-based compensation expense, costs of conducting clinical trials, including amounts paid to clinical centers, clinical research organizations and consultants, among others, other outside service costs including costs of contract manufacturing, sublicense payments, the costs of supplies and reagents, consulting, and occupancy and depreciation charges. Research and development expenses also include certain payments that we make to Aurigene under our January 2015 collaboration agreement and as amended in September 2016, including, for example, option exercise fees and milestone payments. We expense research and development costs as incurred. We are currently incurring research and development costs under our Hedgehog signaling pathway inhibitor collaboration with Genentech related to the maintenance of third-party licenses to certain background technologies. In addition, we record research and development expense for payments that we are obligated to make to certain third</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">-party university licensors upon our receipt of payments from Genentech related to the achievement of clinical development and regulatory objectives under our collaboration agreement.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following graphic outlines the current status of our programs:</font></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><img src="pipelineupdatedv2a01.jpg" alt="pipelineupdatedv2a01.jpg" style="height:434px;width:624px;"></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With the exception of Erivedge, which is approved for sale to treat advanced BCC and marketed by Genentech/Roche, our programs are in early stages of clinical or preclinical development. Therefore, our ability and that of our collaborators and licensees to successfully complete preclinical studies and clinical trials of these drug candidates, as appropriate, and the timing of completion of such programs, is highly uncertain.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are numerous other risks and uncertainties associated with developing drugs which may affect our and our collaborators&#8217; future results, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, quality of data, rate of progress and cost of clinical trials and other research and development activities undertaken by us or our collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of future preclinical studies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of regulatory approvals and maintaining compliance with regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of establishing sales, marketing and distribution capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of establishing clinical and commercial supplies of our drug candidates and any products that we may develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effect of competing technological and market developments; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and effectiveness of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot reasonably estimate or know the nature, timing and estimated costs of the efforts necessary to complete the development of, or the period in which, material net cash inflows are expected to commence from any of our drug candidates. Any failure to complete the development of our drug candidates in a timely manner could have a material adverse effect on our operations, financial position and liquidity.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative.</font><font style="font-family:inherit;font-size:10pt;">&#32;General and administrative expense consists primarily of salaries, stock-based compensation expense and other related costs for personnel in executive, finance, accounting, business development, legal, information technology, corporate communications and human resource functions. Other costs include facility costs not otherwise included </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in research and development expense, insurance, and professional fees for legal, patent and accounting services. Patent costs include certain patents covered under collaborations, a portion of which is reimbursed by collaborators and a portion of which is borne by us.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC575975C7B4D034E1E507789B7A0EF65"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States requires that we make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Such estimates and judgments include the performance obligations under our collaboration agreements; the estimated repayment term of our debt and related short- and long-term classification; the carrying value of property and equipment and intangible assets; the assumptions used in our valuation of stock-based compensation and the value of certain investments and liabilities. We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We set forth our critical accounting policies and estimates in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which was filed with the SEC on </font><font style="font-family:inherit;font-size:10pt;">February&#160;29, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s46A780E198E210EC504677899CF1619D"></a></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three Months Ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our results of operations for the&#160;three months ended&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Three Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs and expenses: </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of royalty revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,781</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,684</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,772</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">556</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,345</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">411</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues.</font><font style="font-family:inherit;font-size:10pt;">&#160;Total revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Three Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,045</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;by </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, related to a decrease in royalty revenues arising from Genentech and Roche&#8217;s net sales of Erivedge during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the prior year period.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Royalty Revenues.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cost of royalty revenues remained unchanged at </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. We are obligated to make payments to two university licensors on royalties that Curis Royalty earns from Genentech on net sales of Erivedge.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#160;The following table summarizes our research and development expenses incurred during the periods indicated:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Three Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage<br>Increase/<br>(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,970</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,378</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facilities, depreciation and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">433</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">467</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,001</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, as compared to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the same period in 2015, an </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">69%</font><font style="font-family:inherit;font-size:10pt;">. Direct research and development expenses </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in 2015, which was primarily the result of increased costs related to ongoing clinical activities for CUDC-907, including increased clinical site, patient, clinical research organization, formulation and manufacturing and consulting costs for our ongoing Phase 1 clinical trials, as well as initial costs for our Phase 2 trial, which was initiated in January 2016. Employee-related expenses </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in 2015, which was primarily due to additional headcount. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that a majority of our research and development expenses for the foreseeable future will be incurred in connection with our efforts to advance our programs, including clinical and preclinical development costs, option exercise fees, exclusivity option payments, and potential milestone payments upon achievement of certain milestones.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In-process Research and Development.&#160;</font><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we recognized in-process research and development expenses of </font><font style="font-family:inherit;font-size:10pt;">$18.0 million</font><font style="font-family:inherit;font-size:10pt;">, which represented the consideration we paid as part of our amendment to the collaboration agreement with Aurigene. No such expense was recorded for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;General and administrative expenses are summarized as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Three Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Personnel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Occupancy and depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional and consulting services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">574</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insurance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">439</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,425</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total general and administrative expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,772</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses were </font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, as compared to </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the same period in 2015, an </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">69%</font><font style="font-family:inherit;font-size:10pt;">. The increase in general administrative expense was driven primarily by higher personnel costs and stock-based compensation due to increased headcount and an increase in legal service costs related to our intellectual property.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Expense.</font><font style="font-family:inherit;font-size:10pt;">&#32;For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, interest expense was </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to interest accrued on Curis Royalty&#8217;s outstanding debt with BioPharma-II. Interest income was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nine Months Ended</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our results of operations for the&#160;</font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs and expenses: </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of royalty revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,658</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,348</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,285</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49,077</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,520</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues.</font><font style="font-family:inherit;font-size:10pt;">&#32;Total revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty revenues from Genentech</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,403</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(212</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,786</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;by </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the same period in </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, related to a decrease in royalty revenues arising from Genentech and Roche&#8217;s net sales of Erivedge during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the prior year period.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Royalty Revenues.&#160;</font><font style="font-family:inherit;font-size:10pt;">Cost of royalty revenues remained unchanged at </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. We are obligated to make payments to two university licensors on royalties that Curis Royalty earns from Genentech on net sales of Erivedge.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#160;The following table summarizes our research and development expenses incurred during the periods indicated:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage<br>Increase/<br>(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,658</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,379</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,714</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facilities, depreciation and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,342</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,286</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$22.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, as compared to </font><font style="font-family:inherit;font-size:10pt;">$14.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the same period in </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, an </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">53%</font><font style="font-family:inherit;font-size:10pt;">. Direct research and development expenses </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, which was primarily the result of increased costs related to ongoing clinical activities for CUDC-907, including increased clinical site, patient, clinical research organization, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">formulation and manufacturing and consulting costs for our ongoing Phase 1 clinical trials, as well as initial costs for our Phase 2 trial, which was initiated in January 2016. In addition, costs for programs under our Aurigene collaboration increased for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, which costs include a $3.0 million milestone payment to Aurigene upon the FDA acceptance of our CA-170 IND and outside costs to support such programs, including initial costs for our CA-170 Phase 1 trial, which was initiated in June 2016.&#160;In comparison, direct research and development expense for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;includes a $2.0 million milestone payment to Aurigene for selection of the third program under the collaboration. Employee-related expenses </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, which was primarily due to additional headcount, offset by a decrease in stock-based compensation of $0.2 million. Facilities, depreciation and other expenses have increased by </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;due to increased occupancy costs.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that a majority of our research and development expenses for the foreseeable future will be incurred in connection with our efforts to advance our programs, including clinical and preclinical development costs, option exercise fees, exclusivity option payments, and potential milestone payments upon achievement of certain milestones.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In-process Research and Development.&#160;</font><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we recognized in-process research and development expenses of </font><font style="font-family:inherit;font-size:10pt;">$18.0 million</font><font style="font-family:inherit;font-size:10pt;">, which represented the consideration we paid as part of our amendment to the collaboration agreement with Aurigene. For the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we recognized in-process research and development expenses of </font><font style="font-family:inherit;font-size:10pt;">$24.3 million</font><font style="font-family:inherit;font-size:10pt;">, which represented the partial consideration we paid for rights granted to us under the collaboration agreement with Aurigene. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;General and administrative expenses are summarized as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Personnel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Occupancy and depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal services</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional and consulting services</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,724</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,717</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Insurance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,780</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total general and administrative expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,712</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;by </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">, for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in the prior year. The increase in general administrative expense was driven primarily by higher personnel costs and stock-based compensation due to increased headcount and an increase in legal service costs related to our intellectual property.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Expense.</font><font style="font-family:inherit;font-size:10pt;">&#32;For the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, interest expense was </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to interest accrued on Curis Royalty&#8217;s outstanding debt with BioPharma-II. Interest income was </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s682FA1B2C86AB651682B7789B8EF74CB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have financed our operations primarily through private and public placement of our equity securities, license fees, contingent cash payments, research and development funding from our corporate collaborators, debt financings and the monetization of certain royalty rights.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Placement of Equity Securities</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July&#160;2, 2015, we entered into a sales agreement with Cowen and Company, LLC, or Cowen, pursuant to which we may sell from time to time up to $30.0 million of our common stock through an &#8220;at-the-market&#8221; equity offering program, under which Cowen will act as sales agent. Subject to the terms and conditions of the sales agreement, Cowen may sell the common stock by methods deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1933, as amended, including sales made directly on the NASDAQ Global Market, on any other existing trading market for the common stock, or to or through a market maker other than on an exchange. We are not obligated to sell any of the common stock under this sales agreement. Either Cowen or we may at any time suspend solicitations and offers under the sales agreement upon notice to the other party. The sales agreement may be terminated at any time by either party upon written notice to the other party, in the manner specified in the sales agreement. The aggregate compensation payable to Cowen will be 3% of the gross sales price of the common stock sold pursuant to the sales agreement. The shares to be sold under the sales agreement, if any, may be issued and sold pursuant to the currently effective universal shelf registration statement on Form S-3, filed with the Securities and Exchange Commission on July&#160;2, 2015. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we have not sold any shares of common stock pursuant to this sales agreement.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt Financing</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, our wholly owned subsidiary, Curis Royalty, received a $30.0 million loan, at an annual interest rate of 12.25%, pursuant to a credit agreement with BioPharma-II. In connection with the loan, we transferred to Curis Royalty our right to receive certain future royalty and royalty-related payments on the commercial sales of Erivedge that we may receive from Genentech. The loan and accrued interest is currently being repaid by Curis Royalty using such royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty, and is non-recourse to us. The final maturity date of the loan will be the earlier of such date that the principal is paid in full, or Curis Royalty&#8217;s right to receive royalties under the collaboration agreement with Genentech is terminated. Payments to BioPharma-II for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;totaled $5.3 million, of which $3.2 million has been applied to the principal, and the remainder satisfying interest obligations. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Curis Royalty owed a total of $21.3 million, gross of issuance costs, to BioPharma-II, including accrued interest.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments and Monetization of Royalty Rights</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have received aggregate milestone payments totaling $59.0 million under our collaboration with Genentech. In addition, we began receiving royalty revenues in 2012 in connection with Genentech&#8217;s sales of Erivedge in the U.S. and Roche&#8217;s sales of Erivedge outside of the U.S. Erivedge royalty revenues received after December 2012 have been used to repay Curis Royalty&#8217;s outstanding principal and interest under the loan due to BioPharma-II, subject to specified quarterly caps. Erivedge royalty revenues will continue to be used to repay Curis Royalty&#8217;s outstanding principal and interest under the loan due to BioPharma-II. We also remain entitled to receive any contingent payments upon achievement of clinical development objectives and royalty payments related to sales of Erivedge following repayment of the loan. Upon receipt of any such payments, as well as on royalties received in any territory other than Australia, we are required to make payments to certain university licensors totaling 5% of these amounts. In addition, for royalties that Curis Royalty receives from Roche&#8217;s sales of Erivedge in Australia, we are obligated to make payments to university licensors of 2% of Roche&#8217;s direct net sales in Australia until the expiration of the patent in April 2019. After April 2019, the amount we are obligated to pay will decrease to 5% of the royalty payments that Curis Royalty receives from Genentech through February 2022.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, our principal sources of liquidity consisted of cash, cash equivalents, and investments of </font><font style="font-family:inherit;font-size:10pt;">$53.4 million</font><font style="font-family:inherit;font-size:10pt;">, excluding our restricted cash of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. Our cash and cash equivalents are highly liquid investments with a maturity of three months or less at date of purchase, and consist of investments in money market funds with commercial banks and financial institutions, as well as short-term commercial paper and government obligations. We maintain cash balances with financial institutions in excess of insured limits.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash flows for operations have primarily been used for salaries and wages for our employees, facility and facility-related costs for our office and laboratory, fees paid in connection with preclinical and clinical studies, laboratory supplies, consulting fees and legal fees. We expect that costs associated with clinical studies will increase in future periods.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities of </font><font style="font-family:inherit;font-size:10pt;">$26.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily the result of our net loss for the period of </font><font style="font-family:inherit;font-size:10pt;">$49.1 million</font><font style="font-family:inherit;font-size:10pt;">, offset by non-cash charges consisting of the stock issuance to Aurigene as consideration for the amendment to our collaboration agreement with Aurigene, stock-based compensation, non-cash interest expense, amortization of debt issuance costs and depreciation, totaling </font><font style="font-family:inherit;font-size:10pt;">$21.6 million</font><font style="font-family:inherit;font-size:10pt;">. In addition, accounts payable and accrued liabilities increased </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, accounts receivable decreased </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and prepaid assets increased </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to deposits made with vendors.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities of </font><font style="font-family:inherit;font-size:10pt;">$19.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily the result of our net loss for the period of </font><font style="font-family:inherit;font-size:10pt;">$45.5 million</font><font style="font-family:inherit;font-size:10pt;">, offset by non-cash charges consisting of the stock issuance to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aurigene as partial consideration for the collaboration agreement with Aurigene, stock-based compensation, changes in the fair value of our warrant liability, non-cash interest expense and depreciation, totaling </font><font style="font-family:inherit;font-size:10pt;">$27.1 million</font><font style="font-family:inherit;font-size:10pt;">. In addition, accounts receivable increased </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to an increase in Erivedge royalties and prepaid assets increased </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to deposits made with vendors.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to continue to use cash in operations as we seek to advance our drug candidates and at least three programs under our collaboration agreement with Aurigene. In addition, in the future we may owe royalties and other contingent payments to our licensors based on the achievement of developmental milestones, product sales and other specified objectives.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities provided cash of </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and accounted for cash expenditures of </font><font style="font-family:inherit;font-size:10pt;">$22.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, resulting primarily from net investment activity from purchases and maturities of investments for the respective periods. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities used cash of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as a result of principal payments on Curis Royalty&#8217;s loan with BioPharma-II of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, offset by </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in proceeds from the exercise of stock options. Financing activities provided cash of </font><font style="font-family:inherit;font-size:10pt;">$62.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we received </font><font style="font-family:inherit;font-size:10pt;">$64.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds from our underwritten public offering of common stock and proceeds of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from the exercise of stock options. These proceeds were offset by the principal payment on Curis Royalty&#8217;s loan with BioPharma-II of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Funding Requirements</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred significant losses since our inception. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$887.6 million</font><font style="font-family:inherit;font-size:10pt;">. We will require substantial funds to continue our research and development programs and to fulfill our planned operating goals. In particular, our currently planned operating and capital requirements include the need for working capital to support our research and development activities for CUDC-907, CA-170 and other programs under our collaboration with Aurigene, and to fund our general and administrative costs and expenses.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, we announced the FDA acceptance of the IND for CA-170, upon which we paid a $3.0 million milestone payment to Aurigene. In September 2016, we entered into an amendment to our license agreement with Aurigene, pursuant to which Aurigene received </font><font style="font-family:inherit;font-size:10pt;">10,208,333</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock in lieu of receiving up to $24.5 million of milestones and other payments from Curis. In October 2016, we exercised our option related to the third program, upon which we paid a $1.5 million payment to Aurigene. In addition, subject to specified exceptions, we and Aurigene have agreed to collaborate exclusively with each other on the discovery, research, development and commercialization of programs and compounds within immuno-oncology for an initial period of approximately two years from the effective date of the collaboration agreement. At our option, and subject to specified conditions, we may extend such exclusivity for up to three additional one-year periods by paying exclusivity option fees on an annual basis. The first of such option fees will be $7.5 million, to be paid in two equal installments, we currently estimate that these payments will be due in the first and third quarters of 2017. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have historically derived a portion of our operating cash flow from our receipt of milestone payments under collaboration agreements with third parties. However, we cannot predict whether we will receive additional milestone payments under existing or future collaborations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To become and remain profitable, we, either alone or with collaborators, must develop and eventually commercialize one or more drug candidates with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our drug candidates, obtaining marketing approval for these drug candidates, manufacturing, marketing and selling those drugs for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. Other than Erivedge, which is being commercialized by Genentech and Roche, our most advanced drug candidates are currently only in early clinical testing.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the foreseeable future, we will need to spend significant capital in an effort to develop and commercialize products and we expect to incur substantial operating losses. Our failure to become and remain profitable would, among other things, depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our research and development programs or continue our operations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that existing cash, cash equivalents, marketable securities, investments and working capital at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;should enable us to maintain current and planned operations into the second half of 2017. Our future capital requirements, however, may vary from what we currently expect. There are a number of factors that may adversely </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">affect our planned future capital requirements and accelerate our need for additional financing, many of which are outside our control, including the following:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated costs in our research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and cost of obtaining regulatory approvals for our drug candidates and maintaining compliance with regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and amount of option exercise fees, milestone payments, royalties and other payments due to licensors, including Aurigene, for patent rights and technology used in our drug development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of commercialization activities for any of our product candidates that receive marketing approval, to the extent such costs are our responsibility, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unplanned costs to prepare, file, prosecute, defend and enforce patent claims and other patent-related costs, including litigation costs and technology license fees; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unexpected losses in our cash investments or an inability to otherwise liquidate our cash investments due to unfavorable conditions in the capital markets.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek additional funding through public or private financings of debt or equity. The market for emerging life science stocks in general, and the market for our common stock in particular, is highly volatile. Due to this and various other factors, including potentially adverse general market conditions and the early-stage development status of a majority of our drug candidates and the early stage of the commercial U.S. launch of Erivedge, additional funding may not be available to us on acceptable terms, if at all. In addition, the terms of any potential financing may be dilutive or otherwise adversely affect other rights of our stockholders.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also seek additional funds through arrangements with collaborators, licensees or other third parties. These arrangements would generally require us to relinquish or encumber rights to some of our technologies or drug candidates, and we may not be able to enter into such arrangements on acceptable terms, if at all.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we will require additional funding. If we are unable to obtain such additional funding on a timely basis, whether through sales of debt or equity or payments under existing or future collaborations or license agreement, we may be required to:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our drug candidates; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay, limit, reduce or prevent us from establishing sales and marketing capabilities, either internally or through third parties, or other activities that may be necessary to commercialize our drug candidates.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s08D55B25CCFD7AB22C737789B924D3B4"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For detailed information regarding&#160;recently issued accounting pronouncements&#160;and the expected impact on our condensed consolidated financial statements, see Note 13, &#8220;New Accounting Pronouncements,&#8221; in the accompanying Notes to Condensed Consolidated Financial Statements included in Item 1. of Part I of this Form 10-Q.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDE358F8A5990753EB4A57789B940DFFE"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no off-balance sheet arrangements as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="s63C71B99782FE3318E8E7789B95CC234"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current cash balances in excess of operating requirements are invested in cash equivalents, short-term marketable securities, which consist of time deposits and investments in money market funds with commercial banks and financial institutions, short-term commercial paper, and government obligations with an average maturity of less than one year. All marketable securities are considered available-for-sale. The primary objective of our cash investment activities is to preserve principal while at the same time maximizing the income we receive from our invested cash without significantly increasing risk of loss. This objective may be adversely affected by the volatile business environment and continued unpredictable and unstable market conditions.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our marketable securities and long-term investments are subject to interest rate risk and will fall in value if market interest rates increase. While as of the date of this filing, we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents, marketable securities since </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, no assurance can be given that further deterioration in conditions of the global credit and financial markets would not negatively impact our current portfolio of cash equivalents or marketable securities or our ability to meet our financing objectives. Further dislocations in the credit market may adversely impact the value and/or liquidity of marketable securities and long-term investments owned by us. To help manage this risk, we limit our investments to investment grade securities and deposits are with investment grade financial institutions. We believe that the realization of losses due to changes in credit spreads is unlikely as we currently have the ability to hold our investments for a sufficient period of time to recover the fair value of the investment and there is sufficient evidence to indicate that the fair value of the investment is recoverable. We do not use derivative financial instruments in our investment portfolio. We do not believe that a 10% change in interest rate percentages would have a material impact on the fair value of our investment portfolio or our interest income.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s87AC8F681284172CF43B7789B9CA6ED9"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTROLS AND PROCEDURES</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Evaluation of Disclosure Controls&#160;&amp; Procedures</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act&#8221;) means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</font></div><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s57DC8E938FDBFE3D09BB7789B9E6036D"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II&#8212;OTHER INFORMATION</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div><a name="s557CBBD7A46988DAE9987789B9FC508C"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You should carefully consider the following risk factors, in addition to other information included in this quarterly report on Form 10-Q and in other documents we file with the SEC, in evaluating Curis and our business. If any of the following risks occur, our business, financial condition and operating results could be materially adversely affected. The following risk factors restate and supersede the risk factors previously disclosed in &#8220;Part I, Item&#160;1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATING TO OUR FINANCIAL RESULTS AND NEED FOR FINANCING</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have incurred substantial losses, expect to continue to incur substantial losses for the foreseeable future and may never generate significant revenue or achieve profitability.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred significant annual net operating losses in every year since our inception. We expect to continue to incur significant and increasing net operating losses for at least the next several years. Our net losses were </font><font style="font-family:inherit;font-size:10pt;">$49.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and $59.0&#160;million, $18.7 million and $12.3&#160;million for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$887.6 million</font><font style="font-family:inherit;font-size:10pt;">. We have not completed the development of any product candidate on our own. Other than Erivedge</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">, which is being commercialized and further developed by Genentech and Roche under our June 2003 collaboration with Genentech, we may never have a product candidate approved for commercialization. We have financed our operations to date primarily through public offerings and private placements of our common stock and amounts received through various current and past licensing and collaboration agreements. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expense to support such research and development. Our net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; (deficit) equity and working capital.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that our expenses will increase substantially if and as we:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to develop and conduct clinical trials with respect to our lead product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seek to identify and develop additional product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">acquire or in-license other product candidates or technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which we may obtain marketing approval, if any;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintain, expand and protect our intellectual property portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">hire and retain additional personnel, such as clinical, quality control and scientific personnel; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">add equipment and physical infrastructure as may be required to support our research and development programs.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to become and remain profitable depends on our ability to generate significant revenue. Our only source of revenues currently includes licensing and royalty revenues that we earn under our collaboration with Genentech related to the development and commercialization of Erivedge. In addition, all future royalty payments related to Erivedge will service the outstanding debt and accrued interest owed by Curis Royalty to BioPharma-II until the debt is fully repaid. The final maturity date of the loan will be the earlier of such date that the principal is paid in full, or Curis Royalty&#8217;s right to receive royalties under the collaboration agreement with Genentech is terminated.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not expect to generate significant revenues other than those related to Erivedge unless and until we are, or any collaborator is, able to obtain marketing approval for, and successfully commercialize, one or more of our product candidates other than Erivedge. Successful commercialization will require achievement of key milestones, including initiating and successfully completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our collaborators, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of revenues and if or when we might achieve profitability. We and any collaborators may never succeed </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in these activities and, even if we do, or any collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our pipeline of product candidates or continue our operations and cause a decline in the value of our common stock.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We will require substantial additional capital, which may be difficult to obtain, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will require substantial funds to continue our research and development programs and to fulfill our planned operating goals. In particular, our operating and capital requirements currently include the need to support our research and development activities for CUDC-907 and CA-170, as well as development candidates we have and may continue to license under our collaboration with Aurigene. We expect that we will require substantial additional capital to fund the further development of these programs, as well as to fund our general and administrative costs and expenses. Moreover, under the collaboration, license and option agreement with Aurigene, we are required to make milestone, royalty and option fee payments for discovery, research and preclinical development programs that will be performed by Aurigene, which impose significant potential financial obligations on us. The collaboration provides for inclusion of multiple programs, and we have the option to exclusively license compounds once a development candidate is nominated within each respective program.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our development activity-related expenses to substantially increase in connection with CUDC-907, CA-170 and other Aurigene programs. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that existing cash, cash equivalents, marketable securities, investments and working capital at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;should enable us to maintain current and planned operations into the second half of 2017. Our future capital requirements, however, may vary from what we currently expect. There are a number of factors that may affect our planned future capital requirements and accelerate our need for additional working capital, many of which are outside our control, including the following:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated costs in our research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and cost of obtaining regulatory approvals for our drug candidates and maintaining compliance with regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and amount of option exercise fees, milestone payments, royalties and other payments due to licensors, including Aurigene, for patent rights and technology used in our drug development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs of commercialization activities for any of our product candidates that receive marketing approval, to the extent such costs are our responsibility, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unplanned costs to prepare, file, prosecute, defend and enforce patent claims and other patent-related costs, including litigation costs and technology license fees; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unexpected losses in our cash investments or an inability to otherwise liquidate our cash investments due to unfavorable conditions in the capital markets.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek additional funding through public or private financings of debt or equity. The market for emerging life science stocks in general, and the market for our common stock in particular, are highly volatile. Due to this and various other factors, including potentially adverse general market conditions and the early-stage development status of a majority of our drug candidates and the early stage of the commercial U.S. launch of Erivedge, additional funding may not be available to us on acceptable terms, if at all. In addition, the terms of any potential financing may be dilutive or otherwise adversely affect other rights of our stockholders.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also seek additional funds through arrangements with collaborators, licensees or other third parties. These arrangements would generally require us to relinquish or encumber rights to some of our technologies or drug candidates, and we may not be able to enter into such arrangements on acceptable terms, if at all.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate that we will require additional funding. If we are unable to obtain such additional funding on a timely basis, whether through payments under existing or future collaborations or license agreement or sales of debt or equity, we may be required to:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our drug candidates; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay, limit, reduce or prevent us from establishing sales and marketing capabilities, either internally or through third parties, or other activities that may be necessary to commercialize our drug candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We transferred and encumbered certain royalty and royalty-related payments on the commercial sales of Erivedge in connection with our credit agreement with BioPharma-II and, as a result, we could lose all rights to future royalty and royalty-related payments.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, our wholly owned subsidiary, Curis Royalty, received a $30.0 million loan pursuant to a credit agreement with BioPharma-II. In connection with the loan, we transferred to Curis Royalty our right to receive certain future royalty and royalty-related payments on the commercial sales of Erivedge that we receive from Genentech. The loan and accrued interest will be repaid by Curis Royalty using such royalty and royalty-related payments. To secure repayment of the loan, Curis Royalty granted a first priority lien and security interest (subject only to permitted liens) to BioPharma-II in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty, and is non-recourse to Curis.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the credit agreement, neither Curis nor Curis Royalty guaranteed any level of future royalty or royalty-related payments or the value of such payments as collateral to the loan. However, in certain circumstances, the obligations of Curis Royalty to repay the loan may be accelerated under the credit agreement, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if any payment of principal is not made within three days of when such payment is due and payable or otherwise made in accordance with the terms of the credit agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if any representations or warranties made in the credit agreement or any other related transaction document prove to be incorrect or misleading in any material respect when made;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if there occurs a default in the performance of affirmative and negative covenants set forth in the credit agreement or under certain ancillary transaction documents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the failure by Genentech to pay material amounts owed under the collaboration agreement with Genentech because of an actual breach or default by Curis under the collaboration agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a material breach or default by Curis Royalty under certain ancillary transaction documents, in each case, which breach or default is not cured within 30 days after written demand thereof by BioPharma-II;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the voluntary or involuntary commencement of bankruptcy proceedings by either Curis or Curis Royalty and other insolvency-related defaults;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any materially adverse effect on the binding nature of any of the transaction documents or the Genentech collaboration agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if any person shall be designated an independent director of Curis Royalty other than in accordance with its limited liability company operating agreement; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if Curis shall at any time cease to own, of record and beneficially, 100% of the equity interests in Curis Royalty.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of the above were to occur, Curis Royalty may not have sufficient funds to pay the accelerated obligation and BioPharma-II could foreclose on the secured royalty and royalty-related payment stream. In such an event, we could lose our right to royalty and royalty-related payments not transferred to BioPharma-II, including those we would otherwise be entitled to receive if, or when, Curis Royalty satisfied its obligations to BioPharma-II under the credit agreement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The amount of royalty revenue we receive from sales of Erivedge may be adversely affected by sales of a competing drug.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of our collaboration agreement, our subsidiary Curis Royalty entitled to receive royalties on net sales of Erivedge that range from 5% to 7.5% based upon global Erivedge sales by Roche and Genentech. The royalty rate applicable to Erivedge may be decreased in certain specified circumstances, including when a competing product that binds to the same molecular target as Erivedge is approved by the applicable country&#8217;s regulatory authority and is being sold in such country by a third party for use in the same indication as Erivedge or when there is no issued intellectual property covering Erivedge in a territory in which sales are recorded. During the third quarter of 2015, the FDA and CHMP approved an </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional Hedgehog signaling pathway inhibitor marketed by Novartis, sonidegib, for the treatment of adults with locally advanced BCC.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech has advised us that Novartis recorded sales of sonidegib (Odomzo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) in the U.S. during the fourth quarter of 2015 and, accordingly, Genentech began reducing royalties on its net sales in the U.S. of Erivedge during the fourth quarter of 2015 from 5 &#8211; 7.5% to 3 &#8211; 5.5%. We also anticipate that sales of sonidegib could adversely affect sales of Erivedge, including those in the U.S. and ex-U.S. countries, and the resulting revenue we may receive from Genentech. A decrease in sales of Erivedge, or in the royalty rate that we receive for sales of Erivedge could adversely affect our operating results and the ability of our wholly owned subsidiary, Curis Royalty, to satisfy its royalty-secured loan obligation to BioPharma II.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fluctuations in our quarterly and annual operating results could adversely affect the price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our quarterly and annual operating results may fluctuate significantly. Some of the factors that may cause our operating results to fluctuate on a period-to-period basis include:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">payments we may be required to make to collaborators such as Aurigene to exercise license rights and satisfy milestones and royalty obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the status of, and level of expenses incurred in connection with, our programs, including development costs relating to CUDC-907 and CA-170, as well as funding programs that we have and may continue to license and develop under our collaboration with Aurigene;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fluctuations in sales of Erivedge and related royalty payments, including those resulting from the sales of competing products such as Hedgehog signaling pathway inhibitor sonidegib, which is approved in the U.S. and Europe for the treatment of locally advanced BCC and is marketed and sold by Novartis in the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any intellectual property infringement lawsuit or other litigation in which we may become involved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the implementation of restructuring and cost-savings strategies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the occurrence of an event of default under the credit agreement by and among Curis, Curis Royalty and BioPharma-II;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, and non-recurring revenue or expenses under any such agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with regulatory requirements.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If the estimates we make and the assumptions on which we rely in preparing our financial statements prove inaccurate, our actual results may vary significantly.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial statements have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges taken by us, and disclosures related thereto. Such estimates and judgments include the carrying value of our property, the value of equipment and intangible assets, revenue recognition, and the value of certain liabilities, the repayment term of our loan with BioPharma-II, and stock-based compensation expense. We base our estimates and judgments on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. However, these estimates and judgments, and their underlying assumptions, may change over time. Accordingly, our actual financial results may vary significantly from the estimates contained in our financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a further discussion of the estimates and judgments that we make and the critical accounting policies that affect these estimates and judgments, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates&#8221; set forth in this report.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATING TO THE DEVELOPMENT AND COMMERCIALIZATION OF OUR PRODUCTS</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Except for Erivedge, the therapeutic efficacy of our drug candidates is unproven in humans, and we may not be able to successfully develop and commercialize drug candidates pursuant to these programs.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our drug candidates are novel chemical entities and, except for Erivedge, which is approved and being commercialized for advanced BCC in several territories, their potential benefit as therapeutic cancer drugs is unproven. Our ability to generate revenues from these drug candidates, which we do not expect will occur in the short term, if ever, will depend heavily on their successful development and commercialization, which is subject to many potential risks. For example, our drug candidates may not prove to be effective inhibitors of the molecular targets they are being designed to act against, and may not demonstrate in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients any or all of the pharmacological benefits that may have been demonstrated in preclinical studies. These drug candidates may interact with human biological systems in unforeseen, ineffective or harmful ways. If the FDA determines that any of our drug candidates are associated with significant side effects or have characteristics that are unexpected, we may need to delay or abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in connection with our collaboration with Aurigene, we are seeking to discover, develop and commercialize small molecule antagonists for immuno-oncology targets such as immune checkpoint proteins and precision oncology targets, and such efforts may not prove to be successful. As such, outside of our collaboration with Aurigene, we are not aware of any small molecules that target the same immune checkpoint protein interactions in late preclinical or clinical development and we may never be able to successfully develop such drug candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, many drug candidates that initially showed promise in early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound or resulted in their removal from the market. As a result of these and other risks described herein that are inherent in the development and commercialization of novel therapeutic agents, we may never successfully develop, enter into or maintain third party licensing or collaboration transactions with respect to, or successfully commercialize, drug candidates, in which case we will not achieve profitability and the value of our stock may decline.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We depend heavily on the success of our most advanced product candidates. Other than Erivedge, all of our product candidates are still in early clinical or preclinical development. Preclinical studies and clinical trials of our product candidates may not be successful. If we are unable to commercialize our product candidates other than Erivedge or experience significant delays in doing so, our business will be materially harmed.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have invested a significant portion of our efforts and financial resources on our most advanced product candidate, CUDC-907. In addition, under our agreement with Aurigene, we have the option to license specified programs from Aurigene, and in October 2015, we exercised options to exclusively license two programs under this agreement, and in October 2016 we exercised our option to exclusively license a third program, which is focused on evaluating small molecule antagonists of PD1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3) pathways, including small molecules that target PDL1 and TIM3. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on many factors, including the following:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">successful enrollment in, and completion of, ongoing and future clinical trials of CUDC-907 and CA-170 as well as potential compounds that we may develop under our collaboration agreement with Aurigene;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aurigene&#8217;s ability to successfully discover and preclinically develop other drug candidates under the parties&#8217; collaboration agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a safety, tolerability and efficacy profile that is satisfactory to FDA or any comparable foreign regulatory authority for marketing approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">receipt of marketing approvals from applicable regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent of any required post marketing approval commitments to applicable regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establishment of supply arrangements with third party raw materials suppliers and manufacturers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establishment of arrangements with third party manufacturers to obtain finished drug product that is appropriately packaged for sale;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adequate ongoing availability of raw materials and drug product for clinical development and any commercial sales;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and internationally;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">protection of our rights in our intellectual property portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">successful launch of commercial sales following any marketing approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a continued acceptable safety profile following any marketing approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">commercial acceptance by patients, the medical community and third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to compete with other therapies.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully market, commercialize, or distribute our most advanced product candidate, which would materially harm our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If clinical trials of any future product candidates that we, or any collaborators, may develop fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we, or any collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We, and any collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the European Medicines Agency, or the EMA, impose similar requirements. We, and any collaborators, must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of product development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of or intolerability caused by our product candidates, or we may mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us, or any collaborators, and impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. Moreover, if we, or any collaborators, are required to conduct additional clinical trials or other testing of our product candidates beyond the trials and testing that we or they contemplate, if we, or they, are unable to successfully complete clinical trials of our product candidates or other testing, or the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or there are unacceptable safety concerns associated with our product candidates, we, or any future collaborators, may:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incur additional unplanned costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be delayed in obtaining marketing approval for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not obtain marketing approval at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be subject to additional post-marketing testing or other requirements; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be required to remove the product from the market after obtaining marketing approval.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our failure to successfully initiate and complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adverse events or undesirable side effects caused by, or other unexpected properties of, product candidates that we develop may be identified during development and could delay or prevent their marketing approval or limit their use.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adverse events or undesirable side effects caused by, or other unexpected properties of, any product candidates that we may develop could cause us, any collaborators, an institutional review board or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we, or any collaborators, may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in clinical or earlier stage testing have later been found to cause undesirable or unexpected side effects that prevented further development of the compound.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we, or any collaborators, experience any of a number of possible unforeseen events in connection with clinical trials of our product candidates, potential clinical development, marketing approval or commercialization of our product candidates could be delayed or prevented.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We, or any collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent clinical development, marketing approval or commercialization of our current product candidates or any future product candidates that we, or any collaborators, may develop, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulators or institutional review boards may not authorize us, any collaborators or our or their investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, or any collaborators, may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical trials of our product candidates may produce unfavorable or inconclusive results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, or any collaborators, may decide, or regulators may require us or them, to conduct additional clinical trials or abandon product development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number of patients required for clinical trials of our product candidates may be larger than we, or any collaborators, anticipate, patient enrollment in these clinical trials may be slower than we, or any collaborators, anticipate or participants may drop out of these clinical trials at a higher rate than we, or any collaborators, anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our estimates of the patient populations available for study may be higher than actual patient numbers and result in our inability to sufficiently enroll our trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of planned clinical trials of our product candidates may be greater than we anticipate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our third-party contractors or those of any collaborators, including those manufacturing our product candidates or components or ingredients thereof or conducting clinical trials on our behalf or on behalf of any collaborators, may fail to comply with regulatory requirements or meet their contractual obligations to us or any collaborators in a timely manner or at all;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients that enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the clinical trial, increase the needed enrollment size for the clinical trial or extend the clinical trial&#8217;s duration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, or any collaborators, may have to delay, suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulators or institutional review boards may require that we, or any collaborators, or our or their investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their standards of conduct, a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable effects caused by a chemically or mechanistically similar product or product candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our, or any collaborators&#8217;, clinical trial designs or our or their interpretation of data from preclinical studies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we, or any collaborators, enter into agreements for clinical and commercial supplies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the supply or quality of raw materials or manufactured product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient to obtain marketing approval.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product development costs for us, or any collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or they, may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured, or will be completed on schedule or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we, or any collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any collaborators, to bring products to market before we, or any collaborators, do and impair our ability, or the ability of any collaborators, to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that lead to clinical trial delays may ultimately lead to the denial of marketing approval of any of our product candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we experience delays in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. Patient enrollment is a significant factor in the timing of clinical trials, and is affected by many factors, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the size and nature of the patient population;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the severity of the disease under investigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of approved therapeutics for the relevant disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the proximity of patients to clinical sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the eligibility criteria and design for the trial; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, many of our competitors have ongoing clinical trials for drug candidates that could be competitive with our drug candidates. Patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; drug candidates or rely upon treatment with existing therapies that may preclude them from eligibility for our clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enrollment delays in our clinical trials, including for the additional clinical trials of CUDC-907 and CA-170, may result in increased development costs for our drug candidates, which could cause the value of our stock price to decline.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of preclinical studies and early clinical trials may not be predictive of results of future late stage clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot assure you that we will be able to replicate in human clinical trials the results we observed in animal models. Moreover, the outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for our current product candidate or any future product candidates that we, or any future collaborators, may develop.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any new drug applications, or NDAs, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA does not accept or approve our NDAs for any of our product candidates, it may require that we conduct additional clinical trials, preclinical studies or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required trials or studies, approval of any NDA or application that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional trials or studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs. Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product candidates or any companion diagnostics, generating revenues and achieving and sustaining profitability. If any of these outcomes occurs, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Even if any product candidates that we, or any collaborators, may develop receive marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of any collaborators, to market the product.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials of any product candidates we may develop will be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may withdraw their approval of the product or seize the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, or any future collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, or any future collaborators, could be sued and held liable for harm caused to patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the product may become less competitive; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these events could harm our business and operations, and could negatively impact our stock price.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Even if our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never commercialized a product, and even if one of our product candidates is approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the efficacy and safety of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential advantages of the product compared to competitive therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prevalence and severity of any side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the product&#8217;s convenience and ease of administration compared to alternative treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the willingness of the target patient population to try, and of physicians to prescribe, the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations or warnings, including distribution or use restrictions, contained in the product&#8217;s approved labeling;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the strength of sales, marketing and distribution support;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the standard of care for the targeted indications for the product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability and amount of coverage and reimbursement from government payors, managed care plans and other third-party payors.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we have limited financial and managerial resources, we focus on research programs and drug candidates that we believe may have the best potential in certain specific indications. As a result, we may delay or forego pursuit of certain opportunities with our other drug candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future proprietary research and development programs and drug candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have no sales, marketing, or distribution experience and, as such, plan to rely primarily on third parties who may not successfully market or sell any products we develop.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no sales, marketing, or product distribution experience or capabilities. If we receive required regulatory approvals to commercialize any of our drug candidates, we plan to rely primarily on sales, marketing and distribution arrangements with third parties, including our collaborative partners. For example, as part of our agreements with Genentech, we have granted Genentech the exclusive rights to distribute certain products resulting from such collaboration, and Genentech is currently commercializing Erivedge. We may have to enter into additional marketing and/or sales arrangements in the future and we may not be able to enter into these additional arrangements on terms that are favorable to us, if at all. In addition, we may have limited or no control over the sales, marketing, and distribution activities of these third parties, and sales through these third parties could be less profitable for us than direct sales. These third parties could sell competing products and may devote insufficient sales efforts or resources to our products. Our future revenues will be materially dependent upon the successful efforts of these third parties.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek to independently market and sell products that are not already subject to agreements with other parties. If we undertake to perform sales, marketing and distribution functions ourselves, we could face a number of additional risks, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be able to attract and build a significant and skilled marketing staff or sales force;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of establishing a marketing staff or sales force may not be justifiable in light of the revenues generated by any particular product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our direct sales and marketing efforts may not be successful.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We face substantial competition, and our competitors may discover, develop or commercialize products before or more successfully than we do.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our drug candidates face competition from existing and new technologies and products being developed by biotechnology, medical device, and pharmaceutical companies, as well as universities and other research institutions. For example, we are aware of several biotechnology and pharmaceutical companies that have drug development programs relating to compounds that modulate the Hedgehog signaling pathway. We believe that there are currently at least four other companies that have progressed Hedgehog signaling pathway inhibitors into clinical development: Eli Lilly and Company, Exelixis, Inc. in co-development with the Bristol-Myers Squibb Company, and Pfizer Inc, or Pfizer.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the third quarter of 2015, the FDA and CHMP approved another Hedgehog signaling pathway inhibitor, called sonidegib and marketed by Novartis, for the treatment of adults with locally advanced BCC. Under the terms of our collaboration agreement with Genentech, our royalty would be reduced in any country where another drug that binds to the same molecular target receives regulatory approval for the same indication as Erivedge and is subsequently commercialized in that country. As Novartis recorded sales of sonidegib in the U.S. during the fourth quarter of 2015, Genentech began reducing royalties on its net sales in the U.S. of Erivedge accordingly.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, there are several companies developing drug candidates that target the same molecular targets that we are targeting or that are testing drug candidates in the same cancer indications that we are testing. For example, while we are not aware of other molecules in clinical testing that are designed as one chemical entity to target both PI3K and HDAC, there are commercially-available drugs that individually target PI3K or HDAC and there are multiple companies testing PI3K or HDAC inhibitors that are in various stages of clinical development.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, we exercised options to license the first two programs under our collaboration with Aurigene. The first licensed program is focused on the development of orally-available small molecule antagonists of PD1 and VISTA pathways in the immuno-oncology field. The second licensed program is focused on orally-available small molecule inhibitors of IRAK4 in the precision oncology field. We are aware of at least three other companies that are developing IRAK4 inhibitors: Pfizer, Nimbus Discovery in collaboration with Genentech, and TG Therapeutics (in-licensed an IRAK4 inhibitor from Ligand Pharmaceuticals). In addition, there are three approved drugs on the market that target PD1/PDL1 interactions (Bristol-Myers Squibb&#8217;s Opdivo</font><font style="font-family:inherit;font-size:9pt;">&#8482;,</font><font style="font-family:inherit;font-size:10pt;">&#32;Merck&#160;&amp; Co.&#8217;s Keytruda</font><font style="font-family:inherit;font-size:9pt;">&#8482; and </font><font style="font-family:inherit;font-size:10pt;">Roche&#8217;s Tecentriq</font><font style="font-family:inherit;font-size:9pt;">&#8482;</font><font style="font-family:inherit;font-size:10pt;">) and a number of drug candidates in various stages of development that target the similar interactions such as Merck KGaA / Pfizer&#8217;s avelumab, AstraZeneca/MedImmune&#8217;s MEDI4736 and MEDI0680, and others. Additionally, in October 2016, we exercised our option to license the third program under our collaboration with Aurigene, that is focused on the development of orally-available small molecule antagonists of PD1 and TIM3 pathways, including small molecules that target PDL1 within immuno-oncology. We are aware of at least two TIM3 targeting antibodies that are being investigated in clinical trials currently (Novartis&#8217;s MBG453 and Tesaro&#8217;s TSR-022) and there are several others in various stages of preclinical development.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our competitors have substantially greater capital resources, research and development staffs and facilities, and more extensive experience than we have. As a result, efforts by other biotechnology, medical device and pharmaceutical companies could render our programs or products uneconomical or result in therapies superior to those that we develop alone or with a collaborator. For those programs that we have selected for internal development, we face competition from companies that are more experienced in product development and commercialization, obtaining regulatory approvals and product manufacturing. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Other smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, any of these companies may be more successful in obtaining collaboration agreements or other monetary support, approval and commercialization of their products and/or may develop competing products more rapidly and/or at a lower cost.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are not able to compete effectively, then we may not be able, either alone or with others, to advance the development and commercialization of our drug candidates, which would adversely affect our ability to grow our business and become profitable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Even if we, or any collaborators, are able to commercialize any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives, any of which could harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by third-party payors, including government health care programs and private health insurers. If coverage is not available, or reimbursement is limited, we, or any collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or any collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or any future collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues we are able to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or the ability of any future collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any future collaborators, to commercialize successfully any of our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of any future collaborators to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any future collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us, or any future collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated into existing payments for other services.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we, or any future collaborator, obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product liability lawsuits against us could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product liability claims are inherent in the process of researching, developing and commercializing human health care products and could expose us to significant liabilities and prevent or interfere with the development or commercialization of our drug candidates. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Regardless of their merit or eventual outcome, product liability claims would require us to spend significant time, money and other resources to defend such claims, could result in:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased demand for our product candidates or products that we may develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injury to our reputation and significant negative media attention;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant costs to defend resulting litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to trial participants or patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced resources of our management to pursue our business strategy; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the reduced ability or inability to commercialize any products that we may develop.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we currently have product liability insurance for our clinical trials, this insurance is subject to deductibles and coverage limitations and may not be adequate in scope to protect us in the event of a successful product liability claim. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if and when we commercialize any product that receives marketing approval. In addition, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could harm our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATING TO OUR DEPENDENCE ON THIRD PARTIES</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We are reliant on Genentech and Roche for the successful development and commercialization of Erivedge. If Genentech and Roche do not successfully commercialize Erivedge for advanced BCC or develop Erivedge for other indications, our future prospects may be substantially harmed.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Erivedge is FDA-approved for people with advanced BCC in the United States. Erivedge is also approved in over 60 foreign countries. Genentech and/or Roche have filed regulatory submissions in additional territories seeking approval to commercialize Erivedge for this same indication. Outside of BCC, Roche and Genentech are also pursuing its potential development in other diseases including in IPF and MF. Our levels of revenue in each period and our near-term prospects substantially depend upon Genentech&#8217;s ability to successfully develop and commercialize Erivedge in one or more additional indications and to demonstrate its safety and efficacy, as well as its superiority over existing therapies and standards of care. The development and commercialization of Erivedge could be unsuccessful if:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Erivedge is no longer accepted as safe, efficacious, cost-effective and preferable for the treatment of advanced BCC to current therapies in the medical community and by third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech and/or Roche fail to continue to apply the necessary financial resources and expertise to manufacturing, marketing and selling Erivedge for advanced BCC, and to regulatory approvals for this indication outside of the U.S.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech and/or Roche do not continue to develop and implement effective marketing, sales and distribution strategies and operations for development and commercialization of Erivedge for advanced BCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech and/or Roche do not continue to develop, validate and maintain a commercially viable manufacturing process for Erivedge that is compliant with current good manufacturing practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech and Roche do not obtain full approval to commercialize Erivedge in the EU based upon the results of the study of vismodegib in patients with locally advanced or metastatic BCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech and/or Roche do not successfully obtain third party reimbursement and generate commercial demand that results in sales of Erivedge for advanced BCC in any geographic areas where requisite approvals have been, or may be, obtained;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, Genentech, or Roche encounter any third party patent interference, derivation, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:inherit;font-size:10pt;">&#32;review, post-grant review, reexamination or patent infringement claims with respect to Erivedge;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech and/or Roche do not comply with regulatory and legal requirements applicable to the sale of Erivedge for advanced BCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competing products are approved for the same indications as Erivedge, such as the FDA and CHMP approval during the third quarter of 2015 of another Hedgehog signaling pathway inhibitor, sonidegib, marketed by Novartis, for the treatment of adults with locally advanced BCC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">new safety risks are identified; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Erivedge does not demonstrate acceptable safety and efficacy in current or future clinical trials, or otherwise does not meet applicable regulatory standards for approval in indications other than advanced BCC.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, pursuant to the terms of our credit agreement with BioPharma-II, we expect that all royalties that Curis Royalty receives under our collaboration agreement with Genentech will, for the foreseeable future, be remitted to BioPharma-II in repayment of our loan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We depend on third parties for the research and, as applicable, development of certain programs. If one or more of our collaborators fails or delays in developing or, as applicable, commercializing drug candidates based upon our technologies, our business prospects and operating results would suffer and our stock price would likely decline.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our collaboration with Genentech, we have granted to Genentech exclusive rights to develop and commercialize products based upon our Hedgehog signaling pathway technologies. In addition, we entered into a collaboration, license and option agreement with Aurigene pursuant to which Aurigene may develop various immuno-oncology, selected precision oncology and other potential targets which we will have the option to license and advance into clinical trials. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborations involving our product candidates, including our collaborations with Aurigene and Genentech, pose the following risks to us:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaborators each have significant discretion in determining the efforts and resources that they will apply to their respective collaboration with us. If a collaborator fails to allocate sufficient time, attention and resources to our collaboration, the successful development and commercialization of drug candidates under such collaboration is likely to be adversely affected. For example, we are dependent on Aurigene to successfully discover and advance preclinical programs from which we may exercise our option to license drug candidates for future development.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaborators may develop and commercialize, either alone or with others, products that are similar to or competitive with the drug candidates that are the subject of our respective collaborations. For example, Genentech and Roche are involved in the commercialization of many cancer medicines and are seeking to develop several other cancer drug therapies, and Aurigene has other active cancer-focused discovery programs and has also entered into license agreements with other companies that focus on cancer therapies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaborators may change the focus of their development and commercialization efforts or pursue higher-priority programs.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaborators may enter into one or more transactions with third parties, including a merger, consolidation, reorganization, sale of substantial assets, sale of substantial stock or change of control. Any such transaction could divert the attention of our collaborative partner&#8217;s management and adversely affect its ability to retain and motivate key personnel who are important to the continued development of the programs under such collaboration. In addition, an acquirer could determine to reprioritize our collaborator&#8217;s development programs such that our collaborator ceases to diligently pursue the development of our programs, and/or terminates our collaboration.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaborators may, under specified circumstances, terminate their collaborations with us on short notice and for circumstances outside of our control, which could make it difficult for us to attract new collaborators or adversely affect how we are perceived in the scientific, biotech, pharma and financial communities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaborators may utilize our intellectual property rights in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights, or expose us to potential liability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our collaborators were to breach or terminate its arrangement with us, the development and commercialization of the affected drug candidate or program could be delayed, curtailed or terminated.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, our collaboration agreement with Genentech has resulted in the approval of Erivedge for the treatment of advanced BCC in the United States, the European Union, and several other countries. The commercial success of Erivedge in this patient population is dependent on continued investment by Genentech and Roche, and development and market approvals in indications other than in BCC will require significant investments from Genentech and Roche. The success of the further development or commercialization of Erivedge in advanced BCC, and potentially in additional indications, is dependent on a number of factors, including the following:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech is a wholly owned member of the Roche Group, and as such, is subject to the risk that Roche could determine to re-prioritize Genentech&#8217;s commercial or development programs, which could reduce Genentech&#8217;s efforts on the development or commercialization of Erivedge or cause Genentech to terminate our collaboration.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech has the first right to maintain or defend intellectual property rights associated with the drug candidate under its agreement and, although we may have the right to assume the maintenance and defense of our intellectual property rights if Genentech does not, our ability to do so may be compromised by Genentech&#8217;s acts or failures to act.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may not be successful in establishing additional strategic collaborations, which could adversely affect our ability to develop and commercialize products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to seek corporate collaborators or licensees for the further development and commercialization of one or more of our drug candidates in one or more geographic territories, particularly in territories outside of the United States. We do not currently have the resources or capacity to advance these programs into later stage clinical development (i.e., Phase&#160;3) or commercialization on our own, but we are seeking to build such a capacity to enable Curis to retain development and certain commercial rights to most of our programs in at least the United States. Our success will depend, in part, on either our ability to build such capacity, or our ability to enter into one or more collaborations for our drug candidates. We face significant competition in seeking appropriate collaborators and a number of recent business combinations in the biotechnology and pharmaceutical industry may result in a reduced number of potential future collaborators. In addition, collaborations are complex and time-consuming to negotiate and document. Moreover, we may not be successful in our efforts to establish a collaboration or other alternative arrangements because our research and development pipeline may be insufficient, our programs may be deemed to be at too early of a stage of development for collaborative effort and/or third parties may not view </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our drug candidates and programs as having the requisite potential to demonstrate safety and efficacy or as sufficiently differentiated compared to existing or emerging treatments. We are also restricted under the terms of certain of our existing collaboration agreements from entering into collaborations regarding or otherwise developing product candidates that are similar to the product candidates that are subject to those agreements, such as developing product candidates that inhibit the same molecular target. In addition, collaboration agreements that we enter into in the future may contain further restrictions on our ability to enter into potential collaborations or to otherwise develop specified product candidates. Even if we are successful in our efforts to establish new collaborations, the terms that we agree upon may not be favorable to us and such collaboration agreements may not lead to development or commercialization of drug candidates in the most efficient manner, or at all.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, if we fail to establish and maintain additional collaborations related to our drug candidates:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the development of certain of our current or future drug candidates may be terminated or delayed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our cash expenditures related to development of certain of our current or future drug candidates would increase significantly and we may need to seek additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to hire additional employees or otherwise develop additional expertise, such as clinical, regulatory, sales and marketing expertise, for which we have not budgeted;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we will have to bear all of the risk related to the development of any such drug candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our future prospects may be adversely affected and our stock price could decline.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We rely in part on third parties to conduct clinical trials of our internally-developed drug candidates, and if such third parties perform inadequately, including failing to meet deadlines for the completion of such trials, research or testing, then we will not be able to successfully develop and commercialize drug candidates and grow our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the foreseeable future, we expect to rely heavily on third parties such as consultants, clinical investigators, contract research organizations and other similar entities to complete certain aspects of our preclinical testing and clinical trials and provide services in connection with such clinical trials. Despite having contractual remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. These third parties may not complete activities on schedule, or at all, or may not conduct our clinical trials in accordance with the established clinical trial protocol or design. In addition, the FDA and its foreign equivalents require us to comply with certain standards, referred to as &#8220;good clinical practices,&#8221; and applicable regulatory requirements, for conducting, recording and reporting the results of clinical trials. These requirements assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties does not relieve us of these responsibilities and requirements. If any of our third party contractors do not comply with good clinical practices or other applicable regulatory requirements, we may not be able to use the data and reported results from the applicable trial. Any failure by a third party to conduct our clinical trials as planned or in accordance with regulatory requirements could delay or otherwise adversely affect our efforts to obtain regulatory approvals for and commercialize our drug candidates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We depend on third parties to produce our drug candidates, and if these third parties do not successfully formulate or manufacture these drug candidates, our business will be harmed.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no internal manufacturing experience or capabilities, and therefore cannot manufacture any of our product candidates on a clinical or commercial scale. In order to continue to develop drug candidates, apply for regulatory approvals, and commercialize products, we or any collaborators must be able to manufacture drug candidates in adequate clinical and commercial quantities, in compliance with regulatory requirements, including those related to quality control and quality assurance, at acceptable costs and in a timely manner. The manufacture of our drug candidates may be complex, difficult to accomplish and difficult to scale-up when large-scale production is required. Manufacture may be subject to delays, inefficiencies and low yields of quality products. The cost of manufacturing some of our drug candidates may make them prohibitively expensive.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent that we or any collaborators seek to enter into manufacturing arrangements with third parties, we and such collaborators will depend upon these third parties to perform their obligations in a timely and effective manner and in accordance with government regulations. Contract manufacturers may breach their manufacturing agreements because of factors beyond our and our collaborators&#8217; control or may terminate or fail to renew a manufacturing agreement based on their own business priorities, becoming costly and/or inconvenient for us and our collaborators.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any contract manufacturers with whom we or our collaborators enter into manufacturing arrangements will be subject to ongoing periodic, unannounced inspection by the FDA and state and foreign agencies or their designees to ensure strict compliance with current good manufacturing practices and other governmental regulations and corresponding foreign standards. Any failure by contract manufacturers, collaborators, or us to comply with applicable regulations could result in sanctions being imposed, including fines, injunctions, civil penalties, denial by regulatory authorities of marketing approval for drug candidates, delays, suspension or withdrawal of approvals, imposition of clinical holds, seizures or recalls of drug candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business. If we or a collaborator need to change manufacturers, the FDA and corresponding foreign regulatory agencies must approve any new manufacturers in advance. This would involve testing and pre-approval inspections to ensure compliance with FDA and foreign regulations and standards.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If third-party manufacturers fail to perform their obligations, our competitive position and ability to generate revenue may be adversely affected in a number of ways, including;</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, and any collaborators, may not be able to initiate or continue certain preclinical and/or clinical trials of products under development;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, and any collaborators, may be delayed in submitting applications for regulatory approvals for our drug candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, and any collaborators, may not be able to meet commercial demand for any approved products.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Because we rely on a limited number of suppliers for the raw materials used in our drug candidates, any delay or interruption in the supply of such raw materials could lead to delays in the manufacture and supply of our drug candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on third parties to supply certain raw materials necessary to produce our drug candidates for preclinical studies and clinical trials. There are a small number of suppliers for certain raw materials that we use to manufacture our drug candidates. We purchase these materials from our suppliers on a purchase order basis and do not have long-term supply agreements in place. Such suppliers may not sell these raw materials to us at the times we need them or on commercially reasonable terms, or delivery of these raw materials may be delayed or interrupted. Although we generally do not begin a preclinical study or clinical trial unless we believe we have a sufficient supply of a drug candidate to complete such study or trial, any significant delay in the supply of raw materials for our drug candidates for an ongoing clinical trial due to the need to replace a third-party supplier could considerably delay completion of certain preclinical studies and/or clinical trials. Moreover, if we are unable to purchase sufficient raw materials after regulatory approval for our drug candidates, the commercial launch of our drug candidates could be delayed, or there could be a supply shortage, each of which would impair our ability to generate revenues from their sale.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Any contamination in our manufacturing process, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any contamination could materially adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. A material shortage, contamination, recall or restriction on the use of substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacture or the production of clinical material, which could materially and adversely affect our development timelines and our business, financial condition, results of operations, and future prospects.</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATING TO EMPLOYEE MATTERS AND MANAGING GROWTH</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are not able to attract and retain key management and scientific personnel and advisors, we may not successfully develop our drug candidates or achieve our other business objectives.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend upon our senior management team. The loss of the service of any of the key members of our senior management may significantly delay or prevent the achievement of product development and other business objectives. Our officers all serve pursuant to &#8220;at will&#8221; employment arrangements and can terminate their employment with us at any time. In the future, we may be dependent on other members of our management, scientific and development team.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to compete in the biotechnology and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. Our industry has experienced a high rate of turnover of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">management personnel in recent years. If we lose one or more of our executive officers or other key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may seek to acquire complementary businesses and technologies or otherwise seek to expand our operations and grow our business, which may divert management resources and adversely affect our financial condition and operating results.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek to expand our operations, including through internal growth and/or the acquisition of businesses and technologies that we believe are a strategic complement to our business model. We may not be able to identify suitable acquisition candidates or expansion strategies and successfully complete such acquisitions or successfully execute any such other expansion strategies. We may never realize the anticipated benefits of any efforts to expand our business. Furthermore, the expansion of our business, either through internal growth or through acquisitions, poses significant risks to our existing operations, financial condition and operating results, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a diversion of management from our existing operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased operating complexity of our business, requiring greater personnel and resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant additional cash expenditures to expand our operations and acquire and integrate new businesses and technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated expenses and potential delays related to integration of the operations, technology and other resources of any acquired companies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uncertainty related to the value, benefits or legitimacy of intellectual property or technologies acquired;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">retaining and assimilating key personnel and the potential impairment of relationships with our employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incurrence of debt, other liabilities and contingent liabilities, including potentially unknown contingent liabilities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">dilutive stock issuances.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATING TO OUR INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may not be able to obtain and maintain patent protection for our technologies and products, our licensors may not be able to obtain and maintain patent protection for the technology or products that we license from them, and the patent protection we or they do obtain may not be sufficient to stop our competitors from using similar technology.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The long-term success of our business depends in significant part on our ability to:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain patents to protect our technologies and discoveries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">protect trade secrets from disclosure to competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">operate without infringing upon the proprietary rights of others; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prevent others from infringing on our proprietary rights.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical and life science companies, including ours, are generally uncertain and involve complex legal, scientific and factual questions. The laws, procedures and standards that the U.S. Patent and Trademark Office and various foreign intellectual property offices use to grant patents, and the standards that courts use to interpret patents, are not always applied predictably or uniformly and have changed in significant ways and are expected to continue to change. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the U.S. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">law does. Consequently, the level of protection, if any, that will be obtained and provided by our patents if we attempt to enforce them, and they are challenged, is uncertain.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents may not issue from any of the patent applications that we own or license. If patents do issue, the type and extent of patent claims issued to us may not be sufficient to protect our technology from exploitation by our competitors. Our patents also may not afford us protection against competitors with similar technology. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. Prior to March&#160;16, 2013, in the United States, patent applications were subject to a &#8220;first to invent&#8221; rule of law. Applications filed on or after March&#160;16, 2013 (with the exception of certain applications claiming priority to applications filed prior to March&#160;16, 2013, such as continuations and divisionals) are subject to a &#8220;first to file&#8221; rule of law. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Additionally, how the U.S. Patent&#160;&amp; Trademark Office and U.S. courts will interpret the new laws remains significantly uncertain at this time. We cannot be certain that any existing or future application will be subject to the &#8220;first to file&#8221; or &#8220;first to invent&#8221; rule of law, that we were the first to make the inventions claimed in our existing patents or pending patent applications subject to the prior laws, or that we were the first to file for patent protection of such inventions subject to the new laws.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not have rights under patents that may cover one or more of our drug candidates. In some cases, these patents may be owned or controlled by third-party competitors and may prevent or impair our ability to exploit our technology. As a result, we or our current or potential future collaborative partners may be required to obtain licenses under third-party patents to develop and commercialize some of our drug candidates. If we are unable to secure licenses to such patented technology on acceptable terms, we or our collaborative partners may not be able to develop and commercialize the affected drug candidate or candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or products that we license from third parties and are reliant on our licensors. For example, while under our collaboration with Aurigene we have established a joint patent team to coordinate efforts on patent filing, prosecution, maintenance and other patent matters, we do not control the patent process until we have exercised our option to obtain an exclusive license on a program-by-program basis. In addition, we do not control the filing, prosecution of certain patent rights licensed to us under our IAP agreement with Genentech. Therefore, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing, and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may become involved in expensive and unpredictable patent litigation or other contentious intellectual property proceedings, which could result in liability for damages or require us to cease our development and commercialization efforts.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are substantial litigation and other adversarial opposition proceedings regarding patent and other intellectual property rights in the pharmaceutical and life science industries. We may become a party to patent litigation or other proceedings regarding intellectual property rights.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Situations that may give rise to patent litigation or other disputes over the use of our intellectual property include:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiation of litigation or other proceedings against third parties to enforce our patent rights, to seek to invalidate the patents held by third parties or to obtain a judgment that our drug candidates do not infringe such third parties&#8217; patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">participation in interference and/or derivation proceedings to determine the priority of invention if our competitors file U.S. patent applications that claim technology also claimed by us;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiation of opposition, reexamination, post grant review or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:inherit;font-size:10pt;">&#32;review proceedings by third parties that seek to limit or eliminate the scope of our patent protection;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiation of litigation by third parties claiming that our processes or drug candidates or the intended use of our drug candidates infringes their patent or other intellectual property rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiation of litigation by us or third parties seeking to enforce contract rights relating to intellectual property that may be important to our business.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any patent litigation or other proceeding, even if resolved favorably, will likely incur substantial costs and be a distraction to management. Some of our competitors may be able to sustain the cost of such litigation or other proceedings more effectively than we can because of their substantially greater financial resources. In addition, our collaborators and licensors may have rights to file and prosecute claims of infringement of certain of our intellectual property, and we are reliant on them. If a patent litigation or other intellectual property proceeding is resolved unfavorably, we or any collaborative partners may be enjoined from manufacturing or selling our future products without a license from the other party and be held liable for significant damages. Moreover, we may not be able to obtain required licenses on commercially acceptable terms or any terms at all. In addition, we could be held liable for lost profits if we are found to have infringed a valid patent, or liable for treble damages if we are found to have willfully infringed a valid patent. Litigation results are highly unpredictable, and we or any collaborative partner may not prevail in any patent litigation or other proceeding in which we may become involved. Any changes in, or unexpected interpretations of, the patent laws may adversely affect our ability to enforce our patent position. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could damage our ability to compete in the marketplace.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We face risks relating to the enforcement of our intellectual property rights in China and India that could adversely affect our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have historically conducted synthetic chemistry work through a contract research agreement with a medicinal chemistry provider in China. We seek to protect our intellectual property rights under this arrangement through, among other things, non-disclosure and assignment of invention covenants. Enforcement of intellectual property rights and confidentiality protections in China may not be as effective as in the U.S. or other countries. Policing unauthorized use of proprietary technology is difficult and expensive, and we might need to resort to litigation to enforce or defend patents issued to us or to determine the enforceability, scope and validity of our proprietary rights or those of others. The experience and capabilities of Chinese courts in handling intellectual property litigation vary, and outcomes are unpredictable. Further, such litigation may require significant expenditure of cash and management efforts and could harm our business, financial condition and results of operations. An adverse determination in any such litigation will impair our intellectual property rights and may harm our business, prospects and reputation.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we collaborate with Aurigene, an Indian company, in the development of new therapeutic compounds. Some or all of the intellectual property arising from this collaboration may be developed by Aurigene&#8217;s employees, consultants, and third-party contractors, and we have an option right under the collaboration agreement to obtain exclusive licenses Aurigene&#8217;s rights in this intellectual property. Accordingly, our rights depend in part on Aurigene&#8217;s contracts with its employees and contractors and Aurigene&#8217;s ability to protect its trade secrets and other confidential information in India, both before and after we exercise our option to obtain exclusive license rights on a program-by-program basis. Enforcement of intellectual property rights and confidentiality protections in India may not be as effective as in the U.S. or other countries. Policing unauthorized use of proprietary technology is difficult and expensive, and we or Aurigene might need to resort to litigation to protect our trade secrets and confidential information. The experience and capabilities of Indian courts in handling intellectual property litigation vary, and outcomes are unpredictable. Further, such litigation may require significant expenditure of cash and management efforts and could harm our business, financial condition and results of operations. An adverse determination in any such litigation would impair our intellectual property rights and may harm our business, prospects and reputation.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are unable to keep our trade secrets confidential, our technology and proprietary information may be used by competitors.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely heavily on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect this information through confidentiality and intellectual property license or assignment provisions in agreements with our employees, consultants and other third-party contractors, including our contract research agreement with a medicinal chemistry provider in China, as well as through other security measures. Similarly, our agreement with Aurigene requires Aurigene to enter into such agreements with its employees, consultants, and other third-party contractors. The confidentiality and intellectual property provisions of our agreements and security measures </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently developed by competitors.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license rights to technology from third parties, we could lose license rights that are important to our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are party to agreements that provide us licenses of intellectual property or sharing of rights to intellectual property that is important to our business, and we may enter into additional agreements in the future that provide us licenses to valuable technology. These licenses, including our agreement with Aurigene, impose, and future licenses may impose, various commercialization, milestone and other obligations on us, including the obligation to terminate our use of licensed subject matter under certain contingencies. If a licensor becomes entitled to, and exercises, termination rights under a license, we would lose valuable rights and could lose our ability to develop our products. We may need to license other intellectual property to commercialize future products. Our business may suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license or fail to prevent infringement by third parties, if the licensed patents or other rights are found to be invalid, or if we are unable to enter into necessary licenses on acceptable terms.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our current and potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees, or as a result, we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATING TO REGULATORY APPROVAL AND MARKETING OF OUR PRODUCT CANDIDATES AND</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER LEGAL COMPLIANCE MATTERS</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. We, and any future collaborators, are not permitted to market our product candidates in the United States or in other countries until we, or they, receive approval of an NDA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of an NDA.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. Moreover, the FDA or other regulatory authorities may fail to approve the companion diagnostics we contemplate developing with partners. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any delay in obtaining or failure to obtain required approvals could negatively affect our ability or that of any future collaborators to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to market and sell our products in the European Union and other foreign jurisdictions, we, and any future collaborators, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, a product must be approved for reimbursement before the product can be approved for sale in that country. We, and any future collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may file for marketing approvals but not receive necessary approvals to commercialize our products in any market.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We, or any future collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We, or any future collaborators, may seek orphan drug designations for product candidates and may be unable to obtain such designations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain orphan drug exclusivity for that product candidate. Generally, a product with orphan drug designation only becomes entitled to orphan drug exclusivity if it receives the first marketing approval for the indication for which it has such designation, in which case the FDA or the EMA will be precluded from approving another marketing application for the same drug for that indication for the applicable exclusivity period. The applicable exclusivity period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition and the same drug can be approved for different conditions. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Even if we, or any future collaborators, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could impair our ability to generate revenue.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once marketing approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any future collaborators, must therefore comply with requirements </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we and any future collaborators will not be able to promote any products we develop for indications or uses for which they are not approved.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accordingly, assuming we, or any future collaborators, receive marketing approval for one or more of our product candidates, we, and any future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we, and any future collaborators, are not able to comply with post-approval regulatory requirements, we, and any future collaborators, could have the marketing approvals for our products withdrawn by regulatory authorities and our, or any future collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Any of our product candidates for which we, or any future collaborators, obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of our product candidates for which we, or any future collaborators, obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement an FDA-sanctioned Risk Evaluation and Mitigation Strategy.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we, or any future collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on such products, manufacturers or manufacturing processes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on the labeling or marketing of a product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on product distribution or use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requirements to conduct post-marketing studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warning letters or untitled letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of the products from the market;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to approve pending applications or supplements to approved applications that we submit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recall of products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on coverage by third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fines, restitution or disgorgement of profits or revenues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or withdrawal of marketing approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to permit the import or export of products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product seizure; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may seek a Breakthrough Therapy designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek a Breakthrough Therapy designation for one or more of our product candidates. A Breakthrough Therapy is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drug candidates that have been designated Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated Breakthrough Therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to FDA.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may seek Fast Track designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a product is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a product candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Among the provisions of the Patient Protection and Affordable Care Act, or PPACA, of potential importance to our business and our product candidates are the following:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">extension of manufacturers&#8217; Medicaid rebate liability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expansion of eligibility criteria for Medicaid programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">new requirements to report certain financial arrangements with physicians and teaching hospitals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year that started in 2013 and will stay in effect through 2024 unless additional Congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent product labeling and post-marketing testing and other requirements.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In some countries, such as the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we, or any future collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be subject to certain healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations, and diminished profits and future earnings.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Healthcare providers, third-party payors and others will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements with healthcare providers and third-party payors will expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Potentially applicable U.S. federal and state healthcare laws and regulations include the following:</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Anti-Kickback Statute.</font><font style="font-family:inherit;font-size:10pt;">&#32;The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">False Claims Laws.</font><font style="font-family:inherit;font-size:10pt;">&#32;The federal false claims laws, including the civil False Claims Act, impose criminal and civil penalties, including those from civil whistleblower or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;">&#32;actions against individuals or entities for knowingly presenting, or causing to be presented to the federal government claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">HIPAA.</font><font style="font-family:inherit;font-size:10pt;">&#32;The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing or attempting to execute a scheme to defraud any healthcare benefit program;</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">HIPAA and HITECH.</font><font style="font-family:inherit;font-size:10pt;">&#32;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act, also imposes obligations on certain types of individuals and entities, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">False Statements Statute.</font><font style="font-family:inherit;font-size:10pt;">&#32;The federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Transparency Requirements.</font><font style="font-family:inherit;font-size:10pt;">&#32;The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the U.S. Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests; and</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Analogous State and Foreign Laws.</font><font style="font-family:inherit;font-size:10pt;">&#32;Analogous state laws and regulations, such as state anti-kickback and false claims laws, and transparency laws, may apply to sales or marketing arrangements, and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. Many state laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Foreign laws also govern the privacy and security of health information in many circumstances.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Efforts to ensure that our business arrangements with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, and reputational harm, any of which could substantially disrupt our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;&#160;201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. In addition, we may engage third party intermediaries to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have adopted a Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, we cannot assure you that our employees and third party intermediaries will comply with this code or such anti-corruption laws. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our drug products and other materials are subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Controls. Exports of our products and solutions outside of the United States must be made in compliance with these laws and regulations. If we fail to comply with these laws and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on us and responsible employees or managers; and, in extreme cases, the incarceration of responsible employees or managers.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, changes in our products or solutions or changes in applicable export or import laws and regulations may create delays in the introduction, provision, or sale of our products and solutions in international markets, prevent customers from using our products and solutions or, in some cases, prevent the export or import of our products and solutions to certain countries, governments or persons altogether. Any limitation on our ability to export, provide, or sell our products and solutions could adversely affect our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the most recent global financial crisis, could result in a variety of risks to our business, including weakened demand for our product candidate and our ability to raise additional capital when needed on acceptable terms, if at all. This is particularly true in the European Union, which is undergoing a continued severe economic crisis. A weak or declining economy could strain our suppliers, possibly resulting in supply disruption, or cause delays in payments for our services by third-party payors or our collaborators. Any of the foregoing could harm our business </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Any business that we conduct in China will expose us to risks resulting from adverse changes in political, legal and economic policies of the Chinese government.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conducting business in China exposes us to a variety of risks and uncertainties that are unique to China. The economy of China has been transitioning from a planned economy to a more market-oriented economy. Although in recent years the Chinese government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets, and the establishment of sound corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the Chinese government. In addition, the Chinese government continues to play a significant role in regulating industrial development. It also exercises significant control over China&#8217;s economic growth through the allocation of resources, controlling payment of foreign currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies. Recent evidence of a slowdown in the pace of growth of the Chinese economy could result in interruptions and/or delay of our development efforts in China. If our research and development efforts in China are delayed, we may not realize the reductions in costs anticipated from doing business in China. We would also have to consider moving our chemistry and/or biology research, which is currently conducted by contract research organizations in China, to providers in the U.S. or Europe. Such a move could increase our overall costs for these services, or reduce the total number of chemists and or/biologists that we could engage. In addition, we cannot predict the effect of future developments in the Chinese legal system, including the promulgation of new laws, changes to existing laws, the interpretation or enforcement thereof, or the preemption of local regulations by national laws. Our business could be materially harmed by any changes in the political, legal or economic climate in China, or by the inability to enforce applicable Chinese laws and regulations.</font></div><div style="line-height:120%;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISKS RELATING TO OUR COMMON STOCK</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we fail to meet the requirements for continued listing on the NASDAQ Global Market, our common stock could be delisted from trading, which would decrease the liquidity of our common stock and our ability to raise additional capital.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is currently listed for quotation on the NASDAQ Global Market. We are required to meet specified financial requirements in order to maintain our listing on the NASDAQ Global Market. One such requirement is that we maintain a minimum bid price of at least $1.00 per share for our common stock. Although we currently comply with the minimum bid requirement, our bid price could fall below $1.00 per share in the future. If our bid price falls below $1.00 per share for 30 consecutive business days, we will receive a deficiency notice from NASDAQ advising us that we have 180 days to regain compliance by maintaining a minimum bid price of at least $1.00 for a minimum of ten consecutive business days. Under certain circumstances, NASDAQ could require that the minimum bid price exceed $1.00 for more than ten consecutive days before determining that a company complies. If in the future we fail to satisfy the NASDAQ Global Market&#8217;s continued listing requirements, we may transfer to the NASDAQ Capital Market, which generally has lower financial requirements for initial listing, to avoid delisting, or, if we fail to meet its listing requirements, the OTC Bulletin Board. Any potential delisting of our common stock from the NASDAQ Global Market would make it more difficult for our stockholders to sell our stock in the public market and would likely result in decreased liquidity and increased volatility for our common stock.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our stock price may fluctuate significantly and the market price of our common stock could drop below the price paid by our investors.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading price of our common stock has been volatile and is likely to continue to be volatile in the future. For example, our stock traded within a range of a high price of $5.65 and a low price of $1.09 per share for the period January&#160;1, 2012 through </font><font style="font-family:inherit;font-size:10pt;">October&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. The stock market, particularly in recent years, has experienced significant volatility with respect to pharmaceutical and biotechnology company stocks. Prices for our stock will be determined in the marketplace and may be influenced by many factors, including:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing and result of clinical trials of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements regarding new technologies and/or drug candidates by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">market conditions in the biotechnology and pharmaceutical sectors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">rumors relating to us or our collaborators or competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">litigation or public concern about the safety of our drug candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual or anticipated variations in our quarterly operating results and any subsequent restatement of such results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount and timing of any royalty revenue we receive from Genentech related to Erivedge;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual or anticipated changes to our research and development plans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">deviations in our operating results from the estimates of securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">entering into new collaboration agreements or termination of existing collaboration agreements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse results or delays in clinical trials being conducted by us or any collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any intellectual property or other lawsuits involving us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third-party sales of large blocks of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of our common stock by our executive officers, directors or significant stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">equity sales by us of our common stock to fund our operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the loss of any of our key scientific or management personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA or international regulatory actions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limited trading volume in our common stock; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general economic and market conditions, including recent adverse changes in the domestic and international financial markets.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we cannot predict the individual effect that these factors may have on the price of our common stock, these factors, either individually or in the aggregate, could result in significant variations in price during any given period of time.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We and our collaborators may not achieve projected research, development, commercialization and marketing goals in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We set goals for, and make public statements regarding, the timing of certain accomplishments, such as the commencement and completion of preclinical studies, initiation and completion of clinical trials, and other developments and milestones under our proprietary programs and those programs being developed under collaboration agreements. Genentech is a wholly owned member of the Roche Group, and Roche has also made public statements regarding its expectations for the clinical development, commercialization and marketing of Erivedge, and may in the future make additional statements about its goals and expectations for Erivedge and/or its collaboration with us. The actual timing of these events can vary dramatically due to a number of factors including delays or failures in our and our current and potential future collaborators&#8217; preclinical studies or clinical trials, the amount of time, effort and resources committed to our programs by all parties, and the inherent uncertainties in the regulatory approval and commercialization process. As a result:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our or our current and potential future collaborators&#8217; preclinical studies and clinical trials may not advance or be completed in the time frames we or they announce or expect;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our current and potential future collaborators may not make regulatory submissions, receive regulatory approvals or commercialize approved products as planned; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our current and potential future collaborators may not be able to adhere to our current schedule for the achievement of key milestones under any of our internal or collaborative programs.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we or any collaborators fail to achieve research, development and commercialization goals as planned, our business could be materially adversely affected and the price of our common stock could decline.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, if a company undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income or taxes may be limited. Changes in our stock ownership, some such changes being out of our control, may have resulted or could in the future result in an ownership change. The changes of ownership will result in net operating loss and research and development credit carryforwards that we expect to expire unutilized. If additional limitations were to apply, utilization of a portion of our net operating loss and tax credit carryforwards could be further limited in future periods and a portion of the carryforwards could expire before being available to reduce future income tax liabilities.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Future sales of shares of our common stock, including shares issued upon the exercise of currently outstanding options or pursuant to our universal shelf registration statement could result in dilution to our stockholders and negatively affect our stock price.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Most of our outstanding common stock can be traded without restriction at any time. As such, sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell such shares, could reduce the market price of our common stock. In addition, we have a significant number of shares that are subject to outstanding options and in the future we may issue additional options, warrants or other derivative securities convertible into our common stock. The exercise of any such options, warrants or other derivative securities, and the subsequent sale of the underlying common stock, could cause a further decline in our stock price. These sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have on file with the SEC a &#8220;universal&#8221; shelf registration statement which allows us to offer and sell registered common stock, preferred stock, and warrants from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale. In July 2015, we entered into a sales agreement with Cowen pursuant to which, from time to time, we may offer and sell through Cowen up to $30.0&#160;million of the registered common stock that was on the shelf registration statement pursuant to one or more &#8220;at the market&#8221; offerings. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we have not had any such sales. In addition, with our prior written approval, Cowen may sell these shares of common stock by any other method permitted by law, including in privately negotiated transactions. Sales of substantial amounts of shares of our common stock or other securities under this registration statement could lower the market price of our common stock and impair our ability to raise capital through the sale of equity securities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are not able to maintain effective internal controls under Section&#160;404 of the Sarbanes-Oxley Act, our business and stock price could be adversely affected</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires us, on an annual basis, to review and evaluate our internal controls, and requires our independent auditors to attest to the effectiveness of our internal controls. Any failure by us to maintain the effectiveness of our internal controls in accordance with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, as such requirements exist today or may be modified, supplemented or amended in the future, could have a material adverse effect on our business, operating results and stock price.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We do not intend to pay dividends on our common stock, and any return to investors will come, if at all, only from potential increases in the price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never declared nor paid cash dividends on our common stock. We currently plan to retain all of our future earnings, if any, to finance the operation, development and growth of our business. In addition, the terms of any future debt or credit agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Insiders have substantial influence over us and could delay or prevent a change in corporate control.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we believe that our directors, executive officers and principal stockholders, together with their affiliates, owned, in the aggregate, approximately 57.4% of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership could&#160;harm the market price of our common stock by:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delaying, deferring or preventing a change in control of our company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impeding a merger, consolidation, takeover or other business combination involving our company; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">entrenching our management or the board of directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for our common stock may depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analyst will provide favorable coverage. A lack of research coverage may negatively impact the market price of our common stock. In addition, if one or more of our current or potential future analysts downgrade our stock or change their opinion of our stock, our share price would likely decline. In addition, if one or more of our current or potential future analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">A decline in our stock price may affect future fundraising efforts.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have no product revenues, and depend entirely on funds raised through other sources. One source of such funding is future debt and/or equity offerings. Our ability to raise funds in this manner depends upon, among other things, our stock price, which may be affected by capital market forces, evaluation of our stock by securities analysts, product development success (or failure), and internal management operations and controls.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">We have anti-takeover defenses that could delay or prevent an acquisition that our stockholders may consider favorable, or prevent attempts by our stockholders to replace or remove current management, which could result in a decline in the price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provisions of our certificate of incorporation, our bylaws, and Delaware law may deter unsolicited takeovers or delay or prevent changes in control of our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then-current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interest. For example, we have divided our board of directors into three classes that serve staggered three-year terms, we may issue shares of our authorized &#8220;blank check&#8221; preferred stock, and our stockholders are limited in their ability to call special stockholder meetings.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we are subject to the anti-takeover provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three&#160;years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. These provisions could discourage, delay or prevent a change in control.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB11099F9A8FE459E3ECD7789BA5849F9"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Exhibits.</font></div><div style="line-height:120%;padding-top:16px;text-indent:97px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See exhibit index.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><a name="s4082AC0CEA6809ED49537789BA71C0C7"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:7%;"></td><td style="width:43%;"></td><td style="width:5%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURIS, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 3, 2016</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/&#160;&#160;&#160;&#160;J</font><font style="font-family:inherit;font-size:8pt;">AMES</font><font style="font-family:inherit;font-size:10pt;">&#160;E. D</font><font style="font-family:inherit;font-size:8pt;">ENTZER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">James E. Dentzer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Chief Financial Officer and Chief Administrative Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><a name="sE04F952972FC227099647789BA8D2890"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21EB443801643A9ADD697789AA1A71B6"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:17%;"></td><td style="width:83%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Letter Agreement, dated September 2, 2016, by and between Curis, Inc. and Daniel R. Passeri</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;10.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Amendment to Collaboration, License and Option Agreement, dated September 7, 2016, by and between Curis, Inc. and Aurigene Discovery Technologies Limited</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Purchase Agreement, dated September 7, 2016, by and between Curis, Inc. and Aurigene Discovery Technologies Limited</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Rights Agreement, dated September 7, 2016, by and between Curis, Inc. and Aurigene Discovery Technologies Limited</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section&#160;1350</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section&#160;1350</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment has been requested as to certain portions, which portions have been separately filed with the Securities and Exchange Commission.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>cris-9302016xq3ex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s82F7501FA88C601DEF0ED342516A435E"></a></div><div><div style="line-height:120%;padding-left:528px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURIS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 Maguire Road</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lexington, MA 02421</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Daniel R. Passeri</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c/o Curis, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 Maguire Road</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexington, MA 02421</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dear Dan:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc. (the &#8220;Company&#8221;) appreciates your many years of service in varying roles including as Chief Executive Officer, President, Vice-Chairman of the Board of Directors (the &#8220;Board&#8221;) and as a consultant.  In recognition of such service, this letter agreement will memorialize certain arrangements between the Company and you, as well as resolve any outstanding issues there may be.  This Agreement may be accepted by you by providing an executed agreement which is received by the Company by no later than August 31, 2016, after which time the Agreement and the offer embodied within it, shall be effectively withdrawn. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Recognition Bonus</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; In recognition of your service, the Board has authorized a $250,000 recognition bonus (the &#8220;Recognition Bonus&#8221;).  This bonus will be paid in a lump sum on the tenth (10</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;">) day after your execution of this Agreement (the &#8220;Execution Date&#8221;) provided you have met your obligations under this Agreement.  The Company will issue federal tax form 1099 &#8211; MISC to you with respect to the Recognition Bonus.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Extension of Options&#8217; Exercise Period</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; All outstanding options to purchase shares of the Company&#8217;s common stock in which you have vested as of the Execution Date (as set forth on Exhibit A) shall be amended to extend the exercise period until such date that is twenty-four (24) months following the Execution Date (but in no event shall such exercise period be extended later than the Final Exercise Date (as defined in the applicable option agreement)).  You understand that any option that is so amended to extend the exercise period shall cease to be treated for tax purposes as an incentive stock option.  You also understand that the aforementioned extension of option exercise period is contingent on your having met your obligations under this Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Resignation as a Director and All Other Offices and Capacities</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Effective as of September 14, 2016, and without the need for any further action on the part of you or the Company, you  have voluntarily resigned as a member of the Board of Directors and any other offices and any other capacities with the Company.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Continued Assistance</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; You agree that for two (2) years after the Execution Date, if requested by the Board or the Chief Executive Officer, you will provide reasonable assistance at mutually agreeable times to the Company in connection with business matters and perform any other tasks as reasonably requested by the Company (&#8220;Assistance&#8221;) and cooperate in assisting the Company in defending against and/or prosecuting any litigation or threatened litigation, and, in each case without further remuneration by the Company. The Company agrees to indemnify you and hold you harmless against any and all losses, claims, damages or liabilities to which you become subject in connection with your performance of Assistance pursuant to this Section 4, except to the extent that any loss, claim, damage or liability results  from your gross negligence, willful misconduct or bad faith.  If any action, suit, or proceeding (each an &#8220;Action&#8221;) is brought against you pursuant to which indemnification may be sought pursuant to this Section 4, you will promptly notify the Company in writing of the institution of such Action.  The Company will be entitled to assume the defense of such Action, including the employment of counsel and the payment of expenses in connection with such Action.  You will have the right to employ your own counsel at your own expense if (a) the Company authorizes the employment of such counsel, (b) the Company has failed in its obligation to employ counsel to take charge of such defense, or (c) in the reasonable opinion of the Company&#8217;s counsel, the use of joint counsel presents an unavoidable conflict of interest.  You agree not to settle any Action without the written consent of the Company.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Option Repayment</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#8211;</font><font style="font-family:inherit;font-size:10pt;">On December 18, 2015 you exercised an option purportedly pursuant to your 2000 Incentive Stock Option Agreement, to purchase 45,742 shares at a strike price of $1.57 a share, with a $2.99 value per share, yielding a $64,954 gain on that exercise.  The exercise was more than 90 days after your separation from employment and should not have been processed.  Accordingly, you agree that upon the Execution Date you shall remit a check to the Company for the aforementioned $64,954. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Release</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; In consideration of the Recognition Bonus and the extended exercise period of your options, which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#8220;Released Parties&#8221;) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#8217; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, including, but not limited to, any and all claims arising out of or relating to your engagement as a consultant, your service as a Board member and your past employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167; 2000e et seq., the Age Discrimination in Employment  Act, 29 U.S.C. &#167; 621 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:10pt;">, the Americans With Disabilities Act of 1990, 42 U.S.C. &#167; 12101 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:10pt;">, the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &#167; 2000ff </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:10pt;">, the Family and Medical Leave Act, 29 U.S.C. &#167; 2601 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:10pt;">, the Worker Adjustment and Retraining Notification Act (&#8220;WARN&#8221;), 29 U.S.C. &#167; 2101 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:10pt;">, the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:10pt;">, Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &#167; 1681 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:10pt;">, and the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), 29 U.S.C. &#167; 1001 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:10pt;">, all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act., Mass. Gen. Laws ch. 151B, &#167; 1 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:10pt;">, the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, &#167; 148 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et seq.</font><font style="font-family:inherit;font-size:10pt;">&#32;(Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, &#167;&#167; 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, &#167; 102 and Mass. Gen. Laws ch. 214, &#167; 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, &#167; 1 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq.</font><font style="font-family:inherit;font-size:10pt;">, Mass. Gen. Laws ch. 214, &#167; 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, &#167; 105D, the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, &#167; 52D, and the Cambridge Human Rights Ordinance, Municipal Code Ch. 2.76.010 </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">et</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">seq</font><font style="font-family:inherit;font-size:10pt;">. (City of Cambridge anti-discrimination law), all as amended; all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract, including but not limited to, any claim concerning your right to exercise stock options; all claims to any non-vested ownership interest in the Company, contractual or otherwise; all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this letter agreement prevents you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Continuing Obligations</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#8211; You acknowledge and reaffirm your obligation to keep confidential and not to use or disclose any and all non-public information concerning the Company that you acquired during the course of your engagement as a consultant or service as a board member or past employment with the Company, including, but not limited to, any non-public information concerning the Company&#8217;s business affairs, business prospects, and financial condition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Non-Disparagement</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; You understand and agree that you will not, in public or private, make any false, disparaging, derogatory or defamatory statements to any person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee, board member, consultant, client or customer of the Company, regarding the Company or any of the other Released Parties, or regarding the Company&#8217;s </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">business affairs, business prospects, or financial condition; provided that the foregoing shall not apply to any statements made by you at a meeting of the Board while you remain a member thereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Return of Company Property</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; You confirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, tablets, etc.), Company identification, and any other Company-owned property in your possession or control and have left intact all electronic Company documents, including but not limited to those that you developed or helped to develop during your consulting, past employment and service on the Board.  You further confirm that you have cancelled (or will cancel by the Effective Date) all accounts for your benefit, if any, in the Company&#8217;s name, including but not limited to, credit cards, telephone charge cards, cellular phone and/or wireless data accounts, and computer accounts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Business Expenses and Other Compensation</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your consulting, service on the Board and past employment and that no other reimbursements or other compensation is owed to you except as provided herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amendment and Waiver</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#8211; This letter agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto.  This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators.  No delay or omission by the Company in exercising any right under this letter agreement shall operate as a waiver of that or any other right.  A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Validity</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Confidentiality</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; To the extent permitted by law, and except as required by disclosure requirements under applicable securities laws, you understand and agree that as a condition for payment to you of the consideration herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except as otherwise agreed to in writing by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nature of Agreement</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;You and the Company understand and agree that this letter agreement does not constitute an admission of liability or wrongdoing on the part of either you or the Company.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Acknowledgments and Voluntary Assent</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;">You acknowledge that you have been given twenty-one (21) days to consider this letter agreement, and that the Company is hereby advising you to consult with an attorney of your own choosing prior to signing this letter agreement.  You agree that changes to this Agreement, whether material or immaterial, do not restart the 21 day consideration period.  You understand that you may revoke this letter agreement for a period of seven (7) days after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration of this seven (7) day revocation period.  You understand and agree that by entering into this letter agreement, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that you have received consideration beyond that to which you were previously entitled.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Applicable Law</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This letter agreement shall be interpreted and construed by the laws of the Commonwealth of Massachusetts, without regard to conflict of laws provisions.  You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court located in the Commonwealth of Massachusetts (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to benefits provided to you, your repayment obligation and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements, and commitments in connection therewith.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">Nothing in this paragraph, however, shall modify, cancel or supersede your obligations set forth in paragraph 4 above.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Tax Acknowledgement</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; In connection with the benefits provided to you pursuant to this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such benefits under applicable law.  You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the consideration set forth in paragraphs 1 and 2 of this letter agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If you have any questions about the matters covered in this letter agreement, please contact me.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Very truly yours,</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Marc Rubin</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:336px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">Marc Rubin, M.D.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:336px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">Chair, Compensation Committee</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:336px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:     </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">September 2, 2016&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I hereby agree to the terms and conditions set forth above.  I intend that this letter agreement become a binding agreement between me and the Company.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;padding-top:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/  Daniel R. Passeri                      </font></div><div style="padding-bottom:5px;padding-top:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Daniel R. Passeri</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:5px;padding-top:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">August 30, 2016                               </font></div><div style="padding-bottom:8px;padding-top:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To be signed in a timely manner as set forth in paragraph 15 of this letter agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>cris-9302016xq3ex102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD9F78FCDBA2FC3895FB4D3BFFECF8FAE"></a></div><div><div style="line-height:120%;text-align:left;text-indent:528px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential Materials omitted and filed separately with the</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities and Exchange Commission. Double asterisks denote omissions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FIRST AMENDMENT TO <br>COLLABORATION, LICENSE AND OPTION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THIS FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENT</font><font style="font-family:inherit;font-size:10pt;">&#32;(the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Amendment&#8221;</font><font style="font-family:inherit;font-size:10pt;">) is entered into as of September&#160;7, 2016 (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Amendment Date&#8221;</font><font style="font-family:inherit;font-size:10pt;">), by and between </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AURIGENE DISCOVERY TECHNOLOGIES LIMITED</font><font style="font-family:inherit;font-size:10pt;">, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase&#160;II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Aurigene&#8221;</font><font style="font-family:inherit;font-size:10pt;">), and </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURIS,&#160;INC.</font><font style="font-family:inherit;font-size:10pt;">, a corporation organized under the laws of Delaware, USA, having an address of 4&#160;Maguire Road, Lexington, Massachusetts 02421-3112, USA (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Curis&#8221;</font><font style="font-family:inherit;font-size:10pt;">).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:inherit;font-size:10pt;">&#32;Aurigene and Curis are parties to that certain Collaboration, License and Option Agreement dated January&#160;18, 2015, as amended by that certain letter agreement dated November&#160;4, 2015 (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Agreement&#8221;</font><font style="font-family:inherit;font-size:10pt;">); </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:inherit;font-size:10pt;">&#32;concurrently with the execution of this Amendment, and subject to the terms and conditions of a Stock Purchase Agreement dated as of the Amendment Date (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Second Stock Purchase Agreement&#8221;</font><font style="font-family:inherit;font-size:10pt;">), Curis is issuing the &#8220;Initial Shares&#8221; (as such term is defined in the Second Stock Purchase Agreement) to Aurigene; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:inherit;font-size:10pt;">&#32;the Parties now wish to amend the Agreement to, among other things: (i)&#160;provide for the issuance to Aurigene of additional shares of common stock of Curis; (ii)&#160;provide for the waiver by Aurigene of certain milestone and other payments under the Agreement; (iii)&#160;modify the conditions under which the option to extend the exclusivity of the Parties&#8217; collaboration for the Additional Exclusivity Periods may be exercised; (iv)&#160;agree upon additional terms applicable to selection of the Program Target Profile for PTP4; and (v)&#160;if Curis exercises the Option for PTP3 and/or PTP4, provide for the funding of additional research, development and/or manufacturing funding for the Licensed Programs for PTP3 and/or PTP4; in each case, on the terms and subject to the conditions set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:inherit;font-size:10pt;">&#32;in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Aurigene and Curis agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;font-weight:bold;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Defined Terms.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Capitalized terms used but not otherwise defined in this Amendment shall have the meanings provided in the Agreement, except that the terms &#8220;Initial Shares&#8221; and &#8220;Top&#8209;Up Shares&#8221; shall have the respective meanings provided in the Second Stock Purchase Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuance of Curis Common Stock.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;On the Amendment Date, and subject to the terms and conditions set forth in the Second Stock Purchase Agreement, Curis shall issue to Aurigene the Initial Shares.  For the avoidance of doubt, the Parties hereby agree that, for purposes of Section&#160;6.6(d) of the Agreement, the Initial Shares and any Top-up Shares purchased by Aurigene (in each case, as adjusted for stock splits, stock dividends, combinations, recapitalizations, redemptions, reverse stock splits, share buybacks and the like) shall be excluded from both the numerator and the denominator of the fraction described in the definition of Current POI.  Section&#160;7.3(b) of the Agreement shall apply with respect to the issuance of the Initial Shares and any Top-Up Shares as if such section was set forth in full in this Amendment. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payment Waivers.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;As of the Amendment Date, and subject to the consummation of the issuance of the Initial Shares to Aurigene in accordance with the Second Stock Purchase Agreement, Aurigene hereby waives payment of the following amounts under the Agreement totaling $24,500,000 (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Aggregate Waiver Amount&#8221;</font><font style="font-family:inherit;font-size:10pt;">):  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the first 12-month period of Extended Exclusivity Fees under Section&#160;6.2(b) for each of Licensed Program&#160;1 and Licensed Program&#160;2 to the extent Curis elects to extend the exclusivity of the Parties&#8217; collaboration contemplated by Sections&#160;4.7(b) and 4.8(b) of the Agreement; </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the R&amp;D Program selection milestone payment for PTP4 under Section&#160;6.3 of the Agreement; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;50% of the Option exercise fee for Licensed Program&#160;3 (but only if Licensed Program&#160;3 is either PTP3 or PTP4) under Section&#160;6.5(a) of the Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the Option exercise fee for Licensed Program&#160;4 (but only if Licensed Program&#160;4 is either PTP3 or PTP4) under Section&#160;6.5(a) of the Agreement; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the Acceptance for Filing of first IND milestone payment under Section&#160;6.6(a) of the Agreement, but only with respect to Licensed Program&#160;1 (the IRAK4 program); </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the Initiation of first Phase 1 Trial milestone payment under Section&#160;6.6(a) of the Agreement, but only with respect to Licensed Program&#160;1 (the IRAK4 program) and Licensed Program&#160;2 (the PD-1/VISTA program); and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the Acceptance for Filing of first IND milestone payment under Section&#160;6.6(b) of the Agreement, but only with respect to PTP3 (the PD-1/Tim3 program) and PTP4 (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e., </font><font style="font-family:inherit;font-size:10pt;">to the extent PTP3 or PTP4 constitutes Licensed Program&#160;3 or Licensed Program&#160;4 (in either order)).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent any of the milestone or other payments set forth in paragraphs&#160;3(a) through 3(g) above in this Amendment would not otherwise be payable by Curis, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:10pt;">&#32;in the event one or more of the listed milestone events do not occur (the aggregate amount of such non&#8209;payable payment(s), collectively, the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Unused Waiver Amount&#8221;</font><font style="font-family:inherit;font-size:10pt;">), Curis shall have the right to deduct the Unused Waiver Amount from any one or more of the milestone payment obligations under Sections&#160;6.6(a), 6.6(b) or 6.6(c) of the Agreement for the following milestone events until the Unused Waiver Amount has been fully utilized: (i)&#160;&#8220;First time cumulative Net Sales of a Product throughout the Curis Territory equal or exceed $[**]&#8221;; and (ii)&#160;&#8220;First time cumulative Net Sales of a Product throughout the Curis Territory equal or exceed $[**]&#8221;.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration Exclusivity.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">First Additional Exclusivity Period.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Curis and Aurigene hereby agree that if Curis elects to extend the exclusivity of the Parties&#8217; collaboration contemplated by Section&#160;4.7(a) (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Collaboration Exclusivity&#8221;</font><font style="font-family:inherit;font-size:10pt;">) for the first Additional Exclusivity Period, then notwithstanding Section&#160;4.8(a) or Section&#160;6.2(a) of the Agreement or any other provision of the Agreement to the contrary, the Exclusivity Option Fee for the first Additional Exclusivity Period under Section&#160;6.2(a)(i) of the Agreement shall be payable on the following schedule:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;50% of such Exclusivity Option Fee (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:10pt;">, $3,750,000) shall be payable no later than the expiration of the Initial Exclusivity Period.  The payment of this amount shall result in a first Additional Exclusivity Period extending to September&#160;30, 2017; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;the remaining 50% of such Exclusivity Option Fee (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:10pt;">, $3,750,000) shall be payable on or before the earlier of (x)&#160;September&#160;30, 2017, and (y)&#160;10&#160;days after the closing of the Next Curis Financing.  For purposes hereof, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Next Curis Financing&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;shall mean a financing or series of related financings (including without limitation in which Curis receives consideration in stages or at multiple closings or in separate stand-alone financings that occur that contain substantially similar terms) entered into by Curis primarily for financing/capital raising purposes, in which the Company issues and sells shares of its Common Stock or Preferred Stock or any securities conferring the right to purchase, or exercisable or exchangeable for (with or without additional consideration), its Common Stock or Preferred Stock, to any third party, whether in an underwritten public offering or otherwise.  Payment of the remaining 50% of such Exclusivity Option Fee shall result in continuation of the first Additional Exclusivity Period for its full 12-month duration.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Exclusivity Periods.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Notwithstanding the provisions of Sections&#160;4.8(a) and 6.2(a) of the Agreement to the contrary, and subject to the provisions of Section&#160;14.5 of the Agreement, in the event of a Change in Control (as defined below) of Curis during the Exclusivity Period, then, following such Change in Control, the extension of Collaboration Exclusivity for any Additional Exclusivity Period shall be subject to the mutual written </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">agreement of Aurigene and Curis (or its successor); </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:inherit;font-size:10pt;">&#32;that if, prior to the consummation of such Change in Control: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Curis paid the initial installment of the Exclusivity Option Fee for the first Additional Exclusivity Period as specified in paragraph&#160;4(a)(i) of this Amendment, then the first Additional Exclusivity Period shall continue in full force and effect following consummation of such Change in Control until September&#160;30, 2017 (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:10pt;">, without any requirement that Aurigene and Curis (or its successor) reach mutual written agreement with respect to such period); and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Curis paid both the first and second installments of the Exclusivity Option Fee for the first Additional Exclusivity Period as specified in paragraphs&#160;4(a)(i) and 4(a)(ii), respectively, of this Amendment, then the first Additional Exclusivity Period shall continue in full force and effect following consummation of such Change in Control until expiration of the full 12-month first Additional Exclusivity Period (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:10pt;">, without any requirement that Aurigene and Curis (or its successor) reach mutual written agreement with respect to such period); and </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Curis elected to extend Collaboration Exclusivity for any subsequent Additional Exclusivity Period and paid the corresponding Exclusivity Option Fee to Aurigene as specified in Section&#160;6.2(a), then such Additional Exclusivity Period shall continue in full force and effect in accordance with the terms of the Agreement following consummation of such Change in Control (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:10pt;">, without any requirement that Aurigene and Curis (or its successor) reach mutual written agreement with respect to such Additional Exclusivity Period).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;For purposes of this paragraph&#160;4(b), a </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Change in Control&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;of Curis shall be deemed to have occurred upon the happening of any of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;any &#8220;person&#8221; or &#8220;group&#8221; within the meaning of Section&#160;13(d) or Section&#160;14(d)(2) of the Securities Exchange Act of 1934, as amended (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Exchange Act&#8221;</font><font style="font-family:inherit;font-size:10pt;">), becomes, is discovered to be, or files a report on Schedule&#160;13D or 14D-1 (or any successor schedule, form or report) disclosing that such person is, a beneficial owner (as defined in Rule&#160;13d-3 under the Exchange Act or any successor rule or regulation) of securities of Curis representing more than 50% of the total voting power of the Curis&#8217; then outstanding shares; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">but excluding</font><font style="font-family:inherit;font-size:10pt;">&#32;any such acquisition of securities by (w)&#160;Aurigene or any of its Affiliates, (x)&#160;any employee benefit plan or related trust sponsored or maintained by Curis, (y)&#160;any &#8220;person&#8221; or &#8220;group&#8221; that acquires such securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for Curis through the issuance of equity securities, or (z)&#160;any financial investor that acquires such securities through purchases on the open market;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;individuals who are members of the Board of Directors of Curis as of the Amendment Date (the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Incumbent Board&#8221;</font><font style="font-family:inherit;font-size:10pt;">) cease for any reason to constitute at least a majority of the Board of Directors of Curis; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:inherit;font-size:10pt;">&#32;that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this paragraph&#160;4(b), be considered a member of the Incumbent Board;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Curis is merged, consolidated or reorganized into or with a Third Party or securities of Curis are exchanged for securities of a Third Party, unless the stockholders of Curis immediately prior to such merger, consolidation, reorganization or exchange continue to hold at least a majority of the combined voting power of the surviving entity (or, if the surviving entity is a wholly-owned subsidiary, its parent) immediately after such consolidation, merger, reorganization or exchange; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(4)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;a Sale Transaction with respect to Curis.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PTP4 Selection.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Curis agrees to select PTP4 on or before expiration of the Initial Exclusivity Period.  For clarity, (a)&#160;the Parties hereby agree that the Program Target Profile for PTP4 shall be within the Immuno-oncology area, (b)&#160;Curis&#8217; selection of PTP4 shall be in accordance with the processes set forth in Section&#160;3.1(b)(i) or Section&#160;3.1(b)(ii) of the Agreement, as applicable, and (c)&#160;nothing in this paragraph&#160;5 shall limit Aurigene&#8217;s obligations or Curis&#8217; rights under Section&#160;3.1(c) of the Agreement or modify the exclusivity provisions set forth in the Agreement, including Sections&#160;4.7, 4.8, 4.9 and 4.10.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PTP3 and PTP4 Research Funding.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PTP3.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Subject to, and only after, the closing of the Next Curis Financing, and subject to Curis&#8217; exercise (if any) of the Option for PTP3, Curis shall pay up to an aggregate of $2,000,000 for Supplemental PTP3 Activities (defined below), if performed by or on behalf of Aurigene.  For clarity, Curis shall not be obligated to pay any amounts under this paragraph&#160;6(a) unless and until the later of (x)&#160;the closing of the Next Curis Financing and (y)&#160;the date such Supplemental PTP3 Activities are actually performed and Aurigene has delivered to Curis an invoice for such Supplemental PTP3 Activities.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Supplemental PTP3 Activities&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;shall mean specific research, development and/or manufacturing activities with respect to Program Compounds within the Licensed Program for PTP3 to be recommended by the SOC, and subject to (i)&#160;each Party&#8217;s final approval of the aspects of such activities that are within such Party&#8217;s final decision-making authority pursuant to Sections&#160;2.6(a) and 2.6(b) of the Agreement and (ii)&#160;the execution by the Parties of a written supplemental development plan, including a budget of costs for each such activity, on mutually acceptable terms.  Notwithstanding the foregoing, subject to Curis&#8217; payment when due of the milestone payment for Acceptance for Filing of the first IND for a Product from the Licensed Program for PTP3, the Supplemental PTP3 Activities specifically exclude Aurigene&#8217;s Development Plan responsibilities and Phase&#160;1 Trial supply obligations under Section&#160;5.6 of the Agreement for such Licensed Program, the expenses of which are Aurigene&#8217;s sole responsibility under Section&#160;5.4(b) of the Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PTP4.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Subject to, and only after, the closing of the Next Curis Financing, and subject to Curis&#8217; exercise (if any) of the Option for PTP4, Curis shall pay up to an aggregate of $2,000,000 for Supplemental PTP4 Activities (defined below), if performed by or on behalf of Aurigene.  For clarity, Curis shall not be obligated to pay any amounts under this paragraph&#160;6(b) unless and until the later of (x)&#160;the closing of the Next Curis Financing and (y)&#160;the date such Supplemental PTP4 Activities are actually performed and Aurigene has delivered to Curis an invoice for such Supplemental PTP3 Activities.  </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Supplemental PTP4 Activities&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;shall mean specific research, development and/or manufacturing activities with respect to Program Compounds within the Licensed Program for PTP4 to be recommended by the SOC, and subject to (i)&#160;each Party&#8217;s final approval of the aspects of such activities that are within such Party&#8217;s final decision-making authority pursuant to Sections&#160;2.6(a) and 2.6(b) of the Agreement and (ii)&#160;the execution by the Parties of a written supplemental development plan, including a budget of costs for each such activity, on mutually acceptable terms.  Notwithstanding the foregoing, subject to Curis&#8217; payment when due of the milestone payment for Acceptance for Filing of the first IND for a Product from the Licensed Program for PTP4, the Supplemental PTP4 Activities specifically exclude Aurigene&#8217;s Development Plan responsibilities and Phase&#160;1 Trial supply obligations under Section&#160;5.6 of the Agreement for such Licensed Program, the expenses of which are Aurigene&#8217;s sole responsibility under Section&#160;5.4(b) of the Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corrections.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Correction to Section&#160;1.5.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;In Section&#160;1.5 of the Agreement, the reference to &#8220;Section&#160;3.1(a)&#8221; is hereby corrected to read &#8220;Section&#160;3.1(b)(i)(2).&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Correction to Section&#160;2.6(b).</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;In Section&#160;2.6(b) of the Agreement, the reference to &#8220;Potential PTP&#8221; is hereby corrected to read &#8220;Proposed PTP.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Correction to Sections&#160;3.3(a) and&#160;3.5(b).</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;In Sections&#160;3.3(a) and&#160;3.5(b) of the Agreement, the phrase &#8220;Lead Candidate selection&#8221; is hereby corrected to read &#8220;Program selection.&#8221;  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Correction to Section&#160;5.4(b).</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;In Section&#160;5.4(b) of the Agreement, the phrases &#8220;subject to Section&#160;5.5&#8221; and &#8220;under Section&#160;5.5&#8221; are hereby corrected to read &#8220;subject to Section&#160;5.6&#8221; and &#8220;under Section&#160;5.6,&#8221; respectively.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Effectiveness of Agreement.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;Except as expressly amended by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Counterparts.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;This Amendment may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument.  This Amendment may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Miscellaneous.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;For clarity, Section&#160;8.5(b) and Articles&#160;13 and 14 of the Agreement shall apply with respect to this Amendment.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Signature page follows.</font><font style="font-family:inherit;font-size:10pt;">]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;text-indent:49px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF,</font><font style="font-family:inherit;font-size:10pt;">&#32;the Parties hereto have duly executed this Amendment as of the Amendment Date.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:48px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aurigene Discovery Technologies Limited</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:48px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Curis, Inc.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:  </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ CSN Murthy</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CSN Murthy</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Chief Executive Officer</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Ali Fattaey</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Ali Fattaey</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div><div style="padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">President</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>cris-9302016xq3ex103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD8C20B6C3FF141959342D3359EBDD541"></a></div><div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:480px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.3</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMON STOCK PURCHASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THIS COMMON STOCK PURCHASE AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;), dated as of September 7, 2016 (the &#8220;Effective Date&#8221;) is between Curis, Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and Aurigene Discovery Technologies Limited, a company organized under the laws of India (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Purchaser</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  Capitalized terms set forth herein and not defined shall have the meanings ascribed to such terms under the License Agreement (as defined below). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BACKGROUND</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, the Company and the Purchaser are parties to that certain Collaboration, License and Option Agreement, dated as of January 18, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">License Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;), which contains terms and conditions under which the Company and the Purchaser have agreed to enter into a relationship for the research, discovery and development of human therapeutics; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, in consideration for the terms of the First Amendment to the License Agreement by and between the Company and the Purchaser of even date herewith (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">License Agreement Amendment</font><font style="font-family:inherit;font-size:10pt;">&#8221;), the Company has agreed to issue to the Purchaser shares of the Company&#8217;s Common Stock, $0.01 par value per share (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#8221;) on the terms and subject to the conditions set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOW THEREFORE, In consideration of the mutual promises hereinafter set forth and other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereby agree as follows:</font></div><div style="line-height:120%;padding-left:57px;padding-bottom:16px;text-align:left;text-indent:14px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">1.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Issuance of the Initial Shares</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:10pt;">In consideration of the Purchaser entering into the License Agreement Amendment, the Company agrees to issue to the Purchaser on the Initial Closing Date (as defined below) 10,208,333 shares (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Initial Shares</font><font style="font-family:inherit;font-size:10pt;">&#8221; and with the Top-up Shares (as defined below), the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Shares</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of Common Stock.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:10pt;">At the closing of the sale of the Initial Shares contemplated hereby ( &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Initial Closing</font><font style="font-family:inherit;font-size:10pt;">&#8221;), which shall be held on the date hereof or such other date within three (3) business days of the date of this Agreement as shall be mutually agreed upon by the Company and the Purchaser remotely by facsimile transmission or other electronic means or at such location as the parties may mutually agree (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Initial Closing Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), (i) the Purchaser and the Company shall execute and deliver to each other the Registration Rights Agreement (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration Rights Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;) in the form of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">&#32;attached hereto and the License Agreement Amendment in the form of </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:10pt;">&#32;attached hereto, and (ii) the Company shall instruct the transfer agent for the Common Stock to issue and deliver to the Purchaser an original stock certificate representing the Initial Shares.</font></div><div style="line-height:120%;padding-left:57px;padding-bottom:16px;text-align:left;text-indent:14px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:24px;">2.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Additional Share Purchase Rights.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:10pt;">Subject to Subsection 2(b) below, the first time following the Initial Closing Date that the Company proposes to offer shares of its Common Stock in an underwritten public offering (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsequent Offering</font><font style="font-family:inherit;font-size:10pt;">&#8221;), the Company shall, as soon as practicable after a determination is made by the Company to undertake such public offering (and in any event before filing a preliminary prospectus supplement with the Securities and Exchange Commission), give Purchaser written notice in accordance with Section 8 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company Top-Up Notice</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of such Subsequent Offering. Following receipt of the Company Top-Up Notice, Purchaser may, by written notice delivered by electronic mail to the Company&#8217;s Chief Executive Officer and Chief Financial Officer at any time prior to the Pricing Time (as defined below), elect to purchase from the Company (the &#8220;Top-up Purchase&#8221;), by means of a private placement, all or a portion of such number of shares of Common Stock (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Top-Up Shares</font><font style="font-family:inherit;font-size:10pt;">&#8221;) which, following such Top-up Purchase and the Subsequent Offering, would equal a number of shares of Common Stock that is no greater than the lesser of (i) 19.56% of the shares of Common Stock outstanding after such Top-up Purchase and the Subsequent Offering or (ii) such percentage of shares of Common Stock of the Company that is equal to the difference between 19.56% and the percentage of shares of Common Stock sold, transferred, or otherwise disposed of by Purchaser to a Person other than a Permitted Transferee on or after the Effective Date and prior to the date of such Top-up Purchase.  For purposes of this Agreement, a &#8220;Permitted Transferee&#8221; shall mean any entity that, directly or indirectly through one or more intermediaries, controls, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">is controlled by, or is under common control with the Purchaser.  The percentage amount derived by application of the foregoing sentence shall be referred to herein as the &#8220;Applicable Percentage,&#8221; and the foregoing right to purchase the Top-up Shares in order to retain the Applicable Percentage is referred to herein as the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Top-Up Right</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Applicable Percentage shall be subject to appropriate and equitable adjustment for any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization.  If Purchaser chooses to purchase less than the maximum number of Top-Up Shares at the Subsequent Closing, it shall specify in the notice to Company which ownership percentage less than the Applicable Percentage it intends to achieve after giving effect to the purchase and Subsequent Offering.  The Purchaser&#8217;s exercise of its Top-up Right may be made contingent upon the closing of the applicable Subsequent Offering within a specified period of time.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:10pt;">Notwithstanding the foregoing Subsection 2(a), (i) if the Subsequent Offering results in gross proceeds to the Company that are less than $50.0 million (with $50.0 million being defined as the &#8220;Requisite Proceeds&#8221;), then the Purchaser&#8217;s Top-up Right shall continue to apply to one or more additional Subsequent Offerings until such Requisite Proceeds are received by the Company, and (ii) if a Subsequent Offering results in proceeds to the Company that exceed the Requisite Proceeds, the Top-up Right shall apply only with reference to the sale of Common Stock that results in the Requisite Proceeds, and not with reference to any sale of additional shares of Common Stock that are sold as part of the Subsequent Offering.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:10pt;">The Company Top-up Notice shall state: (i) the Company&#8217;s bona fide intention to undertake the Subsequent Offering, (ii) the estimated number of shares of Common Stock to be offered in the Subsequent Offering, if known, (iii) the expected price and terms and conditions, if any, upon which it proposes to offer its Common Stock in the Subsequent Offering, if then known and (iv) the planned date and time at which the Company expects to enter into an underwriting agreement with the underwriters for the Subsequent Offering (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Pricing Time</font><font style="font-family:inherit;font-size:10pt;">&#8221;), if then known.  If any of the estimated number of shares of Common Stock to be offered in the Subsequent Offering, the expected price upon which the Company proposes to offer its Common Stock in the Subsequent Offering or the Pricing Time are not known at the time the Top-up Notice is delivered, then the Company shall promptly amend such Top-up Notice with such additional terms once known.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:10pt;">Following delivery of the Company Top-Up Notice, the Company shall provide Purchaser reasonable access to enable Purchaser to conduct diligence materially equivalent to that provided to any other person that is contemplating participating in the applicable Subsequent Offering (inclusive of such person&#8217;s representatives).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:10pt;">Notwithstanding anything herein to the contrary, if Purchaser elects to exercise the Top-Up Right, then (i) the Purchaser shall have the right to purchase the same securities, and (ii) the purchase price per Top-Up Share will be the amount that is equal to the public offering price per share at which the Common Stock is sold to the public in the Subsequent Offering (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsequent Offering Price</font><font style="font-family:inherit;font-size:10pt;">&#8221; and such time, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Top-Up Closing Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), as, in each case, is set forth on the cover of the final prospectus filed with the Commission.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:10pt;">Upon any closing of the purchase of Top-Up Shares (each, a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Subsequent Closing</font><font style="font-family:inherit;font-size:10pt;">&#8221; and with the Initial Closing, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Closing</font><font style="font-family:inherit;font-size:10pt;">&#8221;), Purchaser shall pay to the Company the cash purchase price for the applicable Top-Up Shares, calculated by multiplying such number of Top-Up Shares by the Subsequent Offering Price, by wire transfer of immediately available funds, and the Company shall instruct the transfer agent for the Common Stock to issue and deliver to the Purchaser an original stock certificate representing the Top-Up Shares.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(g)</font><font style="font-family:inherit;font-size:10pt;">Each Subsequent Closing shall take place remotely by facsimile transmission or other electronic means or at such location as the parties may mutually agree, within thirty (30) calendar days after the date on which all conditions to such Subsequent Closing, as set forth in Section 5, shall been satisfied or waived (other than those conditions that by their terms are to be satisfied at the Subsequent Closing, but subject to the satisfaction or waiver of such conditions).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Representations and Warranties of the Company</font><font style="font-family:inherit;font-size:10pt;">.  Except as set forth in any schedules delivered herewith (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Disclosure Schedules</font><font style="font-family:inherit;font-size:10pt;">&#8221;), which Disclosure Schedules shall be deemed a part hereof and shall qualify </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">any representation made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules the Company represents and warrants to the Purchaser as of the date of this Agreement and as of the Closing:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Organization and&#160;Good&#160;Standing</font><font style="font-family:inherit;font-size:10pt;">.  The Company has been duly incorporated and organized, and is validly existing in good standing, under the laws of the State of Delaware.  The Company is duly qualified to transact business and is in good standing in the Commonwealth of Massachusetts and in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its business makes such qualification or licensing necessary, except where the failure to be so qualified or licensed has not had and would not reasonably be expected to have a material adverse effect on the ability of the Company to consummate the transactions contemplated hereby.  The Company has the corporate power and authority to enter into and perform this Agreement and the Registration Rights Agreement (collectively, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreements</font><font style="font-family:inherit;font-size:10pt;">&#8221;), to own and operate its properties and assets and to carry on its business as currently conducted and as presently proposed to be conducted.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Authorization and Binding Nature</font><font style="font-family:inherit;font-size:10pt;">.  The execution, delivery and performance by the Company of the Agreements and the issuance and delivery of the Initial Shares has been, and the issuance of any Top-up Shares will be, duly authorized by all requisite corporate action on the part of the Company.  The Agreements constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as enforceability may be limited by securities laws, bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights of creditors generally and by equitable principles, including those limiting the availability of specific performance, injunctive relief and other equitable remedies and those providing for equitable defenses.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Contravention</font><font style="font-family:inherit;font-size:10pt;">.  The execution, delivery and performance by the Company of the Agreements will not, with or without the giving of notice or the passage of time or both, (i) violate or conflict with the provisions of the certificate of incorporation or bylaws of the Company, (ii) violate or conflict with any judgment, decree, order or award of any court, governmental body or arbitrator applicable to the Company or (iii) violate, conflict with or cause a default under any mortgage, indenture, lease, contract or other agreement or instrument, permit, or license to which the Company is subject except, in the case of this clause (iii), any violation, conflict or default that would not reasonably be expected to have a material adverse effect on the Company&#8217;s business, properties, financial position or results of operations (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Material Adverse Effect</font><font style="font-family:inherit;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Governmental Consents</font><font style="font-family:inherit;font-size:10pt;">.  No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Company in order to enable the Company to execute, deliver and perform its obligations under this Agreements, except for such qualifications or filings under applicable securities laws as may be required in connection with the transactions contemplated by this Agreement.  All such qualifications and filings, insofar as they relate to the issuance of the Initial Shares or the Top-Up Shares at the applicable Closing, will, in the case of qualifications, be effective on such Closing and will, in the case of filings, be made within the time prescribed by law.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Capitalization.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The authorized capital stock of the Company consists of (i) 225,000,000 shares of Common Stock, of which, as of September 3, 2016, 130,705,427 shares were issued and 129,482,581 shares were outstanding, and (ii) 5,000,000 shares of Preferred Stock, $0.01 par value per share, of which no shares are issued or outstanding.  All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and nonassessable.  When issued, sold and delivered in accordance with the provisions of this Agreement, the Shares will be duly authorized, validly issued, fully paid and nonassessable, and will be free of restrictions on transfer other than restrictions under this Agreement, the Registration Rights Agreement and applicable state and federal securities laws.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SEC Reports.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The Company has timely filed all reports, schedules and other documents required to be filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exchange Act</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Purchaser has had access, via the website of the Securities and Exchange Commission (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SEC</font><font style="font-family:inherit;font-size:10pt;">&#8221;), to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and all reports filed by the Company under Section 13 of the Exchange Act with the SEC since December 31, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Reports</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The Reports complied in all material respects with the requirements of the Exchange Act, and the </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">respective rules and regulations thereunder when filed. As of their respective dates, the Reports did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(g)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Governmental Permits</font><font style="font-family:inherit;font-size:10pt;">.  The Company owns, possesses or has obtained all licenses, permits, certificates, consents, orders, approvals and other authorizations from, and has made all declarations and filings with, all federal, state, local and other governmental authorities (including foreign regulatory agencies), all self-regulatory organizations and all courts and other tribunals, domestic or foreign, necessary to operate its properties and to carry on its business as conducted as of the date hereof, except where the failure to own, possess, obtain or make would not, individually or in the aggregate, have a Material Adverse Effect.  The Company has not received any actual notice of any proceeding relating to revocation or modification of any such license, permit, certificate, consent, order, approval or other authorization.  To its knowledge, the Company is in compliance with all laws and regulations relating to the conduct of its business as conducted as of the date hereof, except where noncompliance would not reasonably be expected to have a Material Adverse Effect, and all of the descriptions in the Reports of the legal and governmental procedures and requirements of the United States Food and Drug Administration or any foreign, state or local governmental body exercising comparable authority are accurate in all material respects.</font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(h)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Taxes</font><font style="font-family:inherit;font-size:10pt;">.  The Company has filed all material tax returns required to be filed, which returns are true and correct in all material respects, and the Company is not in default in the payment of any taxes, including penalties and interest, assessments, fees and other charges (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tax Penalties</font><font style="font-family:inherit;font-size:10pt;">&#8221;) shown thereon due or otherwise assessed other than those being contested in good faith and for which adequate reserves have been provided or those currently payable without which such Tax Penalties were payable pursuant to said returns or any assessments with respect thereto.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:10pt;">.  The Company maintains insurance of the type and in the amount that the Company reasonably believes is adequate for the business, including, but not limited to, liability insurance for clinical testing and insurance covering all real and personal property owned or leased by the Company against theft, damage, destruction, acts of vandalism and all other risks customarily insured against by similarly situated companies, all of which insurance is in full force and effect.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(j)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:10pt;">.  The Company, to its knowledge, owns or is licensed to use all patents, patent applications, inventions, trademarks, trade names, applications for registration of trademarks, service marks, service mark applications, copyrights, know-how, manufacturing processes, formulae, trade secrets, licenses and rights in any thereof and any other intangible property and assets that are material to the business of the Company as now conducted and as, on the date hereof, proposed to be conducted (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Proprietary Rights</font><font style="font-family:inherit;font-size:10pt;">&#8221;), or is seeking, or will seek, to obtain rights to use such Proprietary Rights that are material to the business of the Company, on the date hereof, as proposed to be conducted.  The Company does not have any knowledge of, and the Company has not given or received any notice of, any pending conflicts with or infringement of the rights of others with respect to any Proprietary Rights or with respect to any license of Proprietary Rights that are material to the business of the Company.  No action, suit, arbitration, or legal, administrative or other proceeding, or investigation is pending, or, to the Company&#8217;s knowledge, threatened, which involves any Proprietary Rights, nor, to the Company&#8217;s knowledge, is there any reasonable basis therefor.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(k)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Property</font><font style="font-family:inherit;font-size:10pt;">. The Company has good and marketable title in fee simple to all items of real property and good and marketable title to all personal property owned by it, in each case free and clear of all liens, encumbrances and defects except such as are described or referred to in the Reports or such as do not materially affect the value of such property and do not interfere with the use made or proposed to be made of such property by the Company; and any real property and buildings held under lease by the Company are, to the knowledge of the Company, held under valid, existing and enforceable leases with such exceptions as are not material and do not interfere with the use made or proposed to be made of such property and buildings by the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(l)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration Rights</font><font style="font-family:inherit;font-size:10pt;">.  Except as described or referred to in the Reports, the Company is presently not under any obligation, and has not granted any rights, to register under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Securities Act</font><font style="font-family:inherit;font-size:10pt;">&#8221;) any of its presently outstanding securities or any of its securities that may be subsequently issued.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(m)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">No Material Adverse Change</font><font style="font-family:inherit;font-size:10pt;">.  Since the filing of the Company&#8217;s most recent Annual Report on Form 10-K, except as described or referred to in the Reports, there has not been any material adverse change in the assets, business, properties, financial condition or results of operations of the Company.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(n)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Litigation</font><font style="font-family:inherit;font-size:10pt;">.  There is no action, suit or proceeding before or by any court or governmental agency or body, domestic or foreign, now pending, or, to the knowledge of the Company, threatened against or affecting the Company which, singly or in the aggregate, could reasonably be expected to have a Material Adverse Effect.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(o)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Disclosure</font><font style="font-family:inherit;font-size:10pt;">.  To the Company&#8217;s knowledge, neither this Agreement nor any certificates made or delivered in connection herewith, when read together, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements herein or therein, in light of the circumstances under which they were made, not misleading.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><font style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(p)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Compliance with Laws</font><font style="font-family:inherit;font-size:10pt;">.  The Company is in material compliance with all applicable laws and, to the Company&#8217;s knowledge, the Company is not under investigation with respect to, and has not been threatened to be charged with or given notice of, any material violation of any applicable laws.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Representations and Warranties of the Purchaser</font><font style="font-family:inherit;font-size:10pt;">.  The Purchaser represents and warrants to the Company that the statements contained in this Section 4 are true and correct as of the date of this Agreement and as of the Initial Closing and the Subsequent Closing.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Investment.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The Purchaser is acquiring the Initial Shares and any Top-up Shares for its own account for investment, not for resale to any other person and not with a view to or in connection with any resale or distribution.  The Purchaser understands that the Initial Shares have not been, and the Top-up Shares, if applicable, will not be, registered under the securities laws of the United States or any other jurisdiction and cannot be transferred or resold except as permitted pursuant to a valid registration statement or an applicable exemption from registration.  The Purchaser acknowledges that there can be no assurance that there will be any market for the Common Stock in the foreseeable future and that, as a result, the Purchaser must be prepared to bear the economic risk of its investment for an indefinite period of time.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Foreign Purchaser</font><font style="font-family:inherit;font-size:10pt;">.  The Purchaser is not a United States person (as defined by Section&#160;7701(a)(30) of the Internal Revenue Code of 1986, as amended) and hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Agreement, including (a)&#160;the legal requirements within its jurisdiction for the receipt of the Shares, (b)&#160;any foreign exchange restrictions applicable to such purchase, (c)&#160;any governmental or other consents that may need to be obtained, and (d)&#160;the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares.  The Purchaser&#8217;s continued beneficial ownership of the Shares will not violate any applicable securities or other laws of the Purchaser&#8217;s jurisdiction as in effect on the date hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Regulation&#160;S Representations and Restrictions</font><font style="font-family:inherit;font-size:10pt;">.  The Purchaser makes the following additional representations, warranties and agreements:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;The Purchaser is </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">not</font><font style="font-family:inherit;font-size:10pt;">&#32;a &#8220;U.S. person&#8221; as defined in Rule&#160;902(k) of Regulation&#160;S promulgated under the Securities Act (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">U.S. Person</font><font style="font-family:inherit;font-size:10pt;">&#8221;).  The offer and sale of the Initial Shares to the Purchaser was made in, and the offer and sale of the Top-up Shares, if applicable, will be made in an &#8220;Offshore Transaction&#8221; (as defined in Rule&#160;902(h)&#160;of Regulation&#160;S), no &#8220;Directed Selling Efforts&#8221; (as defined in Rule&#160;902(c)&#160;of Regulation&#160;S) were or will be made to the Purchaser in the United States, and the Purchaser is not acquiring the Shares for the account or benefit of any U.S. Person;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;The Purchaser will resell the Shares only in accordance with the provisions of Regulation S, pursuant to registration under the Securities Act, or pursuant to an available exemption from registration; and the Purchaser shall not engage in hedging transactions with regard to such Shares unless in compliance with the Securities Act.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Purchaser acknowledges and agrees that the Company shall not register any transfer or resale of the Shares not made (i) in accordance with the provisions of Regulation S, (ii) pursuant to registration under the Securities Act or (iii) or pursuant to an available exemption from registration.  The Purchaser acknowledges and agrees that the certificates evidencing the Initial Shares and any Top-up Shares will bear the legend set forth below (in addition to any other legend required by applicable federal, state or foreign securities laws or provided in any other agreement with the Company:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">ACT</font><font style="font-family:inherit;font-size:10pt;">&#8221;) WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.  THE SHARES MAY NOT BE OFFERED FOR SALE OR SOLD EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S OF THE ACT, PURSUANT TO REGISTRATION UNDER THE ACT, OR AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Authorization and Binding Nature.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The execution, delivery and performance by the Purchaser of the Agreements have been duly authorized by all requisite corporate action on the part of the Purchaser.  The Agreements constitute the valid and legally binding obligations of the Purchaser, enforceable against the Purchaser in accordance with their respective terms, except as enforceability may be limited by securities laws, bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws relating to or affecting the rights of creditors generally and </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">by equitable principles, including those limiting the availability of specific performance, injunctive relief and other equitable remedies and those providing for equitable defenses.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Contravention</font><font style="font-family:inherit;font-size:10pt;">.  The execution, delivery and performance by the Purchaser of the Agreements will not, with or without the giving of notice or the passage of time or both, (i) violate or conflict with the provisions of the certificate of incorporation or bylaws of the Purchaser, (ii) violate or conflict with any judgment, decree, order or award of any court, governmental body or arbitrator applicable to the Purchaser or (iii) violate, conflict with or cause a default under any mortgage, indenture, lease, contract or other agreement or instrument, permit, or license to which the Purchaser is subject other than any violation, conflict or default which would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Access to Information.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The Purchaser has substantial knowledge and experience in making investment decisions of this type and is capable of evaluating the merits and risks of its investment in the Company.  The Company has made available to the Purchaser all documents and other information necessary for the Purchaser to evaluate the merits and risks of its investment in the Company.  The Company has made available to the Purchaser all documents requested and has provided answers to all of its questions relating to an investment in the Company.  In evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representations (whether oral or written) other than as set forth herein.  The Purchaser has had an opportunity to discuss this investment with representatives of the Company and to ask questions of them.  The Purchaser understands that an investment in the Company involves significant risks.  The Purchaser is an &#8220;accredited investor,&#8221; as defined in Rule 501 under the Securities Act.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Ownership of Common Stock</font><font style="font-family:inherit;font-size:10pt;">.  Before giving effect to the issuance to the Purchaser of the Initial Shares, the Purchaser beneficially owns, directly or indirectly, 17,120,131 shares of Common Stock of the Company. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Conditions to Closing</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Conditions of the Purchaser&#8217;s Obligation</font><font style="font-family:inherit;font-size:10pt;">.  The obligation of the Purchaser to consummate the transactions contemplated by this Agreement at the applicable Closing (unless otherwise indicated) is subject to the satisfaction of the following conditions, any one or more of which may be waived by the Purchaser:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:72px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Documentation at Closing.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The Purchaser shall have received prior to or at the Closing all of the following documents or instruments, or evidence of completion thereof, each in form and substance satisfactory to the Purchaser:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;(i) A copy of the certificate of incorporation of the Company, certified by the Secretary of State of the State of Delaware, (ii) (x) as of the Initial Closing Date, a copy of the resolutions of the Board of Directors of the Company evidencing the approval of this Agreement and the License Agreement Amendment, the issuance of the Shares, and the other matters contemplated hereby and (y) as of the Top-Up Closing Date, a copy of the resolutions of the Board of Directors of the Company evidencing the approval of the issuance of the Top-Up Shares and the other matters contemplated hereby, and (iii) a copy of the Bylaws of the Company, all of which shall have been certified by the Secretary of the Company to be true, complete and correct.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;A certificate of the Secretary of the Company which, at the Initial Closing shall certify the names of the officers of the Company authorized to sign this Agreement, and at each Closing, the certificate for the Initial Shares or Top-Up Shares, as applicable, and the other documents, instruments or certificates to be delivered pursuant to this Agreement by the Company or any of its officers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;A certificate of the President and Chief Executive Officer of the Company stating that the conditions specified in Section 5(a)(ii) have been satisfied.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Certificates of Good Standing for the Company from the Secretary of State of the State of Delaware and the Commonwealth of Massachusetts.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Representations and Warranties; Performance of Obligations.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The  representations and warranties made by the Company in Section 3 hereof shall be true and correct in all material respects (other than those representations that are qualified by materiality, which shall be true and correct in accordance with their terms) as of the date of the applicable Closing except for representations and warranties made as of a specific date, which shall be true and correct as of such date, and the Company shall have performed in all material respects all obligations and conditions herein required to be performed or observed by it on or prior to the applicable Closing. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Consents, Waivers, Etc.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The Company shall have obtained all consents or waivers, if any, necessary to execute and deliver this Agreement, issue the Initial Shares and Top-Up Shares, as applicable, and to carry out the transactions contemplated hereby and thereby except for any which, if not obtained or effected would not have a Material Adverse Effect or a material adverse effect on the parties&#8217; ability to close the transaction contemplated by the Agreement.  All corporate and other action and governmental filings necessary to effectuate the terms of this Agreement, the Initial Shares and Top-Up Shares, as applicable, and other agreements and instruments executed and delivered by the Company in connection herewith shall have been made or taken, except for any post-sale filing that may be required under federal or state securities laws except for any which, if not obtained or effected would not have a Material Adverse Effect or a material adverse effect on the parties&#8217; ability to close the transaction contemplated by the Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">License Agreement Amendment</font><font style="font-family:inherit;font-size:10pt;">.  At the Initial Closing, the Purchaser and the Company shall have executed and delivered the License Agreement Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration Rights Agreement.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;At the Initial Closing, Purchaser and the Company shall have executed and delivered the Registration Rights Agreement in the form attached as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Conditions of the Company&#8217;s Obligation</font><font style="font-family:inherit;font-size:10pt;">.  The obligation of the Company to consummate the transactions contemplated by this Agreement at each Closing (unless otherwise indicated) is subject to the satisfaction of the following conditions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Representations and Warranties; Performance of Obligations.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;The representations and warranties made by the Purchaser in Section 4 hereof shall be true and correct in all material respects (other than those representations that are qualified by materiality, which shall be true and correct in accordance with their terms) as of the date of the applicable Closing except for representations and warranties made as of a specific date, which shall be true and correct as of such date, and the Purchaser shall have performed in all material respects all obligations and conditions herein required to be performed or observed by it on or prior to the applicable Closing. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">License Agreement Amendment</font><font style="font-family:inherit;font-size:10pt;">.  At the Initial Closing, Purchaser and the Company shall have executed and delivered the License Agreement Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration Rights Agreement.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;At the Initial Closing, Purchaser and the Company shall have executed and delivered the Registration Rights Agreement in the form attached as </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Lock-Up Agreement</font><font style="font-family:inherit;font-size:10pt;">.   The Purchaser covenants and agrees that, except as specified in this Section 6, it will not, during the period beginning on the date hereof and ending on September 7, 2018, without the prior written consent of the Company, (a) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, contract to dispose of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section&#160;16 of the Securities Exchange Act and the rules and regulations of the SEC promulgated thereunder, with respect to any of the Initial Shares, (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such Initial Shares, in cash or otherwise, or (c) publicly announce an intention to effect any transaction specified in clause (a) or (b).  Notwithstanding the foregoing, the Purchaser is permitted to take any of the actions described under Sections 6(a)-(c) with respect to (i) up to an aggregate of (A) 25% of the Initial Shares from and after March  7, 2017, (B) 50% of the Initial Shares from and after September 7, 2017, (C) 75% of the Initial Shares from and after March 7, 2018, and (ii) any or all of the Initial Shares after any public announcement with respect to the acquisition of the Company by a third </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">party or any change of control of the Company.  For the sake of clarity, the lock-up restrictions set forth in this Section 6 shall no longer be applicable to the Initial Shares from and after September 7, 2018.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Restriction on Public Offering</font><font style="font-family:inherit;font-size:10pt;">. The Company covenants and agrees that it will not, without Purchaser&#8217;s prior written consent (such consent not to be unreasonably conditioned, delayed, or withheld), issue or sell any shares of its Common Stock or Preferred Stock or any securities conferring the right to purchase, or exercisable or exchangeable for (with or without additional consideration), its Common Stock or Preferred Stock,  on or before December 31, 2016 at a price per share less than or equal to $2.40 (as adjusted for stock splits, combinations, recapitalizations and similar events); provided, that the foregoing shall not apply to the authorization or issuance by the Company of shares of Common Stock or options therefor to directors, officers, employees, consultants or advisors pursuant to any stock incentive or employee stock purchase plans, agreements or arrangements in consideration of services in transactions not intended for financing/capital raising purposes.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:10pt;">.    Any notices or other communications required or permitted hereunder shall be sufficiently given if delivered personally, via electronic mail, or via a reputable express courier, with charges prepaid, to the address set forth below or to such other address of which the parties may have given notice. Unless otherwise specified herein, such notices or other communications shall be deemed received one business day after personal delivery or electronic delivery, or three business days after being sent, if sent by reputable express courier.</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If to the Company:</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc.</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 Maguire Road</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexington, Massachusetts 02421</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attention:  President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facsimile: (617) 503-6500</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With a copy to:</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wilmer Cutler Pickering Hale and Dorr LLP</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 Word Trade Center</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, NY 10007</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attn: Steven D. Singer, Esq.</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facsimile: (212) 230-8888</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If to the Purchaser:</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aurigene Discovery Technologies Limited</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39-40, KIADB Industrial Area </font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase&#160;II, Electronic City Hosur Road </font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bangalore - 560100 Karnataka</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">India</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attn:&#160;&#160;&#160;&#160;CSN Murthy, Chief Executive Officer</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facsimile: (91) 80 2852 6285</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Successors and Assigns</font><font style="font-family:inherit;font-size:10pt;">.     No party may assign its rights or obligations hereunder without the prior written consent of the other party.  Subject to the foregoing, this Agreement shall be binding upon and inure to the </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:10pt;">benefit of the parties hereto and their respective successors and assigns.  Any assignment in contravention of this provision shall be void.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Survival of Warranties</font><font style="font-family:inherit;font-size:10pt;">.    The representations and warranties of the Company and the Purchaser contained in this Agreement shall survive the applicable Closing for a period of one year following such Closing, at which time they shall expire and have no further force or effect.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:10pt;">.    This Agreement represents the entire understanding and agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior oral and written and all contemporaneous oral negotiations, commitments and understandings between such parties.  The parties may amend or modify this Agreement, in such manner as may be agreed upon, only by a written instrument executed by the parties hereto.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:10pt;">.    Each party shall pay its own expenses in connection with this Agreement and the transactions contemplated hereby.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:10pt;">. This Agreement shall be governed by and construed in accordance with the laws of the State of New York in the United States, without reference to conflict of laws principles, and the parties hereby consent to the jurisdiction of the courts of the State of New York.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section Headings</font><font style="font-family:inherit;font-size:10pt;">.     The section headings are for the convenience of the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:10pt;">.     The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Counterparts; Facsimile Signatures</font><font style="font-family:inherit;font-size:10pt;">.    This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document.  This Agreement may be executed by facsimile signatures.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Publicity and Nondisclosure</font><font style="font-family:inherit;font-size:10pt;">.  Any proposed announcement, press release or other public disclosure concerning this Agreement and/or any of the amendments, transactions or relationships contemplated hereby shall be subject to the terms of Section 8.5(a) of the License Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Listing of Shares.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;As required by the rules and regulations of any national securities exchange or automated quotation system, the Company agrees to use commercially reasonable efforts to promptly secure the listing of the Shares upon each national securities exchange or automated quotation system upon which shares of its Common Stock are listed and, so long as the Purchaser owns any of the Shares, shall use commercially reasonable efforts to maintain such listing of all the Shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sDE6092C9051B3B993FE5D3359ECE489D"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the date first above written.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURIS, INC.</font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:222px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.58974358974359%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/S/ ALI FATTAEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ali Fattaey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AURIGENE DISCOVERY TECHNOLOGIES LIMITED</font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:222px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.58974358974359%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/S/ CSN MURTHY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CSN Murthy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[Signature Page to Common Stock Purchase Agreement]</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>cris-9302016xq3ex104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF83F32875CAA5856815BD305E9107C0F"></a></div><div><div style="line-height:120%;text-align:left;padding-left:522px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.4</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REGISTRATION RIGHTS AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This REGISTRATION RIGHTS AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;), dated as of September 7, 2016, is entered into between Curis, Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and Aurigene Discovery Technologies Limited, a company organized under the laws of India (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Purchaser</font><font style="font-family:inherit;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BACKGROUND</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, the Company has agreed to issue to the Purchaser 10,208,333 shares (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Initial Shares</font><font style="font-family:inherit;font-size:10pt;">&#8221;) of the Company&#8217;s Common Stock, $0.01 par value per share (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and has granted an option to purchase Top-Up Shares (as defined in the Purchase Agreement (defined below), and together with the Initial Shares, the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Shares</font><font style="font-family:inherit;font-size:10pt;">&#8221;), each on the terms and subject to the conditions set forth in that certain Common Stock Purchase Agreement, dated as of September 7, 2016 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Purchase Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;), by and between the Company and the Purchaser, as consideration under that certain First Amendment to Collaboration, License and Option Agreement dated as of September 7, 2016; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WHEREAS, the Company and the Purchaser desire to provide for certain arrangements with respect to the registration of the Registrable Securities (as defined below) under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Securities Act</font><font style="font-family:inherit;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the parties hereto agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Certain Defined Terms</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Person</font><font style="font-family:inherit;font-size:10pt;">&#8221; means an individual, corporation, partnership, joint venture, limited liability company, governmental authority, unincorporated organization, trust, association or other entity. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Prospectus</font><font style="font-family:inherit;font-size:10pt;">&#8221; means (i) the prospectus included in any Registration Statement contemplated by this Agreement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and (ii) any &#8220;free writing prospectus&#8221; as defined in Rule 405 promulgated under the Securities Act. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registrable Securities</font><font style="font-family:inherit;font-size:10pt;">&#8221; means (a) the Initial Shares, (b) the Top-Up Shares, if and at such time as such Top-Up Shares are issued to Purchaser pursuant to the terms of the Purchase Agreement, and (c) any shares of Common Stock issued or issuable with respect to the Shares by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when (i) a Registration Statement covering such securities has been declared effective by the SEC and such securities have been disposed of pursuant to such effective Registration Statement, (ii) such securities are sold under circumstances in which all of the applicable conditions of Rule 144 promulgated under the Securities Act (or any similar provisions then in force) under the Securities Act are met, (iii) such securities are otherwise transferred and such securities may be resold without subsequent registration under the Securities Act, or (iv) such securities shall have ceased to be outstanding.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration Statement</font><font style="font-family:inherit;font-size:10pt;">&#8221; means any registration statement of the Company which covers any of the Registrable Securities pursuant to the provisions of this Agreement, including the Prospectus, amendments and supplements to such Registration Statement, including post-effective amendments, all exhibits and all materials incorporated by reference in such Registration Statement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SEC</font><font style="font-family:inherit;font-size:10pt;">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Registration Statements</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Resale Registration Statement</font><font style="font-family:inherit;font-size:10pt;">.  The Company, after each Closing Date (as such term is defined in the Purchase Agreement) and, in any event, on or prior to the ninetieth (90th)&#160;day following such Closing Date (and if such day falls on a Saturday, a Sunday or a national holiday, then the next business day thereafter) (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Filing Deadline</font><font style="font-family:inherit;font-size:10pt;">&#8221;), shall prepare and file with the SEC a Registration Statement on Form S-3 (or, if Form S-3 is not then available to the Company, on such form of Registration Statement as is then available to effect a registration for resale of all of the Registrable Securities on a continuous basis by means of a shelf registration), covering the resale of all of the Registrable Securities relating to the shares issued on such Closing Date (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Resale Registration Statement</font><font style="font-family:inherit;font-size:10pt;">&#8221;); provided, however, that if the Filing Deadline shall fall during a period that the Company may not file a registration statement under the Securities Act until such time as it files with the SEC its updated financial statements, then the Filing Deadline shall be no later than twenty (20)&#160;days after the filing date of such updated financial statements with the SEC.  Subject to Section 4(c), the registration of the Resale Registration Statement pursuant to this Section&#160;2(a) shall be effected by means of a shelf registration on a delayed or continuous basis in accordance with the provisions of Rule 415 promulgated under the Securities Act (&#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Rule 415</font><font style="font-family:inherit;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Demand Registration</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i)&#160;&#160;&#160;&#160;At any time after six (6) months after the date of issuance of the Initial Shares or Top-up Shares, as applicable, the Purchaser may request registration under the Securities Act of all or any portion of its Registrable Securities on a Form S-3 registration statement (or any successor to such form) (or, if Form S-3 is not then available, on such form of registration statement as is then available to effect a registration of the Registrable Securities pursuant to this subsection (b)(i)) (each a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Demand Registration</font><font style="font-family:inherit;font-size:10pt;">&#8221;), </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:10pt;">, for the sake of clarity, the Company shall not be required to effect a Demand Registration with respect to any Registrable Securities that are then subject to the lock-up agreement set forth in Section 6 of the Purchase Agreement (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Lock-up Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;). Each request for a Demand Registration shall specify the approximate number of Registrable Securities required to be registered.  Upon receipt of a Demand Registration request, the Company shall cause a Form S-3 registration statement (or any successor to such form) (or, if Form S-3 is not then available, on such form of registration statement as is then available to effect a registration of the Registrable Securities pursuant to this subsection (b)(1)) to be filed within forty-five (45) days after the date on which such request was received by the Company.  The Company shall not be required to effect a Demand Registration more than two (2) times for the Purchaser; provided, however, that a Registration Statement shall not count as a Demand Registration requested under this Section 2(b)(i) unless and until it has become effective and the Purchaser is able to register and sell at least seventy-five percent (75%) of the Registrable Securities requested to be included in such registration.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;If the Purchaser requests a Demand Registration and elects to distribute the Registrable Securities covered by its request in an underwritten offering, the Purchaser shall so advise the Company as a part of its request made pursuant to Section 2(b)(i).  The Company shall select the investment banking firm or firms to act as the managing underwriter or underwriters in connection with such offering; provided, however, that such selection shall be subject to the consent of the Purchaser, which consent shall not be unreasonably withheld, delayed or conditioned.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;The Company shall not include in any Demand Registration any securities which are not Registrable Securities without the prior written consent of the Purchaser, which consent shall not be unreasonably withheld, delayed or conditioned. If a Demand Registration involves an underwritten offering and the managing underwriter of the requested Demand Registration advises the Company and the Purchaser in writing that, in its opinion, the number of shares of Common Stock proposed to be included in the Demand Registration, including all Registrable Securities and all other shares of Common Stock proposed to be included in such underwritten offering, exceeds the number of shares of Common Stock which can be sold in such underwritten offering and/or the number of shares of Common Stock proposed to be included in such registration would adversely affect the price per share of the Registrable Securities proposed to be sold in such underwritten offering, the Company shall include in such Demand Registration (A) first, the number of shares of Common Stock that the Purchaser proposes to sell, and (B) second, the number of shares of Common Stock proposed to be included therein by any other Persons (including shares of Common Stock to be sold for the account of the Company and/or other holders of Common Stock) allocated among such Persons in such manner as they may agree.  If the managing underwriter determines that less than all of the Registrable Securities proposed to be sold by the Purchaser can be included in such offering, then the Registrable Securities of the Purchaser </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to be included in such underwritten offer shall equal the number of securities which the Purchaser is advised by the managing underwriter can be sold in such offering.</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:left;text-indent:0px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Piggyback Registration</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Whenever the Company proposes to register any shares of its Common Stock under the Securities Act (other than a registration effected solely to implement an employee benefit plan or a transaction to which Rule 145 is applicable, or a registration statement on Form S-4, S-8 or any successor form thereto or another form not available for registering the Registrable Securities for sale to the public), whether for its own account or for the account of one or more stockholders of the Company, and the form of Registration Statement to be used may be used for the registration of Registrable Securities (each a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Piggyback Registration</font><font style="font-family:inherit;font-size:10pt;">&#8221;), the Company shall give prompt written notice (in any event no later than thirty (30) days prior to the filing of such Registration Statement) to the Purchaser of its intention to effect such a registration and, subject to Section 3(b) and Section 3(c), shall include in such registration all Registrable Securities with respect to which the Company has received, within fifteen (15) days after the Company&#8217;s notice has been given to the Purchaser, a written request from the Purchaser for inclusion; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:10pt;">, for the sake of clarity in no event shall the Company be required to include Registrable Securities in such Piggyback Registration to the extent that such Registrable Securities are then subject to the Lock-up Agreement.  A Piggyback Registration shall not be considered a Demand Registration for purposes of Section 2(b) of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a Piggyback Registration is initiated as a primary underwritten offering on behalf of the Company and the managing underwriter advises the Company and the Purchaser (if the Purchaser has elected to include Registrable Securities in such Piggyback Registration) in writing that in its opinion the number of shares of Common Stock proposed to be included in such registration, including all Registrable Securities and all other shares of Common Stock proposed to be included in such underwritten offering, exceeds the number of shares of Common Stock which can be sold in such offering and/or that the number of shares of Common Stock proposed to be included in any such registration would adversely affect the price per share of the Common Stock to be sold in such offering, and/or any other marketing or other factors dictate that a limitation be imposed with respect to the number of shares of Common Stock proposed to be included in such registration, the Company shall include in such registration (i) first, the number of shares of Common Stock that the Company proposes to sell; (ii) second, the number of shares of Common Stock requested to be included therein by the Purchaser; and (iii) third, the number of shares of Common Stock requested to be included therein by holders of Common Stock (other than the Purchaser), allocated among such holders in such manner as they may agree.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a Piggyback Registration is initiated as an underwritten offering on behalf of a holder of Common Stock other than the Purchaser, and the managing underwriter advises the Company in writing that in its opinion the number of shares of Common Stock proposed to be included in such registration, including all Registrable Securities and all other shares of Common Stock proposed to be included in such underwritten offering, exceeds the number of shares of Common Stock which can be sold in such offering and/or that the number of shares of Common Stock proposed to be included in any such registration would adversely affect the price per share of the Common Stock to be sold in such offering, and/or any other marketing or other factors dictate that a limitation be imposed with respect to the number of shares of Common Stock proposed to be included in such registration, the Company shall include in such registration (i) first, the number of shares of Common Stock requested to be included therein by the holder(s) requesting such registration and by the Purchaser, allocated pro rata among such holders on the basis of the number of shares of Common Stock (on a fully diluted, as converted basis) and the number of Registrable Securities, as applicable, owned by all such holders or in such manner as they may otherwise agree; and (ii) second, the number of shares of Common Stock requested to be included therein by other holders of Common Stock, allocated among such holders in such manner as they may agree.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall select the investment banking firm or firms to act as the managing underwriter or underwriters in connection with any offering relating to any Piggyback Registration.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Requirements of the Company</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with the filing by the Company of any Registration Statement, the Company shall furnish to the Purchaser (i) a copy of the Prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and (ii) such other documents as the Purchaser may reasonably request, in order to facilitate the public sale or other disposition of the Registrable Securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall use its reasonable best efforts to cause each Registration Statement contemplated by this Agreement to be declared effective or become effective as soon as practicable following the filing thereof with the SEC.  The Company shall notify the Purchaser in writing after any Registration Statement is declared effective.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under Rule 415, or requires the Purchaser to be named as an &#8220;underwriter&#8221; in such Registration Statement, if the Company believes, upon its reasonable determination and upon the advice of counsel, that the Registrable Securities are eligible for registration under Rule 415 or that the Purchaser is not an &#8220;underwriter&#8221; for the purposes of the Securities Act and the registration, as applicable, then the Company shall use its reasonable best efforts to persuade the SEC that the offering contemplated by the Registration Statement is a valid secondary offering and not an offering by or on behalf of the Company (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:10pt;">, the issuer) for the purposes of Rule 415, and/or that the Purchaser is not an &#8220;underwriter,&#8221; as applicable, in which event the Purchaser shall provide to the Company, in writing, all information reasonably requested by the Company to support the Purchaser&#8217;s contention that it is not an &#8220;underwriter.&#8221; The Purchaser shall have the right to participate or have its counsel participate in any meetings or discussions with the SEC regarding the SEC&#8217;s position (unless in the reasonable opinion of the Company or its counsel, such participation will be to the detriment to the Company in that it may cause undue delays in the registration process or for other reasons) and to comment or have its counsel comment on any written submission made to the SEC with respect thereto.  No such written submission regarding the foregoing specifying the Purchaser shall be made to the SEC to which the Purchaser&#8217;s counsel reasonably objects.  The Company shall not agree to name the Purchaser as an &#8220;underwriter&#8221; in such Registration Statement without the prior written consent of the Purchaser. In the event that, despite the Company&#8217;s reasonable best efforts and compliance with the terms of this Section&#160;4(c), the SEC refuses to alter its position that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415, or requires the Purchaser to be named as an &#8220;underwriter&#8221; in such Registration Statement, then the Company shall (i)&#160;remove from the Registration Statement such portion of the Registrable Securities (the &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cut Back Shares</font><font style="font-family:inherit;font-size:10pt;">&#8221;); and/or (ii)&#160;agree to such restrictions and limitations on the registration and resale of the Registrable Securities, in each case as the SEC may require to assure the Company&#8217;s compliance with the requirements of Rule 415.  Upon the SEC&#8217;s initial declaration that the Registration Statement is effective, the Company shall no longer have any obligations under this Agreement to register the Cut Back Shares. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event of any stock split, stock dividend or transaction with respect to the Registrable Securities that increases the number of Registrable Securities, if a then-effective Registration Statement does not cover the resale of such additional number of Registrable Securities, the Company shall amend or supplement any Registration Statement to cover such additional number of Registrable Securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall use its best efforts to register or qualify the Registrable Securities covered by any Registration Statement under the securities laws of each state of the United States; </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:10pt;">, that the Company shall not be required in connection with this Section 4(e) to qualify as a foreign corporation or execute a general consent to service of process in any jurisdiction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Company has delivered preliminary or final Prospectuses to the Purchaser and, after having done so, the Prospectus is amended or supplemented to comply with the requirements of the Securities Act, the Company shall promptly notify the Purchaser and, if requested by the Company, the Purchaser shall immediately cease making offers or sales of shares under the applicable Registration Statement and return all Prospectuses to the Company.  The Company shall promptly provide the Purchaser with revised or supplemented Prospectuses and, following receipt of the revised or supplemented Prospectuses, the Purchaser shall be free to resume making offers and sales under the applicable Registration Statement.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall advise the Purchaser promptly after it shall receive notice or obtain knowledge of the issuance of any stop order by the SEC delaying or suspending the effectiveness of any Registration Statement or of the initiation or threat of any proceeding for that purpose, and it will promptly use commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal at the earliest possible moment if such stop order should be issued.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Requirements of the Purchaser</font><font style="font-family:inherit;font-size:10pt;">.  The Company shall not be required to include any Registrable Securities in any Registration Statement contemplated by this Agreement unless:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Purchaser furnishes to the Company, in writing, such information regarding the Purchaser and the proposed sale of the Registrable Securities by the Purchaser as the Company may reasonably request in writing in connection with such Registration Statement or as shall be required in connection therewith by the SEC or any state securities law authorities; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Purchaser shall have provided to the Company a written agreement to indemnify the Company and each of its directors and officers against, and hold the Company and each of its directors and officers harmless from, any losses, claims, damages, expenses or liabilities (including reasonable attorneys fees) to which the Company or such directors and officers may become subject by reason of any statement or omission in such Registration Statement made in reliance upon, or in conformity with, a written statement by the Purchaser furnished pursuant specifically for use in preparation of such Registration Statement; provided, however, that the Purchaser&#8217;s obligation to indemnify the Company shall be limited to the net amount received by the Purchaser from the sale of the Registrable Securities.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Suspension</font><font style="font-family:inherit;font-size:10pt;">.  The Company may suspend the use of any Registration Statement or Prospectus (a &#8220;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Suspension</font><font style="font-family:inherit;font-size:10pt;">&#8221;) by the Purchaser if the Company determines in good faith that such Suspension is necessary to (A)&#160;delay the disclosure of material non-public information concerning the Company, the disclosure of which at the time, in the good faith opinion of the Company&#8217;s Board of Directors, would be materially detrimental to the Company or its stockholders for a registration to be effected at such time; (B)&#160;amend or supplement the affected Registration Statement or the related Prospectus so that such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein; or (C)&#160;amend or supplement the affected Registration Statement or Prospectus in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, in each case of clauses (A)&#160;through (C), that the Company shall (a)&#160;promptly notify the Purchaser in writing of such Suspension and the reasons therefor, but shall not disclose to the Purchaser any material non-public information giving rise to a Suspension under clause (A); (b)&#160;advise the Purchaser in writing to cease all sales under the Registration Statement or Prospectus until the end of the Suspension; and (c)&#160;use its reasonable best efforts to terminate such Suspension as promptly as practicable. The Company may not exercise its rights pursuant to this Section&#160;6 for more than ninety (90) days in the aggregate in any twelve (12) month period. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:10pt;">.  Except as set forth below, the Company will pay all of the expenses incurred in connection with complying with this Agreement (whether or not any Registration Statement or Prospectus becomes final or effective), including, without limitation: all registration, filing and printing fees, the Company&#8217;s counsel and accounting fees and expenses, costs and expenses associated with clearing the Registrable Securities for sale under applicable state securities laws (including, without limitation, fees, charges and disbursements of counsel in connection with such clearance), all listing fees, expenses incurred by the Company in connection with any &#8220;road show&#8221; and reasonable fees, charges and disbursements of counsel to the Purchaser. The Company shall not be required to pay or reimburse the Purchaser for any underwriting discounts or commissions and fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect to the Registrable Securities being sold. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indemnification</font><font style="font-family:inherit;font-size:10pt;">.  The Company agrees to indemnify and hold harmless the Purchaser against any losses, claims, damages, expenses or liabilities to which the Purchaser may become subject by reason of any untrue statement of a material fact contained in any Registration Statement or any omission to state therein a fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages, expenses or liabilities arise out of or are based upon information furnished to the Company by or on behalf of the Purchaser for use in such Registration Statement.  The Company shall have the right to assume the defense and settlement of any claim or suit for which the Company may be responsible for indemnification under this Section&#160;8.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Termination</font><font style="font-family:inherit;font-size:10pt;">.  All of the Company&#8217;s obligations to register the Registrable Securities under this Agreement shall terminate on the earlier of (a) the fifth (5th) anniversary of the date of this Agreement or (b) the date on which all of the Registrable Securities have been sold by the Purchaser.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Assignment of Rights</font><font style="font-family:inherit;font-size:10pt;">.  This Agreement, and the rights and obligations of the Purchaser hereunder, may be assigned by the Purchaser to any affiliate of the Purchaser to whom the Registrable Securities may be transferred pursuant to the terms of the Purchase Agreement, and such transferee shall be deemed a &#8220;Purchaser&#8221; for the purposes of this Agreement; provided that such transferee provides written notice of such assignment to the Company and agrees to be bound in writing hereby.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:10pt;">.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Specific Performance</font><font style="font-family:inherit;font-size:10pt;">.  In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, the parties hereto shall be entitled to specific performance of the agreements and obligations of the parties hereunder and to such other injunctive or other equitable relief as may be granted by a court of competent jurisdiction.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">13.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:10pt;">.  This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware (without reference to the conflicts of law provisions thereof).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">14.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:10pt;">.    Any notices or other communications required or permitted hereunder shall be sufficiently given if delivered personally, via electronic mail, or via a reputable express courier, with charges prepaid, to the address set forth below or to such other address of which the parties may have given notice. Unless otherwise specified herein, such notices or other communications shall be deemed received one business day after personal delivery or electronic delivery, or three business days after being sent, if sent by reputable express courier.</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If to the Company:</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc.</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 Maguire Road</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lexington, Massachusetts 02421</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attention:  President and Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facsimile:  (617) 503-6500</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With a copy to:</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wilmer Cutler Pickering Hale and Dorr LLP</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 World Trade Center</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New York, NY 10007</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attention: Steven D. Singer, Esq.</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facsimile:  (212) 230-8888</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If to the Purchaser:</font></div><div style="line-height:120%;text-align:left;text-indent:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aurigene Discovery Technologies Limited</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39-40, KIADB Industrial Area </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase&#160;II, Electronic City Hosur Road </font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bangalore - 560100 Karnataka</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">India</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attention:  CSN Murthy, Chief Executive Officer</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facsimile:  (91) 80 2852 6285</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">15.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:10pt;">.  This Agreement constitutes the entire agreement and understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter.  The parties may amend or modify this Agreement, in such manner as may be agreed upon, only by a written instrument executed by the parties hereto.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Counterparts; Facsimile Signatures</font><font style="font-family:inherit;font-size:10pt;">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document.  This Agreement may be executed by facsimile signatures.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Section Headings</font><font style="font-family:inherit;font-size:10pt;">.  The section headings are for the convenience of the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of the parties.</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s1B485EE6FFAFE8EE95F8D305E946FEBC"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.</font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURIS, INC.</font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:222px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.73661670235546%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/S/ ALI FATTAEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ali Fattaey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AURIGENE DISCOVERY TECHNOLOGIES LIMITED</font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:222px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:68.73661670235546%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/S/ CSN MURTHY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CSN Murthy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:222px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:228px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Signature Page to Registration Rights Agreement</font><font style="font-family:inherit;font-size:12pt;">]</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>cris-9302016xq3ex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s67722D3E9982BC4223CD77899ED9E56C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 302</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Ali Fattaey, certify that:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Curis, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:36%;"></td><td style="width:59%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 3, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ A</font><font style="font-family:inherit;font-size:8pt;">LI</font><font style="font-family:inherit;font-size:10pt;">&#160;F</font><font style="font-family:inherit;font-size:8pt;">ATTAEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ali Fattaey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>cris-9302016xq3ex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCF872C8002E9CA0164DC7789A45AEC1F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 302</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, James E. Dentzer, certify that:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Curis, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:36%;"></td><td style="width:59%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 3, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ JAMES E. DENTZER</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James E. Dentzer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial and Chief Administrative Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>cris-9302016xq3ex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCF9E1485FB9CB67A975A7789A7C93B07"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Curis, Inc. (the &#8220;Company&#8221;) for the period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Ali Fattaey, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that:</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:36%;"></td><td style="width:59%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 3, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ A</font><font style="font-family:inherit;font-size:8pt;">LI</font><font style="font-family:inherit;font-size:10pt;">&#160;F</font><font style="font-family:inherit;font-size:8pt;">ATTAEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ali Fattaey</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>cris-9302016xq3ex322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDB78E89CEC5F9C4D32527789A850FD2B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Curis, Inc. (the &#8220;Company&#8221;) for the period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, James E. Dentzer, Chief Financial and Administrative Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that:</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)&#160;The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2)&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:36%;"></td><td style="width:59%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 3, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ JAMES E. DENTZER</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James E. Dentzer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial and Chief Administrative Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>cris-20160930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:19ead8897b824d01b6ded25eb1d83b9b,x:f1648b731b774ed0be78a844e4ebfde1-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:cris="http://www.curis.com/20160930" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="cris-20160930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2016Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4October31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Oct312015_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4October31_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cris:DrugDevelopmentRoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cris:DrugDevelopmentRoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_AcceptanceofINDFilingProgramFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:AcceptanceofINDFilingProgramFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThereafterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramThereafterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cris:DrugDevelopmentRoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Jan12015toJan312015_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CreditAgreementWithBioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ExtendedExclusivityIRAK4ProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ExtendedExclusivityIRAK4ProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3January_2015_September_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">cris:DrugDevelopmentRoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_AcceptanceofINDFilingIRAK4ProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:AcceptanceofINDFilingIRAK4ProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3September6">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ThirdandFourthProgramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ThirdandFourthProgramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_OptionExercisePaymentProgramThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:OptionExercisePaymentProgramThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2003Q2June_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2003-06-01</xbrli:startDate>
			<xbrli:endDate>2003-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThereafterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramThereafterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4October_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3January_2015_September_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2003Q2June_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2003-06-01</xbrli:startDate>
			<xbrli:endDate>2003-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_OptionExercisePaymentProgramFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:OptionExercisePaymentProgramFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThereafterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramThereafterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_AcceptanceofINDFilingProgramThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:AcceptanceofINDFilingProgramThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2003Q2June_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2003-06-01</xbrli:startDate>
			<xbrli:endDate>2003-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2003Q2June30_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:GenentechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2003-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramSelectionFeeProgramFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramSelectionFeeProgramFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ExtendedExclusivityPD1VISTAProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ExtendedExclusivityPD1VISTAProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-07</xbrli:startDate>
			<xbrli:endDate>2016-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">cris:AurigeneDiscoveryTechnologiesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cris:ProgramTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtSecurityAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CreditAgreementWithBioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_CreditFacilityAxis_cris_PrincipalPortionMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cris:PrincipalPortionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CreditAgreementWithBioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_LineOfCreditFacilityAxis_cris_BioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cris:BioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CreditAgreementWithBioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CreditAgreementWithBioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CreditAgreementWithBioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CreditAgreementWithBioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_LineOfCreditFacilityAxis_cris_BioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cris:BioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_LineOfCreditFacilityAxis_cris_BioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cris:BioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_CreditFacilityAxis_cris_PrincipalPortionMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cris:PrincipalPortionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cris:CreditAgreementWithBioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_LineOfCreditFacilityAxis_cris_BioPharmaTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cris:BioPharmaTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember_us-gaap_TitleOfIndividualAxis_cris_NonEmployeeDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cris:TwoThousandAndTenPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cris:NonEmployeeDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_TitleOfIndividualAxis_cris_BoardofDirectorsViceChairmanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cris:BoardofDirectorsViceChairmanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_TitleOfIndividualAxis_cris_OfficersAndDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cris:OfficersAndDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TitleOfIndividualAxis_cris_OfficersAndDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cris:OfficersAndDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TitleOfIndividualAxis_cris_EmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cris:EmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_TitleOfIndividualAxis_cris_EmployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cris:EmployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-02</xbrli:startDate>
			<xbrli:endDate>2016-09-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3September2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-02</xbrli:startDate>
			<xbrli:endDate>2016-09-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3September2_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_us-gaap_DeferredBonusMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredBonusMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2Jun22014toJun22014_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-06-02</xbrli:startDate>
			<xbrli:endDate>2014-06-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2Jan12016toMay312016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001108205</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cris:MrPasseriMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="payment">
		<xbrli:measure>cris:payment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="right">
		<xbrli:measure>cris:right</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="product">
		<xbrli:measure>cris:product</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>cris:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="term">
		<xbrli:measure>cris:term</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="program">
		<xbrli:measure>cris:program</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="patient">
		<xbrli:measure>cris:patient</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="plan">
		<xbrli:measure>cris:plan</xbrli:measure>
	</xbrli:unit>
	<cris:AdditionalPaymentsMadeUnderCollaborativeArrangements contextRef="FI2016Q3_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThereafterMember" decimals="INF" id="Fact-DE438C4760BE0848C75577899901BEC3" unitRef="usd">0</cris:AdditionalPaymentsMadeUnderCollaborativeArrangements>
	<cris:AdditionalPaymentsMadeUnderCollaborativeArrangements contextRef="I2015Q3Oct312015_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-2A455B59E6891DA54C807789996695BF" unitRef="usd">2000000</cris:AdditionalPaymentsMadeUnderCollaborativeArrangements>
	<cris:AvailableForSaleSecuritiesDateRange contextRef="FD2015Q4YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-12FA8FE65710CA3477C7778999565E2B">P12M</cris:AvailableForSaleSecuritiesDateRange>
	<cris:AvailableForSaleSecuritiesDateRange contextRef="FD2015Q4YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-3A903C3F1B41700248037789998BB094">P1M</cris:AvailableForSaleSecuritiesDateRange>
	<cris:AvailableForSaleSecuritiesDateRange contextRef="FD2016Q3YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-04D00CD80DDDE47BE54977899952F55C">P12M</cris:AvailableForSaleSecuritiesDateRange>
	<cris:AvailableForSaleSecuritiesDateRange contextRef="FD2016Q3YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-C84CA329605A5BA40CED77899952316D">P1M</cris:AvailableForSaleSecuritiesDateRange>
	<cris:AvailableForSaleSecuritiesWeightedAverageMaturity contextRef="FD2015Q4YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember" id="Fact-51E804513754F32B6C530CC05B07209E">P4M6D</cris:AvailableForSaleSecuritiesWeightedAverageMaturity>
	<cris:AvailableForSaleSecuritiesWeightedAverageMaturity contextRef="FD2016Q3YTD_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember" id="Fact-5E5D53FB779C84AF929F03087EADBFCE">P2M15D</cris:AvailableForSaleSecuritiesWeightedAverageMaturity>
	<cris:CollaborationAgreementContingentConsiderationPotentialCashPayment contextRef="I2003Q2June30_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-211C859FB98FB79028AC778999731879" unitRef="usd">115000000</cris:CollaborationAgreementContingentConsiderationPotentialCashPayment>
	<cris:CollaborationAgreementContingentConsiderationReceivedFromPartner contextRef="FI2016Q3_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-9E487CB0CE5202D7F3EF77899905F593" unitRef="usd">59000000</cris:CollaborationAgreementContingentConsiderationReceivedFromPartner>
	<cris:CollaborativeAgreementOptionExercisablePeriod contextRef="D2015Q1Jan12015toJan312015_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" id="Fact-BDDEE557F9D95240F736778999696D61">P90D</cris:CollaborativeAgreementOptionExercisablePeriod>
	<cris:CollaborativeAgreementPeriodOfContract contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" id="Fact-2F4DD5FE9D017CA88CE377899955B36F">P2Y</cris:CollaborativeAgreementPeriodOfContract>
	<cris:CollaborativeAgreementPeriodOfContract contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-238322AB26846F1BE2A87789992F3B64">P5Y</cris:CollaborativeAgreementPeriodOfContract>
	<cris:CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember" decimals="INF" id="Fact-893E85C7E7534C3E2D602157008EC285" unitRef="patient">5000</cris:CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment>
	<cris:CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember" decimals="INF" id="Fact-A805133D9E997D8E220B21575E0A1498" unitRef="patient">5000</cris:CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment>
	<cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramFourMember" decimals="-5" id="Fact-AE2DE3E158C1346BDAE4A056A73D217A" unitRef="usd">2500000</cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling>
	<cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember" decimals="-5" id="Fact-B9CEAF4AC61FF5AFA3D1778999658B68" unitRef="usd">3000000</cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling>
	<cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThreeMember" decimals="-5" id="Fact-C2FB4B0CFE6A5B24650A7789996167ED" unitRef="usd">2500000</cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling>
	<cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramTwoMember" decimals="-5" id="Fact-C2EFAAC5F50E85EC5CFDA056A72DA7F0" unitRef="usd">3000000</cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling>
	<cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember" decimals="-5" id="Fact-D3ED118FC27BA6BBD5947789996791E4" unitRef="usd">3000000</cris:CollaborativeArrangementExpensesForAcceptanceOfINDFiling>
	<cris:CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThereafterMember" decimals="INF" id="Fact-491D500DCBF96C058EE7778999219350" unitRef="usd">53000000</cris:CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram>
	<cris:CollaborativeArrangementExpensesForDosingOfFifthPatient contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember" decimals="-5" id="Fact-1A6B2C9657D36F4C69BE77899962794D" unitRef="usd">4000000</cris:CollaborativeArrangementExpensesForDosingOfFifthPatient>
	<cris:CollaborativeArrangementExpensesForDosingOfFifthPatient contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramTwoMember" decimals="-5" id="Fact-9E0A25693BC352FE9141A056A737FBBE" unitRef="usd">4000000</cris:CollaborativeArrangementExpensesForDosingOfFifthPatient>
	<cris:CollaborativeArrangementExpensesForOptionExercise contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramFourMember" decimals="-5" id="Fact-2A36A8353183F4E60C18A056A7437EFA" unitRef="usd">3000000</cris:CollaborativeArrangementExpensesForOptionExercise>
	<cris:CollaborativeArrangementExpensesForOptionExercise contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember" decimals="-5" id="Fact-CE170DBDDB2F92F491BB77899984E306" unitRef="usd">3000000</cris:CollaborativeArrangementExpensesForOptionExercise>
	<cris:CollaborativeArrangementExpensesForOptionExercise contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThreeMember" decimals="-5" id="Fact-310CF361FB11DAF92894778999588A63" unitRef="usd">3000000</cris:CollaborativeArrangementExpensesForOptionExercise>
	<cris:CollaborativeArrangementExpensesForOptionExercise contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramTwoMember" decimals="-5" id="Fact-950A317462D497FDCF74A056A7460EDF" unitRef="usd">3000000</cris:CollaborativeArrangementExpensesForOptionExercise>
	<cris:CollaborativeArrangementExpensesForProgramSelectionFee contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramFourMember" decimals="-5" id="Fact-36F0625517D542006923A056A7404949" unitRef="usd">2000000</cris:CollaborativeArrangementExpensesForProgramSelectionFee>
	<cris:CollaborativeArrangementExpensesForProgramSelectionFee contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThreeMember" decimals="-5" id="Fact-3C79C47A13E21120814277899959CD6F" unitRef="usd">2000000</cris:CollaborativeArrangementExpensesForProgramSelectionFee>
	<cris:CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding contextRef="I2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ThirdandFourthProgramsMember" decimals="INF" id="Fact-E67BC394F99599FF22FFB03EDC34770A" unitRef="usd">2000000</cris:CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding>
	<cris:CollaborativeArrangementNumberofOptionalAdditionalTerms contextRef="FI2015Q4" decimals="INF" id="Fact-2E5FBA1664D31A7DE73F9C103671BCFF" unitRef="term">3</cris:CollaborativeArrangementNumberofOptionalAdditionalTerms>
	<cris:CollaborativeArrangementNumberofProgramsLicensed contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-951BD7460902794DB1E59C41081D7B1E" unitRef="program">2</cris:CollaborativeArrangementNumberofProgramsLicensed>
	<cris:CollaborativeArrangementNumberofProgramsLicensed contextRef="FI2016Q3_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-70A5E5E91EDA8EA43730A07AC7EA38A4" unitRef="program">2</cris:CollaborativeArrangementNumberofProgramsLicensed>
	<cris:CollaborativeArrangementNumberofProgramsLicensed contextRef="I2015Q3Oct312015_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-738927DD046882C319BA9C58BB903C87" unitRef="program">2</cris:CollaborativeArrangementNumberofProgramsLicensed>
	<cris:CollaborativeArrangementNumberofProgramsLicensed contextRef="I2016Q4October31_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-A68D767BC91403EE62419C61E640ED64" unitRef="program">3</cris:CollaborativeArrangementNumberofProgramsLicensed>
	<cris:CollaborativeArrangementOptionFeesNumberofPayments contextRef="FI2015Q4" decimals="INF" id="Fact-AC28ADD82BC860FE8FE8070A5495E72C" unitRef="payment">2</cris:CollaborativeArrangementOptionFeesNumberofPayments>
	<cris:CollaborativeArrangementOptionFeesTotal contextRef="FD2015Q4YTD" decimals="-5" id="Fact-C5AD2B1EEDA6C90BA38C7789990903A0" unitRef="usd">7500000</cris:CollaborativeArrangementOptionFeesTotal>
	<cris:CollaborativeArrangementOptionalAdditionalTerm contextRef="FD2015Q4YTD" id="Fact-904738090BF0DFF19CD89C1086C1B1A4">P1Y</cris:CollaborativeArrangementOptionalAdditionalTerm>
	<cris:CollaborativeArrangementPaymentforLicensedProgram contextRef="D2016Q4October_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-EC90DEE00CE040A60B42FC270FF685B2" unitRef="usd">1500000</cris:CollaborativeArrangementPaymentforLicensedProgram>
	<cris:CollaborativeArrangementPaymentforSelectionofPreclinicalProgram contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-A6DECC74B7B2EF7244C0FC2587C869C1" unitRef="usd">2000000</cris:CollaborativeArrangementPaymentforSelectionofPreclinicalProgram>
	<cris:CollaborativeArrangementPaymentsAgreement contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-599FEEAB70652E9436477789990B36D5" unitRef="usd">6000000</cris:CollaborativeArrangementPaymentsAgreement>
	<cris:CollaborativeArrangementPaymentsAgreement contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember" decimals="-5" id="Fact-24A2B399ABECEDD53A52778999048F3F" unitRef="usd">3000000</cris:CollaborativeArrangementPaymentsAgreement>
	<cris:CollaborativeArrangementPaymentsAgreement contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramTwoMember" decimals="-5" id="Fact-0D24EEA1E611EBAAFC64A056A7486E70" unitRef="usd">3000000</cris:CollaborativeArrangementPaymentsAgreement>
	<cris:CollaborativeArrangementPaymentsAgreementPerProgram contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramFourMember" decimals="INF" id="Fact-A33A292D18247337CD3EA056A73A32D7" unitRef="usd">50000000.0</cris:CollaborativeArrangementPaymentsAgreementPerProgram>
	<cris:CollaborativeArrangementPaymentsAgreementPerProgram contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramOneMember" decimals="INF" id="Fact-578A3BCFE85CD555406A7789996CD1DA" unitRef="usd">52500000</cris:CollaborativeArrangementPaymentsAgreementPerProgram>
	<cris:CollaborativeArrangementPaymentsAgreementPerProgram contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThereafterMember" decimals="INF" id="Fact-3139BA8FA3778163CAC4778999851B0E" unitRef="usd">140500000</cris:CollaborativeArrangementPaymentsAgreementPerProgram>
	<cris:CollaborativeArrangementPaymentsAgreementPerProgram contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThreeMember" decimals="INF" id="Fact-8BFFDD3758ED9E89E9557789995D4406" unitRef="usd">50000000</cris:CollaborativeArrangementPaymentsAgreementPerProgram>
	<cris:CollaborativeArrangementPaymentsAgreementPerProgram contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_cris_ProgramTwoMember" decimals="INF" id="Fact-A2A67AD3B59AF297362AA056A73405AC" unitRef="usd">52500000.0</cris:CollaborativeArrangementPaymentsAgreementPerProgram>
	<cris:CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-0D03743D72790B0F6AAAA07EF693D724" unitRef="product">1</cris:CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries>
	<cris:CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-1F569C950870C234DF51A0838C46E29A" unitRef="right">1</cris:CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier>
	<cris:ConsultingAgreementPeriod contextRef="D2014Q2Jun22014toJun22014_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" id="Fact-EAFE4EE183FA0A4CC8CC7789994113E5">P1Y</cris:ConsultingAgreementPeriod>
	<cris:ConsultingFees contextRef="D2016Q2Jan12016toMay312016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" decimals="-3" id="Fact-118B5CF400F8B63D9EAC7789994B63A5" unitRef="usd">30000</cris:ConsultingFees>
	<cris:CostAndExpensesOfPercentageOfAggregateRoyaltyEarned contextRef="FD2015Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="INF" id="Fact-C0128D97B9C92AA686DA77899931FF25" unitRef="number">0.05</cris:CostAndExpensesOfPercentageOfAggregateRoyaltyEarned>
	<cris:CostAndExpensesOfPercentageOfAggregateRoyaltyEarned contextRef="FD2015Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="INF" id="Fact-66DF69F014204645195D77899910C372" unitRef="number">0.05</cris:CostAndExpensesOfPercentageOfAggregateRoyaltyEarned>
	<cris:CostAndExpensesOfPercentageOfAggregateRoyaltyEarned contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="INF" id="Fact-A24BB3C5EE50F89E6F28778998D1D11E" unitRef="number">0.05</cris:CostAndExpensesOfPercentageOfAggregateRoyaltyEarned>
	<cris:CostAndExpensesOfPercentageOfAggregateRoyaltyEarned contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="INF" id="Fact-937A64CDBCBB564FD9D6778999057E56" unitRef="number">0.05</cris:CostAndExpensesOfPercentageOfAggregateRoyaltyEarned>
	<cris:IssuanceOfCommonStockToLicensees contextRef="FD2015Q3YTD" decimals="-3" id="Fact-5DAF82348F98CBB56A35778998E02FCF" unitRef="usd">23968000</cris:IssuanceOfCommonStockToLicensees>
	<cris:IssuanceOfCommonStockToLicensees contextRef="FD2016Q3YTD" decimals="-3" id="Fact-73C4690C1B06DB97B5FA9BEC5B85C1B7" unitRef="usd">17989000</cris:IssuanceOfCommonStockToLicensees>
	<cris:OtherSignificantNoncashTransactionPercentageofConsiderationReceived contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_OptionExercisePaymentProgramThreeMember" decimals="INF" id="Fact-6BE845CFF0BD4F4D49221CA897B115E7" unitRef="number">0.5</cris:OtherSignificantNoncashTransactionPercentageofConsiderationReceived>
	<cris:PaymentsMadeUnderCollaborativeArrangements contextRef="D2016Q3January_2015_September_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-AD7FF6FC9758C1DFFE5A778999370C60" unitRef="usd">11000000</cris:PaymentsMadeUnderCollaborativeArrangements>
	<cris:PaymentsMadeUnderCollaborativeArrangements contextRef="D2016Q3January_2015_September_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramThreeMember" decimals="-5" id="Fact-775FA5458273CC84009277899948F4E5" unitRef="usd">2000000</cris:PaymentsMadeUnderCollaborativeArrangements>
	<cris:PaymentsforResearchandDevelopment contextRef="FD2016Q1QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-60D08851677A40D38238B029D3ABAC13" unitRef="usd">1000000</cris:PaymentsforResearchandDevelopment>
	<cris:PaymentsforResearchandDevelopment contextRef="FD2016Q2QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-3EC2C5AB7A060F2AFE45B029D3B6F192" unitRef="usd">1000000</cris:PaymentsforResearchandDevelopment>
	<cris:PercentageOfRoyaltyOnNetSales contextRef="D2003Q2June_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-ED12DDE30367833FC0D8778999689E7E" unitRef="number">0.075</cris:PercentageOfRoyaltyOnNetSales>
	<cris:PercentageOfRoyaltyOnNetSales contextRef="D2003Q2June_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="INF" id="Fact-FF4D3047A27A964731A4778999694BD2" unitRef="number">0.050</cris:PercentageOfRoyaltyOnNetSales>
	<cris:PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter contextRef="FI2012Q4_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="INF" id="Fact-E4DDBA6161BEFBB8CB4B778998D5E3A5" unitRef="number">1.05</cris:PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter>
	<cris:ReducedRoyaltyRate contextRef="D2003Q2June_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="INF" id="Fact-16C46D882D900EC72DAC7789990BD83E" unitRef="number">0.02</cris:ReducedRoyaltyRate>
	<cris:ReducedRoyaltyRate contextRef="FD2015Q4QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="INF" id="Fact-FC1FDECD7C1AE9A93C9B778998FCDEA4" unitRef="number">0.02</cris:ReducedRoyaltyRate>
	<cris:ResearchAndDevelopmentContraRevenues contextRef="FD2015Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember" decimals="-5" id="Fact-71DFBFBB4A4569BFCC55778998FFE32F" unitRef="usd">300000</cris:ResearchAndDevelopmentContraRevenues>
	<cris:ResearchAndDevelopmentContraRevenues contextRef="FD2015Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember" decimals="-5" id="Fact-B6E0D5AECEA5D3B40A51778999355ED3" unitRef="usd">400000</cris:ResearchAndDevelopmentContraRevenues>
	<cris:ResearchAndDevelopmentContraRevenues contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember" decimals="-5" id="Fact-6FAFE93B95B24706077E77899908A557" unitRef="usd">100000</cris:ResearchAndDevelopmentContraRevenues>
	<cris:ResearchAndDevelopmentContraRevenues contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember" decimals="-5" id="Fact-E2A9260031A53EBE2D98778998FEC62C" unitRef="usd">400000</cris:ResearchAndDevelopmentContraRevenues>
	<cris:ResearchAndDevelopmentRevenue contextRef="FD2015Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember" decimals="-5" id="Fact-57DF4B06AC2467CDA24C7789995EB0DB" unitRef="usd">100000</cris:ResearchAndDevelopmentRevenue>
	<cris:ResearchAndDevelopmentRevenue contextRef="FD2015Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember" decimals="-5" id="Fact-55160368D14CF49AF5B6778998FAAFB0" unitRef="usd">200000</cris:ResearchAndDevelopmentRevenue>
	<cris:ResearchAndDevelopmentRevenue contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember" decimals="-5" id="Fact-7C9B0C94B2BBDBC98F1577899957F0A2" unitRef="usd">100000</cris:ResearchAndDevelopmentRevenue>
	<cris:ResearchAndDevelopmentRevenue contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember_us-gaap_ProductOrServiceAxis_cris_DrugDevelopmentRoyaltyMember" decimals="-5" id="Fact-C41AA4DD259DBA10E6027789992B6608" unitRef="usd">200000</cris:ResearchAndDevelopmentRevenue>
	<cris:RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-6647C2C2DB4AFDF43B127789990F0EFE" unitRef="number">0.50</cris:RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct>
	<cris:ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo contextRef="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember_us-gaap_TitleOfIndividualAxis_cris_NonEmployeeDirectorsMember" id="Fact-EA104A70F0002157903B77899975DD07">P1Y</cris:ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo>
	<cris:ShareBasedCompensationPlans contextRef="FD2016Q3YTD" decimals="INF" id="Fact-E10F3B9694CE8334EDCD7789996F2EA8" unitRef="plan">2</cris:ShareBasedCompensationPlans>
	<dei:AmendmentFlag contextRef="FD2016Q3YTD" id="Fact-14612290EF1F55FED79A7789992C9092">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2016Q3YTD" id="Fact-36DABCF2044DFA6579BB77899918B3CC">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2016Q3YTD" id="Fact-1A26B47A705D1E79DCE47789992FC757">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2016Q3YTD" id="Fact-077C9A071389F224CBE97789992EA067">2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2016Q3YTD" id="Fact-94A93D4F1179652F0DF777899926A8B7">2016-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2016Q3YTD" id="Fact-E179534DC79E667307D4778999464A7E">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2016Q3YTD" id="Fact-E2E6933C442AD21D176B77899930582C">0001108205</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2016Q4October31" decimals="INF" id="Fact-CC39CE737E2C3F400B5B7789992B7F02" unitRef="shares">140549019</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2016Q3YTD" id="Fact-0E98240D9F0EEF2B58EB778999290F9D">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2016Q3YTD" id="Fact-65D64F1D916CA532C3417789992AAF95">CURIS INC</dei:EntityRegistrantName>
	<dei:TradingSymbol contextRef="FD2016Q3YTD" id="Fact-D36C9BD028A1A0FB24EA77899925C4C8">CRIS</dei:TradingSymbol>
	<us-gaap:AccountsPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-2856BE324C83826AAD51778998FD9B60" unitRef="usd">4217000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-90BE80816FD67B25BB7F778999035B56" unitRef="usd">5056000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-B2502C05279654E3CAF07789997987E3" unitRef="usd">2106000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-773FB6A8522472F9D0557789998AFB6B" unitRef="usd">1857000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2015Q3YTD" decimals="-3" id="Fact-34856ADB3537FE4665F3778998DB5CFE" unitRef="usd">-119000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A3147A8545554F4EA520778999476E02" unitRef="usd">-83000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-8343D6A9D72E02C516F47789992968FF" unitRef="usd">1934000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-6B4CA06A2A68C2704ABA778998F14CA2" unitRef="usd">2324000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-444C2BB11DA3418B823877899924E47A" unitRef="usd">123000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-C3CD9A77B82E675BE8067789991A8C8A" unitRef="usd">115000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedSalariesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-146207A9EEF9B2F7F70E77899917667B" unitRef="usd">1310000</us-gaap:AccruedSalariesCurrent>
	<us-gaap:AccruedSalariesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-12ADC9B0FF61066D3DC87789991EBB7C" unitRef="usd">1637000</us-gaap:AccruedSalariesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-3" id="Fact-5383786724327C891190778999270F9E" unitRef="usd">28000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q3" decimals="-3" id="Fact-C1E97C120F1E04E9D2E27789997E8905" unitRef="usd">26000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2015Q4" decimals="-3" id="Fact-971D50B68B4FD78116C177899974191B" unitRef="usd">903240000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q3" decimals="-3" id="Fact-84E129CDF365E888A175778998DF4406" unitRef="usd">925569000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="FD2015Q3QTD" decimals="-5" id="Fact-31E501C294F12CC5F9977789996A4E78" unitRef="usd">-100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="FD2015Q3YTD" decimals="-5" id="Fact-A3A6E5F6ACD8664233127789997099CA" unitRef="usd">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="FD2016Q3QTD" decimals="-5" id="Fact-38BEEC0E94A4DC836FF77789996AD523" unitRef="usd">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="FD2016Q3YTD" decimals="-5" id="Fact-F4F23352C47FB819E28E77899971B5BA" unitRef="usd">-100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
	<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-94D72E280E1358F13B9A7789993FD790" unitRef="usd">26492000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
	<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4584DB335E88538F510E7789992029C9" unitRef="usd">22653000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-9441B00BA1E9BB56B86277899953967F" unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-4097414DC200FA52F4EF7789996E754D" unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-625BF6E8638C6B84517E7789995EAA20" unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_TitleOfIndividualAxis_cris_BoardofDirectorsViceChairmanMember" decimals="-5" id="Fact-E9E56B28727D4416DA1BDE32B8F0A6E5" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-5" id="Fact-FE95AF09FF1155F0C49A778999883BC1" unitRef="usd">3300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2015Q3YTD" decimals="-3" id="Fact-C258FA200F670CED3BE77789991BA76A" unitRef="usd">44000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A176DA70EECF7134B75877899913A37F" unitRef="usd">36000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-12D76502B45513CF61B477899972D1D0" unitRef="shares">13678899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-0C198AB8EFF20BA500027789996D5550" unitRef="shares">15487348</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-9F6E44ED62E247427ED77789990A8EB2" unitRef="usd">94965000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2016Q3" decimals="-3" id="Fact-BDE76ED59757F0B18E16778998D4F3E1" unitRef="usd">66193000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-9CC6222E54A7C159ACF4778998D70E15" unitRef="usd">85501000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-48072209833D264E5A4177899979D5E0" unitRef="usd">56649000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-88F59249E6B81B8393237789994FB9BF" unitRef="usd">18213000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3F0FF0C110D86B52DAB77789992240F5" unitRef="usd">62304000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1BB98378589573AFADE5778999418A76" unitRef="usd">80517000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-31B5C8765E633B607758778999556BD1" unitRef="usd">16521000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CAC9553C49CE4D87A4927789995FE00A" unitRef="usd">34264000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-603CBDC7CD3C7DD9AB3E778999555A71" unitRef="usd">50785000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-75FB9191BCA85A08B8BA778998D6816C" unitRef="usd">2644000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-3DE6F1F8BC2AC5B1833677899922FCD9" unitRef="usd">46456000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2015Q4_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-D86AA8586C6AA7E0579777899934C6A5" unitRef="usd">49100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-0A4B28A6ACF830303EFE7789996244F5" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-C0A58CA0CDEB66CB825F77899964C3B8" unitRef="usd">32684000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q3_us-gaap_DebtSecurityAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember" decimals="-3" id="Fact-670688ADE27D7319125B77899961ED71" unitRef="usd">32684000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4" decimals="-3" id="Fact-8B7DCACDAF95046C241F7789992D4E89" unitRef="usd">44000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-81AE479AA74893B57331778999858926" unitRef="usd">44000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q3" decimals="-3" id="Fact-D4E8F93DAFF47164597377899977DDDA" unitRef="usd">32000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q3_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-0A74DD79C3296C4D789377899987D311" unitRef="usd">32000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4" decimals="-3" id="Fact-DDC683B3111CC0B29EBF778999085F40" unitRef="usd">16000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-673536A352657516DCA97789997B4679" unitRef="usd">16000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q3" decimals="-3" id="Fact-E2BDEBC8FEE4CA7A2F3C778999833E05" unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q3_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-B551C72EA2D282C538C37789997CEA98" unitRef="usd">5000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4" decimals="-3" id="Fact-E51830B2DC9BF36E2F5177899962C261" unitRef="usd">49072000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-56F2FDA4496E605FD32D7789991C32F0" unitRef="usd">49072000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q3" decimals="-3" id="Fact-9DA0A5B284ACF0FC7B5D7789997D94A5" unitRef="usd">32657000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q3_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-2944155787E67249E14777899977FF9C" unitRef="usd">32657000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="FI2015Q4" decimals="-3" id="Fact-1DB57074303F29CDE836778999085648" unitRef="usd">49100000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="FI2015Q4_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-5811FC531B08828BEA497789996328E2" unitRef="usd">49100000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="FI2016Q3" decimals="-3" id="Fact-D593F454773196C7B87777899979BB86" unitRef="usd">32684000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue contextRef="FI2016Q3_us-gaap_InvestmentTypeAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-73D98E8F1E5F2679BE29778999783804" unitRef="usd">32684000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-F1A75F3B2AAE1E5267AF7789990AFBC9" unitRef="usd">7747000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q3" decimals="-3" id="Fact-1288A24DE2276F95F2F87789990F017B" unitRef="usd">28659000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-9FCFBF452FC271E01D34778998F4D770" unitRef="usd">33091000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q3" decimals="-3" id="Fact-C9EECEB32A9CDA65E79E7789994EB2FE" unitRef="usd">20671000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-55463CC7F850A9F42958778998E84E6C" unitRef="usd">2001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-02307A3F71523E9C534E778998D3C10B" unitRef="usd">7998000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-FFFCD99652A99B146DF27789996D16E0" unitRef="usd">9999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E6F48AC6AB04F9657651778999254ED3" unitRef="usd">13568000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-245DB108E060473141A477899900400E" unitRef="usd">13568000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-612C8E4D29B2E40E223C77899948698A" unitRef="usd">7850000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A348EBB0DED7B691ECC77789994C1467" unitRef="usd">7850000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6CE55E6A09A0B6305C841AEB53F08DA9" unitRef="usd">1250000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A42CC89D72381DE578891AEB5821BB29" unitRef="usd">1250000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0AD36DAFC1152E456588778999595E81" unitRef="usd">16521000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F91216CECCF09075C8E07789995CCBA7" unitRef="usd">16521000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DB718EC9E23A0C03CD651AEB5A5389EF" unitRef="usd">330000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-44C4489D0AEF941AFCFA1AEB5DAAD427" unitRef="usd">330000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q3YTD" decimals="-3" id="Fact-2515C4DCA34EED0EB60B7789991DC806" unitRef="usd">20912000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A2062CF448A732AB73907789992C29A6" unitRef="usd">-12420000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2015Q4" id="Fact-670EB6DD040B0CB852257789990C0F70" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q3" id="Fact-95E56B79140BD03E0459778999494968" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2015Q4" decimals="INF" id="Fact-4BCF99D5EBBAA6CFD7DB77899981E54A" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q3" decimals="INF" id="Fact-DF8BA6068A31B671CDADA0654C42C634" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-68E468C113D0B873E28B77899981382D" unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q3" decimals="INF" id="Fact-ACF73F803C7FD13C8CB9A0654C59665C" unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="INF" id="Fact-29F1EF887D084DC8757277899980C77C" unitRef="shares">130213224</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q3" decimals="INF" id="Fact-7B257BD2821304EFD685A0654C4B786E" unitRef="shares">141217276</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-A76361071E26D8518D2B7789997EBD3D" unitRef="shares">128990378</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q3" decimals="INF" id="Fact-CCD5F9534E9B0E44B469A0654C540FCB" unitRef="shares">139994430</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-BDF73F2267964520D68777899901B0D5" unitRef="usd">1302000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2016Q3" decimals="-3" id="Fact-48F75C8E91AAE3A23C0E7789991F262B" unitRef="usd">1412000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q3QTD" decimals="-3" id="Fact-CB763880EAF123A2950A778999779E52" unitRef="usd">-5488000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q3YTD" decimals="-3" id="Fact-4C9B529EE371504244197789997F7548" unitRef="usd">-45456000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q3QTD" decimals="-3" id="Fact-6CAA96247BE42C0204F37789991186E9" unitRef="usd">-28376000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A1D00F33A4ED847BF41277899983ECD9" unitRef="usd">-49079000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q3QTD" decimals="-3" id="Fact-C141A0BA88737470C50E778999567F47" unitRef="usd">6889000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q3YTD" decimals="-3" id="Fact-BC2864C57416EF894F637789995F0950" unitRef="usd">49021000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q3QTD" decimals="-3" id="Fact-590A790FC2322A252873778999887571" unitRef="usd">29548000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q3YTD" decimals="-3" id="Fact-75A6B9180FD8C46780227789994815AA" unitRef="usd">52441000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2012Q4_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="INF" id="Fact-E1E960C1D2C09B4E3B86778999544805" unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="FD2015Q4YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-3146844A729182E8C94703A6CB50CC42" unitRef="usd">300000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
	<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="FD2016Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-3F7124549BD174CE0EC703A5E127B862" unitRef="usd">200000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2012Q4_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="INF" id="Fact-0F25ED24C23C7E37A6CF7789990EB968" unitRef="number">0.1225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount contextRef="I2016Q3September2_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_us-gaap_DeferredBonusMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" decimals="INF" id="Fact-916EF65371BC71CF18F9FC3B09545127" unitRef="usd">250000</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount>
	<us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1 contextRef="D2016Q3September2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" id="Fact-7902E0AFAEF1312AE419FC40CD52270E">P2Y</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1>
	<us-gaap:DepreciationAndAmortization contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B937C12BC1AA3EE5A64377899907CE75" unitRef="usd">123000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2016Q3YTD" decimals="-3" id="Fact-98D3E86D21A9C1BEE185778998F95CD5" unitRef="usd">141000</us-gaap:DepreciationAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q3QTD" decimals="2" id="Fact-FAB880283AD3A584583B7789995180F2" unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q3YTD" decimals="2" id="Fact-E90786E1AA826377EE677789996A55F7" unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-D975BFB568F89817531977899975D157" unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3YTD" decimals="2" id="Fact-2F4BE4D9D06F0D5AED447789997200C1" unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2016Q3" decimals="-5" id="Fact-AA102F745A7320720DDB77899973C31F" unitRef="usd">7100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember" id="Fact-7203A4B4FE7B0C161FB87789995ADDA4">P2Y10M4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:GainLossOnDispositionOfAssets1 contextRef="FD2015Q3YTD" decimals="-3" id="Fact-A5B977C9B8C16DC8B0CB778999098DC6" unitRef="usd">17000</us-gaap:GainLossOnDispositionOfAssets1>
	<us-gaap:GainLossOnDispositionOfAssets1 contextRef="FD2016Q3YTD" decimals="-3" id="Fact-094A9F6E466A8D9664739BE993FA32DB" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-DA28903C5D6F74E61BA3778998D8FDC1" unitRef="usd">2772000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-B34559E2B2B4DC07FB04778998F7360B" unitRef="usd">9712000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-12D98AD3B88173A923FE778999805DAD" unitRef="usd">4684000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-19226318BE84779E9E6A7789998B922B" unitRef="usd">11743000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-3" id="Fact-7FCC1AE1677CCDFE2A0B778999402FFF" unitRef="usd">8982000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2016Q3" decimals="-3" id="Fact-3C842DEE29109085504D7789991A7AA2" unitRef="usd">8982000</us-gaap:Goodwill>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-80D05CEF73B502E2427A7789994AB3C9" unitRef="usd">76000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-0D98F27C61686313B34177899946BE7C" unitRef="usd">1109000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q3YTD" decimals="-3" id="Fact-42E041240FF20E2FF0AC77899915130D" unitRef="usd">357000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4E5D75709C9FE363D20977899946A331" unitRef="usd">-249000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q3YTD" decimals="-3" id="Fact-FF82FAA38481765CDC8477899930249B" unitRef="usd">339000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q3YTD" decimals="-3" id="Fact-A9E2A387A3536EA235F7778999074B5A" unitRef="usd">265000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="FD2015Q3YTD" decimals="-3" id="Fact-DC75CAF046ACF2FE25527789992A6037" unitRef="usd">-14000</us-gaap:IncreaseDecreaseInRestrictedCash>
	<us-gaap:IncreaseDecreaseInRestrictedCash contextRef="FD2016Q3YTD" decimals="-3" id="Fact-536F00A1F47A8284D83B9BE9BAB1988B" unitRef="usd">0</us-gaap:IncreaseDecreaseInRestrictedCash>
	<us-gaap:InterestExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-5F1235AA81B01B8B65C47789998D0E16" unitRef="usd">827000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2015Q3QTD_us-gaap_LineOfCreditFacilityAxis_cris_BioPharmaTwoMember" decimals="-5" id="Fact-30BD475765B9149D4070778998D3B5C6" unitRef="usd">800000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-4F962CDF50F85357B7917789990D00E7" unitRef="usd">2537000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2015Q3YTD_us-gaap_LineOfCreditFacilityAxis_cris_BioPharmaTwoMember" decimals="-5" id="Fact-00BD5FCDB1B9B9B52386778998F5E0E6" unitRef="usd">2500000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-F084BE90BE359D060992778999646E12" unitRef="usd">657000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3QTD_us-gaap_LineOfCreditFacilityAxis_cris_BioPharmaTwoMember" decimals="-5" id="Fact-769A90096A0C9C1AC735778998E45525" unitRef="usd">700000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1E5CA458BDF24CF2DD32778999860587" unitRef="usd">2126000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3YTD_us-gaap_LineOfCreditFacilityAxis_cris_BioPharmaTwoMember" decimals="-5" id="Fact-55C1769BF401FBCA2DEB778998F68A51" unitRef="usd">2100000</us-gaap:InterestExpense>
	<us-gaap:InterestPayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-775CBA493A67A632BDE6066C8CEE4CCB" unitRef="usd">252000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-1F5DBAD4391ADA54CF58066C70A8E556" unitRef="usd">225000</us-gaap:InterestPayableCurrent>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q3QTD" decimals="-3" id="Fact-BAF12F4FC1064B3459B47789990FD361" unitRef="usd">128000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q3YTD" decimals="-3" id="Fact-4EB6F50227887543F0357789997AA91A" unitRef="usd">252000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q3QTD" decimals="-3" id="Fact-84E5EEB09915537EE38D77899959E9CF" unitRef="usd">101000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4E9A583B8BDF34636BCC7789993C698D" unitRef="usd">325000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-3" id="Fact-EBE99226DFD3F92284EA778999029C0C" unitRef="usd">30455000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2016Q3" decimals="-3" id="Fact-4475A2FB877745BC1DC67789992E5D7F" unitRef="usd">28323000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-FC54B62EA4E219DF434677899949880E" unitRef="usd">94965000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q3" decimals="-3" id="Fact-3BE8471469EA5FE852FB778998F30091" unitRef="usd">66193000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-6318D448EAB8308B82537789998C66E8" unitRef="usd">10758000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-65CA4DEA8720C82067C277899910B160" unitRef="usd">12484000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-66FE0DA9E47C7D85CE9477899979A048" unitRef="usd">4607000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2015Q4_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-8AF96758181C801035AE778998DE46BC" unitRef="usd">4600000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-4FBBFAC35DD096D436D777899944CE78" unitRef="usd">5104000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q3_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-769FA5A3196DEAD4E6AC778998EA8BAD" unitRef="usd">5100000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-AC40AE493BE7EF204C21778998D63B3D" unitRef="usd">19558000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2015Q4_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-F94CE77D26B2BF37926F778998F62AF0" unitRef="usd">19600000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2016Q3" decimals="-3" id="Fact-C61972AA815CC4F2E6A6778999451356" unitRef="usd">15798000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2016Q3_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-9349C65BF74C18078E34778998F97F9B" unitRef="usd">15800000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:MarketableSecuritiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-F0EED538B99D91BDB144778998DC32D6" unitRef="usd">49100000</us-gaap:MarketableSecuritiesCurrent>
	<us-gaap:MarketableSecuritiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-71A444E7827D741921CE7789991C05E5" unitRef="usd">32684000</us-gaap:MarketableSecuritiesCurrent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-395F1063B3AD612EB8C07789991FBFA9" unitRef="usd">62029000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2016Q3YTD" decimals="-3" id="Fact-F82A8002EC279E8F4053778999467BF6" unitRef="usd">-2058000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-4C15B0FC77D235762B4D778999521F4D" unitRef="usd">-22089000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2016Q3YTD" decimals="-3" id="Fact-FBD5C35BD0635E540957778998F8754A" unitRef="usd">16062000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2015Q3YTD" decimals="-3" id="Fact-A498ED15E01337D3AA087789990C3CAE" unitRef="usd">-19028000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1A7B04D43D478B8E007377899958C923" unitRef="usd">-26424000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-4834CF0078F78B64A9FE778998D3BD27" unitRef="usd">-5543000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-E7FEF835D289506B684F778998E1FEFF" unitRef="usd">-45520000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-1B200D00E0CE95A479EB7789998FA843" unitRef="usd">-28345000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-AA56280C122FC77935237789996839EF" unitRef="usd">-49077000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfReportableSegments contextRef="FD2016Q3YTD" decimals="INF" id="Fact-E0895645113EEEF16101778999314E46" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-3E5C1836B668A80E657E7789996EA06C" unitRef="usd">-4844000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3YTD" decimals="-3" id="Fact-A7E1C4F9D14D8C79360F778999705744" unitRef="usd">-43235000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-FD53211A6FDAE61CFF6A7789991B4A50" unitRef="usd">-27789000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-EF805204B00F06214DE977899989DA40" unitRef="usd">-47276000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-8DC0B2F988D569FB4AE4778999245F31" unitRef="usd">249000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-299D3F9A94DB124C12FD77899927C898" unitRef="usd">347000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-AE64A14E98D94C192F0977899973FE32" unitRef="usd">51000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q3" decimals="-3" id="Fact-8B85B0E78B2E993EFF5E7789993B5634" unitRef="usd">3000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-B40FB3535C2390D72E6E778999343C0E" unitRef="usd">65000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-0778A12763FDDA78E46A7789993A634E" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-1FCACDD4316EA1C4EA067789997B08BF" unitRef="usd">65000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-9DCD662AC9BF3D03536C77899939012B" unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-CD60623A5697F6E8EF22778999492486" unitRef="usd">139000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q3" decimals="-3" id="Fact-B8CC9A801214F3CC8E797789993773E7" unitRef="usd">41000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-C4CC03A465B57C8B6A6B778998D7C8DC" unitRef="usd">-699000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-CA9A29FBC68AA2BE7AF8778999677E07" unitRef="usd">-2285000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-CED3408AF62771173D0677899983FF03" unitRef="usd">-556000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-08D495B462B1C5B7D19277899985C9BC" unitRef="usd">-1801000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-5F0033F24006FB797187FC79E4583AA7" unitRef="usd">24500000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_AcceptanceofINDFilingIRAK4ProgramMember" decimals="INF" id="Fact-B056FD0DD7D44A29AB4C1C9CDCD176F8" unitRef="usd">3000000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_AcceptanceofINDFilingProgramFourMember" decimals="INF" id="Fact-7E71A2F53745DB63A70F1C9CD232A7BB" unitRef="usd">2500000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_AcceptanceofINDFilingProgramThreeMember" decimals="INF" id="Fact-38ABF4FE85FB3505D1A91C9CD60DE4B7" unitRef="usd">2500000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ExtendedExclusivityIRAK4ProgramMember" decimals="INF" id="Fact-5D38EA3D26BCE9F9FBA21C9CDE622CCB" unitRef="usd">1000000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ExtendedExclusivityPD1VISTAProgramMember" decimals="INF" id="Fact-5472406F79272CED750E1C9CDA57E033" unitRef="usd">1000000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_OptionExercisePaymentProgramFourMember" decimals="INF" id="Fact-7059D52EB55A08918A631C9CD3724320" unitRef="usd">3000000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_OptionExercisePaymentProgramThreeMember" decimals="INF" id="Fact-DDE4B9680EF25984ECC21C9CD75A06F5" unitRef="usd">1500000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember" decimals="INF" id="Fact-74B6B4F13A48844C723D1C9CDB742051" unitRef="usd">4000000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember" decimals="INF" id="Fact-0DB5940AFA5A267E2D681C9CD8CEBC6B" unitRef="usd">4000000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember_us-gaap_TypeOfArrangementAxis_cris_ProgramSelectionFeeProgramFourMember" decimals="INF" id="Fact-A4FC6D330A28685D76461C9CD4BFE266" unitRef="usd">2000000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 contextRef="D2016Q3September_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-3EFCF055FEA36C98BB42B038FCCC8D2F" unitRef="usd">24500000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-C1C6DCBD2C27AC350980778998F85123" unitRef="usd">95595000</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-61551A9162BD91CAD7F0778999383B0D" unitRef="usd">50485000</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q3YTD" decimals="-3" id="Fact-3DA35B57DAD8C48A39107789991E1C00" unitRef="usd">48000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-676C11D87B83F0CD779477899944FC19" unitRef="usd">269000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-693ADE2BB19492A4562B778998F3F73B" unitRef="usd">1204000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q3" decimals="-3" id="Fact-A2807DF3496C755564497789993062B2" unitRef="usd">1437000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q3YTD" decimals="-3" id="Fact-4ABEF13E3CB70BF0F4E07789992A6E20" unitRef="usd">64619000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q3YTD" decimals="-3" id="Fact-533F3EEE98786574471B9BE9E7EFDA58" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="FD2015Q3YTD" decimals="-3" id="Fact-0C3BE36238E3DAEF255E7789990276A6" unitRef="usd">203000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4ACD9995D51F2273F44877899910BFCE" unitRef="usd">1161000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
	<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="FD2015Q3YTD" decimals="-3" id="Fact-FF9110FFFC1D7742B8A077899945780A" unitRef="usd">73521000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-2C69C40395191A274E597789994E6604" unitRef="usd">66816000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
	<us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="FD2015Q3YTD" decimals="-3" id="Fact-FBE05525BF941151B5AC9BEB8DB297C8" unitRef="usd">19000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
	<us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-D3EFCB8B5B77759E800C0748C968CD6B" unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-C28369835EC89B46ADA677899936473D" unitRef="usd">278000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q3" decimals="-3" id="Fact-4CC66B09F67B1489FC63778998D5329F" unitRef="usd">406000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2015Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-1A43C3D56325278E561F7789997104B4" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-A90D3B7000EEFE0F7E357789994A7F35" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2015Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" decimals="-5" id="Fact-FA06EA73F76E28C80DE47789994E48FF" unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2015Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" decimals="-5" id="Fact-37A9E640BB67C2E07BDB7789994A6125" unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2016Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" decimals="-5" id="Fact-4DE1808EBD5E0EC01A3E7789994BE508" unitRef="usd">300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2016Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" decimals="-5" id="Fact-C464E9EE08382A87A3B277899943BEB6" unitRef="usd">400000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RepaymentsOfDebt contextRef="FD2015Q3YTD" decimals="-3" id="Fact-676171630B04DAB8F9657789992D5279" unitRef="usd">2793000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2015Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_CreditFacilityAxis_cris_PrincipalPortionMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-43832E767A30D566E916778998DA8592" unitRef="usd">2800000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2015Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-A29F48D68A8D18D479F8778998F8C1D5" unitRef="usd">5300000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2016Q3YTD" decimals="-3" id="Fact-9891695C8555B531527F7789994530A9" unitRef="usd">3219000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2016Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_CreditFacilityAxis_cris_PrincipalPortionMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-23D622D582C25CF84E09778998FC9AA4" unitRef="usd">3200000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2016Q3YTD_dei_LegalEntityAxis_us-gaap_SubsidiariesMember_us-gaap_DebtInstrumentAxis_cris_CreditAgreementWithBioPharmaTwoMember" decimals="-5" id="Fact-50381A9D4BF0AC09C729778998E04FED" unitRef="usd">5300000</us-gaap:RepaymentsOfDebt>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2015Q3QTD" decimals="-3" id="Fact-8BDB745B932ADEE6F029778999722177" unitRef="usd">-248000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2015Q3YTD" decimals="-3" id="Fact-157383F0436672C973D2778999701946" unitRef="usd">-212000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2016Q3QTD" decimals="-3" id="Fact-6C83A080E10201C32B497789991CE177" unitRef="usd">-58000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2016Q3YTD" decimals="-3" id="Fact-74A530EE0A98565D356077899981FF98" unitRef="usd">-238000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-BB5A070B2E7BFC01B005778998FBB2AC" unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q1QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-AE5C19BDD606372E5A2D778999603EEE" unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-40A0CF34613CF6FAD57CFC737F47B9E4" unitRef="usd">18000000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-72EB92D41EB9B901534AFC71F44CCD13" unitRef="usd">18000000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3QTD" decimals="-3" id="Fact-277081C795FFCAE01E1D77899988ABE0" unitRef="usd">4001000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q3YTD" decimals="-3" id="Fact-35C08DAD0D95EC8ED2907789997A8025" unitRef="usd">14658000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q3QTD" decimals="-3" id="Fact-8CB6336DF9BF9DDF7E35778998EADD6D" unitRef="usd">6781000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E61BB2500DD3457F88A67789997BE80B" unitRef="usd">22431000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2015Q3QTD" decimals="-3" id="Fact-45EC0B5BF5AB7F8F386E9BE5422DEC58" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2015Q3YTD" decimals="-3" id="Fact-412F5CE98EB4AAAB4F3777899953B071" unitRef="usd">24348000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2016Q3QTD" decimals="-3" id="Fact-896454CEAF586C07FC569BE52999929D" unitRef="usd">17989000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2016Q3YTD" decimals="-3" id="Fact-2B998CC72B233077A5CD9BE553148E1B" unitRef="usd">17989000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestrictedInvestmentsNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-305C84341EDB89D9D85F778998FF5F72" unitRef="usd">153000</us-gaap:RestrictedInvestmentsNoncurrent>
	<us-gaap:RestrictedInvestmentsNoncurrent contextRef="FI2016Q3" decimals="-3" id="Fact-3240EEFF3FB2CBB0391677899976C6BC" unitRef="usd">153000</us-gaap:RestrictedInvestmentsNoncurrent>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-3" id="Fact-0873C9D22BAECA3AA29977899906863E" unitRef="usd">-838536000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q3" decimals="-3" id="Fact-79DE74CB26642BED269F778998DE7018" unitRef="usd">-887613000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2015Q3QTD" decimals="-3" id="Fact-C6E226CC82CF0E07C205778998F3E86A" unitRef="usd">2045000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3YTD" decimals="-3" id="Fact-417B5963818C460D8BD577899989F07C" unitRef="usd">5786000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-3" id="Fact-C7697B7EBC5A884FC95677899984660C" unitRef="usd">1759000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3YTD" decimals="-3" id="Fact-72EC1424E3C2C8821FE27789997456A4" unitRef="usd">5165000</us-gaap:Revenues>
	<us-gaap:RoyaltyExpense contextRef="FD2015Q3QTD" decimals="-3" id="Fact-FCD0E186C8369D5ECDA97789992B3764" unitRef="usd">116000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2015Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-AA7E3A1C786CA7633DCB778999661F1C" unitRef="usd">100000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2015Q3YTD" decimals="-3" id="Fact-DAF1AC16C8C686F55DF27789997E8497" unitRef="usd">303000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2015Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-862B846DA7BBA17469A477899960174C" unitRef="usd">300000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-B660A2504F55AB1636B6778999873FFA" unitRef="usd">94000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-9496D968D2735CCE0554778999680D2C" unitRef="usd">100000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-52983C00E782D82A81C6778999848278" unitRef="usd">278000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyExpense contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-9A1420B801EDA459FAA87789995450ED" unitRef="usd">300000</us-gaap:RoyaltyExpense>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q3QTD" decimals="-3" id="Fact-EB5743A1AFBE8571B9A27789994BAEE4" unitRef="usd">2293000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-69EE0702FE340470BE417789994CAC02" unitRef="usd">2300000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q3YTD" decimals="-3" id="Fact-48FDCC07B1CA3A62E1BF77899936B0A8" unitRef="usd">5998000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-C648FD715559120E922B7789996F1066" unitRef="usd">6000000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q3QTD" decimals="-3" id="Fact-BE40790D8E5169039706778999580706" unitRef="usd">1817000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q3QTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-ABCBCF36B5F0CA55850E778998FEE302" unitRef="usd">1800000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-41AB1FEDB042C4E52A31778998F6518F" unitRef="usd">5403000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_cris_GenentechIncMember" decimals="-5" id="Fact-85A6FF09F626C7979A2277899975E3FC" unitRef="usd">5400000</us-gaap:RoyaltyRevenue>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3QTD" decimals="-3" id="Fact-0FFFDB10FFA207F67CCD77899986C0C3" unitRef="usd">901000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-B76CF07DEAD518D7375677899963BFF6" unitRef="usd">731000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-AFA3A32FD86116732FB9778999576FB1" unitRef="usd">170000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3YTD" decimals="-3" id="Fact-16F684879876B4E0397C7789995311A1" unitRef="usd">2875000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-8BFCEFC4BED7937924A57789998A5E47" unitRef="usd">2104000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-6FAC98C540ECCA242F297789995D35AD" unitRef="usd">771000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3QTD" decimals="-3" id="Fact-6EEE653E893286376EC07789998C3148" unitRef="usd">1630000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-CEDA71ECBD5244FB6C147789998775C7" unitRef="usd">1425000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-8E4BAB3EAB09940F10EA77899964EE96" unitRef="usd">205000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3YTD" decimals="-3" id="Fact-31D1777B7F6B7CD5F2FA7789994B3141" unitRef="usd">3311000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-65D5D4D94627D54F7DAE77899960D39E" unitRef="usd">2780000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-B040D875921AA5949B51778999619BD4" unitRef="usd">531000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2016Q3September2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cris_MrPasseriMember" id="Fact-60DC228F7A82F9560BF1FC7CD056EB95">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_TitleOfIndividualAxis_cris_BoardofDirectorsViceChairmanMember" id="Fact-EBA6C0DF9FACA6AD215BFC34F7069CB4">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember" id="Fact-23B22E544E45F2BC35E1778999715995">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q3YTD" decimals="INF" id="Fact-EF6C809D922BFBF0778177899905E9F8" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q3YTD" decimals="INF" id="Fact-B6EE5DF098F094B46A8A7789990D2B4F" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2015Q3YTD" decimals="INF" id="Fact-34872A40D3C3C6CB0B9D77899901F1D6" unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2016Q3YTD" decimals="INF" id="Fact-A6CFF7F07C4356DCE7C8778999061DC4" unitRef="number">0.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2015Q3YTD" decimals="INF" id="Fact-5D834F4B7AC3DAD509F8778998E6CC73" unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2016Q3YTD" decimals="INF" id="Fact-0FC7528F772C3D6BDA9DDE2E1E58E38B" unitRef="number">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2015Q3YTD" decimals="INF" id="Fact-5618E670A1A7BF95CB48778998E39793" unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q3YTD" decimals="INF" id="Fact-831E33498ADA083D6169778998FBA0DB" unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2015Q3YTD" decimals="INF" id="Fact-8BE409523874CD790B49778998F760C9" unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q3YTD" decimals="INF" id="Fact-90D48A4D9532FC511FA3778998F2F1BF" unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q3YTD" decimals="-5" id="Fact-419943E41A70CE567DBE7789998ED544" unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q3YTD" decimals="-5" id="Fact-E29C5F0E6845404E8E54778999671650" unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember" decimals="INF" id="Fact-AF4E59403CC04F47B4267789996FDCD5" unitRef="shares">4621225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember_us-gaap_TitleOfIndividualAxis_cris_NonEmployeeDirectorsMember" decimals="INF" id="Fact-F442849C01FEE7F9BEE47789996D1F85" unitRef="shares">470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q3YTD" decimals="2" id="Fact-E2B75AE82686E76979BC7789998689B4" unitRef="usdPerShare">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q3YTD" decimals="2" id="Fact-B0DD1EC0CE8B9A126308778999650BD0" unitRef="usdPerShare">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q3" decimals="-5" id="Fact-99FC96C55E7B033711E3778999893B91" unitRef="usd">9200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q3" decimals="INF" id="Fact-25BB0BB8AFB34CBF49737789997A3B72" unitRef="shares">15487348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember_us-gaap_TitleOfIndividualAxis_cris_NonEmployeeDirectorsMember" decimals="2" id="Fact-6E8276CC2D0BDE22C2E077899952EC0F" unitRef="usdPerShare">1.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2016Q3September6" decimals="INF" id="Fact-9794FCBAB60BD2513545B034506CA90C" unitRef="usdPerShare">1.76</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" id="Fact-476BFEA9BA38263694A5778999663972" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="FD2016Q3YTD_us-gaap_PlanNameAxis_cris_TwoThousandAndTenPlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="INF" id="Fact-1B64682F8597D839289B778999785399" unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q3YTD_us-gaap_TitleOfIndividualAxis_cris_EmployeesMember" id="Fact-303A7BE1972150D532217789997283EC">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q3YTD_us-gaap_TitleOfIndividualAxis_cris_OfficersAndDirectorsMember" id="Fact-EA21F37196421760AF3277899935A05A">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q3YTD_us-gaap_TitleOfIndividualAxis_cris_EmployeesMember" id="Fact-4058174162089774BB3877899931644C">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q3YTD_us-gaap_TitleOfIndividualAxis_cris_OfficersAndDirectorsMember" id="Fact-B002F10705DC2CD7E7237789994D2173">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2016Q3" decimals="-5" id="Fact-C9448F4B3AAAE82A7B6E7789997B8544" unitRef="usd">3900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2015Q3YTD" decimals="-5" id="Fact-12913D5A7FF55B81B732778999765942" unitRef="usd">2100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2016Q3YTD" decimals="-5" id="Fact-55FC024A2D3E082ABC2D7789996AD83A" unitRef="usd">2800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-27280172F8EEBE15FCC6FC79A5C1A09B" unitRef="shares">10208333</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="D2016Q3September_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="INF" id="Fact-1974EA8DC715541179AAB02FE4D7EA4F" unitRef="shares">10208333</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="D2016Q3September7_us-gaap_CounterpartyNameAxis_cris_AurigeneDiscoveryTechnologiesLtdMember" decimals="-5" id="Fact-25B7B350342BB55710E0B0313F103534" unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-4BC1F00919CE34DAC34C7789994CDE18" unitRef="usd">-11000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-0D0F9A620AA6171ECBAE778999762B12" unitRef="usd">54000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-AA472D001C51845015DC778998D8B5E4" unitRef="usd">64510000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-29A9CA8B976D0900F35F77899937E850" unitRef="usd">28000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q3" decimals="-3" id="Fact-0BF70FB60CA9693D7A4177899904F6A3" unitRef="usd">37870000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-3" id="Fact-6A8742B8681B0B25768A77899935951D" unitRef="usd">26000</us-gaap:StockholdersEquity>
	<us-gaap:TreasuryStockShares contextRef="FI2015Q4" decimals="INF" id="Fact-9501B26EF0F06A385B8B7789997F902A" unitRef="shares">1222846</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2016Q3" decimals="INF" id="Fact-103671FD43E56390D6C7A0654C50C80E" unitRef="shares">1222846</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-4A64304417C238DAA9A47789992F55AC" unitRef="usd">1524000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q3" decimals="-3" id="Fact-81035CA7062F0E888649778998F14B11" unitRef="usd">1524000</us-gaap:TreasuryStockValue>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q3QTD" decimals="0" id="Fact-8ABCC4065AAF988E30547789998BE867" unitRef="shares">128392413</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q3YTD" decimals="0" id="Fact-2D2766C5DB50B5149C067789996CAC09" unitRef="shares">121634415</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3QTD" decimals="0" id="Fact-286A484FC006190551C67789992072E8" unitRef="shares">132065947</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3YTD" decimals="0" id="Fact-CF728701218BBA78AA2D778999757499" unitRef="shares">130122698</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-A528B719FB9024B7D3BB778999578005">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Collaboration Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:16px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Genentech, Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2003, the Company licensed its proprietary Hedgehog pathway technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop molecules that inhibit the Hedgehog pathway for the treatment of various cancers. The collaboration is currently focused on the development of Erivedge, which is being commercialized by Genentech in the United States and by Genentech&amp;#8217;s parent company, Roche, in several other countries for the treatment of advanced BCC. Pursuant to the agreement, the Company is eligible to receive up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$115.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in contingent cash milestone payments, exclusive of royalty payments, in connection with the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. Of this amount, the Company has received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$59.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to these payments and pursuant to the agreement, the Company is entitled to a royalty on net sales of Erivedge that ranges from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The royalty rate applicable to Erivedge may be decreased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on a country-by-country basis in certain specified circumstances, including when a competing product that binds to the same molecular target as Erivedge is approved by the applicable regulatory authority in another country, and is being sold in such country, by a third party for use in the same indication as Erivedge, or, when there is no issued intellectual property covering Erivedge in a territory in which sales are recorded. In 2015, the FDA and the European Medicine Agency&amp;#8217;s Committee for Medicinal Products for Human Use, or CHMP, approved another Hedgehog signaling pathway inhibitor, Odomzo&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (sonidegib), which is marketed by Novartis, for use in locally advanced BCC. Beginning in the fourth quarter of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Genentech applied the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; royalty reduction on United States sales of Erivedge as a result of the first commercial sale of sonidegib in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2012, Curis formed a wholly owned subsidiary, Curis Royalty, which received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; loan at an annual interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pursuant to a credit agreement between Curis Royalty and BioPharma-II (see Note 7). In connection with the loan, Curis transferred to Curis Royalty its right to receive royalty and royalty-related payments on the commercial sales of Erivedge that it receives from Genentech. The loan and accrued interest is being repaid by Curis Royalty using such royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty and is non-recourse to Curis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in royalty revenue under the Genentech collaboration during the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company recorded costs of royalty revenues within the costs and expenses section of its condensed consolidated statements of operations and comprehensive loss of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. For each of these periods, these amounts are comprised of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the royalties earned by Curis Royalty that the Company is obligated to pay to university licensors. As further discussed in Note 7, the Company expects that all royalty revenues received by Curis Royalty from Genentech on net sales of Erivedge will be used by Curis Royalty to pay principal and interest under the loan that Curis Royalty received from BioPharma-II, subject to specified quarterly caps, until such time as the loan is fully repaid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recorded research and development revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and research and development revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to expenses incurred by the Company on behalf of Genentech that were paid by the Company and for which Genentech is obligated to reimburse the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Genentech incurred expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, under this collaboration, for which the Company is obligated to reimburse to Genentech, and which the Company has recorded as contra-revenues in its condensed consolidated statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:40px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:16px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Aurigene Agreement&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and selected precision oncology targets. Under the collaboration agreement, Aurigene granted the Company an option to obtain exclusive, royalty-bearing licenses to relevant Aurigene technology to develop, manufacture and commercialize products containing certain of such compounds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For each program, Aurigene has granted the Company an exclusive option, exercisable within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90 days&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after Aurigene delivers the relevant data regarding a development candidate, to obtain an exclusive, royalty-bearing license to develop, manufacture and commercialize compounds from such program, including the development candidate and products containing such compounds, anywhere in the world, except for India and Russia. For the development, manufacture, and commercialization of compounds from a particular program and products containing such compounds in India and Russia, Aurigene will grant the Company the royalty-bearing license described above for such program, and the Company will grant Aurigene an exclusive, royalty-free, fully paid license under the Company&amp;#8217;s relevant technology upon exercise of the relevant option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company exercised options to license the first &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; programs under this collaboration, resulting in an aggregate one-time payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (comprised of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; option exercise fee for each program) by the Company to Aurigene. Effective October 2015, the Company agreed to make additional payments to Aurigene totaling up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for supplemental research, development and/or manufacturing activities in support of these &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; programs.&amp;#160;The Company incurred and recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of such costs in the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was paid in the three months ended March 31, 2016.&amp;#160;The remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was incurred and recognized in the three months ended March&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and paid in the three months ended June 30, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Also in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company selected a preclinical program for potential further development within the immuno-oncology part of the collaboration resulting in a one-time &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment. In October 2016, the Company licensed the program and designated CA-327 as the development candidate as described in Note 1, resulting in a one-time &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company anticipates that it will select additional programs under this collaboration in the future, and the Company intends to have the collaboration&amp;#8217;s steering committee recommend such additional programs in order for Aurigene to initiate or continue the relevant preclinical activities described in each program&amp;#8217;s written plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For each option to license (as described above) exercised by the Company, the Company is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; product in each of the United States, specified countries in the European Union, and Japan, and Aurigene is obligated to use commercially reasonable efforts to perform its obligations under the development plan for such licensed program in an expeditious manner.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subject to specified exceptions, Aurigene and the Company have agreed to collaborate exclusively with each other on the discovery, research, development and commercialization of programs and compounds within immuno-oncology for an initial period of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the effective date of the collaboration agreement. At the Company&amp;#8217;s option, and subject to specified conditions, it may extend such exclusivity for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year periods by paying to Aurigene exclusivity option fees on an annual basis. The first of such option fees will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, to be paid in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; equal installments, and the Company currently estimates that these payments will be due in the first and third quarters of 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, beyond the up-to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of exclusivity described above, and subject to specified exceptions and payment by the Company of an annual exclusivity fee on a program-by-program basis, Aurigene and the Company have agreed to collaborate exclusively with each other on each program for which there are ongoing activities in research or development, or for which the Company has exercised its option to acquire an exclusive license (as described above) and the Company or its affiliates or sublicensees are actively developing or commercializing a compound or product from such program in a major market.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For each product that may be commercialized, the Company has granted Aurigene the right, subject to certain conditions, to nominate &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; global drug substance or drug product supplier to provide up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total requirements in the Company&amp;#8217;s territory.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research Payments, Option Exercise Fees and Milestone Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company has agreed to make the following research, option exercise fees and milestone payments to Aurigene:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:6pt;"&gt;&lt;font style="font-family:inherit;font-size:6pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;for the PD1/VISTA and IRAK4 programs: up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$52.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per program, comprised of: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each option exercise, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon acceptance of each IND filing, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon dosing of the fifth patient in the Company&amp;#8217;s first Phase 1 clinical trial in each program, as well as specified approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. Effective October 2015, the Company agreed to make additional payments to Aurigene totaling up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for supplemental research, development and/or manufacturing activities in support of these &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; programs. During the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized and paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Aurigene upon the acceptance of the IND filing for CA-170, a PDL1/VISTA antagonist. Since the inception of the agreement through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has incurred costs totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to these programs under the collaboration;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;for the third and fourth programs: up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per program, comprised of: &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for a program selection fee, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for an option exercise, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon acceptance of an IND filing, as well as development, approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. Since the inception of the agreement through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has made payments to Aurigene totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the third program under this collaboration; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:47px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:23px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;for any program thereafter: up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$140.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per program, comprised of: up to a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$53.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for research fees, an option exercise fee, a preclinical milestone and development milestones, as well as specified filing, approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payments have been made to Aurigene related to such programs under the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Amendment to Collaboration Agreement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. On September 7, 2016, the Company and Aurigene entered into an amendment to the January 2015 collaboration agreement. Under the terms of the amendment, in exchange for the issuance by the Company to Aurigene of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,208,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock, Aurigene waived payment of up to a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in milestones and other payments from the Company that may become due under the 2015 collaboration agreement. The following milestones and other payments have been waived: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment for extended exclusivity related to the IRAK4 program;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment upon acceptance of IND filing related to the IRAK4 program; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment upon dosing of the fifth patient in the Company's Phase 1 clinical trial for the IRAK4 program;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment for extended exclusivity related to the PD1/VISTA program;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment upon dosing of the fifth patient in the Company's Phase 1 clinical trial for the PD1/VISTA program; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of the payment related to the option exercise payment of the third program;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment upon acceptance of IND filing related to the third program; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment for program selection fee of the fourth program;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment for option exercise of the fourth program; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;text-indent:-24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment upon acceptance of IND filing related to the fourth program; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To the extent any of these milestone or other payments described&amp;#160;above would not otherwise be payable by Curis,&amp;#160;e.g.&amp;#160;in the event one or more of the listed milestone events do not occur, the Company will have the right to deduct the unused waiver amount from any one or more of the milestone payment obligations tied to achievement of commercial milestone events. The amendment also provides that upon exercise the option for the third and fourth programs, the Company will provide up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of additional funding for each such licensed program provided that supplemental program activities are performed by Aurigene. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting Summary. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of this amendment, the value of common stock issued to Aurigene equaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the closing share price of the Company&amp;#8217;s common stock of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.76&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share on September 6, 2016, which was the last closing price prior to execution of the amendment. As a result, the Company recognized in-process research and development expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; within its condensed consolidated statement of operations and comprehensive loss for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in recognition of the fact that any compounds that have been and may be licensed from Aurigene are in clinical or preclinical development and will require substantial development, regulatory and marketing approval efforts in order to reach technological feasibility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2016Q3YTD" id="Fact-20B12EF5B52A2A53365A7789991E4298">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss) as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&amp;#160;Gain&amp;#160;on&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Securities&amp;#160; Available-for-Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrealized gain on marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net current period other comprehensive income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, as of September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The above amounts do not reflect a tax effect because the Company expects to record a net loss for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&amp;#160;Losses and&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gain&amp;#160;on&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Securities&amp;#160;Available-for-Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrealized gain on marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net current period other comprehensive income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, as of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-2FD8020B779CE3F26875778998FA651C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2012, Curis&amp;#8217; wholly owned subsidiary, Curis Royalty, received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; loan at an annual interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pursuant to a credit agreement between Curis Royalty and BioPharma-II. In connection with the loan, Curis transferred to Curis Royalty its right to receive royalty and royalty-related payments on the commercial sales of Erivedge that it receives from Genentech (see Note 4(a)). The loan and accrued interest is being repaid by Curis Royalty using such royalty and royalty-related payments. To secure repayment of the loan, Curis Royalty granted a first priority lien and security interest (subject only to permitted liens) to BioPharma-II in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty, and is non-recourse to Curis. Under the terms of the loan, quarterly royalty payments received by Curis Royalty from Genentech will first be applied to pay (i)&amp;#160;escrow fees payable by Curis pursuant to an escrow agreement between Curis, Curis Royalty, BioPharma-II and Boston Private Bank and Trust Company, (ii)&amp;#160;Curis&amp;#8217; royalty obligations to university licensors, (iii)&amp;#160;certain expenses incurred by BioPharma-II in connection with the credit agreement and related transaction documents, including enforcement of its rights in the case of an event of default under the credit agreement and (iv)&amp;#160;expenses incurred by Curis enforcing its right to indemnification under the collaboration agreement with Genentech. Remaining amounts are applied first to pay interest and second, principal on the loan. Curis remains entitled to receive any contingent payments upon achievement of clinical development objectives. Curis Royalty retains its right to royalty payments related to sales of Erivedge following repayment of the loan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The final maturity date of the loan will be the earlier of the date when the principal is paid in full or the termination of Curis Royalty&amp;#8217;s right to receive royalties under the collaboration agreement with Genentech. Because the repayment of the term loan is contingent upon the level of Erivedge royalties received, the short- and long-term classification of the debt is based on the Company&amp;#8217;s estimate of the timing of amounts to be repaid. The Company cannot estimate when the loan will be repaid as repayment is impacted by numerous factors, all of which are beyond the Company&amp;#8217;s control. The repayment term may be shortened or extended depending on the actual level of Erivedge royalties received. In addition, if Erivedge royalties are insufficient to pay the accrued interest on the outstanding loan, any unpaid interest outstanding will be added to the principal on a quarterly basis. The length of the actual repayment period could vary materially to the extent that royalty payments Curis Royalty receives are lower than the Company&amp;#8217;s current estimates, which could arise due to factors beyond the Company&amp;#8217;s control, such as the sale of competing products that result in a lowering of the royalty rates that Curis Royalty is entitled to receive, decreased market acceptance or a failure by Genentech and/or Roche to successfully commercialize Erivedge in territories where it has received regulatory approval. At any time after January&amp;#160;1, 2017, Curis Royalty may, subject to certain limitations, prepay the outstanding principal of the loan in whole or in part, at a price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the outstanding principal on the loan, plus accrued but unpaid interest. The obligations of Curis Royalty under the credit agreement to repay the loan may be accelerated upon the occurrence of an event of default as defined in the credit agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Curis Royalty made payments totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; have been applied to the principal, respectively, with the remainder applied to accrued interest. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded short- and long-term debt of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded short- and long-term debt of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the loan, with such amounts recorded within the Company&amp;#8217;s condensed consolidated balance sheets. In the three months ended March&amp;#160;31, 2016, the Company adopted ASU No.&amp;#160;2015-3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Interest&amp;#8212;Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In accordance with the updated standard, the Company reclassified certain of its debt issuance costs, related to the loan, from assets to a direct deduction from the carrying amount of the related debt liability. The adoption of this guidance did not impact the consolidated statement of operations and comprehensive loss and the impact to the balance sheet was not material.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, the Company recorded related accrued interest on the debt of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, with such amounts included in the Company&amp;#8217;s accrued liabilities section of its condensed consolidated balance sheets. For the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized interest expense related to the loan with BioPharma-II of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, in the condensed consolidated statement of operations and comprehensive loss. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized interest expense related to the loan with BioPharma-II of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, in the condensed consolidated statement of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the fair value of the debt approximates its carrying value due to the expected repayment period and because the interest rate yield is near current market rate yields. Due to the assumptions required in estimating future Erivedge royalties, the expected repayment period and weighting of various royalty projection scenarios, the fair value of the debt is measured using Level 3 inputs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2016Q3YTD" id="Fact-2E5A3E12C77CD52D9AD27789996737AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Accounting for Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shareholder-approved, share-based compensation plans: (i)&amp;#160;the Amended and Restated 2010 Stock Incentive Plan, or the 2010 Plan, adopted as amended by the board of directors in March 2015 and approved by shareholders in May 2015 and (ii)&amp;#160;the 2010 Employee Stock Purchase Plan, or the ESPP, adopted by the board of directors in April 2010 and approved by shareholders in June 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company&amp;#8217;s board of directors granted options to purchase a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,621,225&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock to officers and employees of the Company, both under the 2010 Plan or in the form of inducement awards pursuant to NASDAQ Marketplace Rules. These options vest as to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the shares underlying the award after the first year and as to an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the shares underlying the award in each subsequent quarter, based upon continued employment over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period, and are exercisable at a price equal to the closing price of the Company&amp;#8217;s common stock on the NASDAQ Global Market on the grant dates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company&amp;#8217;s board of directors also granted options to its non-employee directors to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;470,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the 2010 Plan, which will vest and become exercisable in equal monthly installments over a period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one year&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the date of grant. These options were granted at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.76&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, which equals the closing market price of the Company&amp;#8217;s common stock on the NASDAQ Global Market on the grant date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Employee and Director Grants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Vesting Tied to Service Conditions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In determining the fair value of stock options, the Company generally uses the Black-Scholes option pricing model. As discussed below, for employee stock options with market performance conditions, the Company uses a Monte Carlo simulation valuation model. The Black-Scholes option pricing model employs the following key assumptions for employee and director options awarded during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the assumptions noted in the following table:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life (years) - employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life (years) &amp;#8211; officers and directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.4-1.8%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.5-1.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63-70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68-70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividends&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The expected volatility is based on the annualized daily historical volatility of the Company&amp;#8217;s stock price for a time period consistent with the expected term of each grant. Management believes that the historical volatility of the Company&amp;#8217;s stock price best represents the future volatility of the stock price.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The risk-free rate is based on the U.S. Treasury yield in effect at the time of grant for the expected term of the respective grant. The Company has not historically paid cash dividends, and does not expect to pay cash dividends in the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The expected terms and stock price volatility utilized in the calculation involve management&amp;#8217;s best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. GAAP also requires that the Company recognize compensation expense for only the portion of options that are expected to vest. Therefore, management calculated an estimated annual pre-vesting forfeiture rate that is derived from historical employee termination behavior since the inception of the Company, as adjusted. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,487,348&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; stock options outstanding.&amp;#160;The aggregate intrinsic value of employee options outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to exercisable options. The weighted average grant-date fair values of these stock options granted during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.08&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.71&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of the impact of estimated forfeitures, of unrecognized compensation cost related to unvested employee stock option awards outstanding that is expected to be recognized as expense over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.84&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. The intrinsic value of employee stock options exercised during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employee Stock-Based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Daniel Passeri resigned from his position as Vice Chairman of the Company's board of directors. In connection with the related letter agreement with the Company, the board of directors approved a modification to Mr.&amp;#160;Passeri&amp;#8217;s vested common stock options such that the exercise period for all such options shall be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;twenty-four months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As a result, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of additional stock based compensation expense was recorded to account for this modification during the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recorded a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in compensation expense for the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in compensation expense for the three and the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to employee and director stock option grants. The total fair values of vested stock options for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Non-Employee Grants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has periodically granted stock options to consultants for services pursuant to the Company&amp;#8217;s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would also be cancelled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized expense related to non-employee stock options of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and reversed expense of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and reversed expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and recognized expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Total Stock-Based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the condensed consolidated statements of operations and comprehensive loss, including expense related to its ESPP:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;731&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-EC3F7498344A9ABCD1ED77899973C75A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2016Q3YTD" id="Fact-ABFBD44E07F713F1E30677899971789A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Loss Per Common Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, because the effect of the potential common stock equivalents would be antidilutive due to the Company&amp;#8217;s net loss position for these periods. Antidilutive securities consist only of stock options outstanding of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,487,348&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,678,899&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="FD2016Q3YTD" id="Fact-BADD7377C845979D78297789998F2D5D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the fair value hierarchy, the following table shows the fair value as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of those financial assets and liabilities that are measured at fair value on a recurring basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&amp;#160;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&amp;#160;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of September 30, 2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper, bonds and notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper, stock, bonds and notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Other&amp;#160;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Inputs&amp;#160;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Total&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper, bonds and notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper, stock, bonds and notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-E3CCF80191860EF50AB17789998E2F3D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company discloses fair value measurements based on a framework outlined by GAAP which requires expanded disclosures regarding fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i)&amp;#160;independent, (ii)&amp;#160;knowledgeable, (iii)&amp;#160;able to transact, and (iv)&amp;#160;willing to transact. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the fair value hierarchy, the following table shows the fair value as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of those financial assets and liabilities that are measured at fair value on a recurring basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other&amp;#160;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&amp;#160;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of September 30, 2016:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper, bonds and notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper, stock, bonds and notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,785&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&amp;#160;in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Other&amp;#160;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Inputs&amp;#160;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Inputs&amp;#160;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Total&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,568&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper, bonds and notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Municipal bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper, stock, bonds and notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets at fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,517&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No investments held at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were transferred between levels.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-2F35F93DA67D0AA17D5B7789998E9E53">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company discloses fair value measurements based on a framework outlined by GAAP which requires expanded disclosures regarding fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i)&amp;#160;independent, (ii)&amp;#160;knowledgeable, (iii)&amp;#160;able to transact, and (iv)&amp;#160;willing to transact. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:90%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-7AD8A98CDCBE893029EA778999580B88">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gain&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds and notes &amp;#8211; short-term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments have maturities ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with a weighted-average maturity of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gain&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds and notes &amp;#8211; short-term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments have maturities ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with a weighted-average maturity of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2016Q3YTD" id="Fact-938FBBE6591FD665153577899917EB38">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Nature of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of cancers. As used throughout these consolidated financial statements, the term &amp;#8220;the Company&amp;#8221; refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term &amp;#8220;Curis&amp;#8221; refers to Curis, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company conducts its research and development programs both internally and through strategic collaborations. The Company&amp;#8217;s most advanced drug candidate is CUDC-907, which is being investigated in clinical studies in patients with diffuse large B-cell lymphoma and solid tumors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene. In September 2016, the Company entered into an amendment to this agreement, pursuant to which Aurigene received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,208,333&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock in lieu of receiving up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of milestone and other payments from Curis (see Note 4(b)). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The collaboration comprises multiple programs, in which Curis has the option to exclusively license each program, including data, intellectual property and compounds associated with each respective program, once a development candidate is nominated within that program. In October 2015, the Company exercised options to license the first &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; programs under this collaboration. The first licensed program is focused on the development of orally-available small molecule antagonists of programmed death-1 (PD1) and V-domain Ig suppressor of T-cell activation (VISTA) pathways in the immuno-oncology field. The Company has named CA-170, a programmed death ligand-1 (PDL1)/VISTA antagonist, as the development candidate from this program. The second licensed program is focused on orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) enzyme in the precision oncology field and the Company has named CA-4948 as the development candidate from this program. In addition, in October 2015, the Company selected a third program for further development under the collaboration, the second preclinical program within the immuno-oncology field, which is focused on evaluating small molecule antagonists of PD1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3) pathways, including small molecules that target PDL1 and TIM3.  In October 2016, the Company exercised its option to license this third program, and designated CA-327 as the development candidate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is also party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#174;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor, in advanced basal cell carcinoma, or BCC. In addition to BCC, Roche and Genentech are separately conducting studies of Erivedge in other diseases, including in idiopathic pulmonary fibrosis and myelofibrosis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s proprietary small molecule compounds also include CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis, or IAP proteins, and CUDC-305, an orally-available, small molecule antagonist of Heat Shock Protein 90.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United&amp;#160;States by the United States Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company&amp;#8217;s business, including, but not limited to: the Company&amp;#8217;s ability to advance and expand its research and development programs; the Company&amp;#8217;s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties&amp;#8217; collaboration agreement; the Company&amp;#8217;s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company&amp;#8217;s ability to obtain adequate financing to fund its operations; the ability of the Company&amp;#8217;s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.&amp;#224;.r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company&amp;#8217;s ability to obtain and maintain necessary intellectual property protection; development by the Company&amp;#8217;s competitors of new or better technological innovations; dependence on key personnel; the Company&amp;#8217;s ability to comply with regulatory requirements; and the Company&amp;#8217;s ability to execute on its overall business strategies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it receives and makes under its current and potential future collaborations. The results of the Company&amp;#8217;s operations may vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company&amp;#8217;s preclinical studies and clinical trials for its drug candidates; Aurigene&amp;#8217;s ability to successfully discover and develop preclinical programs under the Company&amp;#8217;s collaboration with Aurigene, as well as the Company&amp;#8217;s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech&amp;#8217;s ability to successfully commercialize Erivedge; positive results in Roche and Genentech&amp;#8217;s ongoing clinical trials.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company anticipates that its existing cash, cash equivalents and investments at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; should enable it to maintain current and planned operations into the second half of 2017. The Company&amp;#8217;s ability to continue funding its planned operations beyond this period is dependent upon, among other things, its ability to control expenses and its ability to raise additional funds through equity or debt financings, the success of its collaboration with Genentech, including its receipt of additional contingent cash payments under this collaboration, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of such events is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2016Q3YTD" id="Fact-4BE103D13AC5696A51F87789990D7472">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;13. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the Financial Accounting Standard Board (FASB) issued Accounting Standard Update (ASU) 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which simplifies share-based payment accounting through a variety of amendments. The standard will be effective for annual reporting periods and interim periods within those annual periods, beginning after December&amp;#160;15, 2016, and early adoption is permitted. The Company does not expect the impact of this guidance to be material to its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The standard requires organizations that lease assets to recognize on the balance sheet assets or liabilities, as applicable, for the rights and obligations created by those leases. Additionally, the guidance modifies current guidance for lessor accounting and leveraged leases, and is effective for fiscal years beginning after December&amp;#160;15, 2018, and interim periods within such years. Early adoption is permitted, but the Company does not anticipate electing early adoption. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU, 2016-01, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recognition and Measurement of Financial Assets and Financial Liabilities,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which amends prior guidance on accounting for equity investments and financial liabilities. The new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The guidance is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within such years. Early adoption is permitted but the Company does not anticipate electing early adoption. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August&amp;#160;2014, the FASB issued ASU 2014-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Presentation of Financial Statements&amp;#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to continue as a Going Concern.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;This update is intended to define management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an organization&amp;#8217;s ability to continue as a going concern within one year of the date of issuance of the entity&amp;#8217;s financial statements and to provide related footnote disclosures. This guidance is effective for fiscal years ending after December&amp;#160;15, 2016, and early adoption is permitted. The Company is currently evaluating what effect, if any, the adoption of this guidance will have on the disclosures included in its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU 2015-14, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU 2016-08, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU 2016-12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact that these standards may have on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2016Q3YTD" id="Fact-DF32F7E9E4A068E32C25B0119DDA0793">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the Financial Accounting Standard Board (FASB) issued Accounting Standard Update (ASU) 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which simplifies share-based payment accounting through a variety of amendments. The standard will be effective for annual reporting periods and interim periods within those annual periods, beginning after December&amp;#160;15, 2016, and early adoption is permitted. The Company does not expect the impact of this guidance to be material to its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The standard requires organizations that lease assets to recognize on the balance sheet assets or liabilities, as applicable, for the rights and obligations created by those leases. Additionally, the guidance modifies current guidance for lessor accounting and leveraged leases, and is effective for fiscal years beginning after December&amp;#160;15, 2018, and interim periods within such years. Early adoption is permitted, but the Company does not anticipate electing early adoption. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the FASB issued ASU, 2016-01, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recognition and Measurement of Financial Assets and Financial Liabilities,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which amends prior guidance on accounting for equity investments and financial liabilities. The new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The guidance is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within such years. Early adoption is permitted but the Company does not anticipate electing early adoption. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August&amp;#160;2014, the FASB issued ASU 2014-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Presentation of Financial Statements&amp;#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to continue as a Going Concern.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;This update is intended to define management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an organization&amp;#8217;s ability to continue as a going concern within one year of the date of issuance of the entity&amp;#8217;s financial statements and to provide related footnote disclosures. This guidance is effective for fiscal years ending after December&amp;#160;15, 2016, and early adoption is permitted. The Company is currently evaluating what effect, if any, the adoption of this guidance will have on the disclosures included in its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU 2015-14, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU 2016-08, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU 2016-12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact that these standards may have on its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-8944502DDCA4446404077789998D5BE2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the United States, or GAAP, for complete financial statements and should be read in conjunction with the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as filed with the Securities and Exchange Commission, or the SEC, on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February&amp;#160;29, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the opinion of the Company, the unaudited financial statements contain all adjustments (all of which were considered normal and recurring) necessary for a fair statement of the Company&amp;#8217;s financial position at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the results of operations for the three- and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month periods ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the cash flows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month periods ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The condensed consolidated balance sheet at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the Company&amp;#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company&amp;#8217;s collaboration agreements; the estimated repayment term of the Company&amp;#8217;s debt and related short- and long-term classification; the fair value of the Company&amp;#8217;s debt; the collectability of receivables; the carrying value of property and equipment and intangible assets; the assumptions used in the Company&amp;#8217;s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-FF048934128954AE69EB778998DD19CA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Accrued Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest on debt (Note 7)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,934&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2016Q3YTD" id="Fact-89BB153D3AFDCD30F89D7789994D4125">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Consulting agreement with Daniel R. Passeri&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June&amp;#160;2, 2014, Daniel R. Passeri resigned as Chief Executive Officer of the Company and the Company&amp;#8217;s board of directors appointed Mr.&amp;#160;Passeri to serve as the Vice Chairman of the board of directors. Also on June 2, 2014, the Company and Mr.&amp;#160;Passeri entered into a consulting agreement. The agreement was for an initial term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one year&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, subject to renewal or earlier termination by the parties. The agreement was renewed by the parties through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, after which the agreement between Mr. Passeri and the Company was terminated. Pursuant to the terms of the agreement, Mr.&amp;#160;Passeri was paid an hourly fee or a monthly retainer as consideration for the services rendered by Mr.&amp;#160;Passeri to the Company. During the five months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Mr.&amp;#160;Passeri provided consulting services to the Company on intellectual property, corporate and strategic matters in exchange for payments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per month. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Mr.&amp;#160;Passeri had full-time employment with a third party and was paid an hourly fee for services rendered to the Company during this time. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On September 2, 2016, the Company and Mr. Passeri entered into a letter agreement pursuant to which Mr. Passeri resigned as director and Vice Chairman of the Company's board of directors, which became effective on September 14, 2016. Pursuant to the terms of the Letter Agreement, and in recognition of his many years of service to the Company in varying roles, including as a director and Vice Chairman of the Board, and formerly as Chief Executive Officer, President, and as a consultant, the Board authorized a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recognition bonus payment to Mr.&amp;#160;Passeri and also approved a modification to Mr.&amp;#160;Passeri&amp;#8217;s vested common stock options such that the exercise period for all such options shall be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Mr.&amp;#160;Passeri agreed to provide continued assistance to the Company, without further remuneration, for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, if and when requested by the Board or the Chief Executive Officer. The letter agreement also contains other customary terms and conditions relating to Mr.&amp;#160;Passeri&amp;#8217;s end of service with the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized expenses related to the consulting and letter agreements of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2016Q3YTD" id="Fact-804492EFA71F6222CA287789993F1539">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,637&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;123&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest on debt (Note 7)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;347&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;249&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,934&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2016Q3YTD" id="Fact-235B2DA63F1208C9D69E778998DAB238">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss) as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&amp;#160;Gain&amp;#160;on&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Securities&amp;#160; Available-for-Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrealized gain on marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net current period other comprehensive income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, as of September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The above amounts do not reflect a tax effect because the Company expects to record a net loss for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&amp;#160;Losses and&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gain&amp;#160;on&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Securities&amp;#160;Available-for-Sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, as of December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unrealized gain on marketable securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net current period other comprehensive income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, as of September 30, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2016Q3YTD" id="Fact-C25174211B4DB45BCBE7778999906B2E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the condensed consolidated statements of operations and comprehensive loss, including expense related to its ESPP:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;531&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;731&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,780&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;901&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2016Q3YTD" id="Fact-4B08C1EA0246A3AA5F2F77899955A726">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Black-Scholes option pricing model employs the following key assumptions for employee and director options awarded during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the assumptions noted in the following table:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&amp;#160;&lt;br clear="none"/&gt;&amp;#160;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life (years) - employees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life (years) &amp;#8211; officers and directors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.4-1.8%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.5-1.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63-70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68-70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividends&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;None&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="FD2016Q3YTD" id="Fact-1BEFF9F79D8FE7E4181277899958E830">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gain&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds and notes &amp;#8211; short-term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,072&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gain&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds and notes &amp;#8211; short-term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2016Q3YTD" id="Fact-225FECA72B95544A9AF67789998EF2BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shareholder-approved, share-based compensation plans: (i)&amp;#160;the Amended and Restated 2010 Stock Incentive Plan, or the 2010 Plan, adopted as amended by the board of directors in March 2015 and approved by shareholders in May 2015 and (ii)&amp;#160;the 2010 Employee Stock Purchase Plan, or the ESPP, adopted by the board of directors in April 2010 and approved by shareholders in June 2010.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2016Q3YTD" id="Fact-4C7E859C5D23BFB901C5778998E293B6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is currently a party to a collaboration agreement with Genentech, the terms of which provide for Genentech to make a non-refundable license fee payment, research and development funding payments, contingent cash payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. For a complete discussion of the Company&amp;#8217;s revenue recognition policy, see Note 2(c) included in its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Annual Report on Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>cris-20160930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.curis.com/20160930" xmlns:cris="http://www.curis.com/20160930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20160930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20160930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20160930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cris-20160930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccountingForStockBasedCompensation" roleURI="http://www.curis.com/role/AccountingForStockBasedCompensation">
        <link:definition>2109100 - Disclosure - Accounting for Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingForStockBasedCompensationKeyAssumptionsDetails" roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationKeyAssumptionsDetails">
        <link:definition>2409403 - Disclosure - Accounting for Stock-Based Compensation - Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingForStockBasedCompensationNarrativeDetails" roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationNarrativeDetails">
        <link:definition>2409402 - Disclosure - Accounting for Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingForStockBasedCompensationScheduleOfExpenseDetails" roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationScheduleOfExpenseDetails">
        <link:definition>2409404 - Disclosure - Accounting for Stock-Based Compensation - Schedule of Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingForStockBasedCompensationTables" roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationTables">
        <link:definition>2309301 - Disclosure - Accounting for Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.curis.com/role/AccruedLiabilities">
        <link:definition>2108100 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.curis.com/role/AccruedLiabilitiesDetails">
        <link:definition>2408402 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.curis.com/role/AccruedLiabilitiesTables">
        <link:definition>2308301 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2110100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails">
        <link:definition>2410402 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Summary of Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2310301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentation" roleURI="http://www.curis.com/role/BasisOfPresentation">
        <link:definition>2102100 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.curis.com/role/CollaborationAgreements">
        <link:definition>2104100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsDetails" roleURI="http://www.curis.com/role/CollaborationAgreementsDetails">
        <link:definition>2404401 - Disclosure - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.curis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.curis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.curis.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.curis.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.curis.com/role/Debt">
        <link:definition>2107100 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.curis.com/role/DebtDetails">
        <link:definition>2407401 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.curis.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.curis.com/role/FairValueMeasurements">
        <link:definition>2105100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.curis.com/role/FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2405402 - Disclosure - Fair Value Measurements - Financial Assets or Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.curis.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.curis.com/role/Investments">
        <link:definition>2106100 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.curis.com/role/InvestmentsNarrativeDetails">
        <link:definition>2406403 - Disclosure - Investments -  Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" roleURI="http://www.curis.com/role/InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails">
        <link:definition>2406402 - Disclosure - Investments - Summary of Amortized Cost, Unrealized Gains and Losses and Fair Value of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.curis.com/role/InvestmentsTables">
        <link:definition>2306301 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.curis.com/role/LossPerCommonShare">
        <link:definition>2111100 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareDetails" roleURI="http://www.curis.com/role/LossPerCommonShareDetails">
        <link:definition>2411401 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfBusiness" roleURI="http://www.curis.com/role/NatureOfBusiness">
        <link:definition>2101100 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfBusinessDetails" roleURI="http://www.curis.com/role/NatureOfBusinessDetails">
        <link:definition>2401401 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingPronouncements" roleURI="http://www.curis.com/role/NewAccountingPronouncements">
        <link:definition>2113100 - Disclosure - New Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingPronouncementsPolicies" roleURI="http://www.curis.com/role/NewAccountingPronouncementsPolicies">
        <link:definition>2213201 - Disclosure - New Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.curis.com/role/RelatedPartyTransactions">
        <link:definition>2112100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.curis.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2412401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.curis.com/role/RevenueRecognition">
        <link:definition>2103100 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="cris_AcceptanceofINDFilingIRAK4ProgramMember" name="AcceptanceofINDFilingIRAK4ProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_AcceptanceofINDFilingProgramFourMember" name="AcceptanceofINDFilingProgramFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_AcceptanceofINDFilingProgramThreeMember" name="AcceptanceofINDFilingProgramThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_AdditionalPaymentsMadeUnderCollaborativeArrangements" name="AdditionalPaymentsMadeUnderCollaborativeArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="cris_AurigeneDiscoveryTechnologiesLtdMember" name="AurigeneDiscoveryTechnologiesLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_AvailableForSaleSecuritiesDateRange" name="AvailableForSaleSecuritiesDateRange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_AvailableForSaleSecuritiesWeightedAverageMaturity" name="AvailableForSaleSecuritiesWeightedAverageMaturity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_BioPharmaTwoMember" name="BioPharmaTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_BoardofDirectorsViceChairmanMember" name="BoardofDirectorsViceChairmanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" name="CollaborationAgreementContingentConsiderationPotentialCashPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" name="CollaborationAgreementContingentConsiderationReceivedFromPartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="cris_CollaborativeAgreementOptionExercisablePeriod" name="CollaborativeAgreementOptionExercisablePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeAgreementPeriodOfContract" name="CollaborativeAgreementPeriodOfContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment" name="CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling" name="CollaborativeArrangementExpensesForAcceptanceOfINDFiling" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram" name="CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementExpensesForDosingOfFifthPatient" name="CollaborativeArrangementExpensesForDosingOfFifthPatient" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementExpensesForOptionExercise" name="CollaborativeArrangementExpensesForOptionExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementExpensesForProgramSelectionFee" name="CollaborativeArrangementExpensesForProgramSelectionFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding" name="CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="cris_CollaborativeArrangementNumberofOptionalAdditionalTerms" name="CollaborativeArrangementNumberofOptionalAdditionalTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="cris_CollaborativeArrangementNumberofProgramsLicensed" name="CollaborativeArrangementNumberofProgramsLicensed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="cris_CollaborativeArrangementOptionFeesNumberofPayments" name="CollaborativeArrangementOptionFeesNumberofPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="cris_CollaborativeArrangementOptionFeesTotal" name="CollaborativeArrangementOptionFeesTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementOptionalAdditionalTerm" name="CollaborativeArrangementOptionalAdditionalTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementPaymentforLicensedProgram" name="CollaborativeArrangementPaymentforLicensedProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram" name="CollaborativeArrangementPaymentforSelectionofPreclinicalProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementPaymentsAgreement" name="CollaborativeArrangementPaymentsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementPaymentsAgreementPerProgram" name="CollaborativeArrangementPaymentsAgreementPerProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries" name="CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier" name="CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="cris_ConsultingAgreementPeriod" name="ConsultingAgreementPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_ConsultingFees" name="ConsultingFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned" name="CostAndExpensesOfPercentageOfAggregateRoyaltyEarned" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_CreditAgreementWithBioPharmaTwoMember" name="CreditAgreementWithBioPharmaTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_DrugDevelopmentRoyaltyMember" name="DrugDevelopmentRoyaltyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_EmployeesMember" name="EmployeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ExtendedExclusivityIRAK4ProgramMember" name="ExtendedExclusivityIRAK4ProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ExtendedExclusivityPD1VISTAProgramMember" name="ExtendedExclusivityPD1VISTAProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_GenentechIncMember" name="GenentechIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_IssuanceOfCommonStockToLicensees" name="IssuanceOfCommonStockToLicensees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_MrPasseriMember" name="MrPasseriMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_OfficersAndDirectorsMember" name="OfficersAndDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_OptionExercisePaymentProgramFourMember" name="OptionExercisePaymentProgramFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_OptionExercisePaymentProgramThreeMember" name="OptionExercisePaymentProgramThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived" name="OtherSignificantNoncashTransactionPercentageofConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_PaymentsMadeUnderCollaborativeArrangements" name="PaymentsMadeUnderCollaborativeArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="cris_PaymentsforResearchandDevelopment" name="PaymentsforResearchandDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="cris_PercentageOfRoyaltyOnNetSales" name="PercentageOfRoyaltyOnNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter" name="PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember" name="Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember" name="Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_PrincipalPortionMember" name="PrincipalPortionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ProgramFourMember" name="ProgramFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ProgramOneMember" name="ProgramOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ProgramSelectionFeeProgramFourMember" name="ProgramSelectionFeeProgramFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ProgramThereafterMember" name="ProgramThereafterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ProgramThreeMember" name="ProgramThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ProgramTwoMember" name="ProgramTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_ReducedRoyaltyRate" name="ReducedRoyaltyRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_ResearchAndDevelopmentContraRevenues" name="ResearchAndDevelopmentContraRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="cris_ResearchAndDevelopmentRevenue" name="ResearchAndDevelopmentRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct" name="RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo" name="ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="cris_ShareBasedCompensationPlans" name="ShareBasedCompensationPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_ThirdandFourthProgramsMember" name="ThirdandFourthProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="cris_TwoThousandAndTenPlanMember" name="TwoThousandAndTenPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>cris-20160930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensation" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationNarrativeDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationTables" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilities" xlink:href="cris-20160930.xsd#AccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesDetails" xlink:href="cris-20160930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesTables" xlink:href="cris-20160930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/BasisOfPresentation" xlink:href="cris-20160930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CollaborationAgreements" xlink:href="cris-20160930.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CollaborationAgreementsDetails" xlink:href="cris-20160930.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cris-20160930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="cris-20160930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cris-20160930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="cris-20160930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/Debt" xlink:href="cris-20160930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/DebtDetails" xlink:href="cris-20160930.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/DocumentAndEntityInformation" xlink:href="cris-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurements" xlink:href="cris-20160930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="cris-20160930.xsd#FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurementsTables" xlink:href="cris-20160930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/Investments" xlink:href="cris-20160930.xsd#Investments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsNarrativeDetails" xlink:href="cris-20160930.xsd#InvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:href="cris-20160930.xsd#InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsTables" xlink:href="cris-20160930.xsd#InvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShare" xlink:href="cris-20160930.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShareDetails" xlink:href="cris-20160930.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NatureOfBusiness" xlink:href="cris-20160930.xsd#NatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NatureOfBusinessDetails" xlink:href="cris-20160930.xsd#NatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NewAccountingPronouncements" xlink:href="cris-20160930.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NewAccountingPronouncementsPolicies" xlink:href="cris-20160930.xsd#NewAccountingPronouncementsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactions" xlink:href="cris-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:href="cris-20160930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RevenueRecognition" xlink:href="cris-20160930.xsd#RevenueRecognition" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccruedLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_bbb88956-2391-237d-9ac1-fd1ab1783864" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_AccruedSalariesCurrent_bbb88956-2391-237d-9ac1-fd1ab1783864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4ed680eb-fff6-d6ed-0239-7b9bb87e111b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a5947936-ad1d-a5c1-a96a-7382183b164a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_a5947936-ad1d-a5c1-a96a-7382183b164a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3cb07dbb-b6b9-b4a1-cf56-3d766658ee02" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3cb07dbb-b6b9-b4a1-cf56-3d766658ee02" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/CollaborationAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_30bbf828-dd37-f00d-1301-5ee8c8abf059" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_30bbf828-dd37-f00d-1301-5ee8c8abf059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8cc01d89-cd24-22b5-77d4-23f6bae81aca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_605ccc51-868d-b1f1-b92c-a16352717bd3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_605ccc51-868d-b1f1-b92c-a16352717bd3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b1a68b05-ec26-b896-ce8e-937cca99264e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.curis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_35d7e9b2-6ffb-6e68-f590-8605f30d5f8a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_us-gaap_DepreciationAndAmortization_35d7e9b2-6ffb-6e68-f590-8605f30d5f8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9a24f45c-1e95-3649-7f52-85ed3c472b12" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9a24f45c-1e95-3649-7f52-85ed3c472b12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_77913d2a-d84a-6285-386d-fcf9262888b2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_77913d2a-d84a-6285-386d-fcf9262888b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe59972c-181e-b516-7ec1-09a40fc27526" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe59972c-181e-b516-7ec1-09a40fc27526" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_IssuanceOfCommonStockToLicensees" xlink:label="loc_cris_IssuanceOfCommonStockToLicensees_9b321dbd-94ff-03fd-1dc0-77899002515a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_cris_IssuanceOfCommonStockToLicensees_9b321dbd-94ff-03fd-1dc0-77899002515a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e99fae14-a0f3-93f9-f0e6-bc9b4dc580ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_506d0408-ea3e-649b-78f3-b2efad83f2d9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_880f9863-dd81-7240-4418-c9f1ba4fd53e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9cd29e2f-0081-8adc-bf22-3dace6b78eac" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9cd29e2f-0081-8adc-bf22-3dace6b78eac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_837f4053-a450-75ac-2441-cc071e31e63c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_837f4053-a450-75ac-2441-cc071e31e63c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_2c1ca162-2947-99be-de5d-a58ee5d07618" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_2c1ca162-2947-99be-de5d-a58ee5d07618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_28b01b54-99ee-a57d-f5e5-d013df5c4488" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_28b01b54-99ee-a57d-f5e5-d013df5c4488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df373d95-9aed-55aa-3255-855344ae0add" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_84bd1bb6-943b-e881-35cf-3d692f98b5c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_84bd1bb6-943b-e881-35cf-3d692f98b5c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_7deebd9e-3e56-a0b1-a928-708a4a76b360" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_RepaymentsOfDebt_7deebd9e-3e56-a0b1-a928-708a4a76b360" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.curis.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_f8ec0914-845d-a2a8-d865-8dc286cfe5de" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_RoyaltyRevenue_f8ec0914-845d-a2a8-d865-8dc286cfe5de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_b455d807-bff8-574b-b277-1764b65c6dce" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_b455d807-bff8-574b-b277-1764b65c6dce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_065deb92-7092-46c8-89c6-aef4f67f9809" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_RoyaltyExpense_065deb92-7092-46c8-89c6-aef4f67f9809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_31a96e4a-4151-91e7-cc2e-0e7d3a071471" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_31a96e4a-4151-91e7-cc2e-0e7d3a071471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2b63fac5-7a72-3880-3fd2-630099895af7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:to="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.curis.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/DebtDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5987d7dd-ab82-bea6-ec65-c10216a0873a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1503e99b-7965-ca9e-26eb-ff9af4108a7c" xlink:to="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.curis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/Investments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/InvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba478347-bbf1-ddfc-8a79-7775b3b62a6c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba478347-bbf1-ddfc-8a79-7775b3b62a6c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_65f23050-696a-07fd-30c1-78a5110d800c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_65f23050-696a-07fd-30c1-78a5110d800c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_b1d71fc9-eecd-2005-af97-28330842089f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_b1d71fc9-eecd-2005-af97-28330842089f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.curis.com/role/InvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/LossPerCommonShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/NatureOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/NatureOfBusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/NewAccountingPronouncements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/NewAccountingPronouncementsPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.curis.com/role/RevenueRecognition" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>cris-20160930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensation" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationNarrativeDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationTables" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilities" xlink:href="cris-20160930.xsd#AccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesDetails" xlink:href="cris-20160930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesTables" xlink:href="cris-20160930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/BasisOfPresentation" xlink:href="cris-20160930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CollaborationAgreements" xlink:href="cris-20160930.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CollaborationAgreementsDetails" xlink:href="cris-20160930.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cris-20160930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="cris-20160930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cris-20160930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="cris-20160930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/Debt" xlink:href="cris-20160930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/DebtDetails" xlink:href="cris-20160930.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/DocumentAndEntityInformation" xlink:href="cris-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurements" xlink:href="cris-20160930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="cris-20160930.xsd#FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurementsTables" xlink:href="cris-20160930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/Investments" xlink:href="cris-20160930.xsd#Investments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsNarrativeDetails" xlink:href="cris-20160930.xsd#InvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:href="cris-20160930.xsd#InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsTables" xlink:href="cris-20160930.xsd#InvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShare" xlink:href="cris-20160930.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShareDetails" xlink:href="cris-20160930.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NatureOfBusiness" xlink:href="cris-20160930.xsd#NatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NatureOfBusinessDetails" xlink:href="cris-20160930.xsd#NatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NewAccountingPronouncements" xlink:href="cris-20160930.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NewAccountingPronouncementsPolicies" xlink:href="cris-20160930.xsd#NewAccountingPronouncementsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactions" xlink:href="cris-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:href="cris-20160930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RevenueRecognition" xlink:href="cris-20160930.xsd#RevenueRecognition" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:to="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_EmployeesMember" xlink:label="loc_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:to="loc_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_OfficersAndDirectorsMember" xlink:label="loc_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:to="loc_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:to="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:to="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_TwoThousandAndTenPlanMember" xlink:label="loc_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:to="loc_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:to="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:to="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3D521D6562F0E41B7B3106FB6E50EBDF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_TitleOfIndividualAxis_3D521D6562F0E41B7B3106FB6E50EBDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3D521D6562F0E41B7B3106FB6E50EBDF" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3D521D6562F0E41B7B3106FB6E50EBDF" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_NonEmployeeDirectorsMember" xlink:label="loc_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720" xlink:to="loc_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_BoardofDirectorsViceChairmanMember" xlink:label="loc_cris_BoardofDirectorsViceChairmanMember_8255818E00BFEA7D1D8F06FB6E5088A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720" xlink:to="loc_cris_BoardofDirectorsViceChairmanMember_8255818E00BFEA7D1D8F06FB6E5088A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_FEBAB06E91E95F5D3A6206FB6E50DF79" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_AwardTypeAxis_FEBAB06E91E95F5D3A6206FB6E50DF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A7B43F76F16976C3E25606FB6E506784_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_FEBAB06E91E95F5D3A6206FB6E50DF79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A7B43F76F16976C3E25606FB6E506784_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A7B43F76F16976C3E25606FB6E506784" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_FEBAB06E91E95F5D3A6206FB6E50DF79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A7B43F76F16976C3E25606FB6E506784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_FA9C7C1307F8B03FCB7F06FB6E50B534" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A7B43F76F16976C3E25606FB6E506784" xlink:to="loc_us-gaap_EmployeeStockOptionMember_FA9C7C1307F8B03FCB7F06FB6E50B534" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ShareBasedCompensationPlans" xlink:label="loc_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_113C5D9C8286C3564F0506FB6E5104B7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_113C5D9C8286C3564F0506FB6E5104B7" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo" xlink:label="loc_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_F14E708F78A7551973B3A0142B8A17AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_FB497CAB90A05C891975A0142B8AFE80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_F14E708F78A7551973B3A0142B8A17AF" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_FB497CAB90A05C891975A0142B8AFE80" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_FB497CAB90A05C891975A0142B8AFE80" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_F14E708F78A7551973B3A0142B8A17AF" xlink:to="loc_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/AccruedLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:to="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:to="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/BasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/CollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_GenentechIncMember" xlink:label="loc_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:to="loc_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:label="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:to="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:to="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:to="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:to="loc_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:to="loc_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_A0800FE2DE603CFBE65B27A4516E6FCE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_dei_LegalEntityAxis_A0800FE2DE603CFBE65B27A4516E6FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_371861A6A29C77CF0BD927A4516E1FA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_A0800FE2DE603CFBE65B27A4516E6FCE" xlink:to="loc_dei_EntityDomain_371861A6A29C77CF0BD927A4516E1FA7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_371861A6A29C77CF0BD927A4516E1FA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_A0800FE2DE603CFBE65B27A4516E6FCE" xlink:to="loc_dei_EntityDomain_371861A6A29C77CF0BD927A4516E1FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_67E775BC1A3D242309D327A4516EE308" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_371861A6A29C77CF0BD927A4516E1FA7" xlink:to="loc_us-gaap_SubsidiariesMember_67E775BC1A3D242309D327A4516EE308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_14210CB9ED5E05CB05D627A4516E4451" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_DebtInstrumentAxis_14210CB9ED5E05CB05D627A4516E4451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_83F8073F5597B794E73F27A4516EB7F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_14210CB9ED5E05CB05D627A4516E4451" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_83F8073F5597B794E73F27A4516EB7F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_83F8073F5597B794E73F27A4516EB7F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_14210CB9ED5E05CB05D627A4516E4451" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_83F8073F5597B794E73F27A4516EB7F5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CreditAgreementWithBioPharmaTwoMember" xlink:label="loc_cris_CreditAgreementWithBioPharmaTwoMember_32BCDDAAE7AB1C7710D227A4516EDC82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_83F8073F5597B794E73F27A4516EB7F5" xlink:to="loc_cris_CreditAgreementWithBioPharmaTwoMember_32BCDDAAE7AB1C7710D227A4516EDC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_DrugDevelopmentRoyaltyMember" xlink:label="loc_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:to="loc_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramOneMember" xlink:label="loc_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramTwoMember" xlink:label="loc_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ThirdandFourthProgramsMember" xlink:label="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramThreeMember" xlink:label="loc_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:to="loc_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramFourMember" xlink:label="loc_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:to="loc_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramThereafterMember" xlink:label="loc_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ExtendedExclusivityIRAK4ProgramMember" xlink:label="loc_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingIRAK4ProgramMember" xlink:label="loc_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember" xlink:label="loc_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ExtendedExclusivityPD1VISTAProgramMember" xlink:label="loc_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember" xlink:label="loc_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_OptionExercisePaymentProgramThreeMember" xlink:label="loc_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingProgramThreeMember" xlink:label="loc_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramSelectionFeeProgramFourMember" xlink:label="loc_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_OptionExercisePaymentProgramFourMember" xlink:label="loc_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingProgramFourMember" xlink:label="loc_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:to="loc_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PercentageOfRoyaltyOnNetSales" xlink:label="loc_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ReducedRoyaltyRate" xlink:label="loc_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_900C9F8F1FE4509F264627A45170B0E9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_900C9F8F1FE4509F264627A45170B0E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_800ADB044D6C396697A527A451701E5C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_800ADB044D6C396697A527A451701E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_3995BC1E8A37CFF9991A27A451719AE2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_RoyaltyExpense_3995BC1E8A37CFF9991A27A451719AE2" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned" xlink:label="loc_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ResearchAndDevelopmentRevenue" xlink:label="loc_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ResearchAndDevelopmentContraRevenues" xlink:label="loc_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeAgreementOptionExercisablePeriod" xlink:label="loc_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementNumberofProgramsLicensed" xlink:label="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentsAgreement" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AdditionalPaymentsMadeUnderCollaborativeArrangements" xlink:label="loc_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PaymentsforResearchandDevelopment" xlink:label="loc_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentforLicensedProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries" xlink:label="loc_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeAgreementPeriodOfContract" xlink:label="loc_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementNumberofOptionalAdditionalTerms" xlink:label="loc_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionalAdditionalTerm" xlink:label="loc_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionFeesTotal" xlink:label="loc_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionFeesNumberofPayments" xlink:label="loc_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier" xlink:label="loc_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct" xlink:label="loc_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentsAgreementPerProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForOptionExercise" xlink:label="loc_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling" xlink:label="loc_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForDosingOfFifthPatient" xlink:label="loc_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PaymentsMadeUnderCollaborativeArrangements" xlink:label="loc_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForProgramSelectionFee" xlink:label="loc_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram" xlink:label="loc_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment" xlink:label="loc_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived" xlink:label="loc_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding" xlink:label="loc_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:to="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:to="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:to="loc_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CreditAgreementWithBioPharmaTwoMember" xlink:label="loc_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:to="loc_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:to="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:to="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PrincipalPortionMember" xlink:label="loc_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:to="loc_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_BioPharmaTwoMember" xlink:label="loc_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:to="loc_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter" xlink:label="loc_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:to="loc_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:to="loc_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_CAE2CE9D0142F1ACFCA62600CC44114D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_InvestmentTypeAxis_CAE2CE9D0142F1ACFCA62600CC44114D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_A3722FF9772912D5A5B42600CC44F31B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_CAE2CE9D0142F1ACFCA62600CC44114D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_A3722FF9772912D5A5B42600CC44F31B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_A3722FF9772912D5A5B42600CC44F31B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_CAE2CE9D0142F1ACFCA62600CC44114D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_A3722FF9772912D5A5B42600CC44F31B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_E420FE1709A251D7EDE02600CC44320E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A3722FF9772912D5A5B42600CC44F31B" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_E420FE1709A251D7EDE02600CC44320E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecurityAxis" xlink:label="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:to="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:to="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:to="loc_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/Investments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1D55A103906D7454D3950CC05ED99AB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1D55A103906D7454D3950CC05ED99AB2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_04B2E505BC9895BF7DF40CC05ED81CAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:to="loc_us-gaap_RangeAxis_04B2E505BC9895BF7DF40CC05ED81CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_04B2E505BC9895BF7DF40CC05ED81CAF" xlink:to="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_04B2E505BC9895BF7DF40CC05ED81CAF" xlink:to="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9B70A00D474C9CF0A4BE0CC05ED90C8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7" xlink:to="loc_us-gaap_MinimumMember_9B70A00D474C9CF0A4BE0CC05ED90C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6CED3B43E86DC19FF6710CC05ED95D30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7" xlink:to="loc_us-gaap_MaximumMember_6CED3B43E86DC19FF6710CC05ED95D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_C9D52A23B0A16E3574B80CC05ED9E82F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:to="loc_us-gaap_InvestmentTypeAxis_C9D52A23B0A16E3574B80CC05ED9E82F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_29A972BBFD3E5E1AA3B60CC05ED93B46_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_C9D52A23B0A16E3574B80CC05ED9E82F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_29A972BBFD3E5E1AA3B60CC05ED93B46_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_29A972BBFD3E5E1AA3B60CC05ED93B46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_C9D52A23B0A16E3574B80CC05ED9E82F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_29A972BBFD3E5E1AA3B60CC05ED93B46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_BD8D53FA025396E4F43A0CC05ED92AE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29A972BBFD3E5E1AA3B60CC05ED93B46" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_BD8D53FA025396E4F43A0CC05ED92AE4" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AvailableForSaleSecuritiesDateRange" xlink:label="loc_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1D55A103906D7454D3950CC05ED99AB2" xlink:to="loc_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:label="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1D55A103906D7454D3950CC05ED99AB2" xlink:to="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:to="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/InvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/LossPerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:to="loc_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/NatureOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/NatureOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1B2DE60CB4D6E1486EE8FC20AB7009BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:to="loc_us-gaap_CounterpartyNameAxis_1B2DE60CB4D6E1486EE8FC20AB7009BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE5A8456356E1A0116CDFC20AB708B11_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_1B2DE60CB4D6E1486EE8FC20AB7009BB" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE5A8456356E1A0116CDFC20AB708B11_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE5A8456356E1A0116CDFC20AB708B11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_1B2DE60CB4D6E1486EE8FC20AB7009BB" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE5A8456356E1A0116CDFC20AB708B11" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:label="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A19FAA8BDB41C0CFDEB9FC20AB703F79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE5A8456356E1A0116CDFC20AB708B11" xlink:to="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A19FAA8BDB41C0CFDEB9FC20AB703F79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D043BBC2B8EAAD25F5D3FC20AB70254F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D043BBC2B8EAAD25F5D3FC20AB70254F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E1FF2E8D23939F9A29DBFC20AB7108F9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D043BBC2B8EAAD25F5D3FC20AB70254F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E1FF2E8D23939F9A29DBFC20AB7108F9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E1FF2E8D23939F9A29DBFC20AB7108F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D043BBC2B8EAAD25F5D3FC20AB70254F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E1FF2E8D23939F9A29DBFC20AB7108F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_852EA3FC472674803BABFC20AB7180DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E1FF2E8D23939F9A29DBFC20AB7108F9" xlink:to="loc_us-gaap_SubsequentEventMember_852EA3FC472674803BABFC20AB7180DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_830C6A212B752BA384A0FC20AB71A5F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_830C6A212B752BA384A0FC20AB71A5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_1F68EA858C131DFA48A5FC20AB717E3A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_1F68EA858C131DFA48A5FC20AB717E3A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementNumberofProgramsLicensed" xlink:label="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_E645F167F7303B06AA0FFC20AB714D80" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_E645F167F7303B06AA0FFC20AB714D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/NewAccountingPronouncements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/NewAccountingPronouncementsPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:to="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:to="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_MrPasseriMember" xlink:label="loc_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:to="loc_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredBonusMember" xlink:label="loc_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:to="loc_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ADBD9B0A6D6312F810A8FC3C30018A35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ADBD9B0A6D6312F810A8FC3C30018A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_B8DD4B292A9E4DC251E7FC3C2C95A1F1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_TitleOfIndividualAxis_B8DD4B292A9E4DC251E7FC3C2C95A1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CC0681B65BA98D8A031EFC3C2CAC66C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_B8DD4B292A9E4DC251E7FC3C2C95A1F1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CC0681B65BA98D8A031EFC3C2CAC66C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CC0681B65BA98D8A031EFC3C2CAC66C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_B8DD4B292A9E4DC251E7FC3C2C95A1F1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CC0681B65BA98D8A031EFC3C2CAC66C4" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_BoardofDirectorsViceChairmanMember" xlink:label="loc_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CC0681B65BA98D8A031EFC3C2CAC66C4" xlink:to="loc_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ConsultingAgreementPeriod" xlink:label="loc_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ConsultingFees" xlink:label="loc_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.curis.com/role/RevenueRecognition" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>cris-20160930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB" xlink:to="lab_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on debt (Note 7)</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC" xlink:to="lab_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B56BE45D5B7FE976DE25A0142B990196_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B56BE45D5B7FE976DE25A0142B990196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B56BE45D5B7FE976DE25A0142B990196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B56BE45D5B7FE976DE25A0142B990196" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B56BE45D5B7FE976DE25A0142B990196" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:to="lab_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:type="arc" />
    <link:label id="lab_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB_terseLabel_en-US" xlink:label="lab_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB_label_en-US" xlink:label="lab_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB_documentation_en-US" xlink:label="lab_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_EmployeesMember" xlink:label="loc_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:to="lab_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:type="arc" />
    <link:label id="lab_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D_terseLabel_en-US" xlink:label="lab_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Officers and directors</link:label>
    <link:label id="lab_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D_label_en-US" xlink:label="lab_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officers And Directors [Member]</link:label>
    <link:label id="lab_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D_documentation_en-US" xlink:label="lab_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Officers and directors.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_OfficersAndDirectorsMember" xlink:label="loc_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:to="lab_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_204211144810002190E39F72DFB1E7CD_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_204211144810002190E39F72DFB1E7CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_204211144810002190E39F72DFB1E7CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_204211144810002190E39F72DFB1E7CD" xlink:to="lab_us-gaap_EarningsPerShareAbstract_204211144810002190E39F72DFB1E7CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:to="lab_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26466125FF3CE2F7E62925FD4B829B5D_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26466125FF3CE2F7E62925FD4B829B5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26466125FF3CE2F7E62925FD4B829B5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26466125FF3CE2F7E62925FD4B829B5D" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26466125FF3CE2F7E62925FD4B829B5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds and notes &#8211; short-term</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:to="lab_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:to="lab_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:type="arc" />
    <link:label id="lab_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE_label_en-US" xlink:label="lab_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE_documentation_en-US" xlink:label="lab_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_DocumentAndEntityInformationAbstract" xlink:label="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="lab_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_367734909EACA6AC819977899B3AD67A_terseLabel_en-US" xlink:label="lab_dei_DocumentType_367734909EACA6AC819977899B3AD67A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_367734909EACA6AC819977899B3AD67A_label_en-US" xlink:label="lab_dei_DocumentType_367734909EACA6AC819977899B3AD67A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_367734909EACA6AC819977899B3AD67A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_367734909EACA6AC819977899B3AD67A" xlink:to="lab_dei_DocumentType_367734909EACA6AC819977899B3AD67A" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21_label_en-US" xlink:label="lab_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21" xlink:to="lab_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975" xlink:to="lab_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961" xlink:to="lab_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94" xlink:to="lab_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_847157391E940EE182A877899B3AEA51_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_847157391E940EE182A877899B3AEA51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_847157391E940EE182A877899B3AEA51_label_en-US" xlink:label="lab_dei_TradingSymbol_847157391E940EE182A877899B3AEA51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_847157391E940EE182A877899B3AEA51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_847157391E940EE182A877899B3AEA51" xlink:to="lab_dei_TradingSymbol_847157391E940EE182A877899B3AEA51" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791_label_en-US" xlink:label="lab_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791" xlink:to="lab_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56" xlink:to="lab_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7" xlink:to="lab_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255_label_en-US" xlink:label="lab_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255" xlink:to="lab_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B3BD91103DBF50D12F349BDB932A95AC_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B3BD91103DBF50D12F349BDB932A95AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B3BD91103DBF50D12F349BDB932A95AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B3BD91103DBF50D12F349BDB932A95AC" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B3BD91103DBF50D12F349BDB932A95AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_B773D8A1ACADCC4164B2A010EBC7EC87_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_B773D8A1ACADCC4164B2A010EBC7EC87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B773D8A1ACADCC4164B2A010EBC7EC87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_B773D8A1ACADCC4164B2A010EBC7EC87" xlink:to="lab_us-gaap_EquityAbstract_B773D8A1ACADCC4164B2A010EBC7EC87" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_05D3B023474C915CFBF69C7D10E54267_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_05D3B023474C915CFBF69C7D10E54267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_05D3B023474C915CFBF69C7D10E54267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_05D3B023474C915CFBF69C7D10E54267" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_05D3B023474C915CFBF69C7D10E54267" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="lab_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:to="lab_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1" xlink:to="lab_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development, net</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_71E14070280994511580A0878F355265_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_71E14070280994511580A0878F355265" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_71E14070280994511580A0878F355265_label_en-US" xlink:label="lab_us-gaap_Revenues_71E14070280994511580A0878F355265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_71E14070280994511580A0878F355265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_71E14070280994511580A0878F355265" xlink:to="lab_us-gaap_Revenues_71E14070280994511580A0878F355265" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of royalty revenues</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3" xlink:to="lab_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788" xlink:to="lab_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230" xlink:to="lab_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A" xlink:to="lab_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6_label_en-US" xlink:label="lab_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6" xlink:to="lab_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A" xlink:to="lab_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share (basic and diluted) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares (basic and diluted) (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_88411C48C827C03AE9B89F72DFA914AB_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_88411C48C827C03AE9B89F72DFA914AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_88411C48C827C03AE9B89F72DFA914AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_88411C48C827C03AE9B89F72DFA914AB" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_88411C48C827C03AE9B89F72DFA914AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_24A713DB6DF38451310703A70336D73F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_24A713DB6DF38451310703A70336D73F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_24A713DB6DF38451310703A70336D73F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_24A713DB6DF38451310703A70336D73F" xlink:to="lab_us-gaap_DebtDisclosureAbstract_24A713DB6DF38451310703A70336D73F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="lab_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588_label_en-US" xlink:label="lab_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:to="lab_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80_label_en-US" xlink:label="lab_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:to="lab_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Curis Royalty</link:label>
    <link:label id="lab_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E_label_en-US" xlink:label="lab_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:to="lab_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:to="lab_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:type="arc" />
    <link:label id="lab_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086_terseLabel_en-US" xlink:label="lab_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit agreement with BioPharma-II</link:label>
    <link:label id="lab_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086_label_en-US" xlink:label="lab_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement With Bio Pharma Two [Member]</link:label>
    <link:label id="lab_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086_documentation_en-US" xlink:label="lab_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Agreement With Bio Pharma Two [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CreditAgreementWithBioPharmaTwoMember" xlink:label="loc_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:to="lab_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:to="lab_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:to="lab_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:type="arc" />
    <link:label id="lab_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF_terseLabel_en-US" xlink:label="lab_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal portion</link:label>
    <link:label id="lab_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF_label_en-US" xlink:label="lab_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Portion [Member]</link:label>
    <link:label id="lab_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF_documentation_en-US" xlink:label="lab_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal Portion [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_PrincipalPortionMember" xlink:label="loc_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:to="lab_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:type="arc" />
    <link:label id="lab_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B_terseLabel_en-US" xlink:label="lab_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioPharma-II</link:label>
    <link:label id="lab_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B_label_en-US" xlink:label="lab_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bio Pharma Two [Member]</link:label>
    <link:label id="lab_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B_documentation_en-US" xlink:label="lab_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioPharma-II.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_BioPharmaTwoMember" xlink:label="loc_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:to="lab_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="lab_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal loan amount to Curis Royalty given by BioPharma under credit agreement</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on loan to Curis Royalty given by BioPharma under credit agreement</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:type="arc" />
    <link:label id="lab_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE_terseLabel_en-US" xlink:label="lab_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage equal to the price of the outstanding principal of the loan that may be prepaid</link:label>
    <link:label id="lab_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE_label_en-US" xlink:label="lab_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Prepayment Of Loan Amount For Year Five And Thereafter</link:label>
    <link:label id="lab_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE_documentation_en-US" xlink:label="lab_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage prepayment of outstanding principal amount in whole or in part for year five and thereafter.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter" xlink:label="loc_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:to="lab_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment towards debt obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:to="lab_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:to="lab_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on loan amount to Curis Royalty given by BioPharma under credit agreement</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:to="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense recognized related to loan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75" xlink:to="lab_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:to="lab_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:type="arc" />
    <link:label id="lab_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9_terseLabel_en-US" xlink:label="lab_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mr. Daniel R. Passeri</link:label>
    <link:label id="lab_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9_label_en-US" xlink:label="lab_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mr Passeri [Member]</link:label>
    <link:label id="lab_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9_documentation_en-US" xlink:label="lab_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mr Passeri [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_MrPasseriMember" xlink:label="loc_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:to="lab_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B_label_en-US" xlink:label="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:to="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition bonus</link:label>
    <link:label id="lab_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F_label_en-US" xlink:label="lab_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Bonus [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredBonusMember" xlink:label="loc_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:to="lab_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:to="lab_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:type="arc" />
    <link:label id="lab_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5_terseLabel_en-US" xlink:label="lab_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vice Chairman of Board of Directors</link:label>
    <link:label id="lab_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5_label_en-US" xlink:label="lab_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors Vice Chairman [Member]</link:label>
    <link:label id="lab_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5_documentation_en-US" xlink:label="lab_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Board of Directors Vice Chairman [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_BoardofDirectorsViceChairmanMember" xlink:label="loc_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:to="lab_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:type="arc" />
    <link:label id="lab_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A_terseLabel_en-US" xlink:label="lab_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting agreement term</link:label>
    <link:label id="lab_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A_label_en-US" xlink:label="lab_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Agreement Period</link:label>
    <link:label id="lab_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A_documentation_en-US" xlink:label="lab_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consulting Agreement Period</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ConsultingAgreementPeriod" xlink:label="loc_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:to="lab_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:type="arc" />
    <link:label id="lab_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0_terseLabel_en-US" xlink:label="lab_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting fees per month</link:label>
    <link:label id="lab_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0_label_en-US" xlink:label="lab_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Fees</link:label>
    <link:label id="lab_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0_documentation_en-US" xlink:label="lab_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Monthly consulting fees.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ConsultingFees" xlink:label="loc_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:to="lab_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized recognition bonus payment</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement to provide continued assistance, term (up to)</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Maximum Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting agreement, recognized expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:to="lab_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:type="arc" />
    <link:label id="lab_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95_terseLabel_en-US" xlink:label="lab_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech, Inc.</link:label>
    <link:label id="lab_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95_label_en-US" xlink:label="lab_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech Inc [Member]</link:label>
    <link:label id="lab_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95_documentation_en-US" xlink:label="lab_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech, Inc.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_GenentechIncMember" xlink:label="loc_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:to="lab_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:type="arc" />
    <link:label id="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF_terseLabel_en-US" xlink:label="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aurigene</link:label>
    <link:label id="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF_label_en-US" xlink:label="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aurigene Discovery Technologies Ltd [Member]</link:label>
    <link:label id="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF_documentation_en-US" xlink:label="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aurigene Discovery Technologies Ltd [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:label="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:to="lab_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1_label_en-US" xlink:label="lab_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:to="lab_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1_label_en-US" xlink:label="lab_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:to="lab_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3_label_en-US" xlink:label="lab_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:to="lab_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12_label_en-US" xlink:label="lab_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:to="lab_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:to="lab_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:to="lab_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:type="arc" />
    <link:label id="lab_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C_terseLabel_en-US" xlink:label="lab_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug development royalty</link:label>
    <link:label id="lab_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C_label_en-US" xlink:label="lab_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Development Royalty [Member]</link:label>
    <link:label id="lab_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C_documentation_en-US" xlink:label="lab_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug Development Royalty [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_DrugDevelopmentRoyaltyMember" xlink:label="loc_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:to="lab_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:to="lab_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:type="arc" />
    <link:label id="lab_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001_terseLabel_en-US" xlink:label="lab_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PD1/VISTA programs</link:label>
    <link:label id="lab_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001_label_en-US" xlink:label="lab_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Program One [Member]</link:label>
    <link:label id="lab_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001_documentation_en-US" xlink:label="lab_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Program One [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramOneMember" xlink:label="loc_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:to="lab_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:type="arc" />
    <link:label id="lab_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC_terseLabel_en-US" xlink:label="lab_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IRAK4 programs</link:label>
    <link:label id="lab_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC_label_en-US" xlink:label="lab_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Program Two [Member]</link:label>
    <link:label id="lab_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC_documentation_en-US" xlink:label="lab_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Program Two [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramTwoMember" xlink:label="loc_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:to="lab_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:type="arc" />
    <link:label id="lab_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5_terseLabel_en-US" xlink:label="lab_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Programs three and four</link:label>
    <link:label id="lab_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5_label_en-US" xlink:label="lab_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third and Fourth Programs [Member]</link:label>
    <link:label id="lab_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5_documentation_en-US" xlink:label="lab_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third and Fourth Programs [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ThirdandFourthProgramsMember" xlink:label="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:to="lab_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:type="arc" />
    <link:label id="lab_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2_terseLabel_en-US" xlink:label="lab_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Program three</link:label>
    <link:label id="lab_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2_label_en-US" xlink:label="lab_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Program Three [Member]</link:label>
    <link:label id="lab_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2_documentation_en-US" xlink:label="lab_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Program three.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramThreeMember" xlink:label="loc_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:to="lab_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:type="arc" />
    <link:label id="lab_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545_terseLabel_en-US" xlink:label="lab_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Program four</link:label>
    <link:label id="lab_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545_label_en-US" xlink:label="lab_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Program Four [Member]</link:label>
    <link:label id="lab_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545_documentation_en-US" xlink:label="lab_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Program four.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramFourMember" xlink:label="loc_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:to="lab_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:type="arc" />
    <link:label id="lab_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403_terseLabel_en-US" xlink:label="lab_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Program thereafter</link:label>
    <link:label id="lab_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403_label_en-US" xlink:label="lab_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Program Thereafter [Member]</link:label>
    <link:label id="lab_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403_documentation_en-US" xlink:label="lab_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Program thereafter.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramThereafterMember" xlink:label="loc_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:to="lab_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:type="arc" />
    <link:label id="lab_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B_terseLabel_en-US" xlink:label="lab_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended exclusivity, IRAK4 program</link:label>
    <link:label id="lab_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B_label_en-US" xlink:label="lab_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extended Exclusivity, IRAK4 Program [Member]</link:label>
    <link:label id="lab_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B_documentation_en-US" xlink:label="lab_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extended Exclusivity, IRAK4 Program [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ExtendedExclusivityIRAK4ProgramMember" xlink:label="loc_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:to="lab_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:type="arc" />
    <link:label id="lab_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1_terseLabel_en-US" xlink:label="lab_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceptance of IND filing, IRAK4 program</link:label>
    <link:label id="lab_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1_label_en-US" xlink:label="lab_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acceptance of IND Filing, IRAK4 Program [Member]</link:label>
    <link:label id="lab_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1_documentation_en-US" xlink:label="lab_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acceptance of IND Filing, IRAK4 Program [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingIRAK4ProgramMember" xlink:label="loc_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:to="lab_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:type="arc" />
    <link:label id="lab_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D_terseLabel_en-US" xlink:label="lab_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 1 clinical trial, dosing of fifth patient, IRAK4 program</link:label>
    <link:label id="lab_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D_label_en-US" xlink:label="lab_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial, Dosing of Fifth Patient, IRAK4 Program [Member]</link:label>
    <link:label id="lab_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D_documentation_en-US" xlink:label="lab_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial, Dosing of Fifth Patient, IRAK4 Program</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember" xlink:label="loc_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:to="lab_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:type="arc" />
    <link:label id="lab_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A_terseLabel_en-US" xlink:label="lab_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended exclusivity, PD1/VISTA program</link:label>
    <link:label id="lab_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A_label_en-US" xlink:label="lab_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extended Exclusivity, PD-1/VISTA Program [Member]</link:label>
    <link:label id="lab_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A_documentation_en-US" xlink:label="lab_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Extended Exclusivity, PD-1/VISTA Program [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ExtendedExclusivityPD1VISTAProgramMember" xlink:label="loc_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:to="lab_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:type="arc" />
    <link:label id="lab_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017_terseLabel_en-US" xlink:label="lab_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 1 clinical trial, dosing of fifth patient, PD1/VISTA</link:label>
    <link:label id="lab_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017_label_en-US" xlink:label="lab_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial, Dosing of Fifth Patient, PD-1/VISTA [Member]</link:label>
    <link:label id="lab_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017_documentation_en-US" xlink:label="lab_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial, Dosing of Fifth Patient, PD-1/VISTA</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember" xlink:label="loc_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:to="lab_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:type="arc" />
    <link:label id="lab_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090_terseLabel_en-US" xlink:label="lab_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise payment, program three</link:label>
    <link:label id="lab_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090_label_en-US" xlink:label="lab_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercise Payment, Program Three [Member]</link:label>
    <link:label id="lab_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090_documentation_en-US" xlink:label="lab_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Exercise Payment, Program Three</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_OptionExercisePaymentProgramThreeMember" xlink:label="loc_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:to="lab_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:type="arc" />
    <link:label id="lab_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD_terseLabel_en-US" xlink:label="lab_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceptance of IND filing, program three</link:label>
    <link:label id="lab_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD_label_en-US" xlink:label="lab_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acceptance of IND Filing, Program Three [Member]</link:label>
    <link:label id="lab_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD_documentation_en-US" xlink:label="lab_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acceptance of IND Filing, Program Three [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingProgramThreeMember" xlink:label="loc_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:to="lab_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:type="arc" />
    <link:label id="lab_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9_terseLabel_en-US" xlink:label="lab_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Program selection fee, program four</link:label>
    <link:label id="lab_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9_label_en-US" xlink:label="lab_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Program Selection Fee, Program Four [Member]</link:label>
    <link:label id="lab_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9_documentation_en-US" xlink:label="lab_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Program Selection Fee, Program Four [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramSelectionFeeProgramFourMember" xlink:label="loc_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:to="lab_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:type="arc" />
    <link:label id="lab_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A_terseLabel_en-US" xlink:label="lab_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise payment, program four</link:label>
    <link:label id="lab_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A_label_en-US" xlink:label="lab_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercise Payment, Program Four [Member]</link:label>
    <link:label id="lab_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A_documentation_en-US" xlink:label="lab_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Exercise Payment, Program Four [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_OptionExercisePaymentProgramFourMember" xlink:label="loc_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:to="lab_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:type="arc" />
    <link:label id="lab_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A_terseLabel_en-US" xlink:label="lab_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceptance of IND filing, program four</link:label>
    <link:label id="lab_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A_label_en-US" xlink:label="lab_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acceptance of IND Filing, Program Four [Member]</link:label>
    <link:label id="lab_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A_documentation_en-US" xlink:label="lab_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acceptance of IND Filing, Program Four [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingProgramFourMember" xlink:label="loc_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:to="lab_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:to="lab_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:type="arc" />
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806_terseLabel_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible to receive contingent cash payment for specified clinical development and regulatory objectives (up to)</link:label>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806_label_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Contingent Consideration Potential Cash Payment</link:label>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806_documentation_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration agreement contingent consideration potential cash payment.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:to="lab_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:type="arc" />
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F_terseLabel_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount received for specified clinical development and regulatory objectives</link:label>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F_label_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement Contingent Consideration Received From Partner</link:label>
    <link:label id="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F_documentation_en-US" xlink:label="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration agreement contingent consideration received from partner.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:to="lab_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:type="arc" />
    <link:label id="lab_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A_terseLabel_en-US" xlink:label="lab_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of royalty on net sales</link:label>
    <link:label id="lab_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A_label_en-US" xlink:label="lab_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalty On Net Sales</link:label>
    <link:label id="lab_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A_documentation_en-US" xlink:label="lab_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalty on net sales.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_PercentageOfRoyaltyOnNetSales" xlink:label="loc_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:to="lab_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:type="arc" />
    <link:label id="lab_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B_terseLabel_en-US" xlink:label="lab_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of royalty rate decrease</link:label>
    <link:label id="lab_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B_label_en-US" xlink:label="lab_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduced Royalty Rate</link:label>
    <link:label id="lab_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B_documentation_en-US" xlink:label="lab_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduced Royalty Rate</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ReducedRoyaltyRate" xlink:label="loc_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:to="lab_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized royalty revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989" xlink:to="lab_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989" xlink:type="arc" />
    <link:label id="lab_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B_terseLabel_en-US" xlink:label="lab_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of royalties earned</link:label>
    <link:label id="lab_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B_label_en-US" xlink:label="lab_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost And Expenses Of Percentage Of Aggregate Royalty Earned</link:label>
    <link:label id="lab_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B_documentation_en-US" xlink:label="lab_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost and expenses of percentage of aggregate royalty earned.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned" xlink:label="loc_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:to="lab_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:type="arc" />
    <link:label id="lab_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379_terseLabel_en-US" xlink:label="lab_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development revenue</link:label>
    <link:label id="lab_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379_label_en-US" xlink:label="lab_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Revenue</link:label>
    <link:label id="lab_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379_documentation_en-US" xlink:label="lab_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Historically, this has included FTE reimbursement. It also includes reimbursement of other costs that have been incurred on behalf of a partner.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ResearchAndDevelopmentRevenue" xlink:label="loc_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:to="lab_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:type="arc" />
    <link:label id="lab_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA_terseLabel_en-US" xlink:label="lab_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA_label_en-US" xlink:label="lab_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Contra Revenues</link:label>
    <link:label id="lab_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA_documentation_en-US" xlink:label="lab_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Contra Revenues</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ResearchAndDevelopmentContraRevenues" xlink:label="loc_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:to="lab_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0_terseLabel_en-US" xlink:label="lab_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, option exercisable period</link:label>
    <link:label id="lab_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0_label_en-US" xlink:label="lab_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Option Exercisable Period</link:label>
    <link:label id="lab_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0_documentation_en-US" xlink:label="lab_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative agreement option exercisable period.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeAgreementOptionExercisablePeriod" xlink:label="loc_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:to="lab_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, number of programs licensed</link:label>
    <link:label id="lab_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF_label_en-US" xlink:label="lab_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Programs Licensed</link:label>
    <link:label id="lab_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Programs Licensed</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementNumberofProgramsLicensed" xlink:label="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:to="lab_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement payment</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8_label_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Payments Agreement</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement payments agreement.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentsAgreement" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:to="lab_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:type="arc" />
    <link:label id="lab_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118_terseLabel_en-US" xlink:label="lab_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional payments made under collaborative arrangements (up to)</link:label>
    <link:label id="lab_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118_label_en-US" xlink:label="lab_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Payments Made Under Collaborative Arrangements</link:label>
    <link:label id="lab_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118_documentation_en-US" xlink:label="lab_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional payments made under collaborative arrangements.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_AdditionalPaymentsMadeUnderCollaborativeArrangements" xlink:label="loc_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:to="lab_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:type="arc" />
    <link:label id="lab_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325_terseLabel_en-US" xlink:label="lab_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for research and development</link:label>
    <link:label id="lab_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325_label_en-US" xlink:label="lab_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Research and Development</link:label>
    <link:label id="lab_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325_documentation_en-US" xlink:label="lab_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Research and Development</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_PaymentsforResearchandDevelopment" xlink:label="loc_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:to="lab_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for preclinical program for potential further development</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0_label_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Payment for Selection of Preclinical Program</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Payment for Selection of Preclinical Program</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:to="lab_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for license and designation as the development candidate</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F_label_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Payment for Licensed Program</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Payment for Licensed Program</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentforLicensedProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:to="lab_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, number of products required to commercialize (at least)</link:label>
    <link:label id="lab_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81_label_en-US" xlink:label="lab_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Programs Licensed, Number of Products Required to Commercialize in Specified Countries</link:label>
    <link:label id="lab_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Programs Licensed, Number of Products Required to Commercialize in Specified Countries</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries" xlink:label="loc_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:to="lab_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824_terseLabel_en-US" xlink:label="lab_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement period</link:label>
    <link:label id="lab_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824_label_en-US" xlink:label="lab_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Period Of Contract</link:label>
    <link:label id="lab_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824_documentation_en-US" xlink:label="lab_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative agreement period of contract.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeAgreementPeriodOfContract" xlink:label="loc_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:to="lab_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, number of optional additional terms</link:label>
    <link:label id="lab_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5_label_en-US" xlink:label="lab_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Optional Additional Terms</link:label>
    <link:label id="lab_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Optional Additional Terms</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementNumberofOptionalAdditionalTerms" xlink:label="loc_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:to="lab_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, optional additional term</link:label>
    <link:label id="lab_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23_label_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Optional Additional Term</link:label>
    <link:label id="lab_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Optional Additional Term</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionalAdditionalTerm" xlink:label="loc_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:to="lab_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option fees</link:label>
    <link:label id="lab_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394_label_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Option Fees, Total</link:label>
    <link:label id="lab_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Option Fees, Total</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionFeesTotal" xlink:label="loc_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:to="lab_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of payments</link:label>
    <link:label id="lab_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC_label_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Option Fees, Number of Payments</link:label>
    <link:label id="lab_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Option Fees, Number of Payments</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionFeesNumberofPayments" xlink:label="loc_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:to="lab_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, rights granted to nominate global drug substance or drug product supplier</link:label>
    <link:label id="lab_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3_label_en-US" xlink:label="lab_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights Granted to Nominate Substance or Supplier</link:label>
    <link:label id="lab_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights Granted to Nominate Substance or Supplier</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier" xlink:label="loc_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:to="lab_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:type="arc" />
    <link:label id="lab_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68_terseLabel_en-US" xlink:label="lab_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of contribution (up to)</link:label>
    <link:label id="lab_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68_label_en-US" xlink:label="lab_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of Supply as Percentage of Annual Requirement of Drug Product</link:label>
    <link:label id="lab_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68_documentation_en-US" xlink:label="lab_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right of supply as percentage of annual requirement of drug product.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct" xlink:label="loc_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:to="lab_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, payment per program (up to)</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A_label_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Payments Agreement Per Program</link:label>
    <link:label id="lab_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement payments agreement per program.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentsAgreementPerProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:to="lab_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement expenses, option exercise</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C_label_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Expenses For Option Exercise</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement expenses for option exercise.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForOptionExercise" xlink:label="loc_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:to="lab_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement expenses, acceptance of IND filing</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA_label_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Expenses For Acceptance Of IND Filing</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement expenses for acceptance of IND filing.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling" xlink:label="loc_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:to="lab_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement expenses, dosing of fifth patient</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E_label_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Expenses For Dosing Of Fifth Patient</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement expenses for dosing of fifth patient.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForDosingOfFifthPatient" xlink:label="loc_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:to="lab_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:type="arc" />
    <link:label id="lab_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24_terseLabel_en-US" xlink:label="lab_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments made under collaboration arrangements</link:label>
    <link:label id="lab_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24_label_en-US" xlink:label="lab_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Made Under Collaborative Arrangements</link:label>
    <link:label id="lab_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24_documentation_en-US" xlink:label="lab_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments made under collaborative arrangements.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_PaymentsMadeUnderCollaborativeArrangements" xlink:label="loc_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:to="lab_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement expenses, program selection fee</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8_label_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Expenses For Program Selection Fee</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement expenses for program selection fee.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForProgramSelectionFee" xlink:label="loc_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:to="lab_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, fees (up to)</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3_label_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Expenses For Approval And Commercial Milestones Per Program</link:label>
    <link:label id="lab_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangement expenses for approval and commercial milestones per program.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram" xlink:label="loc_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:to="lab_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued of common stock in exchange for waived payment (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Waived payment of milestone and other payments (up to)</link:label>
    <link:label id="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68_label_en-US" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Significant Noncash Transaction, Value of Consideration Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:to="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patients dosed that trigger payment</link:label>
    <link:label id="lab_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9_label_en-US" xlink:label="lab_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contractual Agreement, Number of Patients Dosed that Trigger Payment</link:label>
    <link:label id="lab_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contractual Agreement, Number of Patients Dosed that Trigger Payment</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment" xlink:label="loc_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:to="lab_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:type="arc" />
    <link:label id="lab_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97_terseLabel_en-US" xlink:label="lab_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of consideration received</link:label>
    <link:label id="lab_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97_label_en-US" xlink:label="lab_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Significant Noncash Transaction, Percentage of Consideration Received</link:label>
    <link:label id="lab_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97_documentation_en-US" xlink:label="lab_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Significant Noncash Transaction, Percentage of Consideration Received</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived" xlink:label="loc_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:to="lab_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:type="arc" />
    <link:label id="lab_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5_terseLabel_en-US" xlink:label="lab_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement to provide additional funding, if options are exercised (up to)</link:label>
    <link:label id="lab_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5_label_en-US" xlink:label="lab_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Licensed Programs, Contingent Obligation to Provide Additional Funding</link:label>
    <link:label id="lab_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5_documentation_en-US" xlink:label="lab_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Licensed Programs, Contingent Obligation to Provide Additional Funding</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding" xlink:label="loc_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:to="lab_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of common stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing share price of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27_label_en-US" xlink:label="lab_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:to="lab_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_807F796792494624CD0AD5514CF1BD46_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_807F796792494624CD0AD5514CF1BD46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_807F796792494624CD0AD5514CF1BD46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_807F796792494624CD0AD5514CF1BD46" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_807F796792494624CD0AD5514CF1BD46" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:to="lab_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:to="lab_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A" xlink:to="lab_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investment &#8211; restricted</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668_label_en-US" xlink:label="lab_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668" xlink:to="lab_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8_label_en-US" xlink:label="lab_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8" xlink:to="lab_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E" xlink:to="lab_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5A07C9C738B0C88AAE3CD5514CF88A08_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_5A07C9C738B0C88AAE3CD5514CF88A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5A07C9C738B0C88AAE3CD5514CF88A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5A07C9C738B0C88AAE3CD5514CF88A08" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_5A07C9C738B0C88AAE3CD5514CF88A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390" xlink:to="lab_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388_label_en-US" xlink:label="lab_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388" xlink:to="lab_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68" xlink:to="lab_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:to="lab_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value&#8212;225,000,000 shares authorized; 141,217,276 shares issued and 139,994,430 shares outstanding at September 30, 2016; 130,213,224 shares issued and 128,990,378 shares outstanding at December 31, 2015</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF" xlink:to="lab_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock (at cost, 1,222,846 shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621" xlink:to="lab_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670" xlink:to="lab_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:to="lab_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_73ACBE00898BDA5C27D81AE8A5BA55AF_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_73ACBE00898BDA5C27D81AE8A5BA55AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_73ACBE00898BDA5C27D81AE8A5BA55AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_73ACBE00898BDA5C27D81AE8A5BA55AF" xlink:to="lab_us-gaap_NetIncomeLoss_73ACBE00898BDA5C27D81AE8A5BA55AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6" xlink:to="lab_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209" xlink:to="lab_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D" xlink:type="arc" />
    <link:label id="lab_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253_terseLabel_en-US" xlink:label="lab_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in consideration for rights granted under collaboration agreement</link:label>
    <link:label id="lab_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253_label_en-US" xlink:label="lab_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance Of Common Stock To Licensees</link:label>
    <link:label id="lab_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253_documentation_en-US" xlink:label="lab_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of common stock to licensees.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_IssuanceOfCommonStockToLicensees" xlink:label="loc_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253" xlink:to="lab_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in restricted cash</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock associated with offerings, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under the Company&#8217;s share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_5F951442319B4318298A1AE8A5C1177C_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_5F951442319B4318298A1AE8A5C1177C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments on Curis Royalty&#8217;s debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_5F951442319B4318298A1AE8A5C1177C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_5F951442319B4318298A1AE8A5C1177C" xlink:to="lab_us-gaap_RepaymentsOfDebt_5F951442319B4318298A1AE8A5C1177C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in)/provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease)/increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CAB7479DCC7ACFE84A41AE8A5C1FFE8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CAB7479DCC7ACFE84A41AE8A5C1FFE8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CAB7479DCC7ACFE84A41AE8A5C1FFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CAB7479DCC7ACFE84A41AE8A5C1FFE8" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CAB7479DCC7ACFE84A41AE8A5C1FFE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69D77F7DD231B31D4EA61AE8A5C1B7B4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69D77F7DD231B31D4EA61AE8A5C1B7B4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69D77F7DD231B31D4EA61AE8A5C1B7B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69D77F7DD231B31D4EA61AE8A5C1B7B4" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69D77F7DD231B31D4EA61AE8A5C1B7B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7" xlink:to="lab_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Amortized Cost, Unrealized Gains and Losses and Fair Value of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92" xlink:to="lab_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A" xlink:to="lab_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:to="lab_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated net unrealized investment gain (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93" xlink:to="lab_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_80CBE8DD798248CA6C9BB016877E48A7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_80CBE8DD798248CA6C9BB016877E48A7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_80CBE8DD798248CA6C9BB016877E48A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_80CBE8DD798248CA6C9BB016877E48A7" xlink:to="lab_us-gaap_StockholdersEquity_80CBE8DD798248CA6C9BB016877E48A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets or Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7EC2132F50B132AC7C939BDB932C9778_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_7EC2132F50B132AC7C939BDB932C9778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7EC2132F50B132AC7C939BDB932C9778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7EC2132F50B132AC7C939BDB932C9778" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_7EC2132F50B132AC7C939BDB932C9778" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76" xlink:type="arc" />
    <link:label id="lab_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B_terseLabel_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, maturity ranges</link:label>
    <link:label id="lab_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B_label_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Date Range</link:label>
    <link:label id="lab_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B_documentation_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available for sale securities date range.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_AvailableForSaleSecuritiesDateRange" xlink:label="loc_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:to="lab_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:type="arc" />
    <link:label id="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530_terseLabel_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments, weighted average maturity</link:label>
    <link:label id="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530_label_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Weighted Average Maturity</link:label>
    <link:label id="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530_documentation_en-US" xlink:label="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available-for-sale securities weighted average maturity.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:label="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:to="lab_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE" xlink:to="lab_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:to="lab_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:to="lab_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:type="arc" />
    <link:label id="lab_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB_terseLabel_en-US" xlink:label="lab_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2010 Plan</link:label>
    <link:label id="lab_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB_label_en-US" xlink:label="lab_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Ten Plan [Member]</link:label>
    <link:label id="lab_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB_documentation_en-US" xlink:label="lab_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Ten Plan [Member]</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_TwoThousandAndTenPlanMember" xlink:label="loc_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:to="lab_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9_label_en-US" xlink:label="lab_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:to="lab_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8_label_en-US" xlink:label="lab_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:to="lab_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche one</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:type="arc" />
    <link:label id="lab_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0_terseLabel_en-US" xlink:label="lab_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-employee directors</link:label>
    <link:label id="lab_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0_label_en-US" xlink:label="lab_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee Directors [Member]</link:label>
    <link:label id="lab_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0_documentation_en-US" xlink:label="lab_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-employee directors.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_NonEmployeeDirectorsMember" xlink:label="loc_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:to="lab_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:type="arc" />
    <link:label id="lab_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2_terseLabel_en-US" xlink:label="lab_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shareholder-approved, share-based compensation plans</link:label>
    <link:label id="lab_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2_label_en-US" xlink:label="lab_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Plans</link:label>
    <link:label id="lab_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2_documentation_en-US" xlink:label="lab_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation, number of plans.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ShareBasedCompensationPlans" xlink:label="loc_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:to="lab_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of vested shares which are exercisable under stock option</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:type="arc" />
    <link:label id="lab_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F_terseLabel_en-US" xlink:label="lab_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period of options</link:label>
    <link:label id="lab_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F_label_en-US" xlink:label="lab_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Vesting Period Two</link:label>
    <link:label id="lab_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F_documentation_en-US" xlink:label="lab_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, vesting period two.</link:label>
    <link:loc xlink:href="cris-20160930.xsd#cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo" xlink:label="loc_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:to="lab_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option granted, exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of employee options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of exercisable options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair values of stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost, net of estimated forfeitures</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost, weighted average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic values of employee stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense related to employee and director stock option grants</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair values of vested stock options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-employee compensation expense, recognized expenses (reversals)</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Key Assumptions for Options Awarded</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Recorded Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:to="lab_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate commercial paper, bonds and notes</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:to="lab_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:type="arc" />
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Security [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B_label_en-US" xlink:label="lab_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecurityAxis" xlink:label="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:to="lab_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:to="lab_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate commercial paper, stock, bonds and notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate commercial paper, stock, bonds and notes</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:to="lab_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>cris-20160930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensation" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationNarrativeDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccountingForStockBasedCompensationTables" xlink:href="cris-20160930.xsd#AccountingForStockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilities" xlink:href="cris-20160930.xsd#AccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesDetails" xlink:href="cris-20160930.xsd#AccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccruedLiabilitiesTables" xlink:href="cris-20160930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="cris-20160930.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/BasisOfPresentation" xlink:href="cris-20160930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CollaborationAgreements" xlink:href="cris-20160930.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CollaborationAgreementsDetails" xlink:href="cris-20160930.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="cris-20160930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="cris-20160930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="cris-20160930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="cris-20160930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/Debt" xlink:href="cris-20160930.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/DebtDetails" xlink:href="cris-20160930.xsd#DebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/DocumentAndEntityInformation" xlink:href="cris-20160930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurements" xlink:href="cris-20160930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="cris-20160930.xsd#FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/FairValueMeasurementsTables" xlink:href="cris-20160930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/Investments" xlink:href="cris-20160930.xsd#Investments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsNarrativeDetails" xlink:href="cris-20160930.xsd#InvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:href="cris-20160930.xsd#InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/InvestmentsTables" xlink:href="cris-20160930.xsd#InvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShare" xlink:href="cris-20160930.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/LossPerCommonShareDetails" xlink:href="cris-20160930.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NatureOfBusiness" xlink:href="cris-20160930.xsd#NatureOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NatureOfBusinessDetails" xlink:href="cris-20160930.xsd#NatureOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NewAccountingPronouncements" xlink:href="cris-20160930.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/NewAccountingPronouncementsPolicies" xlink:href="cris-20160930.xsd#NewAccountingPronouncementsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactions" xlink:href="cris-20160930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:href="cris-20160930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.curis.com/role/RevenueRecognition" xlink:href="cris-20160930.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7760496AA3E55114F7B39F72DFCBC192" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7760496AA3E55114F7B39F72DFCBC192" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_DF0CAD6091A828935B4D9F72DFCBB671" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationKeyAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B56BE45D5B7FE976DE25A0142B990196" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B56BE45D5B7FE976DE25A0142B990196" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:to="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_300698E24223A8F4FE83A0142B9A03E8" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_EmployeesMember" xlink:label="loc_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:to="loc_cris_EmployeesMember_CF27D89A0A6484DF5A2DA0142B9AA9FB" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_OfficersAndDirectorsMember" xlink:label="loc_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_599DAB9A06CC16A494BAA0142B9A2B9D" xlink:to="loc_cris_OfficersAndDirectorsMember_B78C8EC30AB8A0F07F74A0142B9AED2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_AE8BD04507FE2E33A5C9A0142B9A8569" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_FCC50AD76A94300D0BEBA0142B9A0998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_AAFB62C1D852B102E7E5A0142B9A290C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_E38D4B2637A6CCC08E38A0142B9A7810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_E671AEF604BCB98C750DA0142B9A4C6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_EADA03EA84C9BA236F48A0142B9B543B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_E42529F478699060040AA0142B9A2120" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_479CCEB226252333B1E2A0142B9B1369" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47607D34666982DF681A06FB6E4F72C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47607D34666982DF681A06FB6E4F72C4" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_EB23360FD6BED4CB937F06FB6E4FC082" xlink:to="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_TwoThousandAndTenPlanMember" xlink:label="loc_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_203F08A438DA70B9DD8306FB6E4FCE69" xlink:to="loc_cris_TwoThousandAndTenPlanMember_289C9B29E951FE75DA5706FB6E4FD0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_3A0C4BF27D432644092206FB6E4F5CF9" xlink:to="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0DA068D6957CDAD96C6F06FB6E50A6DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_46A9E9245F632F068DDA06FB6E5033E8" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0AB2723EC4B2A2424AC006FB6E505200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_3D521D6562F0E41B7B3106FB6E50EBDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_TitleOfIndividualAxis_3D521D6562F0E41B7B3106FB6E50EBDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_3D521D6562F0E41B7B3106FB6E50EBDF" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_NonEmployeeDirectorsMember" xlink:label="loc_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720" xlink:to="loc_cris_NonEmployeeDirectorsMember_C168B2ED02993B45DA8606FB6E50BCF0" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_BoardofDirectorsViceChairmanMember" xlink:label="loc_cris_BoardofDirectorsViceChairmanMember_8255818E00BFEA7D1D8F06FB6E5088A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_F23824F07031CAEE809D06FB6E505720" xlink:to="loc_cris_BoardofDirectorsViceChairmanMember_8255818E00BFEA7D1D8F06FB6E5088A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_FEBAB06E91E95F5D3A6206FB6E50DF79" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_AwardTypeAxis_FEBAB06E91E95F5D3A6206FB6E50DF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A7B43F76F16976C3E25606FB6E506784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_FEBAB06E91E95F5D3A6206FB6E50DF79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A7B43F76F16976C3E25606FB6E506784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_FA9C7C1307F8B03FCB7F06FB6E50B534" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_A7B43F76F16976C3E25606FB6E506784" xlink:to="loc_us-gaap_EmployeeStockOptionMember_FA9C7C1307F8B03FCB7F06FB6E50B534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_4C93B0AF9DA820AB363B06FB6E4FC80A" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ShareBasedCompensationPlans" xlink:label="loc_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_cris_ShareBasedCompensationPlans_101449540C735E605F6106FB6E509AB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BFEB0D989838A9377B4B06FB6E513B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07D254A66EEFDDFF7A6A06FB6E516C0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_113C5D9C8286C3564F0506FB6E5104B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_113C5D9C8286C3564F0506FB6E5104B7" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo" xlink:label="loc_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo_7E76E023674D4098983D06FB6E51300F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_F77C8AED36E5C5079C2B06FB6E5160F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7E829B868894AFF28D6306FB6E517C22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9C3069CDDBF8069A54D206FB6E517B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3EE65501DB3BC266CBA706FB6E51BCC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A1379E7D3D158091643C06FB6E5127B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_42DFA3B56AD3CBBAB61C06FB6E5150A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_750121DB180A8113C3B906FB6E512DFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_F3B31127711DDDD0C07C06FB6E5190BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D020551FA3B0A05E98F606FB6E51546A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ADD8051DCB6C831DE6B006FB6E511864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_C8DC18F57691B31233FE06FB6E50DF8E" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0D5DE185977AA2AE09C806FB6E51E877" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationScheduleOfExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A58E2B92AA88183EA05EA0142B8A69E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_FB497CAB90A05C891975A0142B8AFE80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_A58E2B92AA88183EA05EA0142B8A69E3" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_FB497CAB90A05C891975A0142B8AFE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_FB497CAB90A05C891975A0142B8AFE80" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0E3E485200CD35AD39A9A0142B8AA4E1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1597CE17FB6D22A4F611A0142B8A177B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C0A21688DB28016D3F12A0142B8AA635" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_45DA1E24E75560D79EECA0142B8A8069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_F14E708F78A7551973B3A0142B8A17AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_FB497CAB90A05C891975A0142B8AFE80" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_F14E708F78A7551973B3A0142B8A17AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_F14E708F78A7551973B3A0142B8A17AF" xlink:to="loc_us-gaap_ShareBasedCompensation_DBF613B0F1A543004D57A0142B8B44BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccountingForStockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4738AC2B33EB5F9CCD199F72DFC9F313" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4738AC2B33EB5F9CCD199F72DFC9F313" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8A4E0305E54B1F9DE80C9F72DFC99CF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4738AC2B33EB5F9CCD199F72DFC9F313" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4F0D666A25F8652CFB409F72DFCA841A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_FC741C5D354285A1F2FF9F72DFD108A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_FC741C5D354285A1F2FF9F72DFD108A5" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_47D77E7021993330CC409F72DFD1CBE7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:to="loc_us-gaap_AccruedSalariesCurrent_643C5D05D438EAE5D346066BE863BCAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_F7DC0E4A22DAA1F54F8A066BE86649CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:to="loc_us-gaap_InterestPayableCurrent_CC2A804CA54D9228C438066BE866F7FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8B5748EA356476FBB6C8066BE86669DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_68456290C03A2396CC3A066BE86324DF" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_C18122BD66439FCB7726066BE866066A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_C84C3C57BC8E3DEF09E69F72DFCF0649" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_C84C3C57BC8E3DEF09E69F72DFCF0649" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_B83F4242D967C44A79929F72DFCFCC07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B773D8A1ACADCC4164B2A010EBC7EC87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B773D8A1ACADCC4164B2A010EBC7EC87" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6ED750B73C145D8E9167A010EBC84B04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_916D1BBC156F13DC2F43B016877D4AF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_916D1BBC156F13DC2F43B016877D4AF5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_96336BD98BCB50ADB217B016877D03C7" xlink:to="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E98EDBDBEAD7A6DA3A80B016877D8753" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8A50A28B62DFC1891A0CB016877D85FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8D889A1E8F53EA51A785B016877D6D16" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_StockholdersEquity_100027A75BD62729EBE7B016877DFF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_E7AB2947F465414545F4B016877D3792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_7BAC146C61EE30FD136BB016877D9F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9B8A3DBA824259BAB47BB016877E9766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_80CBE8DD798248CA6C9BB016877E48A7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9F83AC3B9B8526190586B016877D578C" xlink:to="loc_us-gaap_StockholdersEquity_80CBE8DD798248CA6C9BB016877E48A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_61252A1A34EBAA715EA8A010EAEB5023" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_61252A1A34EBAA715EA8A010EAEB5023" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_DBCE5B7B5E52387AAC5CA010EAEEBEAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/BasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CAB96DE7E372F69D570B9BDB932EEB8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CAB96DE7E372F69D570B9BDB932EEB8A" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6C69B2CE1A6BDBBB22B69BDB932E75CF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B3BD91103DBF50D12F349BDB932A95AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B3BD91103DBF50D12F349BDB932A95AC" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2F8800FD0455B50A1BF69BDB932B36FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/CollaborationAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99C1920DC0EAA443C0FD27A4516B4439" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99C1920DC0EAA443C0FD27A4516B4439" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_1E7F4B71B9BCC044FCF927A4516DFC6E" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_GenentechIncMember" xlink:label="loc_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:to="loc_cris_GenentechIncMember_B7FEB39BBE439D7D427627A4516DDA95" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:label="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_15E78D970553555894FC27A4516DF29B" xlink:to="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A4DDF44799BEA10EBD3627A4516ED9AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_BBDC9976C9EA56ED937227A4516E88F1" xlink:to="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:to="loc_us-gaap_MaximumMember_D6F480B5135B9241991127A4516EFFB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6AC3F4391F84555E859427A4516E57A1" xlink:to="loc_us-gaap_MinimumMember_251451A15779400134BD27A4516EED12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_A0800FE2DE603CFBE65B27A4516E6FCE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_dei_LegalEntityAxis_A0800FE2DE603CFBE65B27A4516E6FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_371861A6A29C77CF0BD927A4516E1FA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_A0800FE2DE603CFBE65B27A4516E6FCE" xlink:to="loc_dei_EntityDomain_371861A6A29C77CF0BD927A4516E1FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_67E775BC1A3D242309D327A4516EE308" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_371861A6A29C77CF0BD927A4516E1FA7" xlink:to="loc_us-gaap_SubsidiariesMember_67E775BC1A3D242309D327A4516EE308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_14210CB9ED5E05CB05D627A4516E4451" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_DebtInstrumentAxis_14210CB9ED5E05CB05D627A4516E4451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_83F8073F5597B794E73F27A4516EB7F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_14210CB9ED5E05CB05D627A4516E4451" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_83F8073F5597B794E73F27A4516EB7F5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CreditAgreementWithBioPharmaTwoMember" xlink:label="loc_cris_CreditAgreementWithBioPharmaTwoMember_32BCDDAAE7AB1C7710D227A4516EDC82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_83F8073F5597B794E73F27A4516EB7F5" xlink:to="loc_cris_CreditAgreementWithBioPharmaTwoMember_32BCDDAAE7AB1C7710D227A4516EDC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_9020EB094BC4E731661E27A4516FD5F8" xlink:to="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_DrugDevelopmentRoyaltyMember" xlink:label="loc_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_4E701335008FC5400E7A27A4516FCB48" xlink:to="loc_cris_DrugDevelopmentRoyaltyMember_F7EEDAC0BCB4ED10F89F27A4516FF72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B0211EAFA50B68DFEB0127A4516FA7AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramOneMember" xlink:label="loc_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ProgramOneMember_DB9ED168DEE645EC20CB27A4516F1001" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramTwoMember" xlink:label="loc_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ProgramTwoMember_39CE807A1E643A4EC46E27A4516F95FC" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ThirdandFourthProgramsMember" xlink:label="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramThreeMember" xlink:label="loc_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:to="loc_cris_ProgramThreeMember_7F91E2C132885564D6B227A4516F56A2" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramFourMember" xlink:label="loc_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_ThirdandFourthProgramsMember_9368038E511ECCE2644027A4516FEEC5" xlink:to="loc_cris_ProgramFourMember_E91F37AA8600A74B797327A4516FC545" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramThereafterMember" xlink:label="loc_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ProgramThereafterMember_C1A54A058CBE07A9F0E327A4516FE403" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ExtendedExclusivityIRAK4ProgramMember" xlink:label="loc_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ExtendedExclusivityIRAK4ProgramMember_70C232D4D0D701225D6727A4516FFA3B" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingIRAK4ProgramMember" xlink:label="loc_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_AcceptanceofINDFilingIRAK4ProgramMember_0CE4751947473B7A49F127A4516FC9B1" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember" xlink:label="loc_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember_66B0D4C7FE1F340C9D6E27A4516FA10D" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ExtendedExclusivityPD1VISTAProgramMember" xlink:label="loc_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ExtendedExclusivityPD1VISTAProgramMember_DB8B4F2BA55BF50CE87227A45170E17A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember" xlink:label="loc_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember_ADCFB5E07E1CC6F056C827A45170F017" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_OptionExercisePaymentProgramThreeMember" xlink:label="loc_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_OptionExercisePaymentProgramThreeMember_96726FA87D41364B976727A45170D090" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingProgramThreeMember" xlink:label="loc_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_AcceptanceofINDFilingProgramThreeMember_20ADDD46211B7A87F44C27A45170EECD" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ProgramSelectionFeeProgramFourMember" xlink:label="loc_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_ProgramSelectionFeeProgramFourMember_2B53DE111DC27EB4DCF527A451702CB9" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_OptionExercisePaymentProgramFourMember" xlink:label="loc_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_OptionExercisePaymentProgramFourMember_5C870839B65EF6A8EA1E27A45170626A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AcceptanceofINDFilingProgramFourMember" xlink:label="loc_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9BBAB46D1A3B73799DC727A4516F5DE5" xlink:to="loc_cris_AcceptanceofINDFilingProgramFourMember_61368C4DA73835E2F21627A45170DA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3E71977E673DF649640227A451706F38" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_08A2BA3BC9C5E2F753FC27A45170950D" xlink:to="loc_us-gaap_SubsequentEventMember_44275AF0AF5FB5AADC5527A4517005A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CC921BA3A6293CC50B2427A4516C8A1E" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborationAgreementContingentConsiderationPotentialCashPayment" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment_FBE8DF48E085556221C927A451704806" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborationAgreementContingentConsiderationReceivedFromPartner" xlink:label="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner_587490B6D1457459809527A45170D63F" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PercentageOfRoyaltyOnNetSales" xlink:label="loc_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_PercentageOfRoyaltyOnNetSales_A1E02DF928493ABF761427A45170CB1A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ReducedRoyaltyRate" xlink:label="loc_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_ReducedRoyaltyRate_52777B4F5B0C723C5C2127A45170116B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_900C9F8F1FE4509F264627A45170B0E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_900C9F8F1FE4509F264627A45170B0E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_800ADB044D6C396697A527A451701E5C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_800ADB044D6C396697A527A451701E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_RoyaltyRevenue_31FF372F957D61F1C81727A451718989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_3995BC1E8A37CFF9991A27A451719AE2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_RoyaltyExpense_3995BC1E8A37CFF9991A27A451719AE2" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned" xlink:label="loc_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned_FC71A2B60416D003C1CF27A45171E31B" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ResearchAndDevelopmentRevenue" xlink:label="loc_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_ResearchAndDevelopmentRevenue_11640807705C60B2BDA227A45171C379" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ResearchAndDevelopmentContraRevenues" xlink:label="loc_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_ResearchAndDevelopmentContraRevenues_B03CAD1AE5169D5C754227A4517119CA" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeAgreementOptionExercisablePeriod" xlink:label="loc_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeAgreementOptionExercisablePeriod_AC2FE50F5D2DE1527C6527A4517170C0" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementNumberofProgramsLicensed" xlink:label="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_6643A4DE459000F61F5C27A45171B7EF" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentsAgreement" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementPaymentsAgreement_BFD0695AAFB058C6661327A451712BF8" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AdditionalPaymentsMadeUnderCollaborativeArrangements" xlink:label="loc_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements_3B23B8CF88EF494D4BE027A451718118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_EA61C2444E5AB93C1FF827A45171E957" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PaymentsforResearchandDevelopment" xlink:label="loc_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_PaymentsforResearchandDevelopment_0EBA3ADE5701239FDB9727A45171E325" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram_91375CA64B3A09A5922B27A4517162C0" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentforLicensedProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementPaymentforLicensedProgram_2AE81D6D6122F20DE0E727A45171D08F" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries" xlink:label="loc_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries_5FCF39A6869D91A7F72427A451710E81" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeAgreementPeriodOfContract" xlink:label="loc_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeAgreementPeriodOfContract_76AD6D567A7E9187311827A451711824" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementNumberofOptionalAdditionalTerms" xlink:label="loc_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms_0D72AA090BF1062F453227A4517192A5" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionalAdditionalTerm" xlink:label="loc_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementOptionalAdditionalTerm_F378D67194753BBAAEBE27A45171FE23" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionFeesTotal" xlink:label="loc_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementOptionFeesTotal_FD97DCBBDD2B9B05E3DF27A451720394" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementOptionFeesNumberofPayments" xlink:label="loc_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementOptionFeesNumberofPayments_8BF9AB36782DF9D15BF127A4517240AC" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier" xlink:label="loc_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier_9CCF9ADAFE187ACE0CDF27A4517260E3" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct" xlink:label="loc_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct_68E9C4AB2AA04E775F8527A45172CE68" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementPaymentsAgreementPerProgram" xlink:label="loc_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementPaymentsAgreementPerProgram_743C6A27A85AEE5B5F3F27A451725A4A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForOptionExercise" xlink:label="loc_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForOptionExercise_35DB9863C5EB4E4EF74127A45172B04C" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling" xlink:label="loc_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling_D4EB19F3DAF38CB3E89B27A4517275BA" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForDosingOfFifthPatient" xlink:label="loc_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient_19827A2F58278F98F62627A45172A98E" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PaymentsMadeUnderCollaborativeArrangements" xlink:label="loc_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_PaymentsMadeUnderCollaborativeArrangements_59AD9576286DA353201D27A451720F24" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForProgramSelectionFee" xlink:label="loc_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForProgramSelectionFee_F9C54B5D5474EED4906F27A4517223A8" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram" xlink:label="loc_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram_E4282C5E22C6F5EF07B527A4517222B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_E50B98B1D3DF7A7DE4E927A45172E3E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_87136DEDACBE818FB65C27A451728F68" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment" xlink:label="loc_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment_EE9CEFF27A359F09FDF927A45172FFA9" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived" xlink:label="loc_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived_31286D24EEC5AC23CEF127A45172FC97" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding" xlink:label="loc_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding_DE2A8CA0725363E55EE627A45172AFC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1D57CE72A8099D03ED1027A4517214C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_CD820973C111109EDC4627A45170FE97" xlink:to="loc_us-gaap_SharePrice_EDCF261350E76FC160A127A451723D27" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_807F796792494624CD0AD5514CF1BD46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_807F796792494624CD0AD5514CF1BD46" xlink:to="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:to="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6C9E913F5A27685F0A8CD5514CF27BDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2D4C9359AE45841B7C43D5514CF2DA18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7CC955FB5C30786828B9D5514CF2D935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_946B7936872978C3FCBAD5514CF294BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_F40C816FE5B0B68821B4D5514CF12DEC" xlink:to="loc_us-gaap_AssetsCurrent_75D8EE355D68DFB1F3CED5514CF26B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ACFA7FCD7EB67B1C35CDD5514CF2BEDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_4CDBFC94547F089455EAD5514CF2C221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:to="loc_us-gaap_Goodwill_010AA56643757E954D1CD5514CF2B668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_F7106C107C2635E17040D5514CF20A13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_26C68DE1ADD6E13DC88BD5514CF1001D" xlink:to="loc_us-gaap_Assets_3123ADB7898D9176F2D3D5514CF768C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_807F796792494624CD0AD5514CF1BD46" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:to="loc_us-gaap_AccountsPayableCurrent_8F9584839C17E84ABE9ED5514CF8900E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5A07C9C738B0C88AAE3CD5514CF88A08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5A07C9C738B0C88AAE3CD5514CF88A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_077DD6FB5C5ED6700682D5514CF8F696" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:to="loc_us-gaap_LongTermDebtCurrent_077DD6FB5C5ED6700682D5514CF8F696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_64FF81F7973046A71BA5D5514CF853C1" xlink:to="loc_us-gaap_LiabilitiesCurrent_846ADD831CBEF7126417D5514CF8C390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B2911945F7215B98D201D5514CF8F7A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_B2911945F7215B98D201D5514CF8F7A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_A1B24B5FCA19D02B196FD5514CF834DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:to="loc_us-gaap_Liabilities_27AA7E68D6AB4277EA70D5514CF88388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3AE9B5189292515E5BF4D5514CF8FA68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:to="loc_us-gaap_CommonStockValue_0268AAEBED28BFC99F7DD5514CF8D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_A35C1F629CDB2879E3DAD5514CF80699" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:to="loc_us-gaap_TreasuryStockValue_2AA8FF0BB07B59ADB6CFD5514CF95621" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_665530856D78F8AA338DD5514CF900AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C7383B406739742402BBD5514CF9DF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9FAFD5BF5FBA13A1EB4DD5514CF8A203" xlink:to="loc_us-gaap_StockholdersEquity_0D51B65987624F96226CD5514CF95670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6AB2A2F9F71EDC232B54D5514CF8EB60" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_79A771C02302E211798BD5514CF927F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E9FC49D3808821C3C0839BDB7C871CDB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E9FC49D3808821C3C0839BDB7C871CDB" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_AA3FD68B7D80D7B70DAE9BDB7C870175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E9FC49D3808821C3C0839BDB7C871CDB" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_03E8FA4FFE075D77180E9BDB7C870924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E9FC49D3808821C3C0839BDB7C871CDB" xlink:to="loc_us-gaap_CommonStockSharesIssued_384E22B27DC91C476AE99BDB7C870E92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E9FC49D3808821C3C0839BDB7C871CDB" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6F9A42D21AC7EAA7178F9BDB7C87DAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E9FC49D3808821C3C0839BDB7C871CDB" xlink:to="loc_us-gaap_TreasuryStockShares_6C1883CC8A1FBDB66BD29BDB7C87CE2A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_73ACBE00898BDA5C27D81AE8A5BA55AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:to="loc_us-gaap_NetIncomeLoss_73ACBE00898BDA5C27D81AE8A5BA55AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="loc_us-gaap_DepreciationAndAmortization_ABDC8E55E00EA077B2D11AE8A5BABDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="loc_us-gaap_ShareBasedCompensation_EB768A3FEA970B468E2E1AE8A5C0A209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_C28981E37C3FF4B8249D1AE8A5C03664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_848A8A2F5E6114F18CC11AE8A5C006F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_1CC7C30517867D4226951AE8A5C0D87D" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_IssuanceOfCommonStockToLicensees" xlink:label="loc_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="loc_cris_IssuanceOfCommonStockToLicensees_AA9BD772773A4E9464B11AE8A5C04253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6A2E4B127E5E7D52BF3A1AE8A5C0E790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_849B85B0518C0FC42A401AE8A5C0A602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_A3288A2BF744EC08C0001AE8A5C07FBC" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_C9E08B0050DC31E82FF01AE8A5C01D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D54EC3E55EDA7D822FA21AE8A5BA4E42" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_23B71C650426D7DBC53D1AE8A5C00E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_218E4C5885091934CE4C1AE8A5B80B65" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7D417FFEF7FCF2BCC4A01AE8A5C13229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_A1D0398197F32325D1FA1AE8A5C1AD9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_BB228360C836EFB40DE91AE8A5C1D39B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87B63A3E823D35EA9EB61AE8A5C19C7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_FC5E4785E5BB790A3F8E1AE8A5C19F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_C5F83444933E6B17F2AF1AE8A5C148BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8757A31E9A602B0BC5F61AE8A5C13893" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_E2A1786B46BB94EF65931AE8A5C18F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8BACFFC0FB5164C6BD4D1AE8A5C132CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4B863E901E06D687E5201AE8A5C1F6BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_5F951442319B4318298A1AE8A5C1177C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:to="loc_us-gaap_RepaymentsOfDebt_5F951442319B4318298A1AE8A5C1177C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3D32B6B7C79FCE8964A61AE8A5C1CE3E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_85497E3F7822EF38BA151AE8A5C11BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_3F24A755285DE956A2401AE8A5C1FEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CAB7479DCC7ACFE84A41AE8A5C1FFE8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CAB7479DCC7ACFE84A41AE8A5C1FFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69D77F7DD231B31D4EA61AE8A5C1B7B4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_45A3465C7B203D42E2391AE8A5B68DBF" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69D77F7DD231B31D4EA61AE8A5C1B7B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="loc_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:to="loc_us-gaap_RoyaltyRevenue_78487C1CDE995F1C2D06A0878F3528A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1C29FDCC8E82AF4D358CA0878F35A562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_71E14070280994511580A0878F355265" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_68F1F6604F409E15B8ECA0878F357B23" xlink:to="loc_us-gaap_Revenues_71E14070280994511580A0878F355265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:to="loc_us-gaap_RoyaltyExpense_CE90C066743B9906CC06A0878F3515B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_EA66C8B7E48AC47B312EA0878F35C2E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8A0D23C5C49809D17C8EA0878F350673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_EE5730189240CF102096A0878F350C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_E279AFFF4F610F790186A0878F357ED2" xlink:to="loc_us-gaap_CostsAndExpenses_2F499F620A29A52D7476A0878F35E788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="loc_us-gaap_OperatingIncomeLoss_9A323D2259398D803054A0878F356230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_84A5B02E5DEA7D43F54DA0878F36612A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:to="loc_us-gaap_InterestExpense_ED2E81934040E0BFAFD3A0878F360AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5A145522ED29290448FAA0878F3660C7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_134044234C98B2E08CB1A0878F364E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="loc_us-gaap_NetIncomeLoss_593DAB9BD05AA1B4D381A0878F36F26A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_DB67B688D47AB3D48154A0878F365B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4356374C762144CEDC4CA0878F366538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0572F099164D98232E74A0878F3457D4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9CB881B434969DE2FE1BA0878F36E73E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D6D472AA9926C2409A8D9F72DFD85DD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D6D472AA9926C2409A8D9F72DFD85DD4" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_A19507CB63799EB6919E9F72DFD8D5F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_24A713DB6DF38451310703A70336D73F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_24A713DB6DF38451310703A70336D73F" xlink:to="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_F64D317A3AE61F7DDF2003A7033D8588" xlink:to="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ECE00ECDC497FED9496A03A7033D1C80" xlink:to="loc_us-gaap_SubsidiariesMember_C77DD55F79993BD8088703A7033D483E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_945C8EEF71C8A71E475D03A7033DB58F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CreditAgreementWithBioPharmaTwoMember" xlink:label="loc_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D7409734994ADFD63CED03A7033E2213" xlink:to="loc_cris_CreditAgreementWithBioPharmaTwoMember_887EADD61C5DB97E942603A7033E9086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_22AFE962C0A1DCB1745903A7033E70A1" xlink:to="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PrincipalPortionMember" xlink:label="loc_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8F78FBB160A5502A895F03A703435AFA" xlink:to="loc_cris_PrincipalPortionMember_E3E767A5DD89110A5B3B03A70343BADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_6AE68540DDE289732C2C03A70343C34E" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_BioPharmaTwoMember" xlink:label="loc_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_8259606E89C5EDE1E78803A70343312A" xlink:to="loc_cris_BioPharmaTwoMember_68D6ACD71D794023A81003A70344364B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8DE13CF5E5F062CCE1D803A7033B8912" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0E0E0EA370390282F87403A703444F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3802CAB63643C32F971003A7034415F4" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter" xlink:label="loc_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter_7E5A70D17EE2B000558B03A7034424FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_RepaymentsOfDebt_97FFD7543375866B808C03A70344E6FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_LongTermDebtCurrent_18CEC16742D878A6366103A7034472C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4D227C3D463D0ABC186E03A70344C11E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_5B7BE994A4FF5B6143A203A70344DE13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6275107A3565AB53F74303A7034476B9" xlink:to="loc_us-gaap_InterestExpense_99D3DB9E532B825BC0AA03A703447A75" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="cris-20160930.xsd#cris_DocumentAndEntityInformationAbstract" xlink:label="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_367734909EACA6AC819977899B3AD67A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_DocumentType_367734909EACA6AC819977899B3AD67A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_AmendmentFlag_9C253D1C8C2FF5861A1577899B3A9E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_DocumentPeriodEndDate_F6B4B3E47185362450D177899B3A8975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_DocumentFiscalYearFocus_43BE1188351961E2D2B477899B3AB961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_DocumentFiscalPeriodFocus_45AEB01974DB694EA5E377899B3A8A94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_847157391E940EE182A877899B3AEA51" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_TradingSymbol_847157391E940EE182A877899B3AEA51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_EntityRegistrantName_322A0C9B33EB1083E40677899B3A5791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_EntityCentralIndexKey_85726AE2A0F4F78CE5D177899B3A8B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_CurrentFiscalYearEndDate_70503847678CF0881DA977899B3A6FE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_EntityFilerCategory_128B5CC02580B884FCB077899B3AB255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cris_DocumentAndEntityInformationAbstract_3F1EA0F08306489AA71F77899B3A82AE" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_1209B9777890C7666C0177899B3B1422" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_05D3B023474C915CFBF69C7D10E54267" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_05D3B023474C915CFBF69C7D10E54267" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_2A51148A06B6E4EBBFD99C7D10E53750" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_58075366C92255055D762600CC3AF945" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_58075366C92255055D762600CC3AF945" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9A16DAA22071ADFA4BE92600CC4262EA" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_767FB66787FF5E0C82432600CC43428D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_620EF5E3DC77A9B74F8D2600CC438417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D7B5EB715EC3FBB2B63B2600CC436B8C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2228AE6AAB6DAECDE04B2600CC438F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_54038B967958BC674C602600CC43137B" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_DBE8596C22FC4093030E2600CC43C8A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3F1F044AB5E74FE8D69B2600CC43DAE8" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:to="loc_us-gaap_MoneyMarketFundsMember_DA39ACEF5873551A24532600CC438B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:to="loc_us-gaap_CommercialPaperMember_16861544FAE39C49439A2600CC44B645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6DED541C299EDC08E6CB2600CC439253" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_77A5E6D4B84CDD155C242600CC444EA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_CAE2CE9D0142F1ACFCA62600CC44114D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_InvestmentTypeAxis_CAE2CE9D0142F1ACFCA62600CC44114D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_A3722FF9772912D5A5B42600CC44F31B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_CAE2CE9D0142F1ACFCA62600CC44114D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_A3722FF9772912D5A5B42600CC44F31B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_E420FE1709A251D7EDE02600CC44320E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_A3722FF9772912D5A5B42600CC44F31B" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_E420FE1709A251D7EDE02600CC44320E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecurityAxis" xlink:label="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtSecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecurityAxis_7F1777A3F9BF3FFF9C28260727C2DB4B" xlink:to="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtSecuritiesDomain_7923BEF986B8303A52CE260727C501BF" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8B2E893F7D7A051D4566260729BD1F57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_652C495255E29C35C70D2600CC422BFE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1A1BD3AA1E1D688EF1C42600CC442CCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosureAbstract_EEBC2FFB93836E40A1DC2600CC44C290" xlink:to="loc_us-gaap_AvailableForSaleSecurities_8BDF31156497AC6E66132600CC45E63E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_A11183B72D13031B0A492600CC44B791" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_F5ED9756CC4107408A252600CC450045" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DD996A0A1C2CEA2211D69F582598F746" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DD996A0A1C2CEA2211D69F582598F746" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_40F1808BD60EFBA56F789F58259846B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/Investments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0B6FA9CB86C6BB56597D9F5825927CD2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0B6FA9CB86C6BB56597D9F5825927CD2" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_CF8286E188AD0D6879C79F5825925D61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A3A301B309AAE9F85FFD0CC05ED5E2C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A3A301B309AAE9F85FFD0CC05ED5E2C8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_04B2E505BC9895BF7DF40CC05ED81CAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:to="loc_us-gaap_RangeAxis_04B2E505BC9895BF7DF40CC05ED81CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_04B2E505BC9895BF7DF40CC05ED81CAF" xlink:to="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9B70A00D474C9CF0A4BE0CC05ED90C8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7" xlink:to="loc_us-gaap_MinimumMember_9B70A00D474C9CF0A4BE0CC05ED90C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6CED3B43E86DC19FF6710CC05ED95D30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F0CB028EC6307FA720940CC05ED80FC7" xlink:to="loc_us-gaap_MaximumMember_6CED3B43E86DC19FF6710CC05ED95D30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_C9D52A23B0A16E3574B80CC05ED9E82F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:to="loc_us-gaap_InvestmentTypeAxis_C9D52A23B0A16E3574B80CC05ED9E82F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_29A972BBFD3E5E1AA3B60CC05ED93B46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_C9D52A23B0A16E3574B80CC05ED9E82F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_29A972BBFD3E5E1AA3B60CC05ED93B46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_BD8D53FA025396E4F43A0CC05ED92AE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_29A972BBFD3E5E1AA3B60CC05ED93B46" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_BD8D53FA025396E4F43A0CC05ED92AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1D55A103906D7454D3950CC05ED99AB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_762D45F04778AEE0D32E0CC05ED76D2A" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1D55A103906D7454D3950CC05ED99AB2" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AvailableForSaleSecuritiesDateRange" xlink:label="loc_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1D55A103906D7454D3950CC05ED99AB2" xlink:to="loc_cris_AvailableForSaleSecuritiesDateRange_797A71490A3BE9A455990CC05ED9B58B" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AvailableForSaleSecuritiesWeightedAverageMaturity" xlink:label="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1D55A103906D7454D3950CC05ED99AB2" xlink:to="loc_cris_AvailableForSaleSecuritiesWeightedAverageMaturity_333E3978CD7019EA80B50CC05ED92530" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26466125FF3CE2F7E62925FD4B829B5D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_26466125FF3CE2F7E62925FD4B829B5D" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_49EAE6E32E416315EFC725FD4B822489" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_ED8CC6BEE6555553862925FD4B82F089" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_FFD40894C4C0D621180C25FD4B82AEA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:to="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_E01E9039EF0E9B87B3FF25FD4B82F646" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1E35CF9D86678A54D24625FD4B820CCA" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_7C33BD9679BDBD8D48B225FD4B82D22D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_85ED25E1C91A084488BC25FD4B82C101" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_09E6662177FA9207E86325FD4B8358D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_85169393D6DE702C540925FD4B838904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3020DB46B359F98212A25FD4B88EEDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_05EA2910228B35420AB025FD4B8214B7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_A26C3D8429C1B02E03D525FD4B889D9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6B5DF32D9A93E445E62E9F582590E3B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6B5DF32D9A93E445E62E9F582590E3B0" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_936D9ED2A9562B0184769F58259093A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_A2EF091BB59C35CA6D0F9F72DFB3EC61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_A2EF091BB59C35CA6D0F9F72DFB3EC61" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ABED15217E9A39F952C09F72DFB3F602" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_204211144810002190E39F72DFB1E7CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_204211144810002190E39F72DFB1E7CD" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8F55F9A0EFC7743FEDCA9F72DFB1AA4C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6DCFEF711AC8FFEFB79C9F72DFB19295" xlink:to="loc_us-gaap_EmployeeStockOptionMember_965E46510FA24F5305E69F72DFB1EC55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44067C80C25B519489149F72DFB10275" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4479DFE5A40399400C7F9F72DFB11159" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572ECEEF89FEB679B8049F72DFB12968" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/NatureOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E0D10CC813EAF6B496AF9BDB93329306" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E0D10CC813EAF6B496AF9BDB93329306" xlink:to="loc_us-gaap_NatureOfOperations_93825BDFB02FAFA5C3C49BDB93320DC7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/NatureOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFB84F173DF173B5D3A7FC20AB70365A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EFB84F173DF173B5D3A7FC20AB70365A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1B2DE60CB4D6E1486EE8FC20AB7009BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:to="loc_us-gaap_CounterpartyNameAxis_1B2DE60CB4D6E1486EE8FC20AB7009BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE5A8456356E1A0116CDFC20AB708B11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_1B2DE60CB4D6E1486EE8FC20AB7009BB" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE5A8456356E1A0116CDFC20AB708B11" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_AurigeneDiscoveryTechnologiesLtdMember" xlink:label="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A19FAA8BDB41C0CFDEB9FC20AB703F79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE5A8456356E1A0116CDFC20AB708B11" xlink:to="loc_cris_AurigeneDiscoveryTechnologiesLtdMember_A19FAA8BDB41C0CFDEB9FC20AB703F79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_D043BBC2B8EAAD25F5D3FC20AB70254F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_D043BBC2B8EAAD25F5D3FC20AB70254F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E1FF2E8D23939F9A29DBFC20AB7108F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_D043BBC2B8EAAD25F5D3FC20AB70254F" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E1FF2E8D23939F9A29DBFC20AB7108F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_852EA3FC472674803BABFC20AB7180DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E1FF2E8D23939F9A29DBFC20AB7108F9" xlink:to="loc_us-gaap_SubsequentEventMember_852EA3FC472674803BABFC20AB7180DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5AB0651D54C094D47A7DFC20AB70D2F5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_830C6A212B752BA384A0FC20AB71A5F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_830C6A212B752BA384A0FC20AB71A5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_1F68EA858C131DFA48A5FC20AB717E3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1_1F68EA858C131DFA48A5FC20AB717E3A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_CollaborativeArrangementNumberofProgramsLicensed" xlink:label="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_E645F167F7303B06AA0FFC20AB714D80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_cris_CollaborativeArrangementNumberofProgramsLicensed_E645F167F7303B06AA0FFC20AB714D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46254CA225341C0D26C4FC20AB71E7DB" xlink:to="loc_us-gaap_NumberOfReportableSegments_C9E57F52BAF855524493FC20AB71671A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/NewAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_5E905522D2C8F98270D29F58254ED7D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_5E905522D2C8F98270D29F58254ED7D5" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_FCDF47218F59598172959F58254E3C76" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/NewAccountingPronouncementsPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_14170A3785DC12943ADFB00EFA19D7EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_420B0B29C8544F3ECD6AB00EFA197934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2225917F5177C8C22641B00EFA1A4502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_91E2BCC8E9F106FC048FB00EFA14FC99" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_22F51EC53C0916983608B0119DA84254" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_88411C48C827C03AE9B89F72DFA914AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_88411C48C827C03AE9B89F72DFA914AB" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_AF8A3AAB6342374F9D119F72DFAAC160" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9956703B008FA5AE51B4FC2874766489" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9956703B008FA5AE51B4FC2874766489" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_B49BA0E5A5FA654AABCFFC28747C4481" xlink:to="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_MrPasseriMember" xlink:label="loc_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_EB1F23F455D680C66313FC28747C1128" xlink:to="loc_cris_MrPasseriMember_02E09A9D61B65406C55EFC28747CBDE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_B8D4573C0119E1B52B3BFC3CE15B76BC" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredBonusMember" xlink:label="loc_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_82FBD7B3CA285763DF8AFC3E5E23F70B" xlink:to="loc_us-gaap_DeferredBonusMember_C81B64CCBCB0AFD680FAFC3D1A99258F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_614232D745FF3BD79161FC3C2EE3F228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ADBD9B0A6D6312F810A8FC3C30018A35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BC7632C4D339036D12B1FC3C2EE61E13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ADBD9B0A6D6312F810A8FC3C30018A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_B8DD4B292A9E4DC251E7FC3C2C95A1F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_TitleOfIndividualAxis_B8DD4B292A9E4DC251E7FC3C2C95A1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CC0681B65BA98D8A031EFC3C2CAC66C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_B8DD4B292A9E4DC251E7FC3C2C95A1F1" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CC0681B65BA98D8A031EFC3C2CAC66C4" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_BoardofDirectorsViceChairmanMember" xlink:label="loc_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_CC0681B65BA98D8A031EFC3C2CAC66C4" xlink:to="loc_cris_BoardofDirectorsViceChairmanMember_E5334A1F1379733E2199FC3C2E0B43D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_14EF2CC861458FC4393CFC28747C6618" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ConsultingAgreementPeriod" xlink:label="loc_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_cris_ConsultingAgreementPeriod_06A25407F64E59BAEDD4FC28747C4C0A" xlink:type="arc" />
    <link:loc xlink:href="cris-20160930.xsd#cris_ConsultingFees" xlink:label="loc_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_cris_ConsultingFees_42665AC9FEE102AE977FFC28747CA8A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount_8C252AB67D576D80C194FC3B0929D5CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_A2155DB884FEF5FE9C02FC3D51942C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_F91FCAD430B831A9BD76FC40CD3A9C65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_D6B23359B8F7EF24326FFC28747CF14C" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ADE863C51F7BF59CF00FC28747CD1F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.curis.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7EC2132F50B132AC7C939BDB932C9778" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7EC2132F50B132AC7C939BDB932C9778" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_A6195F46D379769DA3B39BDB932CB44F" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pipelineupdatedv2a01.jpg
<TEXT>
begin 644 pipelineupdatedv2a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" )1 U,# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \I^%9_XRB^*7_7EH?\
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M]_GC%>I>&/V@/$FI?\%)/$WPT:73V\)Z9X&L]>BB2 K<B]DO9(7+.>"OEJI
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M*@4KO5!G.W!-?0?]N^(O^A?M/_!E_P#:J/[=\1?]"_:?^#+_ .U4 ?.?Q/\
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M3_P9_P#VJC^W_$/_ $+]I_X,O_M5 &EX>L[NQT6T@O98KB\CB07$T<(BCGD
M&YU4$[<GL36E7.?V[XB_Z%^T_P#!E_\ :J0Z]XBQ_P B_:?^#/\ ^U4 <E\!
MG!^*/QBQS_Q5=NP [@Z+IN#^-<]\:OV/[?XV_M0?#GX@:C/93Z5X'T_4K.;1
M;S3TG746NDC\N3<W"F-HU(_I70_#WPSXJ\&>+O&FH2Z18S0^)M9BU"")=0P8
M$33[2U )\KUMB?\ @5==_;OB+_H7[3_P9?\ VJ@#SSXQ_LKO\3OV@_A)XWMM
M573+;X92ZE(^GI;$M?K=6JP+&K[@(E38&P!@D"O*?C'_ ,$S]2^+.N?%9IO&
M*6^B_%OQ#H6I:O9Q6#>:MCIZ#S+-'\T ><5P6QQN)KZ9_MWQ%_T+]I_X,O\
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M?:4,D@!&X96,<]*^J_[=\1?]"_:?^#+_ .U4?V[XB_Z%^T_\&7_VJ@#Y@?\
MX)@W6M^#&@UWQJ=;\0^)_'VG>-_&.HOHZK%KOV,@QV:0^8!!$%2-5.Y]I7[I
MZ5]=1JT?7<5+'@C[O( QCM6)_;OB+_H7[3_P9?\ VJC^W?$7_0OVG_@R_P#M
M5 '1T5SG]N^(O^A?M/\ P9?_ &JC^W?$7_0OVG_@R_\ M5 '1T5SG]N^(O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9X^%GBJX^ OPS^%OASQU=6$BZ;$FD1Z1I]_<CF-+N6T19/*/4X!YZ<\5[47
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MNHW4 +12;J-U "T4FZC=0 M%&:,T %%)NHW4 +12;J-U "T49HS0 449HS0
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M-#32I9M'%T-)?3H6B82JS+YJR!L$ @@$X((%>\W_ (P%ED>0[_1Q54_$)?\
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MIHOA=OB>NG6=S8:CX<:_CMX;2S^S^>C"9-MUNWG<49-I7Y2:V_@=_P $X%^
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MD]1^=+LKEI/B?&D2'[),2W0;Q33\4T'_ "Y3?]_17(=/.CK-E&RN1'Q6B/\
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MN3=]\<4S_A<,7_0/F_[^"CV<BO:1.SW>U&[VKC/^%P1?] ^?_OX*/^%P1?\
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M '^6C_AI&W_Z!-S_ -_EH]A4#V\#U#'^<48KR_\ X:1M_P#H$W/_ '^6D?\
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M?\*/[(N_^?6X_P"_1_PI_P"NV9]D:_\ $,LI[3^\_'O_ (<B?'/_ )X>"?\
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MB7N[_CSNNO\ SR;_  KP,=CJ^,J>VK,^KRW)\/E]+V.&5D5:0]*M_P!AWO\
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M%PU(-0_X^V^BU$W2M#4O#NH?:7Q87G1?^6#?X56_L#4_^@???]^'_P *JD]
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M]$O#NMSQS7EL1YZ9^7IG&?F]:]++Z:GN>)FM2I!I(T%\0:@6QY\W')Y'%/\
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MW_P7:^)-N"1X+\$<<\M=8_\ 1E'^IV8]D8?Z_9.O^7C/U9/B74 /^/\ N/\
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MI(/^0C>_]_3_ (56J&;K1[(:J,T;KQ9J<;QL-2NN1VD?_"F_\)CJ?_00O/\
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MXHLPN ZTDS<TN*CD&7HLPN%%%%%F%PILG^K;Z4ZFRG]VWT-)IV!;GTYX<_Y
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MX-=4TT:'E@/J?K_@?RH69"V,C(..O?K1SR%R4SDO^%:3?\_$7_?%'_"M)O\
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M>QR+?"Z5U"FXBP/]@T@^%<G_ #\1?]\&NVHI>U8_9HXIOA;,1_Q]I_WZJ/\
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M_+5?^^:%U^\S_K5_[YJG%]W\*!UI>SI]C58BKW- :Y=D_P"L3_OFG?VS=_\
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MZSZQ_P"$YU#_ )^5_P"_5 \<Z@?^7E?^_5?(4_\ P4T6%Q_Q13XS_P!!,?\
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M^"X44!X^&MP?^Y@/_P 9I_ZKYA_('^N>4_\ /UGZ$?\ "?:I_P _ _[]T?\
M"?:I_P _ _[]U^=%S_P7<6W;_DF,OT_X2(__ !FJ-U_P7T6W!_XM=-P,_P#(
MPG_XS6O^J68?R"?&N4+>JS])#\0=5 _X^1^,=-_X6-JQ_P"7F+_OV*_-)O\
M@X)CQ_R2V?\ \*$__&:C_P"(@.+O\*YR/3_A(3S_ .0:?^J.8?R&'^OF2?\
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MJ=S>_P"%H:W_ ,_B?]^:#\4-;(_X_$_[\U@TAZ4>R#VE3N;O_"S=<_Y_X_\
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MQ 5/^G)_X#)_C7.3?>I@/-:^RB'M*G<Z>]^+GB"&Y<"\3H/^6%1?\+B\1_\
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MEH@@,LY;<NYG4"/.<,.*S_$O_!,=?$GP,^)'@Y?&-_I]YXW^(<OQ&T_5[:Q
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MN+X4KY8;!SUY]_,E5P'+[L=?GVZ?/OT.[V>/_F/DSX=?\%!KS]GW]BWX&?\
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M^UOX>*_\>6K_ /?J+_&H_P#AK3P\/^7'5_\ OW'_ (UT?ZN8[_GV8_ZZY/\
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MA>N!Q7K0.Y<CI@-GV)P#^=>?7PDZ+]G5IGL4,90Q5+VE&9T'_"RK[_GE;?\
M?)H/Q*OL?ZJV_P"^36!2-]T_2N;V2.CGJ=SH&^)-Z$7]U;<].#S1_P +,O1_
MRRMOR-<_)_J+?_=:H\'UH]D@YZG<Z/\ X6=??\\;?\C1_P +/OA_RQM_R-<Y
M@^M&#ZT^2EV'[5G1-\3[[!_<V_Y&H_\ A:5[_P \;;_ODU@,#M//:H:.2EV%
MSU.YTO\ PM*]_P">-M_WR:#\4KX?\L;;_ODUS5(>E')3[!SU>YTO_"U=0_YX
MVGZT?\+6U#_GC:?K7+T4O8H7-4.H_P"%L:C_ ,\;3]:/^%L:C_SQM/UKEZ*/
M8HS]I4[G4-\6-2"G]S:?K4$GQ@U1$/[BUZ>AKGJAFH]B@]I5.JG^*^HPLG[F
MS^9=QX/6F?\ "WM2_P">%I^1KF;SK'_NU'@^M'LD:<]3N=7_ ,+?U/\ YXVG
MZT?\+?U/_GC:?K7*8/K1@^M'L49^TJ=SJ_\ A;^I_P#/&T_6C_A;^I_\\;3]
M:Y3!]:,'UH]B@]I4[G5GXP:F/^6-I^M0R?&74PW^HM/R-<R0<=:AE^]^-'LD
M'M*G<ZS_ (7)J?\ SPM/UH_X7)J?_/"T_6N3I#TI\E/L'M*G<ZW_ (7+J7_/
M"S_6@_&;4A_RPL_R-<?12]D'M*G<Z[_A=6I_\\+7\C2-\;-3"_ZFT_(UR)Z5
M&WW3]*/9(/:5.YVLOQDU**7;Y-IC9NZ'@U%_PNO4Q_RPM/\ ODURM\<S'W"X
MJ%ONU7)2[![2IW.O_P"%V:G_ ,\;3_ODT?\ "[=3_P">-I^1KC,'UHP?6M?9
M4^P>TJ=SLA\<-6S_ *BR_6C_ (7AJG_/"U_(UQ@'S&EP?6CV5/L'M*G<[)OC
MAJNTX@M,]L@U%_PN_6O^>5A^M<BP.T\]JAH]E3[![2IW.T_X7?K7_/*P_6C_
M (7AK/>*PQ^-<712]G3[![2IW.T_X7AJG_/OIW_?+4?\+QU4?\N^G_@K5Q=%
M9<E+L'M*G<[)OCQJX'_'O9?K49^/&KX_X][+\C7&3?>J,]*?)2[![2IW.]O?
MCIJD-TZK#9$;0>A(S4'_  OK5O\ GVT[_OAZXZ[_ ./E_HM1-]VM/9T^P>TJ
M=SM?^%]ZM_S[Z=_WPU'_  OO5O\ GWT[_OAJX;!]:,'UI^RI]@]I4[G<_P#"
M^]6_Y]]._P"^&H_X7WJW_/OIW_?#5PV#ZT*.>M'LJ?8/:5.YW#_'W5E4_P"C
MZ=_WPU1?\-!ZO_S[:=_WPU<5.,FHJ/94^P>TJ=SNA^T'K&?^/;3_ /OAJ4_M
M#ZP/^7>R_6N$J*7[XH]E3[![2IW/0/\ AH?6/^?>R_6C_AH?6/\ GWLOUK@*
M*/94^P>TJ=SO_P#AH?6/^?>R_6FS?M%:RD3$6]F< G SS7!4V3_5M]*ETZ=M
MAJI4OJSZ@TJZ:\TV"9A\\L:.P'09%67^Z<]*I>'6_P")%9?]<$_D*MLX*'O7
MGMVW/0(9 5.?X0*\VU;]K3X?:+\0$\-W'B33DU1F"-ELPQ.>D;2_=5SV!.:V
MOC5XYTCP9\,=4N]3U2RTR*:UDCBDN)UC5G9"% )(R3VQS7Y10^%+^WU!+$Z?
M<F[=R J!V,A.26#'E@P(!8?=S7XYXD^)%?AZM1H8*"GS?%Y>O8^NX9X;AF,9
MSJ3:73S/V*LKE+V*.6-U>.10RLIR&!Y!!J<1X'XUX_\ L6^++#6OV?\ PU80
MZI8ZA?:3916E^D5P)I+>=5R5?!)!]CS7J^J:Q;Z)I=S>W,\<%M:Q-/+*Y^6-
M%!)8^P )K],R;-:>-P-/&0::FNC_  /F<7AI4*\Z$ELRX6"CGBD$JL>&!_&N
M)^"O[0G@S]HOPI-KG@7Q)I7B?2;>X>UFN[&?S8DE4 E<C/."#CT8>M8OPM_:
M^^&7QKUZUT?PCXXT#Q!J5W927\%O:7?F/+;13&&688ZHL@*;N@88SGBO7NCG
MLSU$L%ZD#M07 ;&1G&<9[5YC'^V)\,)?C*_P\_X3GP\OC=)1 =%:Y"7?F%/,
M$6P\LY3Y@HY(YQ70W?QB\,V/Q3MO [ZU8IXINK%M3ATHR 3R6RMM:95^\4#<
M9'&>* LSK=P_I2@YKS&__:W^&FD_&R'X=W7C3P_!XWNL1KI!N?\ 2&<C<J;N
MF\KR$^\>PJSX]_:F^'GPK^)^A>"_$7B_1=&\6>)F1-)TNZN=ESJ&^01IY2'E
MLN=H([\470[,]$5PXX(/THW@MC(SZ5YW\4_VIOAW\&]=?2O%?BW0M"OX]-DU
MAXKVX6-ELX^'GP3G8IP"W0$@4OQC_:B^'O[//A'3M<\;>+='\,Z/K#!+*[U&
MX\J*X;9OV@MCG8"W/8$G@&@5F>AEL4M4-$U:VUS3[:\M)8YK>]A6XADCZ2QL
M 5;'H0>#5^@ HHHH **** *UW_JV_P!VO+8^3UV\=3V^:O4[L?NV^E>5JRC.
M[H%YP,G&[TKT\K^)GS^<_P 2!Y%^WIXNU#P;^S-?SV%[=:+!=ZMIUIJU] [1
MSV>GSWD:7DBNH+1%(#(^_P#A W=JR/%NG^ /V5?AM=W'@2^_X1[5?%=[I^BV
M=UITG]N23W5S+)Y+F*XN#"7EY3S9& !/S.P!6O=M4L[;5=-N+.ZMXKRTNXRE
MS;RA7@NE(QM96!X(X/%<;IW[-7PYTG0]2T>W^'W@^+2=7F$UU9C1K:.&\="J
MAI%4$,?FE(+%>M=M5-GGTI);GSO\/_VG_B5\0W\,>';+Q-I]AJ%_\2=5\'7F
MJS:7;W$[VMMICW:2M'#,\#7*NO&TE5P-PQFKWA7]I/Q_XTO_  CX'N?&&D^'
M-;OO$WB3PW>^,#I<!-Q'I!#1)!!(WE132^<-V<DB-B!A37TII/PA\*^&SIXL
M/#&@6O\ 8TWVVP$5E'$;.8QF%I(]J;5=E.TD'<!S4>K_  *\&^*/#LVBWWA?
MPW?:5<7<FI26MYIL;03W,C;WN"@./,.,,6()'4<UA["9T^W@?,WQ1_:J^+6D
M?&W7] \*0G7HO!%OH^(H=+TP6GB7[1'%+-/<2S7,;V\)!<1"U1QO!+9QBNPT
MGXA_%KQ9IWQGUO0?%7AF+_A#O$&H^&M TJ^L(X(+B=&B>*6ZO7/+J)"J+Q&T
MA16/->T:S\"/ OB*YTFZU#P=X<O9= A2#3)I]-AFFTR&,?NDC<A7&T9V@9VD
MCFM*[^&'AK5M(UK3;KP[HEQI^OW#S:C:-91207[L,.TB/E&#[$R&!!!YXH]C
M,/;PV.&_8Z^*=]\2/!6LV^KZQK&J>)/#FM2Z9K$&I:5::?/ILPCWFW<6K-!)
MC.Y9XR1(N%/->OK]X?6L7P1\.="^%^A1Z1X9T72-!TF!C)':Z=;):Q*3U<(B
MHN]NC9R<=*VE^\/K54TP)L'UHP?6C!]:,'UIB)8ON_A0.M$0^7\*4#F@JEL/
M'6I*C7K4C#BLM3<=;]34J@[NM10BI3&7&#C!XYZ5$MM3KH[GS'^VKQ\2],[?
M\2U1^/F2UX[L/H?RKZ@^/GP);XH^,K.\&I+IZ0VGE&,0%\G=)_B/SKAO^&-U
M'_,?7_P"7_&OT;),_P !A\'3HU9:H_$.(^$LUQ69U:^'CHV>,>6W]T_E2.AV
M'@]/2O:/^&//^H\/_ %?\:&_8\8C_D.QCW^PKQ^M>M_K1E_\QXG^I.=_\^D>
M"7PP#7/ZNP+U])3?L6/,/^1DC_\  !?\1_.L^Z_84,Y_Y&?!]?L/3_R+6-3B
M? 7^)F]+@G.O^?2/EO5/OUS6N'$E?7%Y_P $^9+G_F;>H_Z!_P#]MK+N_P#@
MFF;L'/C''N=/_P#MM9?ZSX#^9G5_J5G7_/M'QGK1^1OH:Y/5OXN_X5]QWO\
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M*_X5)XD_Z!Y_\"EH7X2^),_\@\_^!2U[KBC%'UJ0?58GA,WPD\2$_P#(//\
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M-U "T4FZC=0 M%)N%&X4 +12;J-U "T4FZC- "T444 %%)N%&X4 +129HS0
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M7\N].'CZV+?<?.2/Q R?RKX]U?\ X*&SZEI-]JGA'P-?>(]'LO!EGXWU"?\
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MP_M;"_\ /V/_ ($CU"+QW96Z\13 #@'8H9N>N!P!]>M2?\+&M/[EQ^5>3O\
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M3/8/^&@-)_Y\]0_*+_XJD/[0>D+_ ,N>H?E%_P#%5Y!44OWQ3^JB^L5#V/\
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M(]N]7:* (54H0.RO@87&!CBIJ** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1PH/44 ?3.\>HHW5SZ_#+PV3_P @'1?_  $C_P#B:<?AGX;'_,!T7_P#C_\
MB: -[=1NK!/PT\-*.="T3CK_ *'%Q_X[0WPT\-(P!T+1 3T!LXN>W]WW'YT
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M/^%8>'/^@!HW_@''_P#$T ;NZC=6%_PK#PY_T -&_P# ./\ ^)H_X5AX<_Z
M&C?^ <?_ ,30!N[J-U87_"L/#G_0 T;_ , X_P#XFC_A6'AS_H :-_X!Q_\
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M#G_0 T;_ , X_P#XFC_A6'AS_H :-_X!Q_\ Q- &[NHW5A?\*P\.?] #1O\
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M1O\ P#C_ /B:/^%8>'/^@!HW_@''_P#$T ;NZC=6%_PK#PY_T -&_P# ./\
M^)H_X5AX<_Z &C?^ <?_ ,30!N[J-U87_"L/#G_0 T;_ , X_P#XFC_A6'AS
M_H :-_X!Q_\ Q- &[NHW5A?\*P\.?] #1O\ P#C_ /B:/^%8>'/^@!HW_@''
M_P#$T ;NZC=6%_PK#PY_T -&_P# ./\ ^)H_X5AX<_Z &C?^ <?_ ,30!N[J
M-U87_"L/#G_0 T;_ , X_P#XFC_A6'AS_H :-_X!Q_\ Q- &[NHW5A?\*P\.
M?] #1O\ P#C_ /B:/^%8>'/^@!HW_@''_P#$T ;NZC=6%_PK#PY_T -&_P#
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MQE\3KZQ^#WB:#Q7INKWNLIJ&L:I=Q"8C[7<3Q/O!:9\A-A "X*\&O2?V[O\
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MM #J*;Y@]1^=+N% "T4U9%;H0>,\'M2AP<\CC@^U "T4C.%ZD#G'-!<+U(%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M '(ZUUWB+2?B%\!OV@/C1KY^"?C+XCZ=\<M/L+S1Y=.%FTFFNE@L#:5J2RR
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M4 +12;J-U "T4FZC- "T4FZC=0 M%)NHS0 M%)NHW4 +12;J-U "T4FZC=0
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M4#_@FI\=E/\ R336_P#O[!_\>I?VCA?YU]Z.?^R,P_D?W,\,^SQ?W(O^^?\
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M9"FZ'<#M(\KD'TQ2:F_LHM*'\[/"?&7["O@CX@322:Q>^-+F:_T-?#VJ2_\
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MD][_ -,/^_='_"57@YS;_7R^E%T%F96ZC>/4?G6K_P );>,.)+?_ +\BF?\
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M_?M__ ?_ .M5F9D&52/OK^=5YBH.?-SCWK?;QQ?@</;9_P"O;_ZU1GQ]J?\
M>M!_V[BH&8MW<(77YV^[47F?]-&KI+OQUJ@=#YUO]WO"O-0_\)_J7]ZT_P#
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M.] QOE?YQ1Y7^<4[=1NH ;Y7^<4>5_G%/HH 9Y7^<4NP>GZ4[-(KAAP0?H:
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M / Q/_K_ ,J\*G!K.O#S7I_ZIX#^4X/]=<X_F/>Y/V\[>(8_X1:7_P "XO\
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M_P"N6:?S'V-<?\%BK"%N/A_?'V_M9>?_ "%5*?\ X+16$#_\DYN_H=949_\
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M-/"2?M11VGAGX=?#_P"(N@^1::KXN\#6,\.HZF\FK0Q3-Y\LN</NR.,U[O\
M9D*M2I2IZ<CLCR98VHHTYG[FB6A+A7VX93N&1CN*_$?XB^ _B3\*O@OX0\8>
M!?AG\1/A=XJMVL;IO&>M_%*.YTW6@\>9?-@FN-G[X_,$.,C->V?L0_L\Z+^W
M7^UC^TI+\6+OQ3XN_P"$,\5C2]&M[GQ!>P0Z9$\MR[+'##*(UV[ H()Y0^E<
MM;)51CS3G_7WFBS)MVL?J=]I3/WE['KZ]*&F79G<,>N:_!.]_:/^)FC?LN/X
M T_Q9X[O]''QINO"D-G;:X\.I7NG*F!IT5\9/.0-G8 PV@L,D5[;H?A+XA?
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MI/[)_P"F]G_W]%;>VI]@]E(@R??\J >?_K59327+#][:]>THJ9M(;:?WT/\
MWT*7M8"]E+N58C\M*O6K46EX7_7P?]]"GC3,]+BW^F\5E[8=*C/N5P.:?BK
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M  3U\+,?^0WKWX);_P#QNJ\O_!.7PG*/^0[XA'T2W_\ C=?2O_"*-_S\V/\
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M!70?_!@:!\/)S_S%=!_\#S2N@]D<Q,WS4VNDE^&\VX?\370?_ \T'X;S$?\
M(5T(^WV\FBZ#V2,#4HV6\;*GHIZ5"W2NIO/AU-+/(QU+0E;  S<@?UJO_P *
MTN/^@OH'_@>::JL/9'-;3_D4;3_D5TG_  K6X_Z"^@_^!YH_X5K<?]!?0?\
MP/-:^U,[,YO:?\BC:?\ (KI?^%:7'_07T'_P/-'_  K2X_Z"^@_^!YH]J:>R
M.993M/T]*AQ75M\-+@J?^)OH'_@>:C_X5A/_ -!G0/\ P8&CVH>R.9 YILQY
MKI_^%8S_ /09T#_P8&HY/A;<%A_Q-]!_\#S1[4R]FCF:*Z;_ (59/_T%]!_\
M#S1_PJR?_H+Z#_X'FCVK-?9',TV4_NV^AKJ/^%63_P#07T'_ ,#S39_A9/Y#
M_P#$XT$?*>?MYX_/BDZCL-4CW;PV=V@V1'/[A/\ T$5->PBXM9D:,2AT92A
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M:Y^/OCC:?^*O\2#W^VR?_'*SKC]H7QW$?E\9>)_;_3I./_(E+_4NM_S]-?\
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M^JL7BE;I^W"U$WW:NCL&HS'^]_WU1C_>_P"^J3!]:,'UK74-1<?[W_?5&/\
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M_O\ O_C77Y^M&?K1[2?</9P['('X)Z!C_CSD_P# A_\ &F?\*1T#_GRD_P#
MB2NRS]:,_6CVD^X>SAV.-_X4CH'_ #Y2?^!$E'_"D= _Y\I/_ B2NRS]:,_6
MCVD^X>SAV.-_X4CH'_/E)_X$24C_  /\/NA'V*3D8_X^'KL\_6@'ZTO:3[A[
M.'8BM+5-/MDBC4B.,!%'7 J:BBI+"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6739878112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRIS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CURIS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001108205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,549,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6740319104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,671<span></span>
</td>
<td class="nump">$ 33,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">49,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,857<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">56,649<span></span>
</td>
<td class="nump">85,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Long-term investment &#8211; restricted</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,982<span></span>
</td>
<td class="nump">8,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">66,193<span></span>
</td>
<td class="nump">94,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,056<span></span>
</td>
<td class="nump">4,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,324<span></span>
</td>
<td class="nump">1,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">5,104<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,484<span></span>
</td>
<td class="nump">10,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">15,798<span></span>
</td>
<td class="nump">19,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">28,323<span></span>
</td>
<td class="nump">30,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value&#8212;225,000,000 shares authorized; 141,217,276 shares issued and 139,994,430 shares outstanding at September 30, 2016; 130,213,224 shares issued and 128,990,378 shares outstanding at December 31, 2015</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">925,569<span></span>
</td>
<td class="nump">903,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock (at cost, 1,222,846 shares)</a></td>
<td class="num">(1,524)<span></span>
</td>
<td class="num">(1,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(887,613)<span></span>
</td>
<td class="num">(838,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">37,870<span></span>
</td>
<td class="nump">64,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 66,193<span></span>
</td>
<td class="nump">$ 94,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6739891792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000,000<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">141,217,276<span></span>
</td>
<td class="nump">130,213,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">139,994,430<span></span>
</td>
<td class="nump">128,990,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">1,222,846<span></span>
</td>
<td class="nump">1,222,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6740183600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalties</a></td>
<td class="nump">$ 1,817<span></span>
</td>
<td class="nump">$ 2,293<span></span>
</td>
<td class="nump">$ 5,403<span></span>
</td>
<td class="nump">$ 5,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development, net</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">5,165<span></span>
</td>
<td class="nump">5,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Cost of royalty revenues</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">6,781<span></span>
</td>
<td class="nump">4,001<span></span>
</td>
<td class="nump">22,431<span></span>
</td>
<td class="nump">14,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">17,989<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,989<span></span>
</td>
<td class="nump">24,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">11,743<span></span>
</td>
<td class="nump">9,712<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">29,548<span></span>
</td>
<td class="nump">6,889<span></span>
</td>
<td class="nump">52,441<span></span>
</td>
<td class="nump">49,021<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(27,789)<span></span>
</td>
<td class="num">(4,844)<span></span>
</td>
<td class="num">(47,276)<span></span>
</td>
<td class="num">(43,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(657)<span></span>
</td>
<td class="num">(827)<span></span>
</td>
<td class="num">(2,126)<span></span>
</td>
<td class="num">(2,537)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(556)<span></span>
</td>
<td class="num">(699)<span></span>
</td>
<td class="num">(1,801)<span></span>
</td>
<td class="num">(2,285)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,345)<span></span>
</td>
<td class="num">$ (5,543)<span></span>
</td>
<td class="num">$ (49,077)<span></span>
</td>
<td class="num">$ (45,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share (basic and diluted) (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares (basic and diluted) (in shares)</a></td>
<td class="nump">132,065,947<span></span>
</td>
<td class="nump">128,392,413<span></span>
</td>
<td class="nump">130,122,698<span></span>
</td>
<td class="nump">121,634,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (28,376)<span></span>
</td>
<td class="num">$ (5,488)<span></span>
</td>
<td class="num">$ (49,079)<span></span>
</td>
<td class="num">$ (45,456)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6744320416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (49,077)<span></span>
</td>
<td class="num">$ (45,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">2,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on disposal of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Non-cash interest expense on investments</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_IssuanceOfCommonStockToLicensees', window );">Issuance of common stock in consideration for rights granted under collaboration agreement</a></td>
<td class="nump">17,989<span></span>
</td>
<td class="nump">23,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">249<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued and other liabilities</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">22,653<span></span>
</td>
<td class="nump">26,492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(26,424)<span></span>
</td>
<td class="num">(19,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of investments</a></td>
<td class="num">(50,485)<span></span>
</td>
<td class="num">(95,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of investments</a></td>
<td class="nump">66,816<span></span>
</td>
<td class="nump">73,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(269)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Decrease in restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="nump">16,062<span></span>
</td>
<td class="num">(22,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock associated with offerings, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock under the Company&#8217;s share-based compensation plans</a></td>
<td class="nump">1,161<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments on Curis Royalty&#8217;s debt</a></td>
<td class="num">(3,219)<span></span>
</td>
<td class="num">(2,793)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash (used in)/provided by financing activities</a></td>
<td class="num">(2,058)<span></span>
</td>
<td class="nump">62,029<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease)/increase in cash and cash equivalents</a></td>
<td class="num">(12,420)<span></span>
</td>
<td class="nump">20,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">33,091<span></span>
</td>
<td class="nump">7,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 20,671<span></span>
</td>
<td class="nump">$ 28,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_IssuanceOfCommonStockToLicensees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to licensees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_IssuanceOfCommonStockToLicensees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards other than stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736677744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Nature of Business</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of cancers. As used throughout these consolidated financial statements, the term &#8220;the Company&#8221; refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term &#8220;Curis&#8221; refers to Curis, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company conducts its research and development programs both internally and through strategic collaborations. The Company&#8217;s most advanced drug candidate is CUDC-907, which is being investigated in clinical studies in patients with diffuse large B-cell lymphoma and solid tumors.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene. In September 2016, the Company entered into an amendment to this agreement, pursuant to which Aurigene received </font><font style="font-family:inherit;font-size:10pt;">10,208,333</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock in lieu of receiving up to </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;"> of milestone and other payments from Curis (see Note 4(b)). </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collaboration comprises multiple programs, in which Curis has the option to exclusively license each program, including data, intellectual property and compounds associated with each respective program, once a development candidate is nominated within that program. In October 2015, the Company exercised options to license the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs under this collaboration. The first licensed program is focused on the development of orally-available small molecule antagonists of programmed death-1 (PD1) and V-domain Ig suppressor of T-cell activation (VISTA) pathways in the immuno-oncology field. The Company has named CA-170, a programmed death ligand-1 (PDL1)/VISTA antagonist, as the development candidate from this program. The second licensed program is focused on orally-available small molecule inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4) enzyme in the precision oncology field and the Company has named CA-4948 as the development candidate from this program. In addition, in October 2015, the Company selected a third program for further development under the collaboration, the second preclinical program within the immuno-oncology field, which is focused on evaluating small molecule antagonists of PD1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM3) pathways, including small molecules that target PDL1 and TIM3.  In October 2016, the Company exercised its option to license this third program, and designated CA-327 as the development candidate. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge</font><font style="font-family:inherit;font-size:9pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;"> (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor, in advanced basal cell carcinoma, or BCC. In addition to BCC, Roche and Genentech are separately conducting studies of Erivedge in other diseases, including in idiopathic pulmonary fibrosis and myelofibrosis.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s proprietary small molecule compounds also include CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis, or IAP proteins, and CUDC-305, an orally-available, small molecule antagonist of Heat Shock Protein 90.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United&#160;States by the United States Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company&#8217;s business, including, but not limited to: the Company&#8217;s ability to advance and expand its research and development programs; the Company&#8217;s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties&#8217; collaboration agreement; the Company&#8217;s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company&#8217;s ability to obtain adequate financing to fund its operations; the ability of the Company&#8217;s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.&#224;.r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company&#8217;s ability to obtain and maintain necessary intellectual property protection; development by the Company&#8217;s competitors of new or better technological innovations; dependence on key personnel; the Company&#8217;s ability to comply with regulatory requirements; and the Company&#8217;s ability to execute on its overall business strategies.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it receives and makes under its current and potential future collaborations. The results of the Company&#8217;s operations may vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company&#8217;s preclinical studies and clinical trials for its drug candidates; Aurigene&#8217;s ability to successfully discover and develop preclinical programs under the Company&#8217;s collaboration with Aurigene, as well as the Company&#8217;s decision to exclusively license and further develop programs under this collaboration; Roche and Genentech&#8217;s ability to successfully commercialize Erivedge; positive results in Roche and Genentech&#8217;s ongoing clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company anticipates that its existing cash, cash equivalents and investments at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> should enable it to maintain current and planned operations into the second half of 2017. The Company&#8217;s ability to continue funding its planned operations beyond this period is dependent upon, among other things, its ability to control expenses and its ability to raise additional funds through equity or debt financings, the success of its collaboration with Genentech, including its receipt of additional contingent cash payments under this collaboration, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of such events is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905366672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. These statements, however, are condensed and do not include all disclosures required by accounting principles generally accepted in the United States, or GAAP, for complete financial statements and should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> as filed with the Securities and Exchange Commission, or the SEC, on </font><font style="font-family:inherit;font-size:10pt;">February&#160;29, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of the Company, the unaudited financial statements contain all adjustments (all of which were considered normal and recurring) necessary for a fair statement of the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and the results of operations for the three- and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and the cash flows for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. The condensed consolidated balance sheet at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Company&#8217;s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company&#8217;s collaboration agreements; the estimated repayment term of the Company&#8217;s debt and related short- and long-term classification; the fair value of the Company&#8217;s debt; the collectability of receivables; the carrying value of property and equipment and intangible assets; the assumptions used in the Company&#8217;s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736678432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is currently a party to a collaboration agreement with Genentech, the terms of which provide for Genentech to make a non-refundable license fee payment, research and development funding payments, contingent cash payments based upon achievement of clinical development and regulatory objectives, and royalties on product sales. For a complete discussion of the Company&#8217;s revenue recognition policy, see Note 2(c) included in its </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6683004544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Collaboration Agreements</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Genentech, Inc.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2003, the Company licensed its proprietary Hedgehog pathway technologies to Genentech for human therapeutic use. The primary focus of the collaborative research plan has been to develop molecules that inhibit the Hedgehog pathway for the treatment of various cancers. The collaboration is currently focused on the development of Erivedge, which is being commercialized by Genentech in the United States and by Genentech&#8217;s parent company, Roche, in several other countries for the treatment of advanced BCC. Pursuant to the agreement, the Company is eligible to receive up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$115.0 million</font><font style="font-family:inherit;font-size:10pt;"> in contingent cash milestone payments, exclusive of royalty payments, in connection with the development of Erivedge or another small molecule Hedgehog pathway inhibitor, assuming the successful achievement by Genentech and Roche of specified clinical development and regulatory objectives. Of this amount, the Company has received </font><font style="font-family:inherit;font-size:10pt;">$59.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to these payments and pursuant to the agreement, the Company is entitled to a royalty on net sales of Erivedge that ranges from </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;">. The royalty rate applicable to Erivedge may be decreased by </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> on a country-by-country basis in certain specified circumstances, including when a competing product that binds to the same molecular target as Erivedge is approved by the applicable regulatory authority in another country, and is being sold in such country, by a third party for use in the same indication as Erivedge, or, when there is no issued intellectual property covering Erivedge in a territory in which sales are recorded. In 2015, the FDA and the European Medicine Agency&#8217;s Committee for Medicinal Products for Human Use, or CHMP, approved another Hedgehog signaling pathway inhibitor, Odomzo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> (sonidegib), which is marketed by Novartis, for use in locally advanced BCC. Beginning in the fourth quarter of </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Genentech applied the </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> royalty reduction on United States sales of Erivedge as a result of the first commercial sale of sonidegib in the United States.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, Curis formed a wholly owned subsidiary, Curis Royalty, which received a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> loan at an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">12.25%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to a credit agreement between Curis Royalty and BioPharma-II (see Note 7). In connection with the loan, Curis transferred to Curis Royalty its right to receive royalty and royalty-related payments on the commercial sales of Erivedge that it receives from Genentech. The loan and accrued interest is being repaid by Curis Royalty using such royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty and is non-recourse to Curis.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> in royalty revenue under the Genentech collaboration during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company recorded costs of royalty revenues within the costs and expenses section of its condensed consolidated statements of operations and comprehensive loss of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. For each of these periods, these amounts are comprised of </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the royalties earned by Curis Royalty that the Company is obligated to pay to university licensors. As further discussed in Note 7, the Company expects that all royalty revenues received by Curis Royalty from Genentech on net sales of Erivedge will be used by Curis Royalty to pay principal and interest under the loan that Curis Royalty received from BioPharma-II, subject to specified quarterly caps, until such time as the loan is fully repaid.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded research and development revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and research and development revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to expenses incurred by the Company on behalf of Genentech that were paid by the Company and for which Genentech is obligated to reimburse the Company.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech incurred expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, under this collaboration, for which the Company is obligated to reimburse to Genentech, and which the Company has recorded as contra-revenues in its condensed consolidated statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aurigene Agreement</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and selected precision oncology targets. Under the collaboration agreement, Aurigene granted the Company an option to obtain exclusive, royalty-bearing licenses to relevant Aurigene technology to develop, manufacture and commercialize products containing certain of such compounds.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each program, Aurigene has granted the Company an exclusive option, exercisable within </font><font style="font-family:inherit;font-size:10pt;">90 days</font><font style="font-family:inherit;font-size:10pt;"> after Aurigene delivers the relevant data regarding a development candidate, to obtain an exclusive, royalty-bearing license to develop, manufacture and commercialize compounds from such program, including the development candidate and products containing such compounds, anywhere in the world, except for India and Russia. For the development, manufacture, and commercialization of compounds from a particular program and products containing such compounds in India and Russia, Aurigene will grant the Company the royalty-bearing license described above for such program, and the Company will grant Aurigene an exclusive, royalty-free, fully paid license under the Company&#8217;s relevant technology upon exercise of the relevant option.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company exercised options to license the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs under this collaboration, resulting in an aggregate one-time payment of </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> (comprised of a </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> option exercise fee for each program) by the Company to Aurigene. Effective October 2015, the Company agreed to make additional payments to Aurigene totaling up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> for supplemental research, development and/or manufacturing activities in support of these </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs.&#160;The Company incurred and recognized </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> of such costs in the three months ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, which was paid in the three months ended March 31, 2016.&#160;The remaining </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> was incurred and recognized in the three months ended March&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and paid in the three months ended June 30, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also in </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company selected a preclinical program for potential further development within the immuno-oncology part of the collaboration resulting in a one-time </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment. In October 2016, the Company licensed the program and designated CA-327 as the development candidate as described in Note 1, resulting in a one-time </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> payment. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company anticipates that it will select additional programs under this collaboration in the future, and the Company intends to have the collaboration&#8217;s steering committee recommend such additional programs in order for Aurigene to initiate or continue the relevant preclinical activities described in each program&#8217;s written plan.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each option to license (as described above) exercised by the Company, the Company is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> product in each of the United States, specified countries in the European Union, and Japan, and Aurigene is obligated to use commercially reasonable efforts to perform its obligations under the development plan for such licensed program in an expeditious manner.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to specified exceptions, Aurigene and the Company have agreed to collaborate exclusively with each other on the discovery, research, development and commercialization of programs and compounds within immuno-oncology for an initial period of approximately </font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;"> from the effective date of the collaboration agreement. At the Company&#8217;s option, and subject to specified conditions, it may extend such exclusivity for up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> additional </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year periods by paying to Aurigene exclusivity option fees on an annual basis. The first of such option fees will be </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, to be paid in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> equal installments, and the Company currently estimates that these payments will be due in the first and third quarters of 2017.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, beyond the up-to </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;"> of exclusivity described above, and subject to specified exceptions and payment by the Company of an annual exclusivity fee on a program-by-program basis, Aurigene and the Company have agreed to collaborate exclusively with each other on each program for which there are ongoing activities in research or development, or for which the Company has exercised its option to acquire an exclusive license (as described above) and the Company or its affiliates or sublicensees are actively developing or commercializing a compound or product from such program in a major market.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each product that may be commercialized, the Company has granted Aurigene the right, subject to certain conditions, to nominate </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> global drug substance or drug product supplier to provide up to </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the total requirements in the Company&#8217;s territory.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research Payments, Option Exercise Fees and Milestone Payments.</font><font style="font-family:inherit;font-size:10pt;"> The Company has agreed to make the following research, option exercise fees and milestone payments to Aurigene:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for the PD1/VISTA and IRAK4 programs: up to </font><font style="font-family:inherit;font-size:10pt;">$52.5 million</font><font style="font-family:inherit;font-size:10pt;"> per program, comprised of: </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> for each option exercise, </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon acceptance of each IND filing, </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon dosing of the fifth patient in the Company&#8217;s first Phase 1 clinical trial in each program, as well as specified approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. Effective October 2015, the Company agreed to make additional payments to Aurigene totaling up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> for supplemental research, development and/or manufacturing activities in support of these </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs. During the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized and paid </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> to Aurigene upon the acceptance of the IND filing for CA-170, a PDL1/VISTA antagonist. Since the inception of the agreement through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has incurred costs totaling </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to these programs under the collaboration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for the third and fourth programs: up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> per program, comprised of: </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> for a program selection fee, </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> for an option exercise, </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> upon acceptance of an IND filing, as well as development, approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. Since the inception of the agreement through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has made payments to Aurigene totaling </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to the third program under this collaboration; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for any program thereafter: up to </font><font style="font-family:inherit;font-size:10pt;">$140.5 million</font><font style="font-family:inherit;font-size:10pt;"> per program, comprised of: up to a total of </font><font style="font-family:inherit;font-size:10pt;">$53.0 million</font><font style="font-family:inherit;font-size:10pt;"> for research fees, an option exercise fee, a preclinical milestone and development milestones, as well as specified filing, approval and commercial milestones, plus specified additional payments for approvals for additional indications, if any. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> payments have been made to Aurigene related to such programs under the collaboration.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Amendment to Collaboration Agreement</font><font style="font-family:inherit;font-size:10pt;">. On September 7, 2016, the Company and Aurigene entered into an amendment to the January 2015 collaboration agreement. Under the terms of the amendment, in exchange for the issuance by the Company to Aurigene of </font><font style="font-family:inherit;font-size:10pt;">10,208,333</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock, Aurigene waived payment of up to a total of </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;"> in milestones and other payments from the Company that may become due under the 2015 collaboration agreement. The following milestones and other payments have been waived: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment for extended exclusivity related to the IRAK4 program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment upon acceptance of IND filing related to the IRAK4 program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment upon dosing of the fifth patient in the Company's Phase 1 clinical trial for the IRAK4 program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment for extended exclusivity related to the PD1/VISTA program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment upon dosing of the fifth patient in the Company's Phase 1 clinical trial for the PD1/VISTA program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">, of the payment related to the option exercise payment of the third program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> payment upon acceptance of IND filing related to the third program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment for program selection fee of the fourth program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment for option exercise of the fourth program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:24px;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;text-indent:-24px;"><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> payment upon acceptance of IND filing related to the fourth program; </font></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent any of these milestone or other payments described&#160;above would not otherwise be payable by Curis,&#160;e.g.&#160;in the event one or more of the listed milestone events do not occur, the Company will have the right to deduct the unused waiver amount from any one or more of the milestone payment obligations tied to achievement of commercial milestone events. The amendment also provides that upon exercise the option for the third and fourth programs, the Company will provide up to </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> of additional funding for each such licensed program provided that supplemental program activities are performed by Aurigene. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Summary. </font><font style="font-family:inherit;font-size:10pt;">Under the terms of this amendment, the value of common stock issued to Aurigene equaled </font><font style="font-family:inherit;font-size:10pt;">$18.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on the closing share price of the Company&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;">$1.76</font><font style="font-family:inherit;font-size:10pt;"> per share on September 6, 2016, which was the last closing price prior to execution of the amendment. As a result, the Company recognized in-process research and development expense of </font><font style="font-family:inherit;font-size:10pt;">$18.0 million</font><font style="font-family:inherit;font-size:10pt;"> within its condensed consolidated statement of operations and comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> in recognition of the fact that any compounds that have been and may be licensed from Aurigene are in clinical or preclinical development and will require substantial development, regulatory and marketing approval efforts in order to reach technological feasibility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736689568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company discloses fair value measurements based on a framework outlined by GAAP which requires expanded disclosures regarding fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and (iv)&#160;willing to transact. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:90%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the fair value hierarchy, the following table shows the fair value as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> of those financial assets and liabilities that are measured at fair value on a recurring basis.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other&#160;Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs&#160;(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2016:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, stock, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Quoted&#160;Prices&#160;in</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other&#160;Observable</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Inputs&#160;(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2015:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,999</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, stock, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,644</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,304</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,517</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No investments held at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> were transferred between levels.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6634432624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Investments</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds and notes &#8211; short-term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,657</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments have maturities ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;"> with a weighted-average maturity of </font><font style="font-family:inherit;font-size:10pt;">2.5</font><font style="font-family:inherit;font-size:10pt;"> months at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds and notes &#8211; short-term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,072</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,072</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments have maturities ranging from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">12 months</font><font style="font-family:inherit;font-size:10pt;"> with a weighted-average maturity of </font><font style="font-family:inherit;font-size:10pt;">4.2</font><font style="font-family:inherit;font-size:10pt;"> months at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Debt Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6509901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6379141&amp;loc=d3e15032-111544<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -Glossary Equity Security<br> -URI http://asc.fasb.org/extlink&amp;oid=6511694<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736695504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Debt</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2012, Curis&#8217; wholly owned subsidiary, Curis Royalty, received a </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> loan at an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">12.25%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to a credit agreement between Curis Royalty and BioPharma-II. In connection with the loan, Curis transferred to Curis Royalty its right to receive royalty and royalty-related payments on the commercial sales of Erivedge that it receives from Genentech (see Note 4(a)). The loan and accrued interest is being repaid by Curis Royalty using such royalty and royalty-related payments. To secure repayment of the loan, Curis Royalty granted a first priority lien and security interest (subject only to permitted liens) to BioPharma-II in all of its assets and all real, intangible and personal property, including all of its right, title and interest in and to the royalty and royalty-related payments. The loan constitutes an obligation of Curis Royalty, and is non-recourse to Curis. Under the terms of the loan, quarterly royalty payments received by Curis Royalty from Genentech will first be applied to pay (i)&#160;escrow fees payable by Curis pursuant to an escrow agreement between Curis, Curis Royalty, BioPharma-II and Boston Private Bank and Trust Company, (ii)&#160;Curis&#8217; royalty obligations to university licensors, (iii)&#160;certain expenses incurred by BioPharma-II in connection with the credit agreement and related transaction documents, including enforcement of its rights in the case of an event of default under the credit agreement and (iv)&#160;expenses incurred by Curis enforcing its right to indemnification under the collaboration agreement with Genentech. Remaining amounts are applied first to pay interest and second, principal on the loan. Curis remains entitled to receive any contingent payments upon achievement of clinical development objectives. Curis Royalty retains its right to royalty payments related to sales of Erivedge following repayment of the loan.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The final maturity date of the loan will be the earlier of the date when the principal is paid in full or the termination of Curis Royalty&#8217;s right to receive royalties under the collaboration agreement with Genentech. Because the repayment of the term loan is contingent upon the level of Erivedge royalties received, the short- and long-term classification of the debt is based on the Company&#8217;s estimate of the timing of amounts to be repaid. The Company cannot estimate when the loan will be repaid as repayment is impacted by numerous factors, all of which are beyond the Company&#8217;s control. The repayment term may be shortened or extended depending on the actual level of Erivedge royalties received. In addition, if Erivedge royalties are insufficient to pay the accrued interest on the outstanding loan, any unpaid interest outstanding will be added to the principal on a quarterly basis. The length of the actual repayment period could vary materially to the extent that royalty payments Curis Royalty receives are lower than the Company&#8217;s current estimates, which could arise due to factors beyond the Company&#8217;s control, such as the sale of competing products that result in a lowering of the royalty rates that Curis Royalty is entitled to receive, decreased market acceptance or a failure by Genentech and/or Roche to successfully commercialize Erivedge in territories where it has received regulatory approval. At any time after January&#160;1, 2017, Curis Royalty may, subject to certain limitations, prepay the outstanding principal of the loan in whole or in part, at a price equal to </font><font style="font-family:inherit;font-size:10pt;">105%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding principal on the loan, plus accrued but unpaid interest. The obligations of Curis Royalty under the credit agreement to repay the loan may be accelerated upon the occurrence of an event of default as defined in the credit agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, Curis Royalty made payments totaling </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> have been applied to the principal, respectively, with the remainder applied to accrued interest. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded short- and long-term debt of </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$15.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded short- and long-term debt of </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$19.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the loan, with such amounts recorded within the Company&#8217;s condensed consolidated balance sheets. In the three months ended March&#160;31, 2016, the Company adopted ASU No.&#160;2015-3</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Interest&#8212;Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:inherit;font-size:10pt;">. In accordance with the updated standard, the Company reclassified certain of its debt issuance costs, related to the loan, from assets to a direct deduction from the carrying amount of the related debt liability. The adoption of this guidance did not impact the consolidated statement of operations and comprehensive loss and the impact to the balance sheet was not material.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company recorded related accrued interest on the debt of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, with such amounts included in the Company&#8217;s accrued liabilities section of its condensed consolidated balance sheets. For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized interest expense related to the loan with BioPharma-II of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statement of operations and comprehensive loss. For the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized interest expense related to the loan with BioPharma-II of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in the condensed consolidated statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the debt approximates its carrying value due to the expected repayment period and because the interest rate yield is near current market rate yields. Due to the assumptions required in estimating future Erivedge royalties, the expected repayment period and weighting of various royalty projection scenarios, the fair value of the debt is measured using Level 3 inputs.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6737326448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest on debt (Note 7)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904881360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting for Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Accounting for Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accounting for Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> shareholder-approved, share-based compensation plans: (i)&#160;the Amended and Restated 2010 Stock Incentive Plan, or the 2010 Plan, adopted as amended by the board of directors in March 2015 and approved by shareholders in May 2015 and (ii)&#160;the 2010 Employee Stock Purchase Plan, or the ESPP, adopted by the board of directors in April 2010 and approved by shareholders in June 2010.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s board of directors granted options to purchase a total of </font><font style="font-family:inherit;font-size:10pt;">4,621,225</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock to officers and employees of the Company, both under the 2010 Plan or in the form of inducement awards pursuant to NASDAQ Marketplace Rules. These options vest as to </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> of the shares underlying the award after the first year and as to an additional </font><font style="font-family:inherit;font-size:10pt;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> of the shares underlying the award in each subsequent quarter, based upon continued employment over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period, and are exercisable at a price equal to the closing price of the Company&#8217;s common stock on the NASDAQ Global Market on the grant dates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s board of directors also granted options to its non-employee directors to purchase </font><font style="font-family:inherit;font-size:10pt;">470,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the 2010 Plan, which will vest and become exercisable in equal monthly installments over a period of </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant. These options were granted at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.76</font><font style="font-family:inherit;font-size:10pt;"> per share, which equals the closing market price of the Company&#8217;s common stock on the NASDAQ Global Market on the grant date.</font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Employee and Director Grants</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vesting Tied to Service Conditions</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the fair value of stock options, the Company generally uses the Black-Scholes option pricing model. As discussed below, for employee stock options with market performance conditions, the Company uses a Monte Carlo simulation valuation model. The Black-Scholes option pricing model employs the following key assumptions for employee and director options awarded during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> based on the assumptions noted in the following table:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years) - employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years) &#8211; officers and directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4-1.8%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5-1.9%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63-70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68-70%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividends</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected volatility is based on the annualized daily historical volatility of the Company&#8217;s stock price for a time period consistent with the expected term of each grant. Management believes that the historical volatility of the Company&#8217;s stock price best represents the future volatility of the stock price.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The risk-free rate is based on the U.S. Treasury yield in effect at the time of grant for the expected term of the respective grant. The Company has not historically paid cash dividends, and does not expect to pay cash dividends in the foreseeable future.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The expected terms and stock price volatility utilized in the calculation involve management&#8217;s best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. GAAP also requires that the Company recognize compensation expense for only the portion of options that are expected to vest. Therefore, management calculated an estimated annual pre-vesting forfeiture rate that is derived from historical employee termination behavior since the inception of the Company, as adjusted. If the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required in future periods.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">15,487,348</font><font style="font-family:inherit;font-size:10pt;"> stock options outstanding.&#160;The aggregate intrinsic value of employee options outstanding at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$9.2 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> related to exercisable options. The weighted average grant-date fair values of these stock options granted during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$1.08</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.71</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">, net of the impact of estimated forfeitures, of unrecognized compensation cost related to unvested employee stock option awards outstanding that is expected to be recognized as expense over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.84</font><font style="font-family:inherit;font-size:10pt;"> years. The intrinsic value of employee stock options exercised during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock-Based Compensation Expense</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, Daniel Passeri resigned from his position as Vice Chairman of the Company's board of directors. In connection with the related letter agreement with the Company, the board of directors approved a modification to Mr.&#160;Passeri&#8217;s vested common stock options such that the exercise period for all such options shall be </font><font style="font-family:inherit;font-size:10pt;">twenty-four months</font><font style="font-family:inherit;font-size:10pt;">. As a result, </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> of additional stock based compensation expense was recorded to account for this modification during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded a total of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;"> in compensation expense for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> in compensation expense for the three and the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to employee and director stock option grants. The total fair values of vested stock options for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Non-Employee Grants</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has periodically granted stock options to consultants for services pursuant to the Company&#8217;s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would also be cancelled.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized expense related to non-employee stock options of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and reversed expense of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, and reversed expense of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and recognized expense of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Total Stock-Based Compensation Expense</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the condensed consolidated statements of operations and comprehensive loss, including expense related to its ESPP:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,425</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,780</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6737326448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss) as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized&#160;Gain&#160;on</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities&#160; Available-for-Sale</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current period other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above amounts do not reflect a tax effect because the Company expects to record a net loss for </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized&#160;Losses and</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain&#160;on</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities&#160;Available-for-Sale</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current period other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e640-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e716-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e709-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reclassification Adjustments<br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736627488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Loss Per Common Share</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is the same as basic net loss per common share for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, because the effect of the potential common stock equivalents would be antidilutive due to the Company&#8217;s net loss position for these periods. Antidilutive securities consist only of stock options outstanding of </font><font style="font-family:inherit;font-size:10pt;">15,487,348</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">13,678,899</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736694528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Related Party Transactions</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consulting agreement with Daniel R. Passeri</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;2, 2014, Daniel R. Passeri resigned as Chief Executive Officer of the Company and the Company&#8217;s board of directors appointed Mr.&#160;Passeri to serve as the Vice Chairman of the board of directors. Also on June 2, 2014, the Company and Mr.&#160;Passeri entered into a consulting agreement. The agreement was for an initial term of </font><font style="font-family:inherit;font-size:10pt;">one year</font><font style="font-family:inherit;font-size:10pt;">, subject to renewal or earlier termination by the parties. The agreement was renewed by the parties through </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, after which the agreement between Mr. Passeri and the Company was terminated. Pursuant to the terms of the agreement, Mr.&#160;Passeri was paid an hourly fee or a monthly retainer as consideration for the services rendered by Mr.&#160;Passeri to the Company. During the five months ended </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, Mr.&#160;Passeri provided consulting services to the Company on intellectual property, corporate and strategic matters in exchange for payments of </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;"> per month. During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, Mr.&#160;Passeri had full-time employment with a third party and was paid an hourly fee for services rendered to the Company during this time. </font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 2, 2016, the Company and Mr. Passeri entered into a letter agreement pursuant to which Mr. Passeri resigned as director and Vice Chairman of the Company's board of directors, which became effective on September 14, 2016. Pursuant to the terms of the Letter Agreement, and in recognition of his many years of service to the Company in varying roles, including as a director and Vice Chairman of the Board, and formerly as Chief Executive Officer, President, and as a consultant, the Board authorized a </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;"> recognition bonus payment to Mr.&#160;Passeri and also approved a modification to Mr.&#160;Passeri&#8217;s vested common stock options such that the exercise period for all such options shall be </font><font style="font-family:inherit;font-size:10pt;">24 months</font><font style="font-family:inherit;font-size:10pt;">. Mr.&#160;Passeri agreed to provide continued assistance to the Company, without further remuneration, for up to </font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;">, if and when requested by the Board or the Chief Executive Officer. The letter agreement also contains other customary terms and conditions relating to Mr.&#160;Passeri&#8217;s end of service with the Company.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized expenses related to the consulting and letter agreements of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904963792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">New Accounting Pronouncements</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standard Board (FASB) issued Accounting Standard Update (ASU) 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which simplifies share-based payment accounting through a variety of amendments. The standard will be effective for annual reporting periods and interim periods within those annual periods, beginning after December&#160;15, 2016, and early adoption is permitted. The Company does not expect the impact of this guidance to be material to its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The standard requires organizations that lease assets to recognize on the balance sheet assets or liabilities, as applicable, for the rights and obligations created by those leases. Additionally, the guidance modifies current guidance for lessor accounting and leveraged leases, and is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within such years. Early adoption is permitted, but the Company does not anticipate electing early adoption. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU, 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities,</font><font style="font-family:inherit;font-size:10pt;"> which amends prior guidance on accounting for equity investments and financial liabilities. The new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within such years. Early adoption is permitted but the Company does not anticipate electing early adoption. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2014, the FASB issued ASU 2014-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to continue as a Going Concern.</font><font style="font-family:inherit;font-size:10pt;">&#160;This update is intended to define management&#8217;s responsibility to evaluate whether there is substantial doubt about an organization&#8217;s ability to continue as a going concern within one year of the date of issuance of the entity&#8217;s financial statements and to provide related footnote disclosures. This guidance is effective for fiscal years ending after December&#160;15, 2016, and early adoption is permitted. The Company is currently evaluating what effect, if any, the adoption of this guidance will have on the disclosures included in its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:inherit;font-size:10pt;">, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;">, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;">, related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact that these standards may have on its consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Direct Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=66092750<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22583-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Indirect Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22580-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Accounting Change<br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Retrospective Application<br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6739862240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company discloses fair value measurements based on a framework outlined by GAAP which requires expanded disclosures regarding fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i)&#160;independent, (ii)&#160;knowledgeable, (iii)&#160;able to transact, and (iv)&#160;willing to transact. GAAP also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:90%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> shareholder-approved, share-based compensation plans: (i)&#160;the Amended and Restated 2010 Stock Incentive Plan, or the 2010 Plan, adopted as amended by the board of directors in March 2015 and approved by shareholders in May 2015 and (ii)&#160;the 2010 Employee Stock Purchase Plan, or the ESPP, adopted by the board of directors in April 2010 and approved by shareholders in June 2010.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standard Board (FASB) issued Accounting Standard Update (ASU) 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which simplifies share-based payment accounting through a variety of amendments. The standard will be effective for annual reporting periods and interim periods within those annual periods, beginning after December&#160;15, 2016, and early adoption is permitted. The Company does not expect the impact of this guidance to be material to its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The standard requires organizations that lease assets to recognize on the balance sheet assets or liabilities, as applicable, for the rights and obligations created by those leases. Additionally, the guidance modifies current guidance for lessor accounting and leveraged leases, and is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within such years. Early adoption is permitted, but the Company does not anticipate electing early adoption. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU, 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities,</font><font style="font-family:inherit;font-size:10pt;"> which amends prior guidance on accounting for equity investments and financial liabilities. The new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within such years. Early adoption is permitted but the Company does not anticipate electing early adoption. The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2014, the FASB issued ASU 2014-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to continue as a Going Concern.</font><font style="font-family:inherit;font-size:10pt;">&#160;This update is intended to define management&#8217;s responsibility to evaluate whether there is substantial doubt about an organization&#8217;s ability to continue as a going concern within one year of the date of issuance of the entity&#8217;s financial statements and to provide related footnote disclosures. This guidance is effective for fiscal years ending after December&#160;15, 2016, and early adoption is permitted. The Company is currently evaluating what effect, if any, the adoption of this guidance will have on the disclosures included in its consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU 2015-14, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:inherit;font-size:10pt;">, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;">, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;">, related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. These standards have the same effective date and transition date of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact that these standards may have on its consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736586752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets or Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the fair value hierarchy, the following table shows the fair value as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> of those financial assets and liabilities that are measured at fair value on a recurring basis.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted&#160;Prices&#160;in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other&#160;Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs&#160;(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2016:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, stock, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,785</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Quoted&#160;Prices&#160;in</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Active Markets</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Other&#160;Observable</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Inputs&#160;(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Inputs&#160;(Level&#160;3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2015:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,568</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,999</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Municipal bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate commercial paper, stock, bonds and notes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,644</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,456</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,213</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,304</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,517</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904925840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Summary of Amortized Cost, Unrealized Gains and Losses and Fair Value of Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds and notes &#8211; short-term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,072</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,072</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amortized cost, unrealized gains and losses and fair value of investments available-for-sale as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total&#160;Fair&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds and notes &#8211; short-term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,657</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,657</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736613632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest on debt (Note 7)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">249</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6634546080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting for Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Key Assumptions for Options Awarded</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Black-Scholes option pricing model employs the following key assumptions for employee and director options awarded during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> based on the assumptions noted in the following table:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years) - employees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years) &#8211; officers and directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.4-1.8%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5-1.9%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63-70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68-70%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividends</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Recorded Stock-Based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded stock-based compensation expense to the following line items in its costs and expenses section of the condensed consolidated statements of operations and comprehensive loss, including expense related to its ESPP:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,425</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">731</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,780</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,104</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736554336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Changes in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss) as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized&#160;Gain&#160;on</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities&#160; Available-for-Sale</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current period other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The above amounts do not reflect a tax effect because the Company expects to record a net loss for </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized&#160;Losses and</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain&#160;on</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities&#160;Available-for-Sale</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net current period other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, as of September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6744338432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 07, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>program </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>segment </div>
<div>program</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>program</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>program</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued of common stock in exchange for waived payment (in shares) | shares</a></td>
<td class="nump">10,208,333<span></span>
</td>
<td class="nump">10,208,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to) | $</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementNumberofProgramsLicensed', window );">Collaboration agreement, number of programs licensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementNumberofProgramsLicensed', window );">Collaboration agreement, number of programs licensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementNumberofProgramsLicensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number of Programs Licensed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementNumberofProgramsLicensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6760342784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 07, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>program </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th">
<div>Jun. 30, 2003 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>payment </div>
<div>right </div>
<div>product </div>
<div>term </div>
<div>program </div>
<div>patient</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>payment </div>
<div>right </div>
<div>product </div>
<div>term </div>
<div>program </div>
<div>patient</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 06, 2016 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Recognized royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,293,000<span></span>
</td>
<td class="nump">$ 5,403,000<span></span>
</td>
<td class="nump">$ 5,998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Cost of royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
<td class="nump">278,000<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms', window );">Collaboration agreement, number of optional additional terms | term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementOptionalAdditionalTerm', window );">Collaboration agreement, optional additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementOptionFeesTotal', window );">Option fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementOptionFeesNumberofPayments', window );">Number of payments | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing share price of common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember', window );">Curis Royalty | Credit agreement with BioPharma-II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal loan amount to Curis Royalty given by BioPharma under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan to Curis Royalty given by BioPharma under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_GenentechIncMember', window );">Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner', window );">Amount received for specified clinical development and regulatory objectives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ReducedRoyaltyRate', window );">Percentage of royalty rate decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Recognized royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Cost of royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned', window );">Percentage of royalties earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_GenentechIncMember', window );">Genentech, Inc. | Drug development royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ResearchAndDevelopmentRevenue', window );">Research and development revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ResearchAndDevelopmentContraRevenues', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_GenentechIncMember', window );">Genentech, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment', window );">Eligible to receive contingent cash payment for specified clinical development and regulatory objectives (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PercentageOfRoyaltyOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_GenentechIncMember', window );">Genentech, Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PercentageOfRoyaltyOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeAgreementOptionExercisablePeriod', window );">Collaboration agreement, option exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementNumberofProgramsLicensed', window );">Collaboration agreement, number of programs licensed | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreement', window );">Collaboration agreement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements', window );">Additional payments made under collaborative arrangements (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PaymentsforResearchandDevelopment', window );">Payments for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram', window );">Payment for preclinical program for potential further development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries', window );">Collaboration agreement, number of products required to commercialize (at least) | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeAgreementPeriodOfContract', window );">Collaboration agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier', window );">Collaboration agreement, rights granted to nominate global drug substance or drug product supplier | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PaymentsMadeUnderCollaborativeArrangements', window );">Payments made under collaboration arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued of common stock in exchange for waived payment (in shares) | shares</a></td>
<td class="nump">10,208,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,208,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Value of common stock issued</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementNumberofProgramsLicensed', window );">Collaboration agreement, number of programs licensed | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentforLicensedProgram', window );">Payment for license and designation as the development candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | PD1/VISTA programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreement', window );">Collaboration agreement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForOptionExercise', window );">Collaboration agreement expenses, option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling', window );">Collaboration agreement expenses, acceptance of IND filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient', window );">Collaboration agreement expenses, dosing of fifth patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | IRAK4 programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreement', window );">Collaboration agreement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForOptionExercise', window );">Collaboration agreement expenses, option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling', window );">Collaboration agreement expenses, acceptance of IND filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient', window );">Collaboration agreement expenses, dosing of fifth patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Programs three and four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding', window );">Agreement to provide additional funding, if options are exercised (up to)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Program three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForOptionExercise', window );">Collaboration agreement expenses, option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling', window );">Collaboration agreement expenses, acceptance of IND filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PaymentsMadeUnderCollaborativeArrangements', window );">Payments made under collaboration arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForProgramSelectionFee', window );">Collaboration agreement expenses, program selection fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Program four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForOptionExercise', window );">Collaboration agreement expenses, option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling', window );">Collaboration agreement expenses, acceptance of IND filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForProgramSelectionFee', window );">Collaboration agreement expenses, program selection fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Program thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements', window );">Additional payments made under collaborative arrangements (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram', window );">Collaboration agreement, fees (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Extended exclusivity, IRAK4 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Acceptance of IND filing, IRAK4 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Phase 1 clinical trial, dosing of fifth patient, IRAK4 program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment', window );">Number of patients dosed that trigger payment | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Extended exclusivity, PD1/VISTA program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Phase 1 clinical trial, dosing of fifth patient, PD1/VISTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment', window );">Number of patients dosed that trigger payment | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Option exercise payment, program three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived', window );">Percentage of consideration received</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Acceptance of IND filing, program three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Program selection fee, program four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Option exercise payment, program four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Acceptance of IND filing, program four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1', window );">Waived payment of milestone and other payments (up to)</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeAgreementPeriodOfContract', window );">Collaboration agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct', window );">Percentage of contribution (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Maximum | PD1/VISTA programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreementPerProgram', window );">Collaboration agreement, payment per program (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Maximum | IRAK4 programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreementPerProgram', window );">Collaboration agreement, payment per program (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Maximum | Program three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreementPerProgram', window );">Collaboration agreement, payment per program (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Maximum | Program four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreementPerProgram', window );">Collaboration agreement, payment per program (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember', window );">Aurigene | Maximum | Program thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_CollaborativeArrangementPaymentsAgreementPerProgram', window );">Collaboration agreement, payment per program (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AdditionalPaymentsMadeUnderCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payments made under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_AdditionalPaymentsMadeUnderCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementContingentConsiderationPotentialCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement contingent consideration potential cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationAgreementContingentConsiderationPotentialCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborationAgreementContingentConsiderationReceivedFromPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement contingent consideration received from partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborationAgreementContingentConsiderationReceivedFromPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeAgreementOptionExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement option exercisable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeAgreementOptionExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeAgreementPeriodOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement period of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeAgreementPeriodOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contractual Agreement, Number of Patients Dosed that Trigger Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementContractualAgreementNumberofPatientsDosedthatTriggerPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement expenses for acceptance of IND filing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementExpensesForAcceptanceOfINDFiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement expenses for approval and commercial milestones per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementExpensesForApprovalAndCommercialMilestonesPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementExpensesForDosingOfFifthPatient">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement expenses for dosing of fifth patient.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementExpensesForDosingOfFifthPatient</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementExpensesForOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement expenses for option exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementExpensesForOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementExpensesForProgramSelectionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement expenses for program selection fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementExpensesForProgramSelectionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Licensed Programs, Contingent Obligation to Provide Additional Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementLicensedProgramsContingentObligationtoProvideAdditionalFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementNumberofOptionalAdditionalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number of Optional Additional Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementNumberofOptionalAdditionalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementNumberofProgramsLicensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number of Programs Licensed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementNumberofProgramsLicensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementOptionFeesNumberofPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Option Fees, Number of Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementOptionFeesNumberofPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementOptionFeesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Option Fees, Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementOptionFeesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementOptionalAdditionalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Optional Additional Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementOptionalAdditionalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementPaymentforLicensedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment for Licensed Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementPaymentforLicensedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Payment for Selection of Preclinical Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementPaymentforSelectionofPreclinicalProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementPaymentsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement payments agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementPaymentsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementPaymentsAgreementPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement payments agreement per program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementPaymentsAgreementPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Programs Licensed, Number of Products Required to Commercialize in Specified Countries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementProgramsLicensedNumberofProductsRequiredtoCommercializeinSpecifiedCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights Granted to Nominate Substance or Supplier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CollaborativeArrangementRightsGrantedtoNominateSubstanceorSupplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost and expenses of percentage of aggregate royalty earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_CostAndExpensesOfPercentageOfAggregateRoyaltyEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Significant Noncash Transaction, Percentage of Consideration Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_OtherSignificantNoncashTransactionPercentageofConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PaymentsMadeUnderCollaborativeArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments made under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_PaymentsMadeUnderCollaborativeArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PaymentsforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_PaymentsforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PercentageOfRoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_PercentageOfRoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ReducedRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ReducedRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ResearchAndDevelopmentContraRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Contra Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ResearchAndDevelopmentContraRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ResearchAndDevelopmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historically, this has included FTE reimbursement. It also includes reimbursement of other costs that have been incurred on behalf of a partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ResearchAndDevelopmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of supply as percentage of annual requirement of drug product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_RightOfSupplyAsPercentageOfAnnualRequirementOfDrugProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration received in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cris_CreditAgreementWithBioPharmaTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cris_CreditAgreementWithBioPharmaTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cris_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cris_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=cris_DrugDevelopmentRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=cris_DrugDevelopmentRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=cris_AurigeneDiscoveryTechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ProgramOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ProgramOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ProgramTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ProgramTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ThirdandFourthProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ThirdandFourthProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ProgramThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ProgramThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ProgramFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ProgramFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ProgramThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ProgramThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ExtendedExclusivityIRAK4ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ExtendedExclusivityIRAK4ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_AcceptanceofINDFilingIRAK4ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_AcceptanceofINDFilingIRAK4ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_Phase1ClinicalTrialDosingofFifthPatientIRAK4ProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ExtendedExclusivityPD1VISTAProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ExtendedExclusivityPD1VISTAProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_Phase1ClinicalTrialDosingofFifthPatientPD1VISTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_OptionExercisePaymentProgramThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_OptionExercisePaymentProgramThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_AcceptanceofINDFilingProgramThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_AcceptanceofINDFilingProgramThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_ProgramSelectionFeeProgramFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_ProgramSelectionFeeProgramFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_OptionExercisePaymentProgramFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_OptionExercisePaymentProgramFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cris_AcceptanceofINDFilingProgramFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cris_AcceptanceofINDFilingProgramFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6755672992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets or Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair value measurements, recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 50,785<span></span>
</td>
<td class="nump">$ 80,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Short-term investments | Corporate commercial paper, stock, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Corporate commercial paper, stock, bonds and notes</a></td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">49,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">16,521<span></span>
</td>
<td class="nump">13,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate commercial paper, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">9,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">7,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">16,521<span></span>
</td>
<td class="nump">18,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) | Short-term investments | Corporate commercial paper, stock, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Corporate commercial paper, stock, bonds and notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">16,521<span></span>
</td>
<td class="nump">13,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) | Corporate commercial paper, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">34,264<span></span>
</td>
<td class="nump">62,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other Observable Inputs (Level 2) | Short-term investments | Corporate commercial paper, stock, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Corporate commercial paper, stock, bonds and notes</a></td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">46,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other Observable Inputs (Level 2) | Corporate commercial paper, bonds and notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">7,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other Observable Inputs (Level 2) | Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">$ 7,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecurityAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecurityAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6735048608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Amortized Cost, Unrealized Gains and Losses and Fair Value of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 32,657<span></span>
</td>
<td class="nump">$ 49,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total Fair Value</a></td>
<td class="nump">32,684<span></span>
</td>
<td class="nump">49,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds and notes &#8211; short-term | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">32,657<span></span>
</td>
<td class="nump">49,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Total Fair Value</a></td>
<td class="nump">$ 32,684<span></span>
</td>
<td class="nump">$ 49,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6735548304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments -  Narrative (Details) - Short-term investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AvailableForSaleSecuritiesWeightedAverageMaturity', window );">Short-term investments, weighted average maturity</a></td>
<td class="text">2 months 15 days<span></span>
</td>
<td class="text">4 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AvailableForSaleSecuritiesDateRange', window );">Short-term investments, maturity ranges</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_AvailableForSaleSecuritiesDateRange', window );">Short-term investments, maturity ranges</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AvailableForSaleSecuritiesDateRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities date range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_AvailableForSaleSecuritiesDateRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_AvailableForSaleSecuritiesWeightedAverageMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale securities weighted average maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_AvailableForSaleSecuritiesWeightedAverageMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6760319024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payment towards debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,219,000<span></span>
</td>
<td class="nump">$ 2,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">$ 5,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">15,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,558,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense recognized related to loan</a></td>
<td class="nump">657,000<span></span>
</td>
<td class="nump">$ 827,000<span></span>
</td>
<td class="nump">2,126,000<span></span>
</td>
<td class="nump">2,537,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cris_BioPharmaTwoMember', window );">BioPharma-II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense recognized related to loan</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember', window );">Curis Royalty | Credit agreement with BioPharma-II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal loan amount to Curis Royalty given by BioPharma under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan to Curis Royalty given by BioPharma under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter', window );">Percentage equal to the price of the outstanding principal of the loan that may be prepaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payment towards debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest on loan amount to Curis Royalty given by BioPharma under credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember', window );">Curis Royalty | Credit agreement with BioPharma-II | Principal portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payment towards debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage prepayment of outstanding principal amount in whole or in part for year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_PercentagePrepaymentOfLoanAmountForYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cris_BioPharmaTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cris_BioPharmaTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cris_CreditAgreementWithBioPharmaTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cris_CreditAgreementWithBioPharmaTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cris_PrincipalPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cris_PrincipalPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6900905440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,637<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on debt (Note 7)</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,324<span></span>
</td>
<td class="nump">$ 1,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6901015728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting for Stock-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ShareBasedCompensationPlans', window );">Number of shareholder-approved, share-based compensation plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares) | shares</a></td>
<td class="nump">15,487,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,487,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of employee options outstanding</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of exercisable options</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair values of stock options (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 1.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, net of estimated forfeitures</a></td>
<td class="nump">7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic values of employee stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair values of vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Non-employee compensation expense, recognized expenses (reversals)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to employee and director stock option grants</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=cris_BoardofDirectorsViceChairmanMember', window );">Vice Chairman of Board of Directors | Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense related to employee and director stock option grants</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,621,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember', window );">2010 Plan | Non-employee directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option granted, exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember', window );">2010 Plan | Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vested shares which are exercisable under stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember', window );">2010 Plan | Tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vested shares which are exercisable under stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, vesting period two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ShareBasedCompensationArrangementbyShareBasedPaymentAwardVestingPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation, number of plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity-based compensation, related to restricted stock units or restricted stock awards, recognized as expense or an asset, if compensation is capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=cris_BoardofDirectorsViceChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=cris_BoardofDirectorsViceChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cris_TwoThousandAndTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=cris_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=cris_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6744353344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting for Stock-Based Compensation - Key Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=cris_EmployeesMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=cris_OfficersAndDirectorsMember', window );">Officers and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=cris_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=cris_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=cris_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=cris_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6735653872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting for Stock-Based Compensation - Schedule of Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,630<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 3,311<span></span>
</td>
<td class="nump">$ 2,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,425<span></span>
</td>
<td class="nump">$ 731<span></span>
</td>
<td class="nump">$ 2,780<span></span>
</td>
<td class="nump">$ 2,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6735802112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) - Summary of Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 64,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">37,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated net unrealized investment gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905046880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">15,487,348<span></span>
</td>
<td class="nump">13,678,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736000192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 02, 2016</div></th>
<th class="th"><div>Jun. 02, 2014</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options outstanding | Vice Chairman of Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cris_MrPasseriMember', window );">Mr. Daniel R. Passeri</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ConsultingAgreementPeriod', window );">Consulting agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cris_ConsultingFees', window );">Consulting fees per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1', window );">Agreement to provide continued assistance, term (up to)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting agreement, recognized expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cris_MrPasseriMember', window );">Mr. Daniel R. Passeri | Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of options</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cris_MrPasseriMember', window );">Mr. Daniel R. Passeri | Recognition bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount', window );">Authorized recognition bonus payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ConsultingAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting Agreement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ConsultingAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cris_ConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cris_ConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cris_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment made to pay deferred cash remuneration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=cris_BoardofDirectorsViceChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=cris_BoardofDirectorsViceChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cris_MrPasseriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cris_MrPasseriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M P04    "  W/6-)2'4%[L4    K @  "P   %]R96QS+RYR96QSK9++;L)
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M3HFII@K,5(+&$>\5+D 3EJA_R0(SLG$"9AV43[?*/-//9&;'X+'*VETHJZ_
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M[M<8'5].7-G&^NZ4^A%]>U7U)U!+ P04    "  W/6-)F5R<(Q &  "<)P
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M]SO(1Q1%=>81G7>+'SLZ!R^DZN^.NLPC+N\K1J\TBJ)6\XC5^W)_S"ZE%K1
M<JHVCZA-<W_,%DU5"?L[;/:T,O@'3E%4;AZ1NX]BM\*&O6X@LD$J-X_('8I?
M])0SZG(6<3GJ8@Q$I<[B4N^7,>,41;W.#O4ZZW4&O=;@T#*=4:\SZG5V:)G.
M:'>04;6S]Y;I^+%3M;.#"G;+HRBJ=G;RVCK^ZQ:Q8<:OM0B]M&NGP68T#PTV
M_G3_J*-QJ++A^@:;[ED2.F-L@ANEON&]G_K:B+9_[,C;EOKK'U!+ P04
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MY7/7C79J3'R>IN+%EJ?'3FW/X[R93MO]^E9@W1F[Z_TEQ^--R_XW4$L#!!0
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M^^D(CR!E$/*%WQ;-CY*!>+X^J3_%;KW[ [?PB/*/:-W@S6:4M-#Q2;H7G'_
MTL)M$&Q0VCB29K(.U8E"B>+O:18ZSG/:^98MM,N$8B$47P@L%8HVOW/'Z\K@
M3$PZVI&'&\RWA3^(AGAOEH:MV'U U-6QSO.[BAV#T"?,/F&*A%D1S*NO)8K_
ME]@79_3B,GUSQ>$FTC>+P_*R0'E%H(P"Y=46/V/NOQ1A9V>JP/3QZ5C2X*1=
M.KPUN[[.AR+>R0>\KD;>PR]N>J$M.:#S-QOOID-TX$UD-[>4#/[_K(&$SH7E
MO5^;]*12X' \?9#UE];_ %!+ P04    "  W/6-)IBY5I:,!  "Q P  &
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M].%FT]TTB!Z"B>SJFI(N_)\E4-#XN/P1UG9Z4E/@L3]^D.67EO\!4$L#!!0
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MC7?3(CKP)K*[+26]_S]KH*!U8?G5KTUZ4BEP.)X_R/I+JW]02P,$%     @
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M7YOTH%+@<#A_C_F/EG\!4$L#!!0    ( #<]8TFJFLH2HP$  +$#   9
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M@#[<;+J;%M%#,%'<W%+2A_^S! I:'Y=W86WSD\J!Q^'T099?6OT%4$L#!!0
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MOS;I2:7 X73^(-LO;?X!4$L#!!0    ( #<]8TD)VCI)H@$  +$#   9
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M=/YFX]VTB Z\B>QF0TGO_\\22&A=6-[YM4E/*@4.A],'67YI]0Y02P,$%
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M\M:O37I2*7 X'#_(\DNK#U!+ P04    "  W/6-)4:9MBZ !  "Q P  &0
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M-YONID/T$$P4-[>4#.'_K(&"SL?EU["V^4GEP.-X_B#K+ZW_ 5!+ P04
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M?FW2DTJ!P_'\0=9?6O\%4$L#!!0    ( #<]8TGE'8!OH@$  +$#   9
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M.G^S\6Y:1 ?>1':SH:3W_V<))+0N+._\VJ0GE0*'P^F#++^T^@M02P,$%
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MIJ8O_0WTA1;]_3V9'[7\/U!+ P04    "  W/6-)%TBGMZ4!  "Q P  &0
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M^FR1_M_BD%[0TV7Z^D;"=:"OH_LZ7Q;(;@AD02";2LP72[S&;)9-\ALF^97
M=M'D&G/_CPFY.#@!N@WWTZ!*#=+&$YIGYR?PD(:#_X&714];>*.Z9=*@H[+N
M^H0+T"AEP85([ER*SCW2><"AL;Z[=7T=[VT<6-6?7^'\*RC_ E!+ P04
M"  W/6-)K4W.^*4!  "Q P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q]4\MNVS 0_!6"'Q#*M..XABP@3A&TAP)!#NV9EE82$9*KD)25_GWYL!4G
M<'/A<V9V=I<L)[0OK@?PY$TKXW:T]W[8,N;J'K1P-SB "3<M6BU\V-J.N<&"
M:!))*\:+8LVTD(9693I[LE6)HU?2P),E;M1:V+][4#CMZ(*>#YYEU_MXP*J2
MS;Q&:C!.HB$6VAV]7VSWJXA(@-\2)G>Q)M'[ ?$E;GXV.UI$"Z"@]E%!A.D(
M#Z!4% J!7T^:[R$C\7)]5G],V0;W!^'@ =4?V?@^F"TH:: 5H_+/./V 4PJW
M4;!&Y=)(ZM%YU&<*)5J\Y5F:-$_Y9KTYT:X3^(G 9\*F2,9SH&3SN_"B*BU.
MQ.;2#B)V<+'EH1 U"=X<C5<I^XBHRF.U6'\KV3$*?<#L,X9GS(Q@07T.P?\?
M8L\OZ/PZ??F%PV6B+W/TY>:ZP.H+@5426&6!N^)JBA\QGY-D%S758+OT=!RI
M<30^%V\^G5_G/4\]>8=7Y2 Z^"5L)XTC!_2ALZDW+:*'8**XN:6D#_]GWBAH
M?5S>A;7-3RIO/ [G#S+_TNH?4$L#!!0    ( #<]8TF\RCM510(  #P(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(V677/B(!2&_THF/Z AW[$3
M,[-J=?=B9SJ]V%ZCHLDT"5E T_WWRY=1.A3UP@!YWO>< PB6(R8?M$:(>9]=
MV].Y7S,V/ <!W=6H@_0)#ZCG;PZ8=)#Q+CD&=" ([J6H:X,(@"SH8-/[52G'
M7DE5XA-KFQZ]$H^>N@Z2?PO4XG'NA_YEX*TYUDP,!%493+I]TZ&>-KCW"#K,
M_1_A\R:4B"3^-&BD-VU/)+_%^$-T?NWG/A YH!;MF+" _'%&2]2VPHE'_JM-
MKS&%\+9]<5_+<GGZ6TC1$K?OS9[5/%O@>WMT@*>6O>'Q)](UI,)PAULJO[W=
MB3+<722^U\%/]6QZ^1S5FP)HF5T0:4$T":+<*8BU()X$<>(4)%J07",43D&J
M!>E5$#H%F19DCPIR+<B_" (UNW)M5I#!JB1X](C:4 ,4^S9\SOGJ[SR^(-07
MK^22"Z(JSU681V5P%D8&LU!,I)G8QBQ-)K$Q*Y-);<R+R60V9FTRN8W9F$PQ
M,0&?DVEB(L?$1-(@U@8SNT'L,(BE0:(,"F!FV:L944RF&'N(Q!$B,4)\8Y Z
M#-)'BLP<!IF1060K<I'=%@DB4,1Q; .73M!(*7>DE!LI62,M%)-+)DI2(#[6
ME)R@D5+A2*DP4DJLD8J;XJWSN+I+K.\2&SMA%#)S%#(S"DGM!N("^/Z\ 8]L
MN=!Y9(7WI_-%0ZK2K[LHN#DC!WA$OR$Y-CWUMICQXU8>F >,&>)&X(G_1FI^
ME4^=%AV8:.:\3=3EICH,#Y>[>OK#4/T'4$L#!!0    ( #<]8TG28-X+K @
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M5_OWF1".A%GX)'['1IS*<P>C,Y?-7+3I=$Y-'4Z&^[$[G_W57U!+ P04
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MR_XPH% HT]WHON@*83=0O+G7]>'GDOX'4$L#!!0    ( #<]8TD0]!EI7P,
M #4/   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;(U779.;(!3]*XX_
M8 44U(QQ9O/9/G1FIP_MLYN0Q%F55,EF^^_K!S&0 O$E*CGWW',!#][DRNJ/
MYD0I=[[*HFKF[HGS\\SSFMV)EEGSPLZT:O\YL+K,>/M8'[WF7--LWP>5A8<
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M@GC*2]:=9V;[!!.F6("&:KM2#7,L<&*2C;B5PH>@$;A6@5@%JD5:SP@H%8D
M-E!8S/L5HDE3;7-$Z"LJB*[BK0 )2P/ 5K+-/6&@)-.>B]L'D,'EH<T4(5;V
MC_9PW3Z  D,>FXE!XCX_#J#L.MBW["L;4!5ELR<H^Y/A2("R4V#S7E]-!6X4
M8$!LXFWF V7W,9P+ A,*O[>]TI%R,IB1&Q496_7;O _&RH[ >EFQ;" 64?%_
MKYWA \]FID@U4V*@L%D5@E-\!MFL"J$)KXH W3Z=S*^* D21;FH\Z8N]I/6Q
M[\8:9\<N%1]*&4?'CN^U;_@>QA=PMH2:\16<K8=^[DZ?)N?L2']D]3&O&N>=
M\;;/Z#N% V.<MLK!2^LZI[:''1\*>N#=;=C>UT-7-SQP=KXUJ6.GG/X#4$L#
M!!0    ( #<]8TFR!52/]0$  -<%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;'V478^<(!2&_XKQ!RP"?G0FCDG7IFDOFFSVHKUF%$>S*!:8<?OO
MRX=:W5!OY.M]SWD."/G$Q9ML*57!>\\&>0E;I<8S +)J:4_D$Q_IH%<:+GJB
M]%#<@!P%);4U]0R@*$I!3[HA+'([]R**G-\5ZP;Z(@)Y[WLB_CQ3QJ=+",-E
MXK6[M<I,@"('JZ_N>CK(C@^!H,TE_ S/96845O"SHY/<] /#?N7\S0R^UY<P
M,@B4T4J9"$0W#UI2QDP@G?CW'/-?2F/<]I?H7VVUFOY*)"TY^]75JM6P41C4
MM"%WIE[Y](W.)20F8,69M-^@NDO%^\42!CUY=VTWV'9R*\EB\QO0;$"K <:'
M!CP;\ <#<&2VKB]$D2(7? J$.XN1F".'9ZQWK@IT,3(T2W:[C*+('P6&60X>
M)M!.\^PTR&J03U'N%,DJ 1I@I4 '%,CZL?5#C/P!\$$ ; /$<QF?]I"#*\-I
M,I<DQ9E/5.Y$&$9^E/@ )=ZAG+PH3I.Z+##QDNPT"/M!D@.09 N"(B](LDF"
MD!]DITG^<SCI 4BZ X%>D'23!,?^L]EJ4'SR@V0'(-D.!'E!LLT/@#"*O21;
M$3SA^ ,*V-S!D=SH#R)NW2"#*U?Z.ML+V7"NJ X5/>GM;?4KNPX8;93I9KHO
MW,/C!HJ/RS.ZON7%7U!+ P04    "  W/6-)>E(IO\,#  #E$0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S,BYX;6R-6$V/FS 0_2N(>P/^ $*4C;0)J=I#
MI54/[9E-G 0MX!3(9OOO"]AA&61/R2& >3/S/,,\;-9W6;W5%R$:YZ/(R_K)
MO33-=>5Y]>$BBK1>R*LHVSLG615ITUY69Z^^5B(]]D9%[E'?#[TBS4IWL^['
M7JK-6MZ:/"O%2^74MZ)(J[];D<O[DTO<Q\#/['QIN@%OL_8&NV-6B++.9.E4
MXO3D/I/5G@4=I$?\RL2]'IT['?E7*=^ZB^_')]?O.(A<')K.1=H>WL5.Y'GG
MJ8W\1SO]C-D9CL\?WK_VTVWIOZ:UV,G\=W9L+BU;WW6.XI3>\N:GO'\3>@X]
MPX/,Z_[?.=SJ1A8/$]<IT@]US,K^>%=WEKXV,QM0;4 ' QJA!DP;L$\#@AIP
M;< ' XX;!-H@& R8RJ6:>Y^Y)&W2S;J2=Z=2Y;ZFW5-%5D%;FX/3IJMVNUM]
M03K$9OV^892MO??.$<!L%8;VF- (2<80,B"\EL# @MI9;.G(G%%N"K$;8TAL
MQ"303V#"["$F-)-E2,I8[X!I!Y'9 4<<\-X!UPZ6D&6I9J(P88^AYA !$B(
M(6)3B&TP"D$"OHP8-W-!@8!2B% *QY28;Z2D,'&/B1<D!C\CMWD6@&2$D(P
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M"FM!.J,%$P"BOFVQC[4@!2UH671JT+!NL2W4L1YDL <MRL:P'F2S>I!A/<A
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MFJLY'UOEN)"LOW?^^?>C_ ]02P,$%     @ -SUC23,L,Z9A @  '@@  !D
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M$S&FXT%DG'#2W<Y5]\-=\1]02P,$%     @ -SUC2:)CVP(N2   ;4,! !0
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MG0=,NFF:SF1KE2RG=V0+0%C(9Z"S632Y?[XCT-P-@F83..>LA6T I[?,K.\
M &$5R I@.7=9?0N_S],2AJY('A"@UY[=+:?A,P342&I.DM^#.ELQ[P[QEA6H
MKMVIDGOAR'D$)F161:RC\%C(9WIA;^']7&$A",?0$#LSH8[=YR!N+9U,M_5/
M]#HRXFB2WF1YCDM 4B4/V />3O&(][WW+JF;DC#QLJFR/.W*OO?E39(+JXZ5
M_#-BX0HUI+RVK-QI_TH\]NO_W04PVN+H,I_N :U$233)BCJ=WN;%HKBY)QH
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M=3$Y?Y_>H]NP*O(\7:S=#LX'Z"78*Z8F'BBRP;]IZ_7M,4 7G#8U!VF0N##
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M,[6NX9 ..:.]O X*Q(.J4&:T(9MMR*2 &A=*Q!+D'=&ARV!Z?7%F=<%7#4X
MK.-M"BM%R^X,^,.4)2N7(M<IJQ[R!!9KFN [?OT'DBZ?JI2C<7]X>Q4[%!C
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MJ$V3)M_D*BE!*'UT=7&=W*#^)]>0_)J7S@.Z-=OMXDSX8,UO;)O+*1',@N+
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M5?_^_P)02P$"% ,4    "  W/6-)B5HD/+P!   F&   $P
M@ $     6T-O;G1E;G1?5'EP97-=+GAM;%!+ 0(4 Q0    ( #<]8TE(=07N
MQ0   "L"   +              "  >T!  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( #<]8TG$RR1#E $  #P7   :              "  =L"  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #<]8TEB:]>ER (  $ *
M   0              "  :<$  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ -SUC23Z(CRH^ 0  :0,  !$              ( !G0<  &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ -SUC29E<G",0!@  G"<  !,
M     ( !"@D  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  W/6-)
M!J$E)DP"  "P"@  #0              @ %+#P  >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( #<]8TG?>DGIJ ,  )L,   /              "  <(1  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  W/6-)>L;ANU("  #U!P  &
M            @ &7%0  >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ -SUC20E1->[% P  =1$  !@              ( !'Q@  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #<]8TDM$)-\ @(  /H%
M   8              "  1H<  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  W/6-)C?Z0,BL$  #*$@  &               @ %2'@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ -SUC2:T'YA8&
M!   E1(  !@              ( !LR(  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( #<]8TEEU+^]GP$  +$#   8              "
M >\F  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  W/6-)
M4L,XI* !  "Q P  &               @ '$*   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ -SUC2:8N5:6C 0  L0,  !@
M     ( !FBH  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M #<]8TGG1K'7GP$  +$#   8              "  7,L  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  W/6-)*\(PJZ$!  "Q P  &0
M            @ %(+@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( #<]8TG9KDG-I $  *\#   9              "  2 P  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ -SUC2:J:RA*C 0
ML0,  !D              ( !^S$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  W/6-)]OE9W: !  "Q P  &0              @ '5
M,P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #<]8TD)
MVCI)H@$  +$#   9              "  :PU  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ -SUC2<V_N8&B 0  L0,  !D
M     ( !A3<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #<]8TD72*>WI0$  +$#   9              "
M >U   !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ -SUC
M2='08A*C 0  L0,  !D              ( !R4(  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  W/6-)BF,@^*,!  "Q P  &0
M        @ &C1   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( #<]8TF\T 79L $  !8$   9              "  7U&  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ -SUC2:U-SOBE 0  L0,
M !D              ( !9$@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  W/6-)O,H[544"   \"   &0              @ % 2@
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #<]8TG28-X+
MK @  -@]   9              "  ;Q,  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ -SUC28?J"ME* P  @1   !D
M ( !GU4  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  W
M/6-)/2!L038"   '"   &0              @ $@60  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #<]8TFX;?RU!0(  &@&   9
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M970S,RYX;6Q02P$"% ,4    "  W/6-),RPSIF$"   >"   &0
M    @ $0:@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M #<]8TEWU1K82P(  +<'   9              "  :AL  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ -SUC2115G+/; 0  C 0  !D
M             ( !*F\  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  W/6-)D($BZG4"  #H"0  &0              @ $\<0  >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( #<]8TFB8]L"+D@
M &U# 0 4              "  >AS  !X;"]S:&%R9613=')I;F=S+GAM;%!+
4!08     +@ N '0,  !(O      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>188</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Accounting for Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccountingForStockBasedCompensation</Role>
      <ShortName>Accounting for Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/NewAccountingPronouncements</Role>
      <ShortName>New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2213201 - Disclosure - New Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/NewAccountingPronouncementsPolicies</Role>
      <ShortName>New Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.curis.com/role/AccountingForStockBasedCompensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/Investments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/AccruedLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Accounting for Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccountingForStockBasedCompensationTables</Role>
      <ShortName>Accounting for Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/AccountingForStockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/NatureOfBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/NatureOfBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/CollaborationAgreementsDetails</Role>
      <ShortName>Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/CollaborationAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair Value Measurements - Financial Assets or Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/FairValueMeasurementsFinancialAssetsOrLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets or Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Investments - Summary of Amortized Cost, Unrealized Gains and Losses and Fair Value of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/InvestmentsSummaryOfAmortizedCostUnrealizedGainsAndLossesAndFairValueOfInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Amortized Cost, Unrealized Gains and Losses and Fair Value of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Investments -  Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments -  Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/Debt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Accounting for Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccountingForStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Accounting for Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Accounting for Stock-Based Compensation - Key Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccountingForStockBasedCompensationKeyAssumptionsDetails</Role>
      <ShortName>Accounting for Stock-Based Compensation - Key Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Accounting for Stock-Based Compensation - Schedule of Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccountingForStockBasedCompensationScheduleOfExpenseDetails</Role>
      <ShortName>Accounting for Stock-Based Compensation - Schedule of Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Accumulated Other Comprehensive Income (Loss) - Summary of Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossSummaryOfChangesDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) - Summary of Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/LossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/LossPerCommonShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cris-20160930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curis.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curis.com/role/RelatedPartyTransactions</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cris-20160930.xml</File>
    <File>cris-20160930.xsd</File>
    <File>cris-20160930_cal.xml</File>
    <File>cris-20160930_def.xml</File>
    <File>cris-20160930_lab.xml</File>
    <File>cris-20160930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001628280-16-020671-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-16-020671-xbrl.zip
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M_6%R%EM=UQK<5#IG7H4B6L8&,XHVT)^I02=<:M^\Z[6W%0I+=2K&3G$=K59
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MO7'+!--A]<-<N&$J#)&Z!0P^@8N5%UEGV'_(<LG_3Y;W/M\!FE=YZOL&BU$
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M97OHRWZENN?MDH>-LE3F<6^B C6GHE8E-H:.K645$(FNF3M!M5 /8F\=/(\
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M82;E<%N,QO+3S,C/<>>#3_"'WFB)Y[(KCI.'JACFA^)S5GP%V_[A(5^,KJ>
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MZ6!?$TG#Q&L%9@@8)%A2HPFMFQ0JQ+UIC%%B\^6<!X9]%=VQ)F!]8&6#8ND
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M6:JGS1<2F3^J-E[FI@J])D W28ZYB9C+G$$+$)XBO@;$!)Y20 YYXP(><*.
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MI&7X?]4R6)>-0.X";:4L2',[:NK'-! KMSKH+M('<Q38:':T1P^Y .V32E
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M:BD,BK?6.N!.5"- I'HJ1H+"-0I\CX1ODN=ZT2O0HB:NJ)Z%CH=8@C%./N4
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M^'&*U!13@8L->C*@H( *->0X EH"IJ]>BYAR]$6%?EPL*$<]HF-@H=@%$1^
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MB%TC79DD98'+:JF*'MQM$9#6D27OU;S#D.*=9A07C-_*\E2S$7S3JYZZ38U
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M5%M$<OH/L7J>!*.FH%E3!6I_U'8"_DVF^7R]8F3G5FIEJ<I2M?E2M?5"=<4
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M) 'U&D]:YX%V='(P97RIQ&3T8RJ\4C8<C;RWLVL</&_E00=T0DK#UU'K&(T
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MTY6X1;VEX=P7TM6SN7LTF_N89W._>'BC.0C9., QQC'&,<:U G"- 19CW&O
MN->>N<ZSN;D?1.,Y%N,/XP_C#^,/XT^3%:/7TH^&9W._4&;J7@R4&W2.3T:U
M@Z0IAX_W<=G_GHC_QF,;LYJZ:VV:C@',;YC?,+]A?L/\AOD-\YO]YC=L2O%L
M[@>%NG@V]X/@U>]TN];:#S4%">H6V"R7]Y@BAIW34VL"ARF"*:+U%%&#S<=T
MP731>KHX!4EQRA3Q5 ODU824>2HW^QG9S]AR*;4_)#;LC(YYLBD3%Q,7RR\F
M,2:QMI$8RZ]Z[;+]JH'BR=RM"]7O*XMF_&'\8?QA_&'\:0Y\V&W-D[F;8=;T
M.R='/+20?0H-$AA,G/E]1R>=H^,3IDZF3J;.YE%G'4YW)E$F4291>P+TM-/K
MVO/:OW;J?.U>_9;.Y-8/I<E1:TC;%-@V:MI<'1"KH5IMU.GW!L\&MU:@4=T*
M".L9+\# FH)<C>)1C6%#)_W.H,NCOIG3,*=A3M-NCPNS&V8WS&Z8W:C[1MW.
M<6_(G*;N4=_YWW_^*4L.KH58O,>Q2S1L:4R^EE^E2+)8>I_"+]+-XA@0YDPD
M?O(-H' 61.[WO_[G?_QY[5Y]%V9>JO%B%W[B!A%^5]P(8 X1EE_D]"]OKB[Z
MW=[)/P;_]^WBC>-[\(5PTX/+P?GYU:C;.^V-3KJ75\?=\5EO.!R=GIZ.+OM7
M@XLW?UTY&Q/.]XS8WG2T.P\4?^#9TD=S]A+AD"==3+?PH_!]%@)^XMO5*Q".
M#@'2,2"Y\_31M6V8E(]I*N;,\Y-C^,*JIVXFG?-H#@2T=#QU[' .I;_.F1M;
M<B8BD9X3A8YPIK&8R]LH_NY$68I[\)S)TOEY//[LW,Y\=^;$.-D@AH?)'_!T
M#W[W"K1*X-=K$>,VM[WK4#W+DU-X=F5%(G%26+7\X<Y$>"V=!<ZFA:]$ZMQ&
M60#KD/!X5_HW\,YI%#LB5*Y(!_Y>"-]STLA)8Q$F4PD_.H$O)G[@ITOG+5PI
M?_BI>N0[QP_I3? I5!6B\(!YE*2.\&Y$F(IK&65)T8T8?L2KBU>5SX7GP).)
MK05+]6H@&$ E6&IZ*V68/V,AD"'"JQ#8D7J[ 13'$ZD\U.-MJQ>+6#J3;"EC
ME?"3R"# O]=VH%]$T,)[WOKO2A4 D6PA"=,Z\(OYT_<PN@VD=RV13]&/YJ_X
M90%5V%J'%O'6OS&NN?6# ,_;N$R?L0B2R)$)LD _F<%A"_.X9[Z,1>S.EJMX
MA8<5I@A?>.1<_/#G@-JTW2R1."BM'.4(<$"^UH%'2-BTN!%^H#:"ZYS[X=J]
M6;AV-]X<ZN.H(NZA@V0$&P@]0&K V<2-_8E$/(VE= (<T4BCV_2#"/ISL41,
MS9"B< /JF(VGWIT$_PR,\/%"[C&+,^ZI:(C=%1:(G\V'AE$\%T&%:_;PFN+!
M)%H=%RA"7_.7-]TW]!GT!C?__'"9I(>U=V%/6F4!5200BT2^S__XL*I^E(LR
MPT)F0')#$'#WP%*^I*?-GS]]X/VO.-JUIBO0@U9FLCZ]D==>P8SN4P/FE: E
M,274Z'8EGQ*2IC[2.T(ACR0:0M67R>$C].P=\+,Q9K[F;_VN995O'[/XFP,K
M9H9W,\,^,\.U^SZMJ9H1J*)H3H".2_!S>II5=IPD R48;*!_53@H\LL$M-A
MQ)NYY8>5&_RPX+6%,1!&J>;#'_!NM0A39\6+#+T8KG$%&C$ NSB.)E2/0':@
M<9&V.,!T$6J5V00UY=07 1I#H#A/LR!PJ 045.3"A&)VS^R^^;!B=G\WNW]Z
MULU>P8SN^WV#;Z%@KTFV6$2Q9J/ ^5+%9\,H9Z3$H-'K@:Z+\C98J3\%L,%R
MT,,R,ST)UOGJ=G=U(UP,%5_ 2=TNU(]HO(  ]$3H2N?63V>KX"]<6!WU2Q0
M+R-?&*% ,@.T7+U'D,-H#02/6>!7N4CE?")C@RR['0=]^%:>3YAHY4D7TEU=
M:(\6>FQGH40'40* ]D,X+=](4H4M&$11$I;VRWG5-%;E X_S( LZQOU[*&E'
MGUC_D>C8?Z ,8Q?=XUQTO1,K/KJC_M-\=+TGWO["K^?-\^9?XO;G?7U++=$7
MMSYW;HEQ7Z'1\[3,,"2("^)/Q@8D1H\#X&BK?:4<YR58/Y,[QXSA[BKVGW79
M8^7>5Z'KG7,CGG6);[6G[=W^^$F8DAM,R9_0O5I"M70"-Y(Z5&98N5Q-+7VF
M%J:6Y\ _TVG6(@(Q/!E,*4PISX&(5'Q=0A734\M/?SRD"+NV[FLM]N!O46_)
M6ULX6IW<OUI+(]OG!'(;F$%C@+6_7)0QCC&.,8XQCC'N=6#<*TYKH?O.13)S
ML-#D1@0\D.!5Y9:].'P8?QA_&'\8?QA_&@@?'DBP=8YN%,IE40R=/6R4KG4\
M:WR+47N=1.[#KS9T$.F==([[3Z^3O \D33E\O(^[/^^)^&\\MC&KJ;LW6M,Q
M@/D-\QOF-\QOF-\POV%^L]_\ADVI9QW5T7J_S5V#))]A@N1C.-*^3;-J"BK4
M+;99.N\Q7?0Z_6-K$Z28(I@B6D\1+"F8+I@N6%)P8/EI@>4L]%7S:C)'ZB"A
M_1GDR=Y&]C8V4DKM#XD-!O8&Y3)I,6DQ:;'T8A)C$F/IU332>NU54%]G49P>
M4&=N/[R123KG6JB&!^OWE4$S_C#^,/XP_C#^- <^[+)^3$Y-DD;N]V=)K;FO
M]]7^&#5U^ T>"[RFX"#[%1H@-IA$"[]#OW,R.F+J9.IDZFP>=;( 91)E$FTT
MB;( 9=^^1?A1E^!B^I4YVZH>%!L BGE1AG.>GM)[N2G@LU=SMBN47F'MV7V@
M:0HRU*TIL$+ G(8Y354;.NKT3VK2AIC3,*=A3L.<YIE<(\QNF-TPNV%VH^X[
M[G:&H_5QU\QI=G;G;!]._R+CN!^SL1T75X&><4^%*_!P[@>X_7@X]XO?SIMO
M[>IY./<K4%AW3HEL_NC%X>, B+?1IQ<:SFU]V?:'<UM?(@_G9DI^3GRK=3BW
M]=7R<&ZFEI?$/]O#N9^)0,K//)R;*>59$)&'<]?I2MRBWM)P[@OIZMG</9K-
M?<RSN5\\O-$<A&P<X!CC&.,8XUH!N,8 BS'N-6#<:\]<Y]G<W ^B\1R+\8?Q
MA_&'\8?QI\F*T6OI1\.SN5\H,W4O!LH-.L<GH]I!TI3#Q_NX[']/Q'_CL8U9
M3=VU-DW' .8WS&^8WS"_87[#_(;YS7[S&S:E>#;W@T)=/)O[0?#J=[I=:^V'
MFH($=0MLELM[3!'#SNFI-8'#%,$4T7J*J,'F8[I@NF@]79R"I#AEBGBJ!?)J
M0LH\E9O]C.QG;+F4VA\2&W9&QSS9E(F+B8OE%Y,8DUC;2(SE5[UVV7[50/%D
M[M:%ZO>513/^,/XP_C#^,/XT!S[LMN;)W,TP:_J=DR,>6L@^A08)#";._+ZC
MD\[1\0E3)U,G4V?SJ+,.ISN3*),HDZ@] 7K:Z77M>>U?.W6^=J]^2V=RZX?2
MY*@UI&T*;!LU;:X.B-50K3;J]'N#9X-;*]"H;@6$]8P78&!-0:Y&\:C&L*&3
M?F?0Y5'?S&F8TS"G:;?'A=D-LQMF-\QNU'VC;N>X-V1.4\>H[V=;F &TM5'=
M)C+V3A;5.=PGQ_"%3;C^%IFYH,Y,!AXZD=96_YAG?Y6+E*8GE8QOT*4Q2NOA
MP\<\W[F5L7326(3)5,:Q])R)3&^E#)T ![4EAW<CA_[[SS]ER<&U$(OW.%>+
MIFG]*D62Q1)!HF; 7?B)&T3XW3<XC+,@<K__]3__X\]WW?@Y"GQWJ?XM;@("
M"O$XO\CI7]Y<72 D_C'XOV\7;QS?@R^$FQ[TKP;'5Z>#B_')\*(['O>&%\=G
MP^'H]/1T='EZ>3QX\]<5!#*A=<_P]$U$>R?^C>I&OV\SZ9Q'<^ I2\=30(8-
ME"Y,9UY"-'$F(H%#CD)'.--8S.5M%']WHBS%/<#A+YV?Q^//SNW,=V=.C,,>
M8GB8_ %/]^!WKSC$!'Z]%C%N<]N[#M6S/#F%9U=6)!(GA57+'^Y,A-?26>"X
M7O@*J.8VR@)$0GB\*_T;>.<TBAT1*N^L W\OA.\Y:50@+>PD\,7$#_QTZ;R%
M*^4//U6/? >$26^"3Z$JFH4'S*,D=81W(\)47,LH2XH&S? C7EV\JGPN/ >>
M3)P^6*I7 Z;Y ,><7O0S%@)E!+P*@1VIMQM <3R1RD,]\;=ZL0!"G&1+&:L<
MJ$0& ?Z]M@/](H(6WO/6?U<R!T2RA21,Z\ OYD_?P^@VD-ZU1-9-/YJ_XI<%
M5&%K'5K$6__&N.;6#P(\;^,R?<8B2"('." \Q4]F<-C"/.Z9+V,1N[/E*E[A
M884IPA<>.1<__#F@-FTW2R3.CBNG6P(<D(MTX!'(L<2-\ .U$5SGW _7[LW"
MM;OQYE ?1Q5Q#QTD(]A Z %2 \XF;NQ/).)I+*5FAOA4_2""_EPL$5,SI"C<
M@#IFXZEWUP7<Q4%>7.X_9G'&/16EN;O" O&S^= PBN<BJ$IMO*9X,&D;C@L4
MH:_YRYON&_H,JI2;?WXX,]?SZ[NP)ZW%@786B$4BW^=_?%C5R,I%F9$R,T:[
M(2ZZ>ZPM7])_WZ\V;M11U?VG#[S_%0< Z>/:Z,J5,;5/[VVV5S"C^_Z112DP
M/A*T)*:$FF:OY%-"TM1'>D<HY,%50ZCZ\C[M\K'XV1C/A^9O_:YEE6\?"QN:
M RMFAG<SPSXSP[7[/JVIFA&HHFA.@(Y+\'-ZFE5VG"0#)1ALH']5."CRRP2T
MV$#$F[GEAY4;_+#@M84Q$$:IYL,?\&ZU"%-GQ8L,O1BN<04:,0"[.(XF5*)!
M=J!QD;8XP'01:I79!#7EU!<!&D.@.$^S('"H*A94Y,*$8G;/[+[YL&)V?S>[
M?WHBTE[!C.[[?8-OH6"O2;981+%FH\#Y4L5GPRAGI,2@T>N!KHOR-EBI/P6P
MP7+0PS(S/0G6^>IV#_[#';P;_;2F<_=CZ1[_&%[(23H./>4"PT5<_BL#8'R5
M;A;3=N#'<T @X8??8H$(,*9-;W @[^ +'HXO1N/3T?G%^=GEZ'30[9]>CI4O
M^'C4/1N-:O<%UT6JA-Z>=%%B^U'X/@O1-PEO5Z\P0&XEC/(L;FPQ![J!K]&?
MDJ0=)PMC"12,7UP#.BC'*.! (M6?5?HP@S"%?_  %):#1 3D=(:+VA&507X@
M4"4,0&3>TUYD1^3K/_* ^@^4K.PX?)SCL'=BQ7-X=/PTSV'OB;<_]?Y6W][N
MU?/FV[+YEMK'+VX3[]R[Y+Z*L.?I;6)($!?$GXP-2(P>!\#15JMOG.M>NTKW
M9UW=.>B#^^/\8$)H,"'\7A@=C:2$G\$08DI@2F!*^"5*'M(DBBF!*>&QJ$8%
MXB54T0E:?OKC(87BM76(:[M+O6P0M]('SBFJ@WH?G*3HOVN+\NO YJU'UHI2
MZYJ*1A[1CZ3UE?R#?N?DN*9*DP? LQ5HA_=QBZ$&)@LPAV0.62.'?'%8M@+E
MF#LR=VP)JC)WM ;*M\>-@65)RR\$7>MX^HYY)_/.AN$D\TZKMO?HY5O@MP+M
MGJI=ON(<ZM(_;"8@UH-VW)WF%72GJ=-GN,?=:3C"QYR&.4TC?&_,99C+,)=A
M+E.O#^L.L#S(5]44[+'FCF(>Q#R(>="S^8+V6-OACI];ZC\W3H%W9H+:'Z6Z
MCMF)17CM8YNY.)K;*3P%0%EY#A:86WE0K^_,X>O9NL/K4<NZ]=.9(QR5?RF]
M P!H+*X+H"ZM5?#V#]>UDD>M6.V^-?U>[VX5T!P*:U,U^(5T5X^L1T=F"<6X
M&)R+P1\:<>%B\!>_O=VKY\VW9?-<#,[U3EP,SLXR)H375P++Q>!,"4P)^!PN
M!F=*X&+P?<FGY&+PIIP$)Z1; ^71::<[Y'+'1N1I-8B/-D[V,X=D#OE"')++
M=9@[,G=D[LC<<<-];S?D@' U>./2;YEY,O-DYMDTY@G&=Z_;?7%XM@+MGJI>
M<C4X5X,WAMFUO'*A3J?A'E<N<(B/.0USFD8XWYC+,)=A+L-<IF8G%I>#,Q-B
M)L1,Z*6=07NL[G Y^.;E<SEXV\O!CP[772R/6K'E<O":2XOO&1SOK0Y_KVN.
MNSDK_C<\6_EI^FDAU63S9(<I[Z>#T=79V>7)\6GOZN+DY+AW/#A64]Y[P\NS
MP=Y.>5? 0C(XRQ+X]IX<^%U99NW#WL\!19*.\S%T#QT?R,69^%$JW5D8!='U
M$@Y\#A)RZ212?D>.">S)DS<RB!:4"0P_SV7L^E2. "PWC&X .L!LO3B[=ERX
MQ/<$)@M/H]A)9]))8RD(;1%2\+LKX^30&2=.ED@/KHBC['H692E>G$C$-PK,
MP#,\9^J'< .\"_8(7Q#R=]13D>'G^<C][@?\[ERMO/BV]\&)Y11>AWO "R;Z
MG' E)A1P7SX(C=M9% 3 V&Y#>'>231+?\T4,U-1QY ]7+E*X0L*1X[,T73@1
M?(AO?5AY+($&8[P8G[=ID?3.S<LSEM,.+/I6 AQAX64N !"!"!  3<*=$10T
MYM#Q+^+H.A;SQ %E;0:8 ] )!<);@8OP %:!F>?7ONM0^?Y$TQY@S+?U$^X-
M/R3 ]9/4$=X-8I:W@H6(W^>_7YP?G':''3@\'Y8%7TTD(K92%_QKPC0_! W(
M#U'!A#5D'NH,\-T"WD[Z!$E#SY]. 6N=0,0@",\.L'V!$RSGBQGP+MJ&BBFF
MV3P")&_'07X,G;^+,!/QDF2;(J_\9*F>@\ #."I")(, B.A&5H_'$=>Q)/($
MLG>)L.%+?S[/PN@@"EW%60A ,I N GP12]=/\-[B]Q3!FL-Z# 1Q+4/IH,A"
MHW;I?,N9%![.+_[<A^=T'& S^;6'0#].T<6%&K?<O1T!2_9HV<0AD!OF&^DX
MBRQ.,J%^4ZA3K G6+@$(GB7%K=OI=T>=P6!@1P]*9@*($)F<L??_28AU [R3
M%*0^(G?@RPRO4KM!DL@6UK31/_6/#H\=N"R ,[:S+U@J7 0T"ZHW(1/Q7J#1
MI=+Y2;<G1NJ\!>GE_ 9BS3EZ.WGW[G!]3XVDQ6^S5<)":0P;@N.<9T'J+\"R
MS?EH!\]0(:;:]$PD=.+1@FZ%DRS(%;ALX+LR!.8E!=R@GX&/@"MP@P[P2]$A
MMAP@B6; ".$J4 3392[X%YA4 322)!$(9:1B(E5Z(F#< FY#UE \'"@;#JHB
M!"JL.8SF(.#SY\!NTIDHY 01\R<WC30IKW*F'ZB%$*=9*$T5]IOO$2^<^G%B
MR1)(;R,[&%R(0%(E%<>IG+<2<VKI>C->?A="S."NN$<3LD =\!"0IP=%QR4G
MF<,7("'A0#/LNQ2FXCH*_20E[J"?.T>Q"3K:[*#GO/U\T7M'Q_W'@0="#<[D
MXS6H0@M@UW#J,=[V3<D]@8>MD/3M'Q^_?AN_0VDYNQ5+DIRXO%4!,/5EX%4D
M.>%L*' )Y^.#WK +RM/:N@ 2U[ DM;Q?>N]^HM<9N^DX&O,W8QKQ!8)U@5JX
MA$2BWG(?F.^#*9RW/_%3D/<(FX\H8 *9@>8,RT7&NH"?#@R*@5\$8.B1\_;C
ME_'_'KT#F?1OX%\YR#:(18):H5-N!-S1Z='HP3  \D+>AB=(K&0[K15"6^ C
MXA)4J.-/LYC8L/G>'+U7N)EZJH8[[C37N/+G%6Q@"^X8.IQQ1!+[CL$+@(G=
MC?" W 1'C<'J%==!-,E@(?3+/'/A+XWYJ.+#?_&YL, 4E,:#@?/VV\=?!R6J
MFQRT^O)$<3.EU#B(N.K=</NAL\+;5M64@K>A0EVR\Y*]^4GU)#I:VT[\:\50
M 2D&_>&=.-$FH9A#!C6T((D _"B64(E;D9<DD*X.G;]%T^E<A.'!+\+Y$KGP
MB%]2I2S2)P6OGT&7"]'T);N+?BV^0D8T5WJD5J348WX&.V71T1BNL%']4'T@
M]HTS367$C\L8=<;KI[@-3U=",<.C=3_MHR33VQL_F4<>6%Z3=[AU$D%PI =N
M(-!@UES0 X$-U$1*] JM_0VW-HN #! ' Z(:120ECR0^4]AJ$Y$ [1,INF Q
M^J ."#J$L_/S"GO"@X;O.ELAG4A "$#IH+!%B1ZU'0?GEX,>WZ^T1@_H"QAQ
MA8#A1[#X(UPV&*"++ !U&>VBJ3^)H\17I=#S)9!2_DU+;+QMMC,J>+$O4]SD
MRG$:ZAX2G *25-;T47^(!+0F&SO;^:_J"JG1 #^(!? U!"&=^,?QYYS':O\)
MO6C0/7[,B_X&6H/S=89FSF?U4.>TV[ZC<B)RPRI/A "Z"J\#M#T74:S:*2;R
M6IFJA51$/K75 4-'4/CKE"L.[XC%0F:I[U:=+""%4*'78@R_@ -2;A[U#=)=
MYKJ@%TXS=./H5TEOW4\("GZ4@1(SD<KKIV7\3(H V+6+CP)X9DD:*UNCN#J6
MUUF0.VCPEM]#M/I+E_S7E  T61J_.OK+JRA2:[E I]!8\ZY<%0&LN[H8*V1#
MKG C8^0(SIQ\ZO3(Q(?C$G&^B@A7EZ6S2+G86XA0@"%)-ODG'"NR5+ 9OQ=>
M ?BL/+_:\T7^THICN#RAQ+DE"R#1CRCQ 3#&GP+OU [733PG=\(:C+<#7Z;8
M8P(T'/+JP/WOMSY 3/S U])?B1(Z0T#7W(][KPORP]:'QS+PZ9$ DL+= V^J
M8KIV2='S#3VV)((U;WBI$:/J C VWKK-E[;;*@U)"*M1$G)UP56GO2D,\0T"
MK+OHAFC,@VW0(I!#YW(:1*\R/R(%0/2@(Y@+]=T$,<K0XC&)%K: ("$^9ON.
MC$.-)JAUP^OEOS(R75000(4BIEF8:\5YB$H]-'] U>M5><=F]_ZRH]TG7Z(E
ML"/X^,LOY\0>5KY&H,(;D^FR<.Z3;H&K"2)A.D%)"SWSH\\S$<^%0V$Y>"=&
M[9PKW,''C\[7;-)QOAZJ%?;[1Q\.X\/@$'6O7[(?H'A&67Q=T ,<M]Y?'IX!
MY59<HQ*U=-1;OB/&>J#&@2FJM*C\_0<?/SX(\*CDP!_T(92(1:@?;/8,D=!V
M\1P^5-! ,^1-;\0=R+0PF4-YBZN=R#1%3"E\O"Z5<2AQ1:?LR85$'JG0_KN$
MEP/+CL)0!CMM#]\+QT]G8W!T';8A%^*'53-[V[/ 0G.SE!9"R(BQ<>"(18 I
M#V.T44I4]CS-5)!341O0(%!_%I"3'F,?:-P2U\.CR;U2!9. TUWE@T (,6P@
M6!*C@.=4V+._D B&XA3FXAHD.NJ=Z*[*_;PD;OPT]\)KM5Q\+]@L,2?U(L6B
M 4?#%,.(>CN;8DOYQNY@("7/@=<MG1M2F\':09$G:%/D9EF"\$$DH?_B^X&/
MQ83<4?&GDDPYU(039KFI.15N2B2\@WA,X3/^'F4I8+?4BI=2@K=MPO2[Y!82
MW9=_F<8 *16_I0.JGN"'0BQNHXWMHC(7CAM</Z:$W,PTUJS\?!T=4R'9=K^7
MN]6V>,6IAWW5DW6_M_;#)H-T)[!L%L@? %,3G[3S'!N!2NY[1Q1>1TB9*P?8
M/L:#5ISO^@MB%)K($S@M4-II?R*9=>A?!UGVC0C4? '2WXUY RV9!H$=U-#*
MD2'9<CZIY(7<K;"O0(0A!3H*]D,!3,.9.A/!%(D>5C?<'BJO"$. =9A)4JC(
M]P&@V_"BB5Q&Q(S1<PQ[ 8O*3PI1G#K9 FTI 1;$=:'KP>.0?:5K+XRC@*S*
M,)\:L7)-+#"/(O?Z$+M&!T2>&R IQPF5!0\5J4(OU"DAFL!RE6P#QS"<>X;3
MAPP&D"2+5&F]Q=L5C*Z5TQ2PKA! V_A!AY29JG#!Y2K )*#1N<H=52R]:G&C
M4$$V/T%U-EA7X[? !]Y @6V%%?"I.%R5G)&W\UM96)&EHH4('&*F,2[POX,@
MGJ']#*N%-0#P;VCK&&8$3@&+R=!]@+AZZ'RL2!N\)@OS#6S5YJLN;]SZI,BA
M(5L#_I.AKH?''<#/">(<GIA6NDPK[Z<HWFCH/33);CT!KI(>)V_'KHM0@F5\
MCJ,P0B 03F"^'1@YUS+Y&)K7 )YAT#8ITNUV2*@[.KOL=0<7O<'X_/CD]&1\
MW+L:J82Z[L7P:-BWDE!G;2"'L_4-6T=CG)SLDI!>S0*OJR<_"+F'I(C?EWRX
M-C7%6C:B2A49W!.UV25U'HO^;>[YV1(N >=*VG*J!/CD//K&:$0?0^=7XFME
M8/"JR(,T]O\U!<8G8L\YB_#?MU?CKV?O@/DF&?#/3=?]OJ!0\-OQU]_?T<,/
MNJ>=)RM+ZB->_MY/ <%<O8LY.96TQ18YEV!\1TLIG:^8G71P)M /_%E)5&.U
M5E2KW"&>^/!2,,Z 7U%.U,&$WJKEN"-*&.4JAD"CSI?*CU1DAVD+,<D!2;8O
M2"LYG>J4%S260'="UXCRSU/XB_2E7$,% >W/B^^*2'=$Q@?=J7\#<T]>^R'%
MG<44Y?IZ)CI&Z!5ZD.M3Q)A&Z>E(L5+5P%($4[&J8'B13$C#4+Y]'6@'?J\M
M1KCS.@,[#WTL<&83RO:7:$[@1Z55W9.>VQ*S XCL2D[B/.TQIS,@H8*"OOZN
MB:1?&Y'\0B%(.^4$513-DY%!?;H6H?]OK?.1517@6S&+2RK2!.TWN@[1$-4.
MG(D(" 62F91I?B%@>.Z%I(QH,+;% LC+50&Y/-V;"L84SD<33-S19028!:[<
ME0KG:1&8"%YHL\%2'4*!@?/(4\2;&T/%+_BR0"4D&41,FJM492J>?H&.[R0K
MM#KU$[24T4.3[$YNH\Y=M$QJ,CWQT+G<3I'*FY-NHLK2_G4HXP:75*7M*CG[
MIC_-R()9)6M9KF2-S+4RO4=T;60S;R;KCJ;K7FUT_451E KG ,;\"KB8*1\S
MGH ASA5MX37EE[\89&:IEHO$(<DS= #Z0 $F A@TA,2A[>R*4R4TL<+@ PHA
MT>PM6(]^C;8.@4^H,#(*U"JM>D4Q4L4)KPDT?YD?)FF<Z=*/TFQ7D>[B+L79
M-JQ<N_N%YY.?&J,VOC).RY&5"4DZ=48>.I",:99TOZM,._3&&3\5?),"R(;_
MN/2?; !/2>T+#$>@7#4!K4"$1 A0*'VB>F=S"=S36X$E<=Z(\L)$JM?AJ/PU
M3=,%Y4O],BF!1ZT#BQ[@1;0\JJ"\%W#:;M\"/.3/J?)(P\U90ES)CY7VY?TS
M2_*-&@".)HF,;^A%@*DNR8@-N+?4'L)DV[M]A=>QPG(Z1DH+-E97,&?3[3"A
M),Q$TB$8B45%YA"E9,N9#*D. C 2/>^Y^"/=KX1V2MW(U.[R<&L%@_"LBKK4
MZG4EXA\4<740HQY&/OSD^TH"IW T_T=ZQF&E6H+GF11:/*B,20_KCFB_XD<N
MWV.I$BTPK+X^LI4\;DE17JC0:S[!].W"O:83J]:?K:B@X#B6I/'0AC2V)XPW
MZ=;;Q2Y F0A,E!IV+K'W3B"/LVN@]/+\X.R.MNK;1P=PO'<TFK CH#\K"B\X
M8RE\OQ8 +ESG_0\_4X#E'.L9XM!Y^S6; .R '/O=XX.C[KOW3EE7BT_[/7>-
M$JF("58WBM"YA,]IU2,_WN"11\7:J;QQ_:@?<Q(E4+\A*F:+O P#*0A.WU.E
MGE,,P*KL @3#2MY)L@"\](U N&8K6!FIW?]8(:D2C5#F4=@5>S*D)2!,F^3>
M  6!0T>X] %H$L<R((JQ:F9+^T'O?X)U6Z[,OY?K<-]$4$:.RXWOR8(A3J,H
MQ?DWAKY"',TDY[M9FO9;6S;FMVG_MZ0)T6I 89IB$*!S#S<BAP;QH[RPI-QJ
MGOKIY1'[/>),OPHR$^[B1C6ZR+Y@3"73M1GG&!\3;JZQG@/'!+T"D.?M-V(U
M)]V3]:Y$3W*.99@^(SWD4$%0AEECO:K8L&%,]=Q4PJGV-L\+++64'*\V:+^%
M7T(4F4P5#T3^=F G(<5$8Q$F5"1]'44JUH7J(>J%Q"4*,%'B4A[#THKP-- )
MK*JL'(A:1P-59<9,%FLH<EVC/*M$:W2H5J^]F50O)=6,:ID-Z'-\@+C5%/0!
M,46Z&1"KYHR7!<^Z .*UBEX4LY,JPEBRQIQ%IZMX09O(+7?59F.(IU']:J0P
MBB!-:>F4<J=T5M1Y%:OW-6[,(C**(L7X5(RX,%*+1)\H]D'A!)A45TEGO.:'
MW^@?'#7IB'7($?:#"<U@<HTI@'UNXK\=CV-^TFX@8N6GTWZG@!B%HC33S;!8
M79I0L?7*TA1MP:7!?7#O=9L$]X\HI/SIDB)3,@;N,:=]?S*<H"C>?Z&$(]N1
MCO(,-KA=?&-I"V-IT<K2@GQIVPY1T\2]'O->?1[S1YS,;R*.H]N#KVZTD$XE
M+(6;_HP/H+2I2Y !GK\QEOBXHS$L:E.?HHK[>5Y8N/D\*CEMRJXNHU'X0).N
M,*\#SEHKSQTP0L,#2EBI"KT\WV.Q8ON@?9\8]?1YU0/8[S+)'RXUBRX$+G'B
MI.2HNN46,5E8ZBK/IY>C+%<*12X'-K+W7=S;AB,LUVJ+_179GMJBSJ5]9;7H
MN,HU7@M:[894$@O)(CLFGWR&A;M+]>]#$DTNK@;]J^'EZ>71N'LRNASTS_O'
M9]U>[_3B8MP=G@YJ[]S$<76.JW-<?<^,:HZK<UR=X^K[Y\;GN#K'U3FNSG%U
MCJMS7)WCZ@T0R!Q7Y[@ZQ]4YKMX\SL1Q=8ZK<UR=X^H<5^>X.L?5.:[.<76.
MJS]#7'UC'-R,H7\R#*1STXLW#CW3=/TT+0S7TF[=,#MIAQC[Z/3HZ+C;O[@X
M'Q\='9T<=8^Z0]7,871Q?'9IIYE# XOUSP0VS,6FVP9<ZS%@3FIH280N3J(6
M;1][JD?\O=B\TGE+D<)$2I32Z/-4YMXF!ZIR2[K%+(,K8%].KWOP#R+ ,79P
M""1\@6_XHMK7(75^/?A_!LLH9B3-HEN,V'5T(^I\_10>4'[HO*,O&BDF&RU\
MMI.EZ0Q?%-DI#C;=BM7D'A<;W*]V9]7]5U4_[?'XLPIB4OL]67: 6?<1E$Y5
M=(]K3_L_@;I+5Z@!VJJ_1T7ZOU". +*>''K_6WB0R:.A_#%6Y%#-X^%00$W]
M()^Q@3LHI[L1N"Y_:+\V &0.JD+>U98NO<06EJ&=G>8!?</3>&JQ$59-;@W;
M7.&C0G%0@$(C$*&142EM62C ?M_*&O0\ :(X%:51W[_%+^!Y2N6\E7%I5L.C
M0E1C CKQ&!$ Z/#ZG=&7DU)D5/"C>-==_?_*I:EF<RCAV](R+5=%-L8$RXES
M,S!>#^AB*Z\%A=*.#7] $RJ+B(I%9O0LD+?R)(L,4B,#J>0X\KK$ #[VO3UV
M9<ILT<A6$JS:,0BVX]P*;*E(34"5-9B+$9W N'D,)D98B^"H*5LT\]\47\GG
M ,F['MT2@?Q-V=R42+ ND5>ZQ^ZNP"NU$YT'&#%3?2-!B2T][&4,3W7L_ Y&
M>9+Z<VI;B@0CDB2;YT/)J#4^V>Q:<J&&BD=+'O5D-6$'9Z06GJ8BA\E(#'*T
MA[V*ZLJS^I4:-19KR35\,MZW^*<>TG6WZ&^N6Z[G;T+%),_]I9&G=YP$Y3LH
M748Y<1*:WZUV&2'JX -HZ QU559M=E<33.Y^_@<=@C"]-^6<0\R_T!MP11R3
M@5<\MC+Q#@]<M9/4^1 X0QSS9]3)Z+[SQF&;LRTV+:[,)$'W$(YAU)G3U!(]
M3*K^I&)1.4*L)HY5TL7&JC%[KAFA&P;'E<+A$LDG%=1H#X4GLDA$R;>&%BVR
MO%P%]BF)2(T<N)'JH-65*NM(Q:!T0A1HRED0Z/!V3,%T.&9)@PLJ^2X/=4O9
M=BU5W%;H/S2R%Q_GB;JZZAZ-3@='O?[H]/AH?'ER>GE&GJC1Q47O]'R\KYZH
ML>O&Z$8W -B.0'J^<)/[DV%8-GB?1AB>@Q6]?_26C#?W'[GB\K[M^46/6,XV
MQ%KKL6J> GXV'ZK,Y\K!]2I]6:TUPEU9N6IUV^O"GD"" D8>D#1=)/)]_H=:
MN&K*BIO9TCNWZ,XZJG1M+2"[<^M;W7UW\-\/;;Y;N;_WQ-M/7O;UKVGS#VN%
M/(G2-)I76QCW@51,VC$_J^LK7U&5"GWSD ;#." "#?CW,]\#(K;*1'=D2568
M%\L=O+D;5IJR-21ZBQ]Z OQ_=>E_=<!R _P,-N)B?G5<FZB]R^N SY_$H+N#
M;O67-V$4RC<_:=-_W1OQT)[5C)N,F[O@YF9?S1VHN>[#N;]Q^&YMY3],A/O]
M.L8AFBCZH_C]?[FNE-/I"V#QJJ)1AYIJ&K$O2>];P=X4@/W)%G3N1; [H/1(
M8!#Z685&KW,R&-8.D::<_39.]&PH\8HE)W.:U\YI!KTN<YK:])W]4FL^Q]%4
M4E8-ALGD/4[#+3IZ_QX=_3$@>X#&70,-[:XPWT=!33GHND4R2]Y]IH?^@.F!
M#>4'&<H4:91)JCH&3%+G[6^8IC%<KT.T0%%68?NBI-;O6Q,]>Z^\L9GX#,)J
MCTCKN,^DQ7;13O"C9)1:R*F&>,6+4M7@R)Y?\Q[8- 4YV)9JD'C:-WKJ'YTR
M/;$M9B>U%!O(U8-- \ F;,P4R">16N,5*7O!A?O MQ?1AWYGT#]Z>9 U!7O8
MPFUH()29&3.S'4*IIP-F9G6H:3]1/OK&Z^^N/[F_1L0L*?FBRJ\^BSA=?L/^
M,4)UGGALDY.SL][QX&(POKHXOQATKT:G%ZK)R='%4:]_O*^E)1J*#H'1,>%X
MY\D_ML)DT+=78:(^XN65/E!8NJ1;)Q?E?JH(\D*$O@R<+X>PVR2!1]:R1>M%
M-)]"Y^]9*(W>%1W=FG)M0U@W!NQ!4A>[\YDOI\[E#^EF5%;V:3KU71FO]G?)
MB_4VE?M-:'X,W.#YL733**;)#I%/';!_C0_+->4+2"/JA4C-6?&I?\ K8278
MVEL4!:[KCSUTQMBT+U);=8H=KBYTXSLI*5=%I2+J'KF. *KFVL 'D>C)+'"7
M3RVA\KK/-:1XS)GE#6BM/*R#17[_I/I;;$(9REOLTQA3/U@?:U]5 W8JO:0I
M&M)9 #D7/?BKVZ8'Y/,VBBN+.3=65ORK,%JMZ%)S._7\'=TK5W4:22N[F\CT
M%OL4 9(4!+&"W02!'%[8-O=S%F-+8 (M==Z WXH62,6C.YL1#Q^V$#Y6N3NS
M*,/NO%.I>ML[U#$!OH@E5KYBE[9DI>M:WNJAZ%H:8U\%W;=H&W$9>SET+K(X
M[WHV10JG=UIMSU#G06[<HFZQ[)E4;+9U-<\2^[,!Z5.1-$U)TJ7/';@Y7J#
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MAKZ.+J_Z9Y?/.O2U]LK:<7L*7SM..I,.'K4(E\Y,>':6G=Y&5I[C)(B.LRA
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M(W*";,LIFAQ3-N+SS%'\M):GKO%D36+V7D0]TZP@<4CUH['-/Q!;R7!9X(^
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MID*2?\ZD\/, W)Z#CS[^\C]02P,$%     @ -SUC29 PU&KS%   6<X  !4
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MIC6LRRPS.GT/-T+>GS3ACB(;8K$FZGZ*F3X'M]S%[NTV4XTY4*%L:#H)!^O
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MU CMP7]@T9@,L%PBL3J_?(@%W4Y8<<>T8Y02X0M. E!/"B<-D6"55,H*.\;
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MB"YNY8G25/+,BLDNW->87Z:+#VO@5XM?KM+T]D6<REYDL^6B^LUZ<OL%P+L
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M>FT'>Q RB26VS#H.D*$$5+L#+"1H'E<>23BI!\[U@NR8V1B#37VQ\5';B<$
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MW^3ZML9UL)NPLMM5.;E.%YFZ*K,U#E]+?W1O6KN-Q 2K1Q#*, T0*  A,UM
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MH]J49<DYA>7<,EQ*>J/,HY3N3$&AFOX\89%#FU>(+A#UNB#I,KPH8=(VYKQ
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MWU\4=.#?\WJ3Y67];_GV4."F.3P\MGD:^NV1!<CV5HH'=Y41$@"<1B%&O@=
M"A*:C/EMA*1VM6:$:3L=TX-QMN5M(5D&,:/O!$LB?@RW299'G,2.BQ'GR_=S
M,<9IC;MQN'E.:Y]S8N"-,W8&;N/$M1+67'6M;F+^_K&,,+4$(I[74RP DGPH
M2UX'G(@ _E@V?\OJHAA.AWW,]\6OY:Y\.#RL,,Z2$!(WC0.8N #2B 9C)$9
MZG3H8D#;WFMET-[<,FS'$Z<U0W?C/'3X%"+?$EB3B8-+P/M#1D5NL,,M=L9S
MMQ_;OO/K*WW'7J"<P)>OA<TE=:<%!=%%T7(NI"X*X,(";/ZMA4^]./43&'H1
M#@DA(&:_,<"/8E<J<[D8T+,%V [?T@*LJ*N7$F M>/D'"+"O])T?-,!V5LT:
M8"6[T_\M 5:6ELD#K)+?9@FPPY+[WRI>1;<M]]]/9P@TC%Q,LQ#X"4E03*(
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MU-Q:YPH_UQ<^)HA=BBZ9,>;EDL@<1Z+G#M_7=_FNOYJ35+NFVI:;KH)\M_G
M$ Q'"][?9N4NWZW+?/N)_4[17J W5IDG_ (]UP5>FF2\!@5FGL]OTT,>Q"C
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M:?JFB(L#'X,@)@D%$489H&-3U ="QUBU&IAL CG@4ID@R9(F,Y6TR)?J?'*
MI#6IE.5,969ID3O=Z>4 S=@<\ZFMKTXT%:E9CJRJFW!VRJG%AY#$TF_[8K<I
M-O3;>GMHRJ_E_GN["]-#&":\@$ /IGX*T@BX$ 9I.&[V9]@3*L<TV)QE^1U
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M,3^.@[)H;";U$KF+.&4_/L&T:'B>X\;Y?\'/P'4>\]KYRL&U&@7_!<+@!@#
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MNZII?BOV[V\_Y]]6O +32WP01AZ*?.@#F R/<*$T"T+)JF*C;4^H=/T5Q:>
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M4$Y[YE43=7));3WPTX;O;S\6CU7=[LM_*NY:%"N":,"D'"8XBX,@@+Z/O(Q
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MU<(X(#!*X[X-' 18ZHHUN2];WT?8.UN&8_+A?*3@^JA4H&HQ@TL%^\LQHLR
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MK*ZU9(X#UXP)-M:(TY9+%9AP3Z'58[;>;[+;!Y'7Q@YM/A@E)$  !21PO0A
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MT:_^_(?N._0/]HC4G__P_U!+ P04    "  W/6-)5)[K$6!1  #__@, %0
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M[F5P* W$2 A*&;%,HRW53%UBW+!!P>U2$V<SMRX (BF5Y'_?,'$2>LR5$@P
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M]!X6:MJ[81[OE 37B  !. ?4,*"1MJH\WX0&\UH9=+7R>7\(K#4IFX91%6.
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M6A?S.P57ZQX)%L0AI!&W1D)#. M+9TN?DZ@&IH:>*- MIL[B=V]XNEHNXMO
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ML+PDDH 0X=6&9L: Z39EZF6'$YIF=G<W5,MZR>M9OYD%0:0'?<%]71)!%-4
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M3XE.8_AEGQ(!ZA22$" D-*8$ :5!R0M(=)U$O<LY)3IWQVQ3%/W?Y'X4=ST
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M"0 1              "  0    !C<FES+3(P,38P.3,P+GAM;%!+ 0(4 Q0
M   ( #<]8TD3W-!J] T  '6.   1              "  >2^  !C<FES+3(P
M,38P.3,P+GAS9%!+ 0(4 Q0    ( #<]8TF0,-1J\Q0  %G.   5
M      "  0?-  !C<FES+3(P,38P.3,P7V-A;"YX;6Q02P$"% ,4    "  W
M/6-)DNWEK;(V   ,H ( %0              @ $MX@  8W)I<RTR,#$V,#DS
M,%]D968N>&UL4$L! A0#%     @ -SUC2:G>X_97A@  N_T& !4
M     ( !$AD! &-R:7,M,C Q-C Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( #<]
M8TE4GNL18%$  /_^ P 5              "  9R? 0!C<FES+3(P,38P.3,P
>7W!R92YX;6Q02P4&      8 !@"* 0  +_$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
